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SUMMARY 
In Graves’ orbitopathy (GO) tissue remodelling by increased proliferation, excess 
adipogenesis and hyaluronan overproduction, cause exophthalmos. My initial work 
followed reports by others of enophthalmos in some glaucoma patients treated with 
Bimatoprost (prostaglandin F2α, PGF2α) eye drops. I hypothesized that this could be 
due to reduced proliferation or adipogenesis and/or increased lipolysis; any of which 
could improve GO. In vitro models used to investigate possible mechanisms 
demonstrated that PGF2α reduced proliferation by prolongation of G2/M (flow 
cytometry) and adipogenesis (evaluated morphologically, by oil red O staining and Q-
PCR measurement of adipogenesis markers) of 3T3-L1 and human orbital fibroblasts 
(OF). These effects were reversible upon drug withdrawal. GO OFs proliferated 
significantly more rapidly and also displayed higher adipogenic potential than non-
GO. There was no effect of PGF2α, on basal or norepinephrine-induced lipolysis in 
3T3-L1 or human OFs, either GO or non-GO.  
 
The data helped us secure NISCHR funding for a clinical trial ‘Prostaglandin F2-alpha 
eye drops (Bimatoprost) in thyroid eye disease: a randomised controlled double blind 
crossover trial’. Following informed consent, 31 clinically inactive (late phase) GO 
patients were randomised to receive Bimatoprost or placebo eye drops daily for three 
months followed by a two-month drug washout period before switching to the opposite 
treatment for three months. I concluded that 3 months Bimatoprost treatment is not 
effective in reducing proptosis in late phase GO patients. 
 
My subsequent work investigated truncated TSHR variants (TSHR_v2) and 
thyrostimulin. The former could act as TSH/TRAB binding proteins whilst the latter 
could bind to and activate the TSHR and contribute to GO pathogenesis. I found no 
evidence of a role for thyrostimulin in GO. TSHR_v2 transcripts and protein are more 
abundant than full length TSHR in OF and during adipogenesis are significantly higher 
in GO than non-GO. TSHR_v2 may be secreted and provide a binding protein for 
TSHR ligands and thus alter intracellular TSHR signalling. 
 
GD patients lose weight during active disease but gain more following treatment. Our 
group reported that TSHR activation leads to a ‘browning’ of fat from various depots. 
I performed ex vivo analysis on neck fat for brown, beige and white adipose tissue 
markers. The samples were GD patients (previously hyperthyroid/positive TSAB), 
toxic goitre (previously hyperthyroid/no TSAB) and euthyroid. I found no difference in 
expression of UCP1 and PGC1α. There were general reductions in ZIC1, CITED1, 
HOXC9 and LEPTIN markers in GD which may explain the altered body composition 
in these patients. 
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Chapter One 
1  INTRODUCTION 
 Origin of thyroid gland 
The thyroid gland is named from its association with the laryngeal thyroid cartilage 
which resembles a Greek shield or ‘thyreos’. Thyroid gland is an important organ in 
human health. The hypothalamus and posterior portion pituitary gland are derived 
from down growth of the prosenchephalon (forebrain) and the anterior pituitary gland 
is from the up growth of the Rathke’s pouch of the oral ectoderm- The thyroid gland 
emerges from the primitive pharynx and visible as a bud around day 20-22. The bud 
proliferates ventrally and expands laterally to form the typical bilobed appearance of 
the thyroid gland. This is followed by caudal migration which completes by day 45-50 
reaching its final destination. During the downward migration, it is joined laterally by 
the ultimobrachial body (from 4th pouch) which contains C cells. Finally the onset of 
folliculogenesis begins at day 70 [1, 2]. At this stage thyroid hormone associated 
genes are expressed according to a strict temporal pattern- Thyroglobulin (TG), 
Thyroperoxidase (TPO) and TSH receptor (TSHR) followed by sodium iodide 
symporter (NIS) and dual oxidases Duox1/2. Therefore prior to this foetal 
development is fully dependent on maternal thyroid hormone. 
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 Thyroid hormones biosynthesis and secretion 
Inorganic form of iodine (iodide) enters the thyroid follicular cells and undergoes 
several metabolic steps to form thyroxine (T4) and triiodothyronine (T3). These steps 
and its inhibitors (see Table 1 and Figure 1) are as follows: 
1. Active transport of iodide (iodide trapping) 
2. Iodination of tyrosyl residues of TG 
3. Coupling of iodothyrosine molecules 
4. Storage 
5. Colloid resorption 
6. Proteolysis of TG with the release of T4, T3, rT3 
7. Deiodination of iodothyrosine and recycling of the iodide 
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Table 1: Steps involved in thyroid hormone biosynthesis and respective inhibitors. ClO4-, 
perchlorate; SCN-, thiocyanate; MMI, methimazole; PTU, propylthiouracil; I-, iodide; MIT, 
monoiodotyrosine; DIT, diiodotyrosine; T4, thyroxine.  
Steps Inhibitors 
Iodide transport ClO4-, SCN- 
Iodination MMI, PTU 
Coupling MMI, PTU 
Colloid resorption Colchicine, Lithium, I- 
Proteolysis I- 
Deiodination of DIT & MIT Dinitrotyrosine 
Deiodination of T4 PTU 
4 
Figure 1: Schematic representation of a thyroid follicular cell illustrating the main steps in 
thyroid hormone biosynthesis. AC, Adenylate cyclase; Ca2+, calcium; cAMP, cyclic adenosine 
monophosphate; D2, deiodinase 2, DAG, diacylglycerol; DIT, diiodotyrosine; H2O2, hydrogen 
peroxide; IP3, inositol 1,4,5-trisphosphate; DEHAL1, iodotyrosine dehalogenase 1; Na+, 
sodium; NADP+, nicotinamide adenine dinucleotide phosphate; NIS, sodium iodide 
symporter; PDS, Pendrin or sodium-independent chloride/iodide transporter; PLC, 
phospholipase C; MIT, monoiodotyrosine; T3, triiodothyronine; T4, thyroxine; TG, 
thyroglobulin; TPO, thyroperoxidase; TSH, thyrotropin; TSHR, thyrotropin receptor. Adapted 
from Hormone synthesis: Thyroid iodine metabolism, Alvin Taurog. Werner and Inghar’s. The 
Thyroid, 7th edition 1996. 
The pituitary thyrotropin (TSH) level controls all the steps of thyroid hormone 
metabolism including the iodide uptake and the release of thyroid hormones. This is 
achieved mainly via TSH binding to TSHR and activation of cAMP downstream 
signalling cascades [3]. The ability of thyroid gland to concentrate iodide is not unique 
to itself but also found in other tissues such as salivary gland, gastric mucosa, 
2Na+
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AC PLC
DAG 
+ IP3
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mammary glands, choroid plexus, placenta and skin [4]. 
At the basolateral membrane, iodide is actively transported against an 
electrochemical gradient into the thyroid follicular cytoplasm by the sodium iodide 
symporter (NIS). NIS is dependent on the sodium gradient created by the Na+/K+ 
adenosine triphosphatase (ATPase). At the apical membrane, iodide efflux into the 
colloid is mediated partly by another transporter called Pendrin, also known as 
sodium-independent chloride/iodide transporter. Iodide molecules are also passively 
transported through other putative I- channels across the apical membrane into the 
colloid.  
At the apical-colloid interface, iodide is oxidized by TPO to generate active iodinating 
species in the presence of hydrogen peroxide (H2O2). The generation of hydrogen 
peroxide is mediated by the calcium-dependent reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) dual oxidase type 2 (DUOX2) [5]. TG which is 
secreted into the colloid serves as a matrix for synthesis of T4 and T3. The thyroid 
hormones are formed firstly by iodination of selected tyrosyl residues (organification) 
catalysed by TPO enzyme which results in the formation of monoiodotyrosine (MIT) 
or diiodotyrosine (DIT). Subsequently, two iodotyrosines are coupled to form either 
T3 or T4 in a reaction that is also catalysed by TPO enzymes. The coupled thyroid 
hormones-thyroglobulin are stored as colloid in the follicular lumen. When needed, 
thyroglobulin is internalized into the follicular cell by pinocytosis and digested in 
lysosomes to generate T4 and T3. These are then released into the bloodstream 
through unknown mechanisms. Recent studies indicate that monocarboxylate 
transporter (MCT) 8 and 10 play major roles in the efflux of the thyroid hormones from 
the thyroid cells [6]. The remaining MIT and DIT in the follicular cell are then 
deiodinated by the iodotyrosine dehalogenase 1 (DEHAL1) to release iodide which is 
then recycled for thyroid hormone synthesis. 
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In the circulation, 99% of thyroid hormones are bound to plasma protein. Thyroid 
binding globulin (TBG) carries about 70% of the total T4 and T3. Albumin carries 
around 15-20% and Transthyretin/thyroxine-binding prealbumin around 10-15% of 
the total thyroid hormones. The latter 2 binding proteins have a lower binding affinity 
and hence readily available to be released rapidly. Lipoproteins transport a minor 
proportion of the circulating T4 and T3. Only 0.03% of T4 and 0.3% of T3 exist in free 
form. 
 Regulation of thyroid function 
As mentioned above, TSH is the major stimulus of thyroid hormone production and 
secretion. It is produced in the anterior pituitary gland by thyrotroph cells. The TSH 
secretion is pulsatile with 6-18 pulses per 24 hours in adults and increase in both 
frequency and amplitude in the late evening and early morning. The exact mechanism 
controlling the pulsatility is unknown but more likely influenced by TRH secretion and 
the suprachiasmatic nucleus of the hypothalamus [7]. TRH is produced in the 
paraventricular nucleus of the hypothalamus and secreted into the portal circulation. 
This is then carried to the anterior pituitary gland where it activates TRH-R1 receptors 
to synthesize and secretes TSH  and  subunits, also posttranslational 
glycosylation-important for its biological activity.  TRH-R2 has been identified in 
rodents but no role identified in human yet [8]. TRH also stimulates prolactin, and in 
some patients, growth hormones and gonadotropins. 
TSH secretion is tightly regulated by T4 and T3 levels. TSH secretion is also 
controlled by other cell surface and nuclear receptors. These receptors include 
somatostatin receptor -2 and -5 (SST2 and SST5), catecholamine receptors, 2 
isoforms of thyroid receptor, RXR (retinoid-X-receptor-) and glucocorticoid receptor. 
As the name implies, somatostatin is an inhibitor of growth hormone. It also inhibits 
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TSH secretion partly via a Gi coupled receptor which inhibits adenylyl cyclase [9]. 
Activation of 2 and  adrenergic receptors also stimulates the release of TSH. On 
the other hand, dopamine agonist probably via D2 receptor blocks TSH release via 
inhibition of cAMP accumulation [10]. The role of vitamin A analogues and inhibition 
of TSH release came about when bexarotene, an RXR ligand used to treat cutaneous 
T-cell lymphoma, was shown to cause reversible central hypothyroidism [11]. High 
dose steroid inhibits TSH secretion directly and indirectly via TRH release. With the 
exception of RXR ligand, none of the blocking substances cause hypothyroidism as 
the impact of T4 and T3 reduction on TSH release if far too potent and overcomes 
the inhibition process. 
 Thyroid hormone metabolism 
Thyroxine is a prohormone and must be activated to T3 in order to exert its effect. 
The prolonged half-life of T4 (1 week) renders it very stable as opposed to T3 half-life 
of 1 day. Only approximately 20% of T3 is produced by the thyroid gland whilst the 
majority (80%) of T3 is produced by extra thyroidal deiodination. This is achieved by 
deiodinase enzymes with 3 subtypes namely Deiodinase-1, -2 and -3. D2 contributes 
more to plasma T3 by deiodination of outer tyrosyl ring of the T4. In contrast, both T4 
and T3 can be inactivated by deiodination of the inner tyrosyl residue (Figure 2). 
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Figure 2: Thyroid hormone metabolism steps by 3 deiodinases. D1, deiodinase type 1; D2, 
deiodinase type 2; D3, deiodinase type 3; T4, tetraiodothyronine; T3, triiodothyronine; rT3, 
reverse triiodothyronine; T2, diiodothyronine. 
The 3 deiodinase proteins share approximately 50% sequence homology and are 
membrane bound by a single transmembrane segment (Table 2). D1 and D3 are 
located in the cellular membrane with the catalytic region in the cytosol whilst D2 is 
located in the endoplasmic reticulum membrane again with catalytic region in the 
cytosol [12]. Deiodinase 1 is coded by DIO1 gene located on chromosome 1 p32-p33. 
The D1 activities can be potentiated by T3 and selenium, and inhibited by cytokines 
TNF-α, IL-1β, interferon-γ and fasting state. Deiodinase 2 is coded by DIO2 gene 
located on chromosome 14q24.3. Its action is enhanced by cold exposure, 
norepinephrine, isoproterenol, insulin and glucagon; and inhibited by growth hormone. 
The deiodinase 3 gene is located on chromosome 14q32. It is found predominantly in 
brain and skin. Elevated thyroid hormone, sex steroid level and critical illness have 
been associated with high D3 activity. Other nondeiodination metabolism 
pathways of thyroid hormones have been described, and include ether bond
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cleavage [13], deamination/decarboxylation of the alanine side chain, 
glucuronidation and O-methylation [14, 15].  
Table 2: Type of deiodinases with its locations and functions 
Type Location Function 
Deiodinase 1 Liver, kidney, thyroid, pituitary Deiodinate either 
outer (5’) and 
inner (5) tyrosyl 
residues 
Deiodinase 2 Many tissues including bone, skin, skeletal 
muscle, CNS, fat, thyroid, pituitary, placenta, 
vascular smooth muscle 
Major activating 
enzyme 
Deiodinate the 
outer (5’) tyrosyl 
residues  
Also degrade rT3 
Deiodinase 3 CNS, skin and placenta Major inactivating 
enzyme  
Deiodinate the 
inner (5) tyrosyl 
residues 
Thyroid hormone action 
Thyroid hormones regulate a wide range of human biological and pathological 
activities. They play a crucial role in the foetal growth and development of the nervous 
system and also in the later part of childhood. In adulthood, thyroid hormones are 
primarily responsible for regulating metabolism (temperature, carbohydrates, lipids, 
protein) and also have an effect on mental status and bone turnover. 
Thyroid hormone exerts its effects via its nuclear receptors. They are members of a 
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large family of nuclear receptors that include those of the steroid hormones. They 
function as hormone-activated transcription factors and modulate gene expression. 
In the absence of thyroid hormone, thyroid hormone receptors usually bind DNA 
leading to transcriptional repression. Hormone binding is associated with a 
conformational change in the receptor that causes it to function as a transcriptional 
activator. Human thyroid hormone receptors are encoded by two genes, designated 
 and  and located on chromosome 17 and 3 respectively [16, 17].  
Like other nuclear receptors, thyroid hormone receptors consist of three functional 
domains: 
1. A transactivation domain at the N-terminus that interacts with other 
transcription factors and forming complexes which can activate or suppress 
transcription.  
2. A DNA-binding domain (DBD) that binds to sequences of promoter DNA 
known as thyroid response elements (TRE). 
3. A ligand-binding domain (LBD) and dimerization domain at the C-terminus. 
As shown in Figure 3 there is considerable variation among transactivation and 
ligand-binding domains. The -2 isoform has a unique C-terminus consisting of 122 
amino acids that replace part of LBD and does not bind triiodothyronine (T3). 
Therefore, -2 may act as inhibitor of TH action by competing for binding to TREs. 
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Figure 3: The different isoforms of thyroid receptors depicting highly conserved DNA binding 
(DBD) and Ligand binding domain (LBD) but marked divergence in terms of transactivating 
domain. 
 
Currently, four different thyroid hormone receptors are recognized suggesting an 
extraordinary level of complexity of thyroid hormone effects. These are: TR-1, -2, 
-1 and -2. TR-1 and -1 proteins are expressed in almost all tissues with TR-1 
having highest expression in the brain, heart, brown fat and muscle. TR -1 is highest 
in the liver and kidney. TR-2 is highest in the brain and testis with TR -2 is 
predominantly located in the anterior pituitary and hypothalamus. 
Thyroid hormone receptors bind to thyroid or T3 response elements (TRE). A TRE is 
composed of two or more AGGTCA "half sites". The half sites of a TRE can be 
arranged as direct repeats, palindromes or inverted repeats [18]. Thyroid hormone 
receptors can bind to a TRE as monomers, as homodimers or as heterodimers with 
the retinoid X receptor (, , ) with heterodimer being the major forms of the 
receptors. The TR can exist in a ligand-free state: where T3-free receptor/RXR 
heterodimer complex interacts with a group of corepressor molecules which has 
histone deacetylase activity (HDA). This forms a compact, "turned-off" conformation 
of chromatin leading to repression of gene transcription. In the ligand-bound state, 
the TR/RXR heterodimer complex binds to a group of coactivator proteins. This turns 
on histone transacetylase (HAT) activity, which imposes an open configuration on 
adjacent chromatin leading to gene transcription. Thyroid hormone resistance 
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syndrome has been identified in humans whereby they are clinically euthyroid but 
have elevated thyroid hormone with inappropriately normal TSH. It is an autosomal 
dominant disorder due to mutation in the carboxyl terminus of the TR. The mutation 
is mostly contained within 3 hotspots in the LBD and adjacent hinge region. The 
mutation renders TR less able to bind to thyroid hormone or leads to abnormal 
interaction with one of the cofactors involved in TH action [19, 20]. Recently, a 
mutation in TRA gene has been identified leading to mutant TR-1 and -2 proteins 
[21]. These patients have a distinct phenotype (macrocephaly, thickened calvarium, 
broad faces, skin tags, motor dyspraxia, slow speech), normal thyroid function test 
but low T4:T3 ratio. 
 Disorders of thyroid gland 
Thyroid disorders are very common and tend mainly to occur in women. About 1 in 
20 people suffer from some kind of thyroid disorder. Clinical presentations of thyroid 
disorders are commonly a result of lack of thyroid hormone secretion 
(Hypothyroidism) or excessive thyroid hormone secretion (Hyperthyroidism). 
 Hypothyroidism 
Due to heterogeneous symptoms and signs of hypothyroidism the diagnosis of 
hypothyroidism relies heavily upon laboratory tests. Primary hypothyroidism is 
defined by a low serum free thyroxine (T4) concentration with elevated serum thyroid-
stimulating hormone (TSH) concentration. As the name suggests the ‘primary’ 
indicates that the disorder is due to failure of the thyroid gland. Secondary 
hypothyroidism is characterized by a low serum T4 concentration and a normal or low 
serum TSH concentration. Subclinical hypothyroidism is defined by a normal free T4 
concentration in the presence of an elevated TSH concentration above the normal 
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reference range and up to 10 mu/L. The prevalence of hypothyroidism using National 
Health and Nutrition Examination Survey data (NHANES III) is around 4.6 percent 
with the majority of this contributed by subclinical disease (4.3%) and smaller 
contribution by overt hypothyroidism (0.3%). Serum TPO autoantibody (please see 
below) concentrations are elevated in 11 % of this population. Whilst the Whickham 
survey revealed the UK prevalence of overt hypothyroidism of 0.1-2% [22]. 
 Causes of hypothyroidism 
Primary hypothyroidism may be caused by disease or treatment that destroys the 
gland itself. Worldwide iodine deficiency is still a major cause of hypothyroidism. In 
iodine sufficient areas, autoimmune thyroiditis is the commonest cause. Other causes 
of hypothyroidism are depicted in Table 3.  
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Table 3: Causes of hypothyroidism 
Primary hypothyroidism 
Chronic autoimmune thyroiditis 
Iatrogenic e.g. Thyroidectomy 
Radioiodine therapy or external irradiation 
Iodine deficiency or excess 
Drugs – iodine, thionamides, lithium, amiodarone, interferon-alfa, interleukin-2, 
perchlorate, tyrosine kinase inhibitors 
Infiltrative diseases – amyloidosis, scleroderma, fibrous thyroiditis, 
hemochromatosis, sarcoidosis 
Congenital thyroid dysgenesis, or defects in thyroid hormone synthesis 
Transient hypothyroidism 
Painless (silent, lymphocytic) thyroiditis or post-partum thyroiditis 
Subacute granulomatous thyroiditis 
Subtotal thyroidectomy 
Following radioiodine therapy for Graves' hyperthyroidism 
Following withdrawal of suppressive doses of thyroid hormone in euthyroid 
patients 
Central hypothyroidism 
Pituitary disease 
Hypothalamic disease 
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 Clinical manifestations of hypothyroidism 
Clinical symptoms of hypothyroidism are heterogeneous but most patients with overt 
hypothyroidism will have symptoms and signs of hypothyroidism. On the other hand, 
patients may have minimal symptoms and signs, or at the other extreme, may present 
as myxoedema coma. Table 4 illustrated clinical manifestation of hypothyroidism. 
Table 4: Common symptoms associated with hypothyroidism. 
Symptoms of hypothyroidism 
Fatigue 
Lethargy 
Cold intolerance 
Weight gain 
Mental sluggishness 
Depression 
Constipation 
Hoarseness 
Dry skin 
Reduced appetite 
Menorrhagia 
Arthralgia 
Myalgia 
Paraesthesia 
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 Hyperthyroidism  
The term hyperthyroidism refers to overproduction of thyroid hormones while 
thyrotoxicosis refers to a clinical state that results from elevation of thyroid hormones 
in the blood stream from any cause [23]. From the NHANES III survey, 
hyperthyroidism was found in 1.3 % with 0.5 percent overt and 0.7 % subclinical [24]. 
The prevalence of overt hyperthyroidism from the Whickham survey is approximately 
the same around 1.3-1.9% [22]. 
The diagnosis of hyperthyroidism is based upon thyroid function tests with most 
patient having high free T4/T3 and suppressed TSH. Some patients may have only 
elevation in T3 (and suppressed TSH) due to an increase in thyroidal secretion of T3 
and peripheral conversion of T4 to T3. This is called T3 thyrotoxicosis. Some 
hyperthyroid patients may have elevated T4 only with normal T3. This may be seen 
in patients with intercurrent illness whereby there is a reduction in extra thyroidal 
conversion of T4 to T3 due to reduced deiodinase activity. Upon recovery, these 
patients will subsequently have T3 elevation. With currently used sensitive assays, 
patients with minimal or no symptoms may present with suppressed TSH and normal 
T4 and T3. This is called subclinical hyperthyroidism. Very rarely patients will have 
elevated T4/T3 with non-suppressed TSH either due to TSH secreting pituitary 
adenoma or thyroid hormone resistance.  
 Causes of hyperthyroidism 
The commonest cause of hyperthyroidism in any age group is Graves’ disease 
followed by toxic multinodular goitre which is also the commonest cause in the older 
age group. Graves’ disease will be discussed in detail below. A toxic nodular goitre 
(TNG) or Plummer's disease is a thyroid gland that contains autonomously 
functioning thyroid nodules, with resulting hyperthyroidism. The thyroid production is 
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independent of TSH and thyroid stimulating antibodies. It represents a spectrum of 
pathology ranging from a single hyperfunctioning nodule (toxic adenoma) to multiple 
hyperfunctioning nodules (toxic multinodular gland). The word ‘Toxic’ in thyroid terms 
means hyperthyroid state. It was first described by Dr. Henry Plummer in 1913. The 
hyperfunctioning nodule/s are readily seen on radioiodine or technetium scan with 
classical circumscribed increased uptake “hot nodules” on the imaging. In toxic 
multinodular goitre there may also be areas of reduced uptake or “cold nodules”. 
The majority of these nodules are caused by somatic mutations leading to constitutive 
activation of TSHR G protein coupled receptor in 20-80% and less frequently in the 
adenylate cyclase-stimulating G alpha protein [25]. Signs and symptoms of TNG are 
similar to those of other types of hyperthyroidism. 
Other causes of hyperthyroidism can be divided into normal or high radioiodine 
uptake against lower uptake. Table 5 illustrates causes of hyperthyroidism.  
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Table 5: Causes of hyperthyroidism 
Hyperthyroidism with a normal or high radioiodine uptake 
Autoimmune  
Graves' disease 
Hashitoxicosis 
Autonomous thyroid tissue  
Toxic adenoma (some may be due constitutively active mutant TSHR) 
Toxic multinodular goitre 
TSH-mediated hyperthyroidism 
TSH secreting pituitary adenoma 
Non-neoplastic TSH-mediated hyperthyroidism 
Human chorionic gonadotropin-mediated hyperthyroidism 
Hyperemesis gravidarum 
Trophoblastic tumour 
Choriocarcinoma 
Familial gestational hyperthyroidism (Mutant TSHR sensitive to HCG) 
Hyperthyroidism with low radioiodine uptake 
Thyroiditis 
Postpartum thyroiditis 
Painless thyroiditis (silent thyroiditis, lymphocytic thyroiditis) 
Subacute granulomatous (de Quervain's) thyroiditis 
Amiodarone (Type II) 
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Radiation thyroiditis 
Exogenous thyroid hormone intake 
Excessive replacement therapy 
Intentional suppressive therapy 
Factitious thyrotoxicosis 
Ectopic hyperthyroidism 
Struma ovarii 
Metastatic follicular thyroid cancer 
Thyroid adenoma infarction 
 
 Clinical manifestations of hyperthyroidism 
The diagnosis of hyperthyroidism is usually evident in patients with typical clinical and 
biochemical manifestation of the disease.  Some other patients, especially the elderly, 
may have minor clinical signs, but definite biochemical hyperthyroidism. Majority of 
the patients will have symptoms as depicted in Table 6. Weight loss is a very common 
complaint due to the hypermetabolic states but some patients may present with 
weight gain due to excessive appetite stimulation. 
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Table 6: Symptoms of hyperthyroidism 
Symptoms of hyperthyroidism 
Anxiety 
Tremor 
Hyperactivity 
Palpitation 
Increased appetite 
Weight loss 
Increase sweat 
Heat intolerance 
Myopathy 
Amenorrhea/Oligomenorrhea 
Increase in bowel frequency 
 
 Graves’ disease 
Graves’ disease (GD) which is the commonest cause of hyperthyroidism is caused 
by thyroid-stimulating autoantibodies (TSAB) that bind to the thyroid stimulating 
hormone (TSH) receptor (TSHR) on thyroid follicular cells causing excess production 
of thyroid hormone as well as thyroid growth causing goitre. Although the exact 
mechanism leading to its development is unknown, genetic and environmental factors 
are thought to be involved. GD prevalence is about 0.5 % with females being affected 
7.5 times more often than men and peak incidence between 30-50 years old [26]. It 
is named after an Irish physician named Robert Graves who in his lecture in 1835 
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described a patient of his as “newly observed affectation of the thyroid gland in 
female” [27]. A decade prior to this, a Welsh physician Caleb Hillier Parry (1755-1822) 
gave a clinical picture of GD in 1786. This was not published but subsequently 
reported in his posthumous collection of unpublished writings in 1825 [28]. However 
going back 800 years ago in 12th century, a Persian physician Sayyid Ismail al-Jurjani 
has noted association of exophthalmos with goitre in his "Thesaurus of the Shah of 
Khwarazm", the major medical dictionary of its time [29]. In Europe, it is known as 
Basedow’s disease/syndrome after description by a German physician Karl Adolph 
von Basedow [30]. Other less common names include Parry’s disease, Begbie’s 
disease (named after Dr. James Begbie [31]) and Flajani’s disease after a description 
by 2 Italian physicians Giuseppe Flajani (1741-1808) in 1802 and Antonio Giuseppe 
Testa (1756-1814) in 1810 [32]. Clinically, patients present with hyperthyroidism 
alone but may be one of 3 pathognomonic features of GD namely exophthalmos, nail 
clubbing or pretibial myxoedema. The latter 2 are very rare phenomena. The thyroid 
is usually diffusely enlarged. The histology of the thyroid gland in patients with GD is 
characterized by diffuse hyperplasia and hypertrophy of follicular cells with retention 
of lobular architecture and prominent vascular congestion. Colloid is pale with 
scalloped margins. There may be lymphocytic infiltration in which the majority of the 
lymphocytes are T cells but B cells may be present.  
 Thyroid autoantibodies 
Alterations in thyroid gland function result from the action of either stimulating or 
blocking autoantibodies on cell membrane receptors; or destructive nature of the 
autoantibodies on thyroid follicular cells. Three principal thyroid autoantigens are 
involved in autoimmune thyroid disease. These are TPO, TG and TSHR. These 
antigens will be further discussed in GO section below. Both TPO (TPOAB) and TG 
(TGAB) antibodies are found in 30% to 75% of GD patients [33, 34]. TPOAB is 
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normally found to be associated with Hashimotos’s, atrophic and post-partum 
thyroiditis.  It appears to be involved in the tissue destructive processes associated 
with the hypothyroidism. The appearance of TPOAB usually precedes the 
development of hypothyroidism. Some studies suggest that TPOAB may be cytotoxic 
to the thyroid via complement mediated pathway [35]. The role of TGAB is less clear. 
Rather than being pathogenic, TGAB presence probably reflects the destructive 
process in thyroid gland exposing TG leading to the formation of TGAB.  
In 1956, GD sera was found to contain an immunoglobulin described as a long-acting 
thyroid stimulator (LATS) that inhibited the binding of radiolabelled TSH to thyroid 
membranes, suggesting that such activity was due to the presence of TRAB [36, 37]. 
More detail about TRAB will be provided below. Two most commonly used methods 
of assessing TRAB are competition assays and bioassays. The competition assays 
employ competition by TSHR autoantibodies for ligand (TSH or monoclonal antibody) 
binding to the TSHR. The ligand may be radiolabelled or tagged with an enzyme or 
fluorescent dye. This is also known as TBII (TSH-binding inhibitor immunoglobulin) 
assay. The assay quantifies patient’s immunoglobulins that inhibit the binding of TSH 
to TSHR therefore it measures both TSAB and TSHR blocking antibodies (TBAB). 
Bioassays involve culturing thyroid cells or nonthyroidal cells expressing the 
recombinant human TSHR. They measure TSHR stimulating antibodies through their 
effect on cyclic adenosine monophosphate (cAMP) production in a cell line 
transfected with TSHR. TBAB is also measured using the bioassay by measuring the 
ability of patient's IgG or serum to inhibit TSH activity by 30%-40% depending the 
local laboratory reference range. Of note neither of the assays measure neutral TSHR 
antibodies, i.e. antibodies which bind the TSHR but have no biological activity and do 
not inhibit TSH binding. These currently used assays are also unable to measure 
antibodies that stimulate different pathways as described by Morshed et al [38].  
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TRAB can stimulate different subtypes of G proteins including Gs with cAMP 
pathways leading to an increase in NIS synthesis/activity and also thyroid hormones 
synthesis/secretion. TRAB also stimulate Gq and the PKC pathways leading to cell 
proliferation [39].  Weetman et al suggested TSAB are predominantly immunoglobulin 
G1 (IgG1) subclass suggesting that they are oligoclonal or possibly monoclonal in 
origin in contrast to TPOAB and TGAB which are polyclonal [40]. In terms of clinical 
utility, TRAB levels are frequently used to diagnose GD in the absence of extra 
thyroidal manifestations. Its predictive value for GD relapse remains questionable [41] 
possibly due to the presence of TRAB having varying biological activity and which 
may not be detected in all assays.  
 Risk factors for GD  
Several factors that predispose to GD have been proposed. As mentioned above, the 
fact that GD is more common in females and age group of 30-50 years of age 
suggests there are hormones or age related factors that contribute to the 
susceptibility. Females are known to handle infections differently than males and 
respond better to infection and vaccine than males [42]. These protections are partly 
mediated by IL-4-mediated T helper type  2 (Th2) response by inhibition of IFN-γ 
production and by increasing anti-inflammatory T-cell immunoglobulin mucin-3 (Tim-
3) and T regulatory (Treg) cell populations [43]. Oestrogen has been shown to 
increase production of antibody, IL4, IL10 and TGF-. At high levels, such as in 
pregnancy, oestrogen inhibits T cells with the opposite effect at low level [44]. This 
explains why most autoimmune diseases go into remission during pregnancy and a 
similar phenomenon is observed in GD patients. Some patients even come off their 
anti-thyroid drug during pregnancy. Another explanation is likely due to suppression 
of the immune system in order to avoid rejecting the foetus through generation of 
specific regulatory T cells [45]. On the other hand, the postpartum period is well 
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known to be associated with GD onset or relapse [46]. Autoimmune diseases in males 
are characterized by acute inflammation, the appearance of autoantibodies, and a 
proinflammatory Th1 immune response whilst in female, these are associated with 
more with chronic, fibrotic Th2-mediated pathology and Th17 responses [47].  
There is evidence of GD clustering in families suggesting there must be genetic 
susceptibility in these individuals.  Although this is not an absolute risk factor but may 
collectively contribute towards the development of GD. Twin studies show that there 
is higher concordance of autoimmune thyroid disease (AITD) in monozygotic twins 
than dizygotic in which genetics have been suggested to explain up to 75% of the 
total phenotypic variance in GD [48-50]. Known genes that predispose patients to GD 
include human leucocyte antigen (HLA), cytotoxic T lymphocyte-associated 4 
(CTLA4), forkhead box P3 (FOXP3), protein tyrosine phosphatase nonreceptor 
22 (PTPN22) and the TSHR itself. Patients with GD express HLA-B8 more often than 
controls [51]. A North America study found that HLA-DRB1*08 and DRB3*0202 were 
associated with GD whilst DRB1*07 was protective [52]. This reflects the way the 
antigen being presented influences the autoimmune process. CTLA4 is expressed by 
activated T cells and transmits an inhibitory signal to T cells. CTLA4 is homologous 
to CD28 on T cells, and both molecules bind to CD80 and CD86 on antigen-
presenting cells. CTLA-4 binds CD80 and CD86 with greater affinity than CD28. 
CTLA4 transmits an inhibitory signal to T cells whilst CD28 transmits a stimulatory 
signal [53]. An increase in frequency of the G (alanine) allele of CTLA-4 was seen in 
GD compared with control subjects (odds ratio = 1.58 corrected P<0.0002) [54]. 
FOXP3 is a regulatory factor for the development and function of Treg cells. Certain 
polymorphisms in FOXP3 gene have been associated with GD [55, 56]. PTPN22 is 
involved in limiting the adaptive response to antigen by dephosphorylating and 
inactivating the T cell receptor (TCR). In lymphocytes, PTPN22 physically associates 
with CSK (c-Src kinase which is an important suppressor of the Src family kinases 
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that mediate TCR signalling). TSHR polymorphisms in the intron 1 gene region also 
have been shown to be associated with GD [57].  It is yet unknown how this region 
contributes to the susceptibility for GD but speculatively might be involved in 
generating TSHR splicing variant or microRNAs.  
Multiple clinical studies support associations between cigarette smoking and both GD 
and GO. For example, Smoking carries a risk for GD with an odds ratio of 1.9 which 
can increase to 2.6 if the patient smokes more than 25 cigarettes per day [58, 59]. A 
meta-analysis from 8 studies showed an odds ratio for GD of 3.30 (95% CI, 2.09 to 
5.22) among current smokers as compared with persons who had never smoked. In 
ex-smokers there was no significant excess risk of Graves' disease (OR=1.41, 95% 
CI: 0.77-2.58) [60] suggesting smoking cessation can reduce the risk of GD. A 
stronger correlation was noted with regard to the association of smoking with GO and 
will be discussed below. The proposed mechanism on how smoking contributes to 
the pathogenesis of GD include structural alterations in TRAB, making it more 
immunogenic, enhancement of immunologic responsiveness to factors responsible 
for the initiation of GD or impairment of tolerance to thyroid autoantigens [61].  
Micro-organisms have long been thought to be implicated in GD, e.g. Yersinia 
enterocolitica has TSHR-like structures on its surface which have been suggested to 
trigger GD. This was elegantly demonstrated by Banga’s work on murine monoclonal 
TSAB [62]. His group raised a germline precursor of TSAB which did not react with 
the TSHR, but instead binds the porins of Yersinia enterocolitica. The group also 
raised recombinant TSAB chimeras with heavy and light chain variable regions of 
mature TSAB. Only TSAB chimeras with a heavy chain recognizing the TSHR had 
TSHR stimulating properties. The data suggested early precursor B cells are 
expanded by Yersinia enterocolitica porins. These subsequently underwent somatic 
hypermutation to acquire a cross-reactive pathogenic response to TSHR. It also 
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showed the role of variable region of heavy chain in TSHR recognition. 
Patients often reported stressful events prior to onset of GD. Using toxic nodular 
goitre as a control, Matos-Santos et al. has reported that there were higher stressful 
life events within 1 year prior to the GD onset [63]. Similar findings were reported by 
an Italian study [64]. Various drug treatments can induce GD. For example Interferon 
alpha treatment has been associated with autoimmune thyroid disease for both 
Hashimoto’s thyroiditis and GD [65]. Between 10-30% multiple sclerosis (MS) patient 
on Alemtuzumab a monoclonal antibody against the T cell antigen CD52 developed 
GD. This will be discussed further below [66, 67].  
 Immune mechanism 
There are several mechanisms known to be operated by our immune system in order 
for it to distinguish between self and foreign antigens and to make the decision 
between tolerance and immunity. One of the mechanisms is central tolerance by 
clonal deletion (reviewed in [68]). During lymphocyte development in the thymus or 
bone marrow for T and B lymphocytes respectively, cells that bind to self-MHC 
receptors are positively selected for maturation, those that do not die by apoptosis. 
Subsequently, these maturing lymphocytes are exposed to self-antigens presented 
by antigen presenting cells in these organs. Any cells that recognise self-antigens will 
be elimination or inactivated (anergy) before they develop into fully immunocompetent 
lymphocytes a process known as negative selection. Some of weakly self-recognizing 
T cells are not eliminated but differentiated into natural regulatory T cells (nTreg cells) 
which exert peripheral tolerance to any autoreactive T cells. Peripheral tolerance 
develops after T and B cells mature and enter the systemic circulation, peripheral 
tissues and lymph node [69]. Not all self-antigens are expressed in the thymus and 
bone marrow so additional mechanisms for tolerising autoreactive mature T and B 
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cells are necessary. In these cases, naive CD4+ helper T cells can be differentiated 
under influence of appropriate cytokines into induced Treg cells (iTreg cells). 
Peripheral deletion of CD4+ T cells seems to be dependent on signalling through Fas 
ligand and one of the molecular mechanisms responsible for inducing peripheral 
clonal anergy is signalling via CTLA4 molecule. There are different theories for 
breaking tolerance which include molecular mimicry resulting in cross-activation; 
epitope spreading- autoimmune responses to endogenous epitopes secondary to the 
release of self-antigens during an autoimmune/ inflammatory response; and 
bystander activation (adjuvant effect) [70].  
There are various mechanisms that have been suggested as the means by which 
infections can initiate and/or exacerbate autoimmune diseases. One mechanism is 
molecular mimicry. This is where a foreign antigen shares sequence or structural 
similarities with self-antigens. This is then sufficient enough to result in the cross-
activation of autoreactive T or B cells by that foreign-derived peptides. However 
current evidence for molecular mimicry in GD is very weak. Some GD sera have been 
found to interact with plasmid-encoded proteins of enteropathogenic Yersinia 
enterocolitica [71]. In Denmark discordant GD twin studies, GD twin has higher odds 
of prior Yersinia enterocolitica infection in this case measured by IgA or IgG towards 
Yersinia enterocolitica outer membrane protein [72]. Against this is the fact that the 
majority of patients who have had the infection do not develop GD. 
Bystander activation as a mechanism leading to autoimmune disease has gained 
support through the use of experimental animal models such as for type 1 DM [73]. 
In this case local insult must have happened to thyroid follicular cells by any means 
(infections or immune attacks). This local reaction leads to inflammation, tissue 
damage, and the release of antigen/s (TSHR, IGF1R etc.) resulting in the re 
stimulation of resting autoreactive T cells. This is further supported by observation 
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that the normal thyroid gland does not express HLA class II molecules but in GD 
patients it does. This can be induced by viral infections of thyroid follicular cells, or it 
may be induced by cytokines such as IFN- produced by T cells [73]. Molecular 
mechanisms underlying breakdown of the immune-tolerance to TSHR are not fully 
understood. 
 In vivo models of GD 
Most efforts have used TSHR-induced models in BALB/c mice and a wide range of 
GD and GO-like models have been described. Fibroblast transfected with full length 
TSHR with MHC class II molecule has been used successfully to induce GD in AKR/N 
mice [74]. Using chimeras of TSHR/ leutropin-choriogonadotropin receptor (LH-
CGR), TBII  but not TSAB was induced with TSHR lacking C-terminal part of ECD but 
not with the construct lacking N-terminal part [75]. Prabhakar’s group later showed 
that immunization with TSHR ECD is sufficient to induce GD [76].  
Whilst there were some successes in inducing GD, inducing GO has proven to be 
challenging. The first animal model with ocular changes suggestive of GO involved 
primed T cells transfer from BALB/c and NOD mice previously immunized with either 
TSHR extra cellular domain as a maltose-binding protein fusion (ECD-MBP) or by 
genetic immunization using cDNA for the full length human TSHR cloned into a 
eukaryotic expression vector [77, 78]. The latter was injected into muscle and 
assumed to be taken up by the muscle and expressed/presented on the cell surface. 
The T cells were further primed in vitro using ECD-MBP before being injected into the 
recipient mice. In approximately 20% of BALBc mice receiving TSHR primed cells the 
orbits appeared to have GO phenotypes. Different mouse strains exhibit different 
phenotypes when immunized with TSHR. In the BALBc mice, thyroid lymphocytic 
infiltration comprised B cells and immunoreactivity for IL-4 and IL-10 indicating 
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predominantly Th2 cell response. In contrast, in the NOD mice thyroids there were 
CD8+ T cells, and immunoreactivity for interferon gamma indicating Th1 response. 
None of the NOD recipients of primed and non-primed cells displayed GO. 
Unfortunately, the model could not be reproduced here in Cardiff despite using similar 
protocol, chow, housing and mice supplier [79] indicating that other factors, most likely 
the microbial environment, modulate the induced immune response. Recent progress 
has been made by Banga’s group using in vivo electroporation of TSHR A-subunit 
plasmid into female BALB/c mice at 2 different locations. The group was able to 
reproduce functional antibodies to TSHR and antibodies to IGF-1 receptor α-subunit 
with GO histopathological evidence of adipogenesis, fibrosis, and muscle damage in 
both locations. In vivo MRI scans of mouse orbital region demonstrated evidence of 
orbital muscle hypertrophy and proptosis of the eye. Additionally, eyelid 
manifestations of chemosis, including congested and dilated orbital blood vessels, 
were apparent. Interestingly, there was no inflammatory infiltrate in orbital tissue 
suggesting “hit-and-run” immune-mediated inflammatory event [80, 81].  
We can conclude from the animal models that TSAB can be generated with difficulty 
hence hyperthyroidism is rarely apparent. Since most researchers employ the human 
TSHR to induce disease, the sequence difference between the 2 species might 
explain this difficulty. One group has employed the adenovirus expressing mouse 
TSHR A subunit in wild-type BALB/c and B6 mice but failed to generate any TSHR 
antibodies even with Treg depletion [82] suggesting the difficulties in breaking mouse 
TSHR tolerance. However, the group managed to generate TSAB in TSHR KO 
BALB/c mice which further supports the concept that these mice were unable to 
develop central tolerance to the TSHR due to lack of thymic expression of the TSHR.  
As Graves-like hyperthyroidism cannot be expected to occur in TSHR KO mice, the 
same authors later performed adoptive transfer of splenocytes from the immunized 
TSHR KO mice to immunodeficient athymic nude BALB/c mice. This successfully 
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induced transient TSAB and hyperthyroidism (less than 4 weeks) in a small proportion 
of the mice (20%) and later was followed by development of TBAB and 
hypothyroidism. Interestingly macrophage infiltration was observed in the retrobulbar 
muscles and adipose tissues in 2 out of 9 mice which were TRAB positive but 
euthyroid throughout the experiments [83]. 
There is an induced human model of GD/GO which develops in multiple sclerosis 
patients treated with Alemtuzumab, a monoclonal antibody to CD52, resulting in 
elimination of >95% of circulating lymphocytes [66]. During immune reconstitution, B 
cells almost double but T cells at about 30-40% of pretreatment values. Approximately 
one third develop GD and a fifth of these have GO. GD patients displayed significantly 
higher CD8 lymphocyte counts 15-18 months later and lower memory: naive T cell 
ratio. Similar immune reconstitution phenomenon was noted from the report of three 
cases of GD after highly active antiretroviral therapy in patients with HIV infection [84]. 
These cases have given us a unique way of looking at mechanism of breakdown in 
self-tolerance in GD/GO. 
 Thyrotropin receptor (TSHR) 
As mentioned above, the autoantigen in GD is the TSHR a member of the G protein 
coupled receptor family which in the thyroid signals mainly through Gs, although other 
cascades may also be involved. Virtually all patients with GD have TRAB indicating 
that TSHR probably is the most logical candidate autoantigen. TSHR belongs to a 
large family of G protein–coupled receptors and is encoded by 10 exons spread over 
58 kilobases located on long (q) arm of chromosome 14 at position 31 (from base pair 
80,954,989 to base pair 81,146,302) (Figure 4) [85, 86].  
 31 
 
Figure 4: TSHR gene location on chromosome 14 at position q31.1 (left picture) and 
corresponding 10 exons and amino acid positions. Adapted from 
http://atlasgeneticsoncology.org/Genes/TSHRID290ch14q31.html 
  
The TSHR expression is regulated by a TATA-less promoter containing binding sites 
for GABP (GA Binding protein- named due to the fact that it binds to DNA sequences 
rich in guanine and adenine) [87], TTF1 (Thyroid transcription factor-1) [88], CREB 
(cAMP-response element binding protein) [89], ATF2 (Activating Transcription Factor 
2) [90], TR/RXR (Thyroid hormone receptor/retinoid X receptor) [91], SSBP (single 
strand binding protein)  and ICER (inducible cAMP early repressor) [89] (Figure 5). 
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Figure 5: TSHR promoter with known regulatory elements with approximate locations. cAMP-
response elements (CRE) is a constitutive enhancer and can be activated by CREB (CRE 
binding protein) or ATF2 (Activation Transcriptor 2) and repressed by ICER (inducible cAMP 
early repressor). This binding can be modulated by SSBP (single strand binding protein). TR 
(Thyroid hormone receptor) and RXR (retinoid X receptor) overlaps with CRE binding sites 
and can repress the TSHR transcription. There are 2 binding sites for TTF1 (Thyroid 
transcription factor-1). TTF1, TR, RXR are modulated by phosphorylation; GAPD is modulated 
by methylation and CRE is modulated by both. Modified from Garcia-Jimenez et al [92]. 
 
The TSHR gene codes for 764 amino acid protein consisting of seven transmembrane 
segments connected by three extra- and three intracellular loops. It contains two 
subunits; α/A subunit, corresponding to the extracellular domain (ECD) (residues 21-
415) coded by first 9 exons plus the first 300 base pairs of exon 10 and, the β/B 
subunit, is mainly the transmembrane domain (TMD) (residues 416-764) encoded by 
the rest of exon 10 [90]. These A and B subunits are formed by sequential 
intermolecular cleavage by uncharacterized metalloprotease enzyme. This generates 
a C peptide of approximately 50 amino acids [93-95]. The intermolecular cleavage is 
almost complete in human thyroid tissue but full length uncleaved TSHR can be found 
on cell surface in L cells stably transfected with the TSHR receptor and also 
unprocessed mannose-rich monomeric precursor intracellularly [96]. The finding of 
high ratio of TSH B to A subunits (3:1) in thyroid membrane preparation suggests 
shedding phenomena of the TSHR  A subunits [97] which can be found in the 
circulation [98]. The process is believed to be achieved by disulphide bridge break 
down by enzyme protein disulphide isomerase [99].  
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Figure 6: Schematic drawing of TSHR peptide anchored to the cell membrane by B subunit. 
The full length TSHR is derived from 21-764, extra cellular domain 21-415 amino acids with 
the first 20 amino acids as signal peptide. List of anti-TSHR antibodies with corresponding 
amino acid position (in brackets) in which the antibodies were raised. ECD = extracellular 
domain. Modified from Rapoport et al [100]. 
 
The Beta subunit of TSHR is constitutively active and the presence of TSH ECD [101] 
and interaction with trans membrane domain 6 [102] are critical for the maintenance 
of inactive state. TSHR binding sites have been studied through deletion-mutation 
analysis and antibodies panel (Figure 6) [103, 104]. These studies indicate that there 
are multiple discontinuous TSH binding regions mainly located in the A subunit and 
one segment (aa 381-385) for B subunits.  
One of special features of TSHR is that it composed of two cysteine clusters flanking 
nine leucine-rich repeats (LRRs). The LRRs form a succession of -strands and -
helices organized into a horseshoe-shaped structure.  Each of LRR is made up of 20 
± 24 amino acids forming a -strands followed by an -helix [105]. These are 
arranged in such a way that -strands form a concave surface of the horseshoe and 
-helices form a convex surface of the receptor. It has been proposed that TSH 
interact with residues of the -strands on the  concave surface [105].  
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Figure 7: Alignment of the -strands of the nine LRRs of the TSHR ectodomain with the X 
residues are represented to better visualize the inner cusp of the ectodomain that putatively 
faces hormones and the possible interactions between side chains of these amino acids. 
Numbering starts from the first amino acid of the signal peptide of each receptor. Adapted 
from Smits et al [105]. 
 
The evidence that TSHR may exist in an oligomeric state is slowly gathering 
momentum and was initially provided by studies using antibodies [106] and more 
recently by fluorescence resonance energy transfer (FRET) technology [107].  The 
presence of dimerization influences TSHR behaviour. Unstimulated TSHRs has been 
shown to form oligomers [106] that return to the monomer state with TSH [108].  TSAB 
is proposed to favour formation of TSHR dimers whilst TSHR blocking antibodies, are 
unable to bring about this conformational change. After TSH binding, a constitutively 
oligomeric TSHR dissociates into active monomers (or dimers in TSAB binding case), 
which will be subsequently recruited to the lipid rafts to interact with G proteins 
thereby initiating the signalling cascade. 
 In the case of TSH, the signal is rapid and brief because of faster movement of 
monomers into the lipid rafts, in contrast to the retarded movement of the dimers. 
Multivalent blocking TSHR antibodies may cross-link the oligomers, thereby 
preventing them from dissociating and impeding their entry into lipid rafts [109].  
The dominant monomer has been suggested to exert a negative effect on the 
LRR1 LRR2 LRR3 LRR4  LRR5  LRR6 LRR7 LRR8 LRR9  
X1 Q55 S79 T104 K129 F154 L180 D203 S229 K250 
X2 T56 R80 H105 F130 I155 T181 A204 L230 E251 
L 
X3 K58 Y82 E107 G132 E157 K183 Y206 D232 I253 
L 
X4 I60 S84 R109 F134 T159 Y185 N208 S234 R255 
X5 E61 I85 N110 N135 D160 N186 K209 Q235 N256 	
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neighbouring monomer [110, 111].  On the other hand, if TSHR is present at low 
levels, it is less likely to form any kind of homo/heterodimer and so may activate 
different signalling cascades compared with cells undergoing adipogenesis where 
TSHRs are more abundant (will be described in more detail below).  To add to the 
complexity, several TSHR variants (TSHR_v) have been described [112, 113] which 
lack the transmembrane domain and if expressed as protein would lead to soluble 
receptor products which could serve as TSH/TRAB binding proteins or even as 
autoantigens. NCBI describes two alternatively spliced variants, TSHR isoform 2 
precursor (NM_001018036.1) and TSHR isoform 3 precursor (NM_001142626.1). 
According to NCBI (http://www.ncbi.nlm.nih.gov/ieb/research/acembly/) there are 
potentially 10 alternatively spliced variants, based upon cDNAs deposited in 
GenBank. These are derived from normal and neoplastic human tissues and cell 
lines. Currently, there is no evidence for protein expression of these splice variants. 
These will be discussed in more detail in chapter 4. 
1.9.5.1 TSHR distribution 
Initially thought to be thyroid specific, it is now clear that the TSHR is expressed in 
many other locations, predominantly adipose tissue. Several methodologies have 
been applied to investigate TSHR in fat including PCR, northern blot and functional 
studies. Using northern blot analysis and polymerase chain reaction, Cone et al have 
shown that TSHR mRNA was present in virtually all adipose tissue of the guinea pig 
but not in the retro orbital tissues [114]. This was later supported by in vitro study of 
human infant inguinal adipocytes obtained by collagenase digest. This showed the 
presence of TSHR in infant adipocytes [115] and that it is highly responsive to TSH 
and TSAB inducing lipolysis which can be blocked with blocking antibodies. 
Subsequently Feliciello et al were able to infer that TSHR transcripts are expressed 
in the human retro-orbital tissue [116] and was later confirmed by Crisp et al study by 
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northern blot analysis as 4.6 and 1.7kb transcripts [117]. The latter author also 
showed TSHR protein expression using immunohistochemistry [118]. TSHR 
expression was found to be increased during adipogenesis in rodents [119] and when 
human preadipocytes differentiate into mature adipocytes; indeed elevated TSHR 
expression in GO orbital fat is an indicator of ongoing adipogenesis [120]. The 
consensus is that in both rodents and humans, TSHR is expressed in any fat depot 
undergoing adipogenesis i.e. the lineage specific differentiation process in which new 
adipose cells are generated from mesenchymal stem cell precursors. Orbital fat 
derives from neural crest, unlike other adipose depots which originate in the 
mesoderm, consequently its regulation may differ from other depots as will be 
described later. 
1.9.5.2 TSHR intracellular pathways 
TSHR is known to activate mainly the Gs cAMP pathway but also activates several 
other G protein subtypes (Gi/o, Gαq/α11, and G12/13) [121, 122], non G protein 
pathways such as β-arrestin-1 [123]  and other signalling pathways [124, 125]. 
Classically, upon TSH binding to TSHR there is an exchange of GDP for GTP bound 
to G-protein alpha-s subunits, followed by dissociation of the beta/gamma 
heterodimers. G-protein alpha-s in turn activates all isoforms of adenylate cyclase. 
After stimuli, adenylate cyclase increases levels of cAMP in the cell and activates 
Protein kinase, cAMP-dependent (PKA) inactive complex which results in PKA 
activation. The activated PKA phosphorylates multiple downstream target proteins 
one of which is cAMP responsive element binding protein (CREB) which will bind to 
its receptors on the promoter region of the DNA exerting various gene transcription 
processes including expression of thyroglobulin (TG), thyroid peroxidase (TPO), 
sodium iodide symporter (NIS), and the thyroid transcription factors TTF1/NKx2.1, 
TTF2/FoxE1, and PAX [126, 127]. Every intermediary in the pathway described above 
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may additionally interact with different molecules belonging to other pathways.  
In human thyrocytes and rat FRTL-5, Gαq/α11 coupling stimulates Protein kinase C 
(PKC) pathways by generating phospholipase C (PLCβ). The PKC pathways has 
been associated with hyaluronan generation in GO [128]. The PKC pathways 
activation requires supraphysiological TSH concentrations [124, 129] although not all 
research agrees with this finding [130]. The PLC catalyses hydrolysis of 
phosphatidylinositols in the membrane yielding di-acyl-glycerol (DAG) and inositol tri 
phosphate (IP3) as second messengers. DAG directly stimulates PKC. IP3 increases 
cytosolic Ca+2 levels which act through a number of effectors including PKC itself 
[121, 131] and Nuclear factor of activated T-cells (NFAT) transcription factor protein. 
NFAT plays an important role on cytokine gene transcription regulation [132]. Calcium 
via calmodulin –a calcium sensor protein activates the serine/threonine phosphatase 
calcineurin (inhibited by ciclosporin and FK506). This in turn rapidly dephosphorylates 
NFAT proteins, resulting in a conformational change that exposes a nuclear 
localization signal leading to NFAT nuclear import [133]. In thyroid, the PLC-IP3-DAG 
pathway controls thyroid hormone production by activating production of H2O2 and 
subsequent iodination of thyroglobulin for thyroid hormone synthesis [134]. 
TSHR may also couple to Gαi1, which inhibits adenylyl cyclase and decrease cAMP 
levels whilst Gβγ dimers may induce multitudes of other pathways  which include 
adenylyl cyclases [135], PI3K/AKT (PKB)-FOXO [136] and PLC [137] pathways.  
 Extra thyroidal manifestations of GD 
GD also can be uniquely identified in clinical settings by its extra thyroidal 
manifestations. They are thyroid acropachy or clubbing, pretibial myxoedema and 
orbitopathy also known as Graves’ orbitopathy (GO).  
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1.9.6.1 Thyroid acropachy 
Thyroid acropachy is the least common manifestation of GD and characterized by 
digital clubbing, soft-tissue swelling of the hands and feet, and periosteal reaction with 
new bone formation. Rarely this can affect the midportion of the diaphysis of the 
phalanx and femur [138]. Its presence is normally associated with pretibial 
myxoedema and orbitopathy. It develops chronologically after the GD and GO onset. 
The skin can be pigmented and hyperkeratotic. It is often painless but some patients 
may have pain due to severe swelling [138]. It has similar pathological characteristic 
those of pretibial myxoedema [139].  
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1.9.6.2 Pretibial myxoedema  
Pretibial myxoedema is also a rare manifestation of GD. It occurs in approximately 
1.5% of GD and 6% of GO patients [140, 141]. It is also called localized myxoedema 
or thyroid dermopathy. Although commonly located in the pretibial area, it has been 
described in other locations including feet, nasal bridge [142] and traumatic areas 
such as shoulders [143] and surgical scars [144]. Histologically, skin biopsy shows a 
large amount of glycosaminoglycans especially hyaluronan in the dermis but not 
epidermis with some mononuclear cell infiltration and hyperkeratosis [145].  
Clinically it is characterized by bilateral, asymmetric, non-pitting scaly thickening of 
the skin as one or a few well-demarcated papules or nodules. The pretibial 
myxoedema is usually asymptomatic but some patients might complain of itchiness 
or even pain. It takes several months for the lesion to develop before stabilizing.  In 
some cases, it can regress spontaneously. In the worst case scenario it can develop 
into elephantiasis type of limbs [140]. The diagnosis of pretibial myxoedema is based 
upon the history and the characteristic appearance of the skin lesion; biopsy is rarely 
needed unless the diagnosis is uncertain. 
The indications for treatment include pruritus, local discomfort, or for cosmetic 
reasons. As per management of GO, normalization of thyroid function is needed by 
means of anti-thyroid drug or surgery. RAI is feared to worsen the myxoedema due 
to higher TRAB titre following the treatment. Smoking cessation and losing weight are 
also highly recommended. Nightly topical application of corticosteroids is the 
preferred initial treatment. For those who are not responding intralesional injections 
of triamcinolone acetonide has been tried with success in a small case series [146]. 
In elephantiasic form the use of compressive stocking has been found beneficial 
[147]. Some have recommended complete decompressive physiotherapy [148]. 
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 Graves’ orbitopathy  
Graves’ orbitopathy (GO), also known as thyroid eye disease (TED) usually occurs in 
people with Graves’ disease.  GO is a rare condition having an incidence of 
approximately 10-16 per million per year with the estimated prevalence of 2-4/10,000 
[149]. Approximately 25-50% of GD patients will have GO with the majority of patients 
presenting with concurrent thyrotoxicosis.  
 Clinical manifestations of GO 
Most of the signs and symptoms of GO are a direct consequence of expansion of 
intraorbital volume and the majority of patients present concomitantly with 
thyrotoxicosis. In about 20 percent of patients, GO precedes the onset of 
thyrotoxicosis by a number of months. Rarely the onset of GO and thyrotoxicosis can 
be separated by several years [150, 151].  In its mildest form GO causes irritation of 
the eye with excessive tearing, discomfort, and redness of the conjunctiva. Some 
symptoms are related to corneal exposure secondary to lid retraction or proptosis 
such as dry eyes, grittiness and photophobia. Most of these will be mistakenly treated 
for other conditions such as viral conjunctivitis or allergic reaction leading to a delay 
in treatment. All GD patients should be reminded about the possibility of eye disease 
and to be aware of these salient symptoms and also to remind their health 
professionals about this possibility. Even in its mildest form, GO can greatly interfere 
with the activity of daily life. Rarely, patient can present with severe eye disease with 
double vision and protrusion of the eyes and in 3-5% of cases this may lead to sight 
loss [26, 152]. Patients may complain of retro orbital pain on eye movements from 
swollen and inflamed retro orbital contents.  In terms of double vision or diplopia, the 
symptoms could range from a mild form i.e. occurs only when the patient is tired to 
disabling constant double vision. In addition most patients with GO have reduced 
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quality of life [153] and suffer long-term psychological distress due to the disfiguring 
appearance resulting from the eye ball protrusion [154], an effect that is often 
underestimated by health care professionals.  
GO signs are mainly related to orbital tissues inflammatory processes and oedema. 
At early stages, there could be evidence of periorbital soft tissue involvement such as 
conjunctival and periorbital erythema and/or oedema. This could extend to caruncle 
and plica inflammation.  The periorbital oedema was thought to reflect decreased 
venous drainage due to vascular compression within the orbital space [155]. Eyelid 
retraction is the commonest sign of GO [156] and may be present on the primary gaze 
(Dalrymple's sign) or subtly during down ward gaze also known as lid lag (Von 
Graefe's sign). The phenomenon is primarily due to sympathetic hyperactivity of the 
levator and/or Muller's muscle [157] in the thyrotoxic state and levator hypertrophy 
and fibrosis at later stages [158] . Proptosis although unsightly is a natural process in 
an attempt to decompress the retroorbital content of an orbit. This is to protect the 
optic nerve but at the expense of exposure keratitis. Although this is a characteristic 
finding of GO, it is not always present and does not correlate with disease severity 
especially in elderly patients with enlarged muscles at the orbital apex. In the absence 
of proptosis, inflamed swollen retroorbital content can compress the optic nerve 
leading to dysthyroid optic neuropathy (DON). Any reduction of visual acuity, reduced 
colour perception, relative afferent pupil defect (RAPD) and/or visual field defect signs 
in GD patient should be treated as potential DON until proven otherwise. There will 
be evidence of restrictive diplopia which develops due to extraocular muscle oedema 
and/or fibrosis. This tends to affect inferior and medial rectus muscles. Of note, 
younger patients tend to have orbital fat expansion whereas older patients tend to 
have extraocular muscles swelling causing diplopia/DON in the absence of proptosis 
[159]. 
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GO has a natural history first described by Rundle [160] where he did sequential 
measurements in untreated GO patients. After an initial rapid dynamic phase which 
usually lasts for 6 months but rarely can last more than 1 year [161], the disease 
continues to get worse until it reaches a point of maximum severity, and this is 
followed by a slow decrease in severity until it reaches a static/inactive plateau phase 
that is improved but not resolved to the baseline condition. Unfortunately 
approximately 50% of the patient will be left with the obvious signs of GO in the 
inactive phase [162]. The duration of the natural history is highly variable (from 
months to years) and unpredictable with some patients progressing whilst others 
regress or remain unchanged [163].  
 Clinical diagnosis and investigations 
Clinical diagnosis of GO is largely based on history and typical findings of ocular 
examination. However, all patients should have baseline thyroid function test with 
TSH receptor antibody. Clinical evaluation should be thorough and to include visual 
acuity examination (LogMAR chart), relative afferent pupil defect (RAPD), colour 
vision (HRR or Ishihara plates), eyelid retraction, palpebral aperture (including 
lagophthalmos and Bell’s phenomenon), motility assessment, corneal/optic disc 
assessment and measurement of intraocular pressure. Photographs can help 
documenting the change of appearances. Proptosis should be measured in 
standardized way ideally with the same Hertel exophthalmometer and fixed 
intercanthal distance. The GO should then be graded for activity using clinical activity 
score (CAS) and severity into mild, moderate to severe or sight-threatening to 
facilitate management decisions [164].  
Computed tomography or magnetic resonance imaging of the orbits is indicated if 
there is any uncertainty about the cause of orbitopathy particularly in a patient with 
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unilateral proptosis. The differential diagnosis includes orbital cellulitis, orbital 
myositis and orbital inflammatory syndrome (also known as orbital pseudotumor). 
Patient with cellulitis will have evidence of infection such as fever and an increase in 
inflammatory markers.  Extra ocular muscle tendons are involved in orbital myositis. 
Isolated enlargement of rectus muscle together with very rapid disease progression 
are suggestive of orbital pseudotumor rather than GO. Other rare differentials to 
include are orbital tumour, carotid artery cavernous sinus fistulas, acromegaly and 
other causes of infiltrative disease such as metastases, sarcoidosis, lymphoma and 
amyloidosis. 
 Risk factors 
Current smoking, rather than lifetime exposure, is the strongest risk factor for 
developing GO [165-167]. Odds ratios as high as 20.2 for current smokers and 8.9 
for combined current smokers and ex-smokers have been reported [168]. In general, 
GD patients who smoke are approximately 5 times more likely to develop GO than 
non-smokers [166, 169, 170]. Smokers tend to have more severe disease than non-
smokers [166]. There is evidence for a dose-response relationship between smoking 
and the severity of GO [166, 169]. These patients responded poorly/delayed to 
treatment [171] especially after radioiodine  therapy [172]. Passive smoking has also 
been indirectly linked to a higher GO prevalence in childhood GO (under 10 years 
old) [173]. In vitro studies have demonstrated that cigarette extract can increase the 
biological processes which underpin GO, i.e. adipogenesis and overproduction of 
hyaluronan (HA) [174]. Smoking also exerts other effects including changing the 
composition of tears [175], increasing IL-6 receptors [176], and HLA-DR expression 
on orbital fibroblasts [177]. GO is 3-6 times more common in women than men [156, 
178] although men tend to have more severe disease this more likely confounded by 
the higher smoking rate in men [178]. Radioiodine treatment also has been 
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associated with risk of developing GO in the order of 15-30% [172, 179, 180]. This is 
probably due to thyroid follicular cell destruction and the release of the auto antigens, 
T cell activation, higher and prolonged TRAB antibodies [181] and an increase in 
serum inflammatory cytokines [182]. Thyroid dysfunction, and more so 
hypothyroidism [183] than hyperthyroidism, has been associated with an increased 
risk for severe GO with an odds ratio of 2.8 [184].  
 Genetics of GO 
Genetic factors are important for some diseases, but in GO they are not absolute 
predisposition factors. The current dogma of the development of GO depends on 
complex interactions between genetic, environmental, and endogenous factors. The 
search for genetic susceptibility loci in GO has so far been disappointing and not to 
justify genetic testing to guide preventative strategies or therapy. 
In GO, significant associations between exophthalmos and/or soft tissue changes 
were found with HLA DR3 with relative risk of approximately 3.7. These patients were 
found to be more resistant to radioiodine therapy than patients negative for these 
antigens [185]. Weetman et al. tested the possible association of HLA-DQB and HLA-
DPB alleles with GD, with or without severe orbitopathy, by PCR of genomic DNA 
and allele-specific oligonucleotide probing. HLA-DPB 2.1/8 was found to be less 
prevalent in GO patients (2.5%) than in non-GO patients (20.8%) or controls (30%), 
albeit the GO protective effect of this HLA-DPB allele is weak [186]. 
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is expressed on activated T cells. It binds 
to B7 present on APCs and functions as a negative regulator of T cell activation. 
CTLA4 gene is located on chromosome 2q33 [187]. The polymorphism in the CTLA-
4 gene (A/G at codon 17) in GO confers a risk to GO as the strength of the association 
of the G allele with GO increases with the severity of GO with odds ratio up to 3.06 
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(p=0.01) for most severe GO. This was independent of male sex, smoking status, or 
previous radioiodine treatment. This is not specific for GO as it is found in other 
autoimmune conditions but rather confers a risk for autoimmune disease in general. 
Lastly, polymorphisms in the IL23 receptor (IL-23R) gene are found to be associated 
with GO [188]. IL-23 is known to promote sustained cellular immunity by promoting 
survival and cytokine production (e.g. IFN-γ) of Th1 memory cells [188]. It is also a 
survival factor for the Th17 subset, recently identified as major effectors of 
autoimmune tissue damage [189]. Yet again, it is also found in other autoimmune 
conditions such as rheumatoid arthritis [190] and Crohn’s disease [191]; it also hints 
at an important role for the innate immune system in autoimmune conditions including 
GO. However, none of these studies yield any confirmed susceptibility loci for GO 
because the various polymorphism data were found either to be weak or non-specific. 
 Treatments 
For the majority of patients with mild disease the treatment is mainly supportive with 
ocular lubrication and oral selenium treatment [192]. Oral nonsteroidal anti-
inflammatory agents (NSAIDs) may be considered. Patients should be advised to stop 
smoking and the disease symptoms and signs tend to resolve as thyroid function 
normalises. Rehabilitative surgery (Müllerectomy or blepharoplasty) can be offered 
once the disease becomes inactive and stable. 
Current treatments for moderate to severe GO rely heavily on major 
immunosuppressive therapies. Glucocorticoids are the mainstay of treatment and 
used initially to suppress acute inflammatory changes. These are effective when 
given at an early active phase of the disease. They also have beneficial effect on soft 
tissue swelling, ocular motility and visual acuity but a limited effect on proptosis [193]. 
Although numerous different oral and parenteral regimes have been reported, high-
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dose intravenous (IV) glucocorticoid pulses are superior to oral with response rates 
of about 80% compared to 60% for the oral route and significantly fewer adverse 
events than with oral glucocorticoid [194]. The morbidity and mortality of IV 
glucocorticoid therapy are around 6.5 and 0.6% respectively [193, 195]. These can 
be avoided by keeping the cumulative dose less than 8 grams in one course of 
therapy [196]. Other second-line immunosuppressive agents have been used with or 
without glucocorticoids with varying effects. However, the routine use of such drugs 
in the management of severe TED has been limited by fears about their potential 
toxicity.  
The immune modulator rituximab, which is a chimeric mouse-human monoclonal 
antibody directed against the CD20 antigen on B lymphocytes, has been trialed in 
GO. The CD20 antigen presents on pre and mature B cells but not stem cells, B-cell 
precursors and antibody-producing plasma cells. Results were conflicting with Marius 
Stan and colleagues reporting that that there were no differences against the placebo 
with patients’ clinical activity score and their secondary outcomes which included 
quality of life scores [197]. Mario Salvi’s group described considerable improvement 
in their primary outcome measured which was clinical activity score and also 
secondary outcomes including eye motility, GO-QOL assessment, and the reduced 
number of surgical procedures in patients after rituximab treatment even at lower 
dose [198]. The reasons for this disagreement are unclear but may be related to the 
differences in the study designs and patient selection (The duration of GO was less 
than 6 months in Salvi’s group compared to 1 year in the Stan’s group).  
Orbital radiotherapy given at cumulative dose of 20Gy per orbit is particularly useful 
in improving diplopia [199, 200]. Combinations of cyclosporine and glucocorticoids 
have been shown to achieve a better initial treatment response than either agent 
alone [201, 202]. Azathioprine (AZT) has not been shown to be of benefit as a single 
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[203] agent but the outcome of the multicentre CIRTED study, which has combined 
radiotherapy and/or AZT with the steroid is currently awaited [204]. Other unproven 
or being developed treatments includes IV immunoglobulins [205, 206], etanercept 
(anti-TNF) [207], somatostatin analogues [208, 209], Teprotumumab (IGF-1 receptor 
antagonist antibodies, NCT01868997), TSH-R-blocking antibodies and small-
molecule-ligand antagonists [210]. 
Most patients with GO have mild disease which improves spontaneously and do not 
require corrective surgery. Surgical decompression is usually reserved for inactive 
GO but rarely has to be performed due to sight threatening GO unresponsive to 
medical treatment. This is normally followed by a rehabilitative surgery at a later 
stage. 
 
 Target Autoantigens in GO 
1.10.6.1 TSHR as an autoantigen  
TSHR was discussed in detail in previous sections and will be further described in 
Chapter 4. TSAB levels are associated with GO prevalence and severity [211-214] 
but TBII correlate only with GD and the hyperthyroid state but not GO [212, 213]. 
However, there are recent data showing close correlation between TSAB and to a 
lesser extent TBII with both activity and severity of GO [215, 216]. In terms of 
response to treatment, persistent elevation of both TBII and TSAB has been 
associated with non-response to treatment for GD [39] suggesting a role for TSHR 
autoantibodies in disease activity and its maintenance. This last study indicated that 
GD patients who relapses are most likely to develop GO. The lack of consistency with 
regard to TBII assays more likely reflects the mixture of stimulating and blocking 
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antibodies, thus studies showing an association with GO might have studied samples 
in which TSAB predominate and vice versa. 
However, the fact that not all GO patients have TSAB and may even be euthyroid or 
hypothyroid has prompted people to seek other explanations. Work from our group 
[217] demonstrated ‘neutral’ TSHR antibodies able to bind but having no effect on 
known TSHR signalling. Indeed TSHR signalling may be far more complex than 
initially thought (reviewed by Latif et al [218]). Little is known about the effects of 
TSHR activation at various stages during differentiation from pre to mature adipocyte 
(see below) and the cascades stimulated will depend on the types and abundance of 
G proteins available in the cell [219]. As described above, G protein coupled receptors 
(GPCR) also can exist as monomers or oligomers. Oligomerization is the term used 
to describe dimeric, tetrameric, or higher-order complexes between GPCR monomers 
[220]. The activation of different GPCR complexes will have major influence on 
subsequent G protein signalling pathways. TSHR is generally found at low abundance 
in extra thyroidal tissue but during adipogenesis TSHR levels were found to increase 
[118].  
1.10.6.2 Insulin like growth factor-1 receptor (IGF1R) 
Others have searched for additional autoantigenic targets; the IGF1R was first 
proposed by Weightman and colleagues who demonstrated high affinity IGF1 binding 
sites on orbital fibroblasts [221]. More recently extensive work from Terry Smith and 
his colleagues has confirmed this finding and further showed that TSHR and IGF1R 
co-localize to orbital cell membranes [222]. TSH induced ERK phosphorylation can 
be blocked by an IGF-1R-blocking monoclonal antibody suggesting that IGF-1R might 
mediate some TSH-provoked signalling. This group are conducting a large scale trial 
to evaluate a monoclonal antibody which blocks IGF1R in GO 
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(https://clinicaltrials.gov/ct2/show/NCT01868997).  
Efforts to demonstrate autoantibodies to the IGF1R have had mixed success. Minich 
et al used GO patients sera and purified IgG for IGF1R binding and concluded that 
IGF1R autoantibodies exist but with similar prevalence (approximately 10%) between 
normal and GO [223]. They also found that this IgG are antagonist in nature and 
concluded that anti-IGF-IR antibodies are uninvolved in the pathogenesis of GO. 
Whilst Varewijck et al [224] suggested that in subset of GO patients with high TBII, 
IGF-IR stimulating activity is increased with age. Neumann & Gershengorn propose 
that cross-talk between the TSHR and IGF1R, rather than direct IGF1R activation, 
might stimulate the tissue remodelling [225].  
1.10.6.3 Thyroglobulin 
Thyroglobulin (TG) is produced by thyroid follicular cells, is the substrate for thyroid 
hormones and the first thyroid autoantigen described. Rodents immunized with TG 
develop thyroiditis and sera from some patients with thyroid disease contain 
antibodies which bind to TG in immunohistochemical analysis using thyroid slices. TG 
is a 660 kDa, dimeric protein encoded by a gene located on the long arm of 
chromosome 8 [226].  TG production is controlled by TSH, it is secreted and stored 
in the follicular lumen as colloid.  
In the 1970’s, Joseph P. Kriss postulated that thyroidal TG is transported to the orbital 
tissues through the lymphatic system via veins in the inferior orbital fissure and then 
initiates the inflammatory processes leading to GO [227]. The same group also 
provided evidence for TG/anti-TG immune complexes in the orbit [228].The TG 
hypothesis was modified by reports that it shares antigenic epitopes with 
acetylcholinesterase – an abundant enzyme in the highly innervated orbital muscles 
[229]. More recently, Marino et al. demonstrated that TG is present in the orbit; 
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furthermore it is iodinated suggesting that it is the product of the thyroid gland [230, 
231]. The significance of these findings is unclear since GO patients do not have 
particularly elevated anti-TG antibody titres and patients with Hashimoto’s thyroiditis 
generally do not have evidence of GO.  
1.10.6.4 Thyroid peroxidase 
Thyroid peroxidase (TPO) is the second major thyroid autoantigen, previously known 
as the microsomal antigen, with TPO antibodies being a feature of destructive 
thyroiditis [232]. The 110kD protein is encoded by a gene on chromosome 2 
comprising 17 exons, its expression is controlled by TSH; TPO has similarity with 
myeloperoxidase. TPO antibodies are present in almost all Hashimoto’s patients but 
only in 50% of those with GD. Lai et al. have demonstrated significantly higher levels 
of TPO messenger ribonucleic acid (mRNA) and protein in orbital fat tissue of GO 
compared to normal subjects [233]. As far as we are aware, this is the only evidence 
to suggest that TPO has a role in GO, in fact the absence of TPO autoantibodies has 
been reported in various studies in GO. 
1.10.6.5 Other candidate antigens  
Other potential candidate antigens are G2S proteins (55 kDa fragment of the FOX-
P1 transcription factor), non-tissue-specific membrane protein called D1 (64 kDa) and 
calsequestrin (63 kDa), a calcium-binding protein localized in the sarcoplasmic 
reticulum of the skeletal muscle fibre [234-236]. Skeletal muscle and cardiac 
calsequestrins are encoded by CASQ1 and CASQ2 gene respectively [237]. It is 
interesting to see from microarray data, that CASQ2 gene is up-regulated (confirmed 
with QPCR) in the GD thyroid from patients with GO (relative to those without eye 
disease) while genes encoding TG, TPO and TSHR were not differentially expressed 
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[238]. It is proposed that CASQ2 gene upregulation may generate production of 
autoantibodies in the thyroid and sensitized T-lymphocytes, which cross-react with 
calsequestrin in the extraocular muscle of patients who develop orbitopathy. 
 Tissue Remodelling in GO 
As mentioned above, expansion of tissues in the orbit causes proptosis; the two main 
mechanisms in operation are overproduction of extracellular matrix (ECM) 
components, especially hyaluronan (HA) and excess adipogenesis.  
Adipogenesis is a process in which preadipocytes differentiate into mature adipose 
tissues (see Figure 8). Most of our current understanding of adipogenesis has been 
derived using the murine 3T3L1 cell line. Although 3T3L1 cell lines can spontaneously 
differentiate into adipocytes when maintained in a high concentration of foetal calf 
serum, this normally takes weeks but the process can be accelerated by employing 
adipogenic cocktails containing high concentrations of insulin, glucocorticoids and 3-
isobutyl-1-methylxanthine (IBMX). Additional components may also be included in the 
differentiation mix including PPARγ agonists such as pioglitazone, triiodothyronine, 
biotin, pantothenate and indomethacin. Insulin is known to mimic insulin-like growth 
factor-1 and activates MAP (mitogen-activated protein kinase pathways) [239] and 
PI3 kinase pathways [240]. Phosphorylation of Akt in turn phosphorylates the 
inhibitory transcription factor FOXO1 causing it to exit from the nucleus leading to 
increase adipogenic genes transcription. Glucocorticoids induce expression of 
C/EBP-δ (early adipogenic gene) which in turn contributes to an increase in PPAR-γ 
expression and production of prostacyclin which increases intracellular cAMP [241, 
242]. IBMX is a nonselective phosphodiesterase inhibitor which raises intracellular 
cAMP and protein kinase A (PKA) which is required for transcriptional activation of 
PPARγ [243]. PPARγ transcript levels then increase followed by heterodimer complex 
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formation with the retinoic X receptor (RXR) with subsequent increase in 
adipogenesis related genes transcription. PPARγ is known as the master regulator of 
adipogenesis. It is a transcription factor and encoded by the PPARγ gene. The human 
PPARγ gene has nine exons. Alternate splicing and alternate transcription start sites 
generate the PPARγ1 and PPARγ2 mRNAs, which differ at their 5'-ends. PPARγ1 is 
encoded by eight exons, and PPARγ2 is encoded by seven exons with six common 
exons 1 to 6 [244]. The two isoforms of PPARγ are detected in the human: PPARγ1 
(found in nearly all tissues except muscle) and PPARγ2 (mostly found in adipose 
tissue and the intestine).  
Primary cells are more challenging to differentiate but the information gathered is 
more relevant. In the orbit, Thy-1 negative  [245]  fibroblasts can be induced to 
differentiate when cultured in appropriate adipogenic medium [246] whereas Thy1 
positive cells are more likely to undergo differentiation to myofibroblasts and cause 
fibrosis. Adipogenesis contributes to orbital expansion because a fibroblast has a 
diameter of 30 microns but that of a mature adipocyte is 150 microns, as mentioned 
above, during differentiation expression of the target antigen TSHR is increased.  
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Figure 8: Stages of adipocyte differentiation. Preadipocytes can undergo spontaneous 
differentiation in culture medium (CM) or the process can be accelerated by differentiation 
medium (DM) containing insulin, dexamethasone and cyclic adenosine monophosphate 
(cAMP). The process contributes to orbital expansion as a fibroblast has a diameter of 30 
microns but a mature adipocyte is 150 microns. The Transcription factor cascade is depicted 
on the left side of the diagram. The initial adipogenic induction rapidly induces expression of 
the CAAT/enhancer-binding proteins (C/EBPs) C/EBPδ and β. These in turn induces 
peroxisome proliferator-activated receptor-γ (PPAR-γ) and C/EBPα genes activation which 
are the key transcriptional regulators of adipocyte differentiation. PPARγ activates the 
promoter of C/EBPα and vice versa. Also C/EBPα has a stimulatory effect on itself creating a 
positive-feedback loop which in turn feeds into adipocytes related gene induction (see text for 
more detail). 
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1.10.7.1 Adipogenesis regulation by TSAB 
Several research groups have addressed this issue but with varying responses 
because 1) they have not studied the same cell populations 2) have employed 
different culture conditions 3) used a variety of methods to activate the TSHR.  
Zhang et al have shown that activation of TSHR in human orbital OF can stimulate 
the early stages of adipogenesis [247]. The studies were performed by introducing an 
activating mutant TSHR into OF using viral vectors. The mutants used were L629F 
and M453T, which previously have been reported in two newborns with non-
autoimmune hyperthyroidism and proptosis [248, 249] and are similar (but not 
identical) to TSAB activation. Using cultured mouse embryonic stem cells, Lu et al 
showed that TSH can stimulate adipogenesis, even in the absence of adipogenic 
factors, suggesting that TSHR activation can initiate the early lineage commitment 
process [250]. The same study also showed that TSH can enhance adipogenesis in 
the presence of adipogenic cocktails (Insulin, T3 and PPARγ). Human monoclonal 
TSAB (M22) is able to interact with TSHR via both cAMP/pI3K pathways in Fisher Rat 
Thyroid cell Line (FRTL-5) [38]. Rebecca Bahn’s group have investigated M22 effects 
in human OF and reported that they are able to enhance their differentiation into 
adipocytes partly via the PI3K signalling cascade, i.e. it mimics the action of insulin 
[251]. Of interest the patient from whom M22 was derived did not have GO. 
1.10.7.2 Over-production of ECM 
In GO, the over-production the GAGs particularly HA in the orbital adipose tissue and 
extraocular muscle leads to oedema with consequent proptosis and diplopia 
respectively. Several extracellular matrix (ECM) components are overproduced in GO 
including collagens and glycosaminoglycans (GAGs). GAGs can be classified into 
four groups: chondroitin/dermatan, heparin/heparan, keratan and hyaluronic acid 
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(HA) (Table 7).  
 
Table 7: Classes of GAGs and their disaccharide building blocks 
Class Disaccharide U H Modifications 
Hyaluronic acid 
GlcA (β1,3) 
HNAc (β1,4) 
GlcA Glucosamine None 
Heparin/heparan 
U2X (α/β1,4) 
HNY,3X,6X (α1,4) 
IdoA/GlcA Glucosamine 
X – sulfated Y 
– acetylated/ 
sulfated 
Chondroitin/ 
dermatan 
U2X (α/β1,3) 
HNAc,4X,6X (β1,4) 
IdoA/GlcA Galactosamine X – sulfated 
Keratan 
Gal6X (β1,4) 
HNAc,6X (β1,3) 
Gal Glucosamine X – sulfated 
The abbreviations used: α-l-iduronic acid, IdoA or I; α-d-glucuronic acid, GlcA or G; U is uronic sugars, 
H is either α/β-d-glucosamine (GlcNAc) or β-d-galactosamine (GalNAc) depending on the GAG class; 
β-d-galactose, Gal; Acetylation (COCH3) is indicated using Ac and sulfation (SO3) using S. Adapted 
from Sasisekharan et al [252]. 
 
These differ in their disaccharide building blocks; uronic sugars (glucuronic acid or 
iduronic acid) or galactose; sulfation and/or acetylation. The GAGs are synthesised 
by the Golgi apparatus except HA which is produced by integral membrane synthases 
and immediately secreted as the disaccharide chain elongates. HA is the only non-
sulfated form of the GAGs and is a major contributor to GO orbital expansion as it is 
able to absorb up to 1000x its weight in water. HA is generated by 3 HA synthetase 
(HAS) enzymes and broken down by hyaluronidases. The 3 HAS isoforms each 
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possess distinct activities and produce HA molecules of differing length [253]; HAS1 
(has tissue specific expression [254]), HAS2 (proinflammatory and inducible [255]) 
and HAS3 isoform which is associated with a resting, non-pathological phenotype 
and present in most cell types [256]. 
Hyaluronidases break down HA via degradation of the β-N-acetyl-D-glucosaminidic 
linkages in the HA polymer. There are currently six hyaluronidases genes known to 
be present in the human genome in 2 clusters of triplicates (Figure 9): HYAL-1, -2 
and -3 genes are clustered in the chromosome 3p21.3 locus (found to be expressed 
in human orbital OFs and increased by the activation of TSHR and hyaluronidase 3 
was increased by IGF1R [257]) and HYAL-4, HYAL-P1 (which is a pseudogene: 
transcribed but not translated) and PH20 (encodes sperm hyaluronidases necessary 
for fertilisation) in the chromosome 7q31.3 locus [258]. HYAL-1, -2 and -3 are 
considered acidic type as these are maximally active at acidic pH [259] whilst PH20 
is has maximal activity at neutral pH [260]. HYAL-1 and HYAL-2 are the two major 
hyaluronidases for the degradation of HA. HYAL-1 can degrade high molecular weight 
HA down to small oligomers (tetrasaccharides) whilst HYAL-2 able to degrade HA to 
an approximately 20 kDa product (approximately 25 disaccharide units ) [261]. Little 
is known about HYAL-3 and 4. 
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Figure 9: Chromosomal orientation of the six hyaluronidase genes at their two respective 
chromosomal sites in triplicates. Modified from Csoka et al [258]. 
 
1.10.7.3 ECM regulation by TSAB  
Various immune and endocrine factors have been implicated in the upregulation of 
HA production. Since TSAB causes GD, it is logical that these antibodies have been 
investigated but with conflicting results. The difference may be due to the differing 
ligands used to activate the TSHR. The group of Terry Smith reported that although 
Graves’ IgGs are able to increase HA production, the effect is not mediated via the 
TSHR (using recombinant TSHR) but the IGF1R [222]. 
 In contrast, our own data indicate that TSHR activation (cAMP) in 
preadipocyte/fibroblasts (PF) does increase HA production. Comparison of gene 
expression profiles of PF experiencing TSHR activation (L629F or M453T as 
described above) or not revealed significant upregulation of HAS1 and HAS2 in the 
former. Furthermore, a monoclonal antibody devoid of TSAB activity also produced 
the same effect – suggesting that signalling cascades other than cAMP might be 
involved [262]. 
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van Ziejl et al found contradictory results [263] using different ligands; recombinant 
TSH (rhTSH) and GD-IgG, they reported that the former increased cAMP by 25-50% 
but GD-IgG had no effect. Accordingly, no HAS mRNA and HA synthesis were 
detected. The same author tested the same theory in differentiated OF and found that 
both rhTSH and GD-IgG induced a cAMP response. Only some samples showed 
HAS1 upregulation but not HAS2 and 3.  There was no measurable HA in rhTSH but 
marked HA response in GD-IgG [264]. These studies suggest that TSAB are more 
likely to regulate HA production via cAMP in orbital cells undergoing adipogenesis. 
Zhang and colleagues also demonstrated that adipogenesis and HA production are 
linked in the orbit; they went on to dissect the signalling pathways implicated, major 
depot specific differences which might explain why orbital fat expands when other 
depots in GD/GO patients tend to shrink [265]. In this study, adipogenesis in orbital 
preadipocytes was accompanied by HA accumulation and significantly increased 
HAS2 transcripts (but not HAS 1 and 3) and in contrast to subcutaneous cells, 
differentiation significantly decreased secreted HA and HAS2 transcript levels. IGF-I 
alone did not increase HAS2 levels, but inhibition of Akt increased orbital HAS2 
transcripts but not subcutaneous preadipocytes. In subcutaneous preadipocytes 
inhibition of mTOR leads to an increase in IGF-1 mediated HAS2 production in 
contrast by a MAPK kinase inhibitor in orbital fibroblasts. 
Studies from Smith’s group indicate that immunoglobulins from GO patients are able 
to stimulate ECM production, also production of cytokines from orbital fibroblasts 
[266, 267]. Their explanation is IGF1R autoantibodies but others invoke TSHR/IGF1R 
cross-talk. 
Most in vitro models use 2D cultures, a major advance proposed by Ezra and Bailly 
who cultured orbital fibroblasts in a 3D collagen matrix to study both processes [268]. 
Traditional 2D cell cultures lack the metabolic and proliferative gradients that are 
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present in the human body. 3D extracellular environments are the way our cells 
routinely operate in vivo. In theory 3D cultures should provide more physiological 
environments for cell adhesions, mechanical force and diffusible factors interactions 
than the conventional 2D models.  The major finding from Ezra and Bailly’s work was 
that in both thy-1 positive and negative orbital fibroblast (further discussed below), 
adipogenesis can be induced in 3D culture without the need for chemical stimulation 
and under pressure stress although slightly lower potential in Thy-1 positive [268].  In 
this 3D model Thy-1 expression has some impact but not all on adipogenic 
differentiation potential. However, it has no impact on the contractile phenotype 
potential.  
1.10.7.4 Fibrocyte or Fibroblast 
Smith and colleagues have suggested that TSHR expressing cells in the orbit might 
be fibrocytes rather than in situ mesenchymal stem cells [269]. Fibrocytes are 
circulating bone marrow derived cells which express unique CD34, CD13, CD45 and 
CXCR4 surface markers. These cells synthesize collagen I and are involved in 
inflammation, tissue remodelling and fibrosis [269-271]. The same group have shown 
that GD patients have increased fibrocyte numbers in their peripheral blood which 
spontaneously express TSHR at levels comparable to those found on thyroid 
epithelial cells and respond to TSH by producing IL-6 and TNF-α. These cells also 
can differentiate into adipocytes and myofibroblasts when treated with PPAR-γ 
ligands and TGF-β respectively [272].  
Even though many people have studied orbital fibroblasts in vitro, very few have 
assessed their surface markers to indicate what cell types are present. Orbital 
fibroblasts display heterogeneous phenotypes in culture. As mentioned previously, 
this includes expression of cell surface marker of Thy-1 (CD90) in approximately 65% 
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of the orbital fat cell population but nearly all fibroblast within extraocular muscles 
[273]. Thy-1 is a 25-kilodalton glycoprotein and involved in the transduction of 
extracellular signals. Thy-1 function in orbital fibroblast is currently unknown. Thy-1 
orbital population has been shown capable of producing hyaluronan, prostaglandin 
E2, IL-6 [274, 275]  and are capable of myofibroblast differentiation [276] which can 
participate in inflammation, repair, and fibrosis. Whilst Thy-1 negative population is 
capable of differentiation into mature fat cells. Within the orbit, relative proportions of 
Thy-1+ and Thy-1− fibroblasts and their degree of exposure to TGF-β may affect 
disease expression, including whether muscle or fat expansion predominates and the 
extent of fibrosis that develops. Recently Eckstein group has shown that orbital 
fibroblasts possess surface markers of pluripotent mesenchymal stem cells (MSC) 
that are CD29, CD44, CD71, CD73, CD90, CD105, and CD166 with capability of 
adipogenic, osteogenic, chondrogenic, myogenic, and neuronal differentiation [277]. 
 Study objectives 
As discussed, the main pathological features of GO include expansion of orbital fat, 
mononuclear cell infiltration of orbital connective tissue and muscle, and tissue 
remodelling, which culminate in fibrosis and diminished eye motility [278]. The key 
mechanisms are excessive adipogenesis and secretion of glycosaminoglycans in the 
orbit, which increase volume and cause exophthalmos [279]. The opposite effect, 
enophthalmos (recession of the eye into the orbit), has been described in patients 
with glaucoma (intraocular hypertension) treated topically with Bimatoprost (PGF2α), 
a prostaglandin analogue [280-282]. This side effect is more noticeable if only one 
eye is exposed to treatment as the treated eye is easily comparable with the 
unexposed eye. However, since most patients receive treatment to both eyes it is 
possible that the incidence of enophthalmos in Bimatoprost treated patients has been 
underestimated. I hypothesised that the enophthalmos in glaucoma patients treated 
 61 
with Bimatoprost is secondary to reductions in orbital tissue proliferation, 
adipogenesis and/or increased lipolysis. Since these processes underpin the tissue 
remodelling in GO, prostaglandin analogue therapy could be useful in this disease.  
There is close clinical and temporal association between GD and GO suggesting an 
autoimmune response to common antigen/s in the orbit and thyroid gland. Since the 
TSHR is expressed in fat [118] and virtually all patients with hyperthyroid GO have 
TSAB, the receptor is the most logical candidate.  Apart from TSH and TSAB, novel 
ligands for the TSHR have been described including thyrostimulin, which comprises 
novel α2 and β5 subunits [283]. It has high TSHR affinity but very little is known about 
its location and function; it has not been detected in the circulation suggesting 
paracrine effects. Transgenic mice over-expressing the α2 subunit had no overt 
phenotype but overexpression of β5 in mice is associated with hyperthyroidism, 
weight loss and proptosis [284]. These facts suggest it is a potential major contributor 
to the GD and GO disease processes. In contrast, several TSHR variants have been 
described which lack the transmembrane domain leading to soluble receptor products 
which could serve as TSH/TSAB/thyrostimulin binding proteins. Potentially these 
variants could promote pathogenesis of GO by inducing further production of TSAB 
or protect against GO by either ‘neutralizing’ TSAB or inducing immune tolerance. I 
hypothesised that variation in expression of TSHR binding protein (truncated TSHR 
variants) and/or novel ligands such as thyrostimulin, might provide a mechanism to 
protect against or exacerbate GO. 
Another difficult problem for GD patients (who lose weight during active disease) is 
weight gain following treatment. Increases of up to 10kg in weight from baseline [285, 
286] have been recorded.  Whilst this may reflect at least in part; excessive treatment 
with anti-thyroid measures and subsequent alteration of a patient’s baseline thyroid 
axis; it may also arise due to changes in peripheral fat. There are two types of adipose 
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tissue; white adipose tissue (WAT) mainly responsible for fat storage and brown 
adipose tissue (BAT) responsible for heat dissipation (GD patients are heat 
intolerant). GD weight loss has been attributed to the lipolytic effects of thyroid 
hormone [287] but the TSHR is expressed in fat and our lab has reported that TSHR 
activation (by TSAB) leads to a ‘browning’ of fat from various depots in vitro (15). 
Analysis has suggested that a diagnosis of GD (as opposed to other causes of thyroid 
over-activity such as toxic goitre), is an independent predictor of weight gain [288], 
raising the possibility that TSAB, not only modify orbital fat, but also have long-term 
effects on peripheral adipose tissue. I hypothesised that TSAB which alter fat biology 
in the orbit, might also have long-term effects on peripheral adipose tissue 
composition and TSHR activation per se may contribute to changes in body 
composition separately from the effects of thyroid hormone levels. 
The first aim of my thesis was to investigate the effects of Bimatoprost eye drops in 
vitro on proliferation, adipogenesis and lipolysis to determine whether it might be of 
benefit in GO. (Chapter 2). This was followed by randomised controlled double blind 
crossover trial on the effect of Bimatoprost on GO (Chapter 3). My second aim was 
to measure the relative expression of TSHR variants, TSHR full-length and 
thyrostimulin transcripts and protein in GO orbits compared with non-GO in ex vivo 
samples and how this compares with the level of adipogenesis. This aspect was 
investigated using the in vitro model (Chapter 4). Finally, I would hope to delineate 
the effect of TSAB and thyroid hormone on adipogenesis by studying GD neck fat 
samples (experienced TSAB stimulation and hyperthyroid state) with 2 different 
controls: toxic multinodular goitre - the tissues experienced hyperthyroid state without 
TSAB stimulation and normal who were euthyroid with negative TSAB. My aim was 
to investigate the effect of TSHR activation on brown, beige and white adipose tissue 
formation in ex vivo human neck fat tissues (Chapter 5).  
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Chapter Two 
2 PROSTAGLANDIN F2α (PGF2α) EFFECTS ON ADIPOCYTE 
BIOLOGY RELEVANT TO GRAVES’ ORBITOPATHY 
2.1 INTRODUCTION 
The prostaglandins (PG) are a group of active lipid molecules having multiple 
hormone-like effects in humans. They are different from hormones as there is no 
specific organ producing it or organ target but they are present in most cells and act 
either via autocrine (acting on the source cell itself) or paracrine (acting on the 
adjacent cells) routes.  They are synthesized from the essential fatty acids which form 
part of the plasma membrane. An intermediate arachidonic acid is created from 
diacylglycerol via phospholipase-A2 which proceeds to either the cyclooxygenase or 
the lipoxygenase pathway to form either prostaglandin and thromboxane or 
leukotriene respectively. Prostaglandin F2α (PGF2α) is produced following the 
sequential oxidation of arachidonic acid by cyclooxygenases 1 and 2 followed by 
terminal prostaglandin F synthase (See Figure 10).  
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Figure 10: Prostaglandins biosynthesis. Modified from Ricciotti et al 2011 [289]. PGD2, 
prostaglandin D2; PGE2, prostaglandin E2; PGI2, prostaglandin I2 or prostacyclin; TXA2, 
Thromboxane; HPETE, hydroperoxyeicosatetraenoic acid; LTA4-E4, Leukotriene A4-E4. 
 
 
 
Figure 11: Molecular structure of PGF2α depicting 20 carbon atoms including a 5-carbon ring. 
Adapted from Coulthard et al 2012 [290]. 
 
Studies into PGF2α function have led to the generation of analogues, including 
Latanoprost, Travoprost, Carboprost and Bimatoprost. These have proven efficacy, 
when used topically during glaucoma therapy, to lower intraocular pressure (IOP). It 
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is believed that PGF2α lowers IOP by increasing aqueous humour outflow through 
both the uveoscleral and trabecular meshwork routes by mimicking the action of 
naturally occurring prostamides [291] which stimulate production of matrix 
metalloproteinases (MMPs). MMPs are a family of neutral, zinc-dependent enzymes 
that can hydrolyze extracellular matrix proteins and proteoglycans [292]. These 
molecules are secreted as inactive proenzymes also known as zymogens and 
become activated by proteolytic truncation. There are multiple types of MMP and each 
MMP type targets specific peptide sequences in ECM macromolecules for cleavage. 
The most commonly used subtypes are the collagenases, the gelatinases, the 
stromelysins, and the membrane-type MMPs. MMPs have been shown to increase 
degradation of ciliary muscle ECM which increases uveoscleral flow [293].  Exposure 
of ciliary smooth muscle cells to PGF2α induces at least four different MMPs including 
MMP-1, MMP-2, MMP-3, and MMP-9 [294]. Each of these has an Activator protein 1 
(AP-1) regulatory element within their promoter [295]. This regulatory element 
promotes transcription when it is bound by a regulatory complex containing Fos and 
Jun family proteins [296]. Treatment of ciliary smooth muscle cells with PGF2α induces 
c-fos expression supporting the view that PGF2α induction of MMPs is mediated by 
AP-1 activation [297].  
These positive effects of PGF2α are not without the balance of some adverse effects. 
There are emerging case reports worldwide of deepening of the lid sulcus and/or 
enophthalmos developing in patients treated with Bimatoprost, albeit in small 
numbers [280-282, 298-300]. This side effect is more noticeable if only one eye is 
exposed to treatment as the treated eye is easily comparable with the unexposed 
eye. However, since most patients receive treatment to both eyes it is possible that 
the incidence of enophthalmos in Bimatoprost treated patients has been 
underestimated. This effect can be reversed by discontinuation of the prostaglandin 
analogue therapy. A possible mechanism by which PGF2α agonists might produce 
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enophthalmos is through reduction of orbital fat volume [301]. A PGF2α receptor 
agonist has been shown to be a potent inhibitor of adipose differentiation in new-born 
rat precursor cells [302]. This raises the possibility that PGF2α exerts direct effects on 
adipose tissue precursors. The inhibition of this adipose tissue differentiation may be 
mediated via PGF2α binding to a member of the G-protein coupled receptor family 
known as Prostaglandin F receptor (FP) [303]. This receptor is encoded by the 
PTGFR gene located on chromosome 1 in humans [304] and chromosome 3 in mice 
[305]. A splice variant has been described as FP(S) which lacks transmembrane-7 
and the intracellular carboxyl tail [306]. FP(S) has been suggested to form a 
heterodimer complex with FP to exert its effects [307]. The FP receptor is a Gq 
coupled receptor, which once activated leads to release of inositol-1,4,5-
trisphosphate and diacylglycerol which in turn increases the Ca2+ level [304, 308, 
309]. Previous work from others, using the murine preadipocyte 3T3-L1 cell line, 
reports that PGF2α inhibits adipogenesis via a calcineurin dependent mechanism by 
blocking expression of critical adipogenic transcription factors PPARγ and C/EBPα 
[310]. This mechanism can be negated by calcineurin inhibitors such as Cyclosporine 
and Tacrolimus (FK506) [311] which might explain inconsistent results in the 
management of Graves’ Orbitopathy (GO) with these agents [312, 313]. Other main 
effects of the FP receptor are uterine contraction [314], luteolysis [315], and 
bronchoconstriction [316]. 
The opposite of enophthalmos, i.e. exophthalmos is a feature of GO. This represents 
a poorly understood component of Graves’ disease (GD) and was described in detail 
in chapter 1. Graves’ disease is caused by thyroid stimulating antibody and there are 
indirect demonstrations that they might also be important in GO [262]. The main 
features of GO include orbital connective tissue fat pad expansion, tissue and 
extraocular muscle infiltration with mononuclear cells, and tissue remodelling that 
leads to fibrosis and reduced eye motility. GO has an annual adjusted incidence rate 
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of 3 men and 16 women per 100,000 population [156]. So called subclinical (minimal 
or no clinical signs or symptoms) involvement is quite common approaching up to 
70% of adults with GD detected via MRI or CT scanning [279]. 
2.1.1 3T3-L1 cell lines 
3T3-L1 cell lines have been fundamental in cardiometabolic disease research for over 
5 decades.  3T3 cell lines were developed by Todaro and Green in 1962 from Swiss 
albino mouse embryonic fibroblasts  [317]. In their study, the embryos were originally 
minced and digested with trypsin before being grown in suspension and later forming 
a monolayer.  The cells were then cultured for 3 or 6 days with a fixed amount of cells 
being inoculated. Lower than 3 x 105 cells in the inoculum were associated with poor 
growth rate whilst the higher inoculums were associated with higher growth rate and 
multilayer formation before being limited to grow any further by contact inhibition. 3 x 
105 inoculums after 20-30th passages, the cells started to have constant rate of growth 
which was described as ‘established cell lines’. These cells were sensitive to contact 
inhibition and able to remain in a resting state for long periods. Green later described 
the isolation of a clone from 3T3 clones, also known 3T3-L1, which accumulated lipid 
droplets when they entered a resting state induced by a high concentration of serum 
up to 30% [318].  
The '3T3-L1’ abbreviation used refers to “3 x 105 cells cultured for 3 days before being 
trypsinised and transferred to another plate; L1 simply denotes L1 clone. In culture 
medium, 3T3-L1 exhibits a fibroblast-like morphology and can be induced to 
differentiate to mature adipocytes by adipogenic cocktail (see below) making it a 
useful model to study adipocyte differentiation [319, 320]. The adipogenesis process 
is associated with increase in fatty acid transcription factors including 
CCAAT/enhancer binding protein alpha (C/EBPα) and peroxisome proliferator-
activated receptor gamma (PPARγ) [319]. Although initially thought that the cells need 
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to undergo mitotic clonal expansion (2-3 cycles of growth after growth arrest) before 
going into adipogenesis, this later was found not to be a necessary step for 3T3-L1 
to differentiate into adipocytes [239].  
Primary orbital preadipocytes are the model of choice for the current study but there 
are limitations because of their scarcity and slow growth. 3T3-L1 on the other hand 
so far have provided most known knowledge on adipogenesis. It is immortalized and 
easily managed. They are relatively accurate representations of true preadipocytes, 
based on ultrastructure and their ability to form fat pads when injected into athymic 
mice. However, despite their strengths as preadipocyte models, there are differences: 
i. Aneuploid rather than diploid 
ii. Regulation of cell cycle events are different between cell lines and 
primary cultures of human preadipocytes 
iii. More recently, using gene array technology, similarities and 
differences in clusters of genes regulated during adipogenesis have 
been described between the widely used 3T3-L1 cell line and primary 
mouse preadipocytes 
I made use of this cell line because apart from the convenience and short duration of 
replication, it allows development of the right methods and techniques before 
embarking on the study on primary orbital preadipocytes.  
I hypothesised that the observed enophthalmos in patients treated with PGF2α is 
secondary to reductions in orbital tissue proliferation, adipogenesis and/or increased 
lipolysis. The aim was to investigate which of these is affected, using 3T3-L1 cell lines 
and human orbital fibroblasts, to determine whether the drug might be useful as a 
treatment for GO. 
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2.2 MATERIAL AND METHODS 
All tissue culture components were obtained from Lonza (Verviers, Belgium) and 
reagents from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. 17-phenyl trinor 
Prostaglandin F2α free acid (PGF2α) was obtained from Cayman Chemical and diluted 
in Dimethyl sulfoxide (DMSO) to produce a stock solution of 1 millimolar (10-3M). 
Working concentrations were from 10-6 to 10-8 molar concentration. Please see Figure 
12 for the summary of the methods used in the study. 
 
Figure 12: A flow diagram illustrating methods used to study the effect of PGF2α eye drops on 
orbital adipose tissue remodelling. 
 
2.2.1 Tissue specimen and preparation 
The 3T3-L1 preadipocyte cell line was obtained from the American Type Culture 
Collection (Rockville, MD). They were cultured in complete medium (see Table 8). 
Orbital tissue samples were collected, with informed consent and local research 
ethics committee approval.  GO patients (n=5; 3 females and 2 males with median 
age of 50 years of age (range 39-54 years) were diagnosed on clinical grounds based 
 70 
on the presence of typical clinical features in the context of autoimmune thyroid 
disease. The GO samples were obtained from patients undergoing decompression 
surgery and having inactive disease with a clinical activity score below 2. None of 
these patients had previous orbital radiotherapy. Only one patient had steroid 
treatment and was on the treatment during orbital decompression. The non-GO 
samples (n=5; 3 males and 2 females, median age 53 years old (range 52-60 years) 
were from individuals free of thyroid or other inflammatory eye disease who 
underwent augmented blepharoplasty. Orbital preadipocyte/fibroblasts (OF) were 
obtained from explant cultures. Briefly, orbital fat biopsies were diced and placed in 6 
well plates in 1.5 ml of complete medium (Table 8) and allowed to attach so that OF 
migrated out from the tissue. Once OFs were adherent, the plates were washed with 
culture media and OFs were grown to confluence replacing media every 7 days. The 
cells were detached with 1.5 ml of trypsin and frozen in liquid nitrogen (please see 
below) until further use. Cells were used at low passage number (≤3) thus not every 
sample was used for each experiment. 
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Table 8: Complete medium containing 10% foetal calf serum 
Component 
Volume in millilitres to make 
200 millilitres of complete 
medium. 
Dulbecco's Modified Eagle Medium 
(Cat no. BE12-741F) 
85 
Ham’s F12 
(Cat no. BE12-615F) 
85 
Foetal Calf Serum 
(Cat no.DE14-802F) 
20 
Penicillin/Streptomycin 
(10 000iu penicillin/ml 10 000iu 
streptomycin/ml) 
(Cat no. DE17-602E) 
4 
Pyruvate 
(Cat no. BE13-115E) 
2 
Bicarbonate 7.5% 
(Cat no. BE17-613E) 
2 
 
2.2.2 Passaging cells 
Both types of cells were thawed rapidly at 37°C and then cultured in 10 ml CM in 75 
cm2 flasks .CM medium were replaced every 3rd day for 3T3-L1 and once a week for 
OF. Once the cells reached 75% confluence, they were trypsinised and counted for 
subsequent experiments. A proportion of the cells were frozen using freezing mixture 
(90% FCS 10% DMSO) in a cryo vial at 1°C/hour using a Nalgene cryo container with 
100% isopropyl alcohol before being transferred into liquid nitrogen for long term 
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storage.  
2.2.3 Preadipocyte/fibroblast culture and cell counting 
Five thousand cells (3T3-L1 or OF) were plated in CM and allowed to attach for 1 
day; PGF2α at 10-8M concentration was then added only on day 0 to test for 
reversibility or daily to mimic current topical application in clinical practice. PGF2α at 
10-8M concentration was chosen as this is physiological concentration. In some 
experiments 10-6M concentration was chosen to replicate pharmacological 
concentrations of the drug. Control cells were cultured in CM containing 0.02% v/v 
DMSO. Due to the very short half-life of the product and rapid proliferation rate of the 
3T3-L1 cell line, direct cell counting (Cellometer®) was performed on days 1, 2 and 
3. In contrast, the low population doubling time (PDT) of primary OF required that cell 
counts were performed on day 5. Individual experiments were done in triplicate and 
repeated at least twice. Results are expressed as mean ± SD. 
2.2.4 Trypan blue exclusion 
Trypan blue analysis (0.1%) was carried out after 24 hours exposure to 10-6 to 10-8 
molar of PGF2α. To make 0.2% for use with cellometer; trypan 0.4% (stock solution) 
was diluted with PBS or complete media 1:1 volume i.e. 1 ml of trypan blue 0.4% with 
1 ml of PBS or CM. To stain cells equal volumes of cell suspension and trypan blue 
were mixed. 
2.2.5 In vitro adipogenesis 
The various cell populations were plated in 6 well plates in CM. Adipogenesis was 
induced in confluent cells by replacing with differentiation medium (DM) (see Table 
9) for 7 (3T3-L1) or 15 (OF) days. Prostaglandin F2α was introduced together with DM 
on day 0 at 10-8M, 10-7M and 10-6M concentration; DM ± PGF2α was changed every 3 
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days. Reversibility was tested by applying PGF2α (10-6M) for a limited number of days 
(3, 6, 9, 12 or 15 days) to allow cell recovery. Adipogenesis was assessed 
microscopically to detect the accumulation of lipid droplets and also by oil red O 
staining and QPCR analysis of markers of differentiation. 
Table 9: Differentiation medium (DM). 100 millilitres of 2X DM was prepared as below. An 
equal volume of CM was added to give a 10% FCS for human primary culture and 5% FCS 
for 3T3-L1. 
Component Volume Final Concentration 
DMEM (Lonza) 44.5 ml  
Ham’s F12 (Lonza) 44.5 ml  
FCS (Lonza) 10/20 ml 
10% (human), 
5% (3T3-L1) 
Biotin (Sigma B-4639) 64ul µl 33 μM 
Pantothenate (Sigma P-5155) 200 µl 17 μM 
T3 (Sigma T-5516) 1.4 µl 1 nM 
Hydrocortisone (Sigma H-
2270) 
20 µl 1 μM 
Pioglitazone (Takeda) 20 µl 1 μM 
Insulin (Sigma I-1882) 570 µl 500 nM 
 
2.2.6 Oil red O staining/Absorption 
Saturated (0.25-0.5% in isopropanol) oil red O stock solution can be stored for up to 
1 month. Prior to use, 12 ml saturated solution were mixed with 8 ml distilled water, 
left at room temp for 5-10 minutes. This was filtered using Whatman filter paper and 
used within 2 hours.  
For cells to be stained, the medium was removed and washed with 1 ml PBS or 
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HBSS. The cells then fixed in 500 µl 60% isopropanol for 10 minutes then washed x 
1 with 1 ml PBS and 100 µl Oil red O was added per well and left for 15 minutes at 
room temperature. Oil red O was then removed carefully. If the cells were going to be 
photographed, they were rinsed with 1 ml 60% isopropanol and washed with 1 ml 
water. If oil red O staining was to be quantified, they were washed at least x 4 with 1 
ml water until all precipitate was removed and 200 ul 100% isopropanol was added 
per well. The extracted Oil red O was then transferred to a 96 well plate and read at 
OD490. 
2.2.7 Lipolysis 
Adipogenesis was induced in vitro using DM (as above) in 3T3-L1; on day 7 the DM 
was replaced by serum free medium (SFM). Mature human orbital adipocytes were 
obtained by collagenase digest and centrifugation on a phthalic acid dinonyl ester 
gradient (see Figure 13) and resuspended in SFM. In both cases, varying 
concentrations of PGF2α were introduced alone (unstimulated lipolysis) or combined 
with 10-8M to10-6M L-Norepinephrine (stimulated lipolysis) for 4 hours. Cell 
suspensions/supernatants were extracted and free glycerol assays (Cayman 
Chemical) were performed according to the manufacturer’s instructions, after 15-
minute incubation with the assay reagents the OD was read at 490nm. 
2.2.8 Collagenase digest 
Collagenase Type 2 was prepared by dissolving 300 mg in 10 ml of DMEM and filter-
sterilization. This was frozen in 1 ml aliquots and stored at -20°C. 7.5% BSA was 
prepared by adding 7.5 g in 100 ml of distilled water, dissolved at 37°C in a water 
bath and filter-sterilised. The fat then was cut into small pieces and transferred into a 
20 ml universal container (UC). Three ml tissue was used per UC to which was added 
7 ml HBSS, 2 ml BSA, 1 ml collagenase. This was incubated at 37°C in a water bath 
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for 1 hour and shaken every 5 minutes to facilitate the digestion. The sample was 
then spun at 4°C for 5 minutes at 1500 rpm (see Figure 13). The mature adipocytes 
and preadipocytes were removed and resuspended in culture medium. 
 
Figure 13: Showing disaggregated layers which separate after centrifugation. 
 
2.2.9 Cell cycle analysis using flow cytometry 
3T3-L1 cells and OFs were plated in 75 cm2 flask, allowed to attach for 24 hours and 
then treated with 10-6M PGF2α for 48 hours and 5 days respectively. The cells were 
detached with 5 ml of trypsin and neutralised with 5 ml of CM. These were then 
washed twice with 5 ml of PBS. Each time the cells were spun at 1000 rpm for 5 
minutes. They then were fixed in 1 ml ice cold 70% ethanol and stored at -20°C before 
analysis. At this temperature, the fixed cells can be stored for a few weeks prior to PI 
staining. Before analysis, ethanol was removed by centrifugation at 2000 rpm for 5 
minutes and washed twice with 1 ml PBS. Finally, samples were resuspended in 
468.75 µl PBS with propidium iodide 25 µl of 1 mg/ml stock (final concentration 50 
µg/ml) and RNAse A 6.25 µl of 4 mg/ml stock (50 ug/ml) to a final volume of 500 µl. 
The tube was then wrapped in aluminium foil to protect it from light and left to incubate 
overnight at 4°C. Flow cytometry was performed on BD FACS Canto II using 
L i p i d s   
M a t u r e   a d i p o c y te s      O i l   
          Ca n   b e   u s e d   f o r   r e p e a t   di g e s t i o n   i f   r e q u i r e d  
P r e a d i p o c y t e s   +   R B C   
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FACSDiva 6.0 software from Becton Dickinson and Co. (Mountain View, CA). 
Propidium iodide was detected using the 575/26nm channel. Forward light scatter, 
side light scatter, and fluorescence emissions were collected for 10000 cells. Results 
were analysed using FlowJo software version 10.0.5 (Tree Star, Inc). 
2.2.10 RNA extraction  
This was performed using Tri Reagent (Sigma Catalogue Number T9424). “This 
product, a mixture of guanidine thiocyanate and phenol in a monophase solution, 
effectively dissolves DNA, RNA, and protein on homogenization or lysis of tissue 
sample. After adding chloroform and centrifuging, the mixture separates into 3 
phases: top layer; an aqueous phase containing the RNA, the interphase containing 
DNA, and an organic phase containing proteins”. 
For 6 well plates, medium was aspirated and cells were washed using 1 ml/well PBS 
followed by 1 ml/well Tri reagent. The cells were resuspended in the Tri reagent and 
when lysis was complete, were transferred to a 1.5 ml Eppendorf tube. This could be 
processed immediately or frozen at -80°C for future processing. For each 1 ml of Tri 
Reagent, 200 µl of chloroform was added and centrifuged at 13000 rpm at 4°C for 15 
minutes. Centrifugation separates the mixture into 3 phases: a colourless upper 
aqueous phase (containing RNA), an interphase (containing DNA), and a red organic 
phase (containing protein). 
The aqueous phase was then transferred into a new 1.5 ml vial. 500 µl of 
isopropanolol was added to each 1 ml of clear supernatant to precipitate RNA. This 
was gently mixed by turning the vial upside down several times and allowed to rest at 
room temperature for 10 minutes. The mixture then was spun at 13000 rpm at 4°C 
for 10 minutes.  The RNA precipitate would form a pellet on the side and bottom of 
the tube. The supernatant was then carefully removed. 1 ml of 75% ethanol was 
 77 
added to the RNA pellet to purify the RNA from excess salts, followed by a quick 
vortex then spun at 8000 rpm at 4°C for 5 minutes. The alcohol was removed and the 
remaining drops were carefully removed with a 200 µl pipette tip. The pellet was 
allowed to dry at room temperature for 10-15 minutes. The pellet was dissolved with 
6 µl of RNAse free water followed by a quick vortex and spun twice. The RNA 
concentration was then measured using NanoDrop™ Lite Spectrophotometer - 
Thermo Scientific. An absorbance A260/280 ratio of 1.8 or more was considered 
acceptable. 
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2.2.11 Reverse transcription (First-strand synthesis of cDNA) 
All the components are from Promega supplier. 
Components Volume (µl) 
dNTPs (C1141) 4 
oligodT 500 µg/ml (C1101) 4 
5X Buffer (M531A) 4 
M-MLV Reverse Transcriptase 
200 u/µl (M1705) 
1 
RNAse inhibitor 40 u/µl (N2511) 1 
Total (Master mix) 14 
RNA 1 µg 6 
TOTAL VOLUME 20 
 
1 µg RNA was made up to 6 µl with RNAse free water in a 500 µl vial. This was heated 
in a heat block at 60°C for 10 minutes to denature secondary structures within the 
template. Meanwhile the master mix was prepared, all components except the 
Moloney Murine Leukaemia Virus (M-MLV) reverse transcriptase enzyme. After 10 
minutes, the RNA was transferred immediately onto ice for 5 minutes to prevent 
secondary structure from reforming. The reverse transcriptase enzyme was finally 
added to the master mix and 14 µl was then added into each RNA sample. The 
reaction mix was placed in a thermocycler machine with the following settings: 37°C 
for 1 hour (Reverse Transcription step), 95°C for 5 minutes (Destroyed RT enzyme) 
and hold at 4°C. The resultant cDNA was stored at -20°C. 
2.2.12 Primer design 
The primers were designed using primer 3 software (http://primer3.ut.ee/). As far as 
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possible the primer pairs were designed to cross exons in order to reduce the chance 
of amplifying contaminating genomic DNA. The primers were ordered at 25 nmol 
scale and desalted for purity. Please see Table 10 for primer pairs used in these 
experiments.  
 
Table 10: PCR primers used indicating exon location and size of amplicon. 
 
Accessio
n number 
Forward  Reverse  
Amplicon 
size (bp) 
Arp 
(mouse) 
NM_01885
3.3. 
GAGGAATCAGATGAGGATATG
GGA (Exon 7) 
AAGCAGGCTGACTTGGTT
GC (Exon 7) 
72 
Gapdh 
(mouse) 
NM_00128
9726.1. 
ATGCTCGCCACAGAATCCACA
C (Exon 8) 
AACCGGCAGCCCTTGACT
TG (Exon 8) 
124 
Ptgfr 
(mouse) 
NM_00896
6.3 
ATGTTTGCTGTGTTCGTGGC 
(Exon 2) 
GGCCATTGTTACCAGAAA
GGG (Exon 3) 
330 
APRT 
(human) 
NM_00103
0018.1 
GCTGCGTGCTCATCCGAAAG 
(Exon 3) 
CCTTAAGCGAGGTCAGCT
CC (Exon 5) 
247 
LPL 
(human) 
NC_00000
8.11 
GAGATTTCTCTGTATGGACC 
(Exon 7) 
CCTTAAGCGAGGTCAGCT
CC (Exon 9) 
275 
PTGFR 
(human) 
NM_00095
9.3 
GCCCATCCTTGGACATCGAG 
(Exon 2) 
GGCCATTGTAACCAGAAA
TGGG (Exon 3) 
304 
 
Primers were reconstituted using RNAse free water to produce stock solutions of 100 
uM. For QPCR, an optimization step was performed using forward and reverse 
primers at 100, 300 and 500 nM final concentration, a total of 9 combinations (see 
Table 11).  
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Table 11: Primer concentrations grid 
Final concentration in 25 µl volume 
by using 0.5 µl of primer mix 
Volume of primer stock used (µl) 
100 nM 10 
300 nM 30 
500 nM 50 
+ H2O 100 
 
For example, in order to get 100 nM of forward and 300 nM of reverse primers in the 
final reaction mix, the primer mix was prepared by adding 10 µl of forward and 30 µl 
of reverse primers 100 µM stock with 60 µl of RNAse free water.  
2.2.13 Standard polymerase reaction 
The following programme was used to amplify the gene of interest: Initial denaturation 
- 95°C for 5 minutes; amplification steps - 94°C 30 sec, 60°C 30 sec, 72°C 30 sec (35 
cycles); final extension - 72°C for 10 minutes and hold at 4°C. Please see Table 12. 
. 
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Table 12: Standard PCR reaction components 
Component Volume (µl) 
Primer mix 1 
dNTPs 1 
10X Buffer 2.5 
H2O 19 
Taq polymerase 0.5 
DNA template 1 
TOTAL 25 
 
2.2.14 Agarose gel electrophoresis analysis of PCR product 
PCR products were analysed in a 2% agarose gel containing 400 ng/ml ethidium 
bromide (Promega). 10 µl of PCR samples or DNA ladder mixed with 2 µl 6X loading 
dye (Promega 6190A) before being loaded onto the gel. The gel was then run at 100V 
for 45 minutes. The DNA was then visualised on an UV transilluminator, and 
photographed using Alpha Innotech MultiImage II, Alpha Imager HP, and wave length 
of 365 nm.   
2.2.15 DNA purification 
PCR purity was achieved using Wizard SV gel and PCR clean-up system (Promega 
A98281) according to the manufacturer’s instructions. Briefly following 
electrophoresis, the DNA band was excised from the gel, placed in a 1.5 ml Eppendorf 
tube with 10 μl membrane binding solution per 10 mg of gel slice and incubated at 
50–65°C until the gel slice was completely dissolved. An equal volume of membrane 
binding solution was added to the PCR amplification. Meanwhile SV minicolumn was 
inserted into collection tube. The dissolved gel mixture was added to the minicolumn 
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assembly. This was incubated at room temperature for 1 minute followed by 
centrifugation at 13000 rpm for 1 minute.  Flow-through was discarded and the 
minicolumn was reinserted into the collection tube. 700 μl membrane wash solution 
(ethanol added) was added then centrifuged at 1300 rpm for 1 minute. Flow-through 
was discarded again and this time 500 μl membrane wash solution was added and 
centrifuge for 5 minutes. The collection tube was emptied and the column assembly 
was recentrifuged for 1 minute with the Eppendorf tube lid open (or off) to allow 
evaporation of any residual ethanol. Minicolumn was carefully transferred to a clean 
1.5 ml microcentrifuge tube where 20 μl of RNAse free water was added and 
incubated at room temperature for 1 minute. Finally, this was centrifuged at 13000 
rpm for 1 minute to elute the DNA which was stored at –20°C. 
2.2.16 DNA sequencing 
To confirm that the PCR amplicon was the intended product, the DNA sample 
was sequenced. Each sequence reaction contained 2 µl Big Dye Terminator 
V3.1 Sequence Reaction mix (Life Technologies, Grand Island, NY, USA), 2 µl 
forward primer (10 pmol/µl) and approximately 50 ng (typically 5 µl) of purified PCR 
made up to 10 µl with H2O. Sequencing reactions were run on a PCR machine (see 
Table 13). 
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Table 13: Programme used for sequencing 
Number of cycles Temperature °C Time 
28 
96 10 sec 
50 5 sec 
60 4 min 
 
Prior to sequencing, PCR products were precipitated using sodium acetate. 1.5 µl of 
3 M sodium acetate (pH 5.4), 7 µl of water and 31.5 µl of absolute ethanol were added 
to each 10 µl sample to be sequenced then vortexed and incubated at room 
temperature for 15 minutes. Samples were centrifuged for 20 minutes at 4°C at 
13,000 rpm, the supernatant was carefully discarded and the DNA pellet was washed 
with 250 µl of 70% ethanol (vortexed and spun for 10 minutes). Supernatant was 
removed and the samples were dried in a heat block at 95 °C for 1 minute – lid open 
to evaporate the ethanol - before re-suspension and analysis on an ABI 3100 Genetic 
Analyser.  
2.2.17 Quantitative polymerase chain reaction 
Quantitative polymerase chain reaction was performed using Sybr Green QPCR 
mastermix (Stratagene Cat no 600548) and a Stratagene (La Jolla, CA) MX3000P 
light cycler. QPCR master mix was prepared as per Table 14. Negative template 
control was prepared with 24 µl master mix along with 1 µl distilled water, while 
remaining wells were filled with 24 µl of master mix and 1 µl cDNA. To avoid 
contamination, negative template control was prepared first and capped, followed by 
cDNAs and finally the standards.  
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Table 14: Quantitative PCR components 
Components Volume (µl) 
Sybr green 12.5 
H2O 11 
Primer mix 0.5 
Master mix subtotal 24 
cDNA 1 
 
The QPCR plate was spun at 1500 rpm for 3 minutes. The following programme 
setting was used: 
Table 15: QPCR programme - 2 Steps amplification with dissociation curve setting 
Segment Temperature (°C) Duration 
Number of 
cycle 
1 
Enzyme 
Activation 
50 2 min 
1 
95 2 min 
2 
PCR 
95 15 secs 
40 
60 30 secs 
3 
Dissociation 
curve 
95 1 minute 
1 55 30 secs 
95 30 secs 
 
To allow quantification of the transcript copy numbers (TCN) per microgram input 
RNA of the gene product, standard curves were used; these comprised either the 
target gene cloned into a plasmid or serial dilutions of the target PCR amplicon. In 
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addition, transcripts for a housekeeping gene were measured so that values could be 
expressed relative to this (transcripts per 1000 housekeeping gene). In a single Q-
PCR experiment, all measurements were made in duplicate.  
The estimation of the TCN of the standard was based on the assumption that the 
average weight of a base pair (bp) is 650 Daltons. This means that one mole of a bp 
weighs 650 g and that the molecular weight of any double stranded DNA template 
can be estimated by taking the product of its length (in bp) and 650. The inverse of 
the molecular weight is the number of moles of template present in one gram of 
material. Using Avogadro's number, 6.022x1023 molecules/mole, the number of 
molecules of the template per gram can be calculated: mol/g x molecules/mol = 
molecules/g. Finally, the number of molecules or number of copies of template in the 
sample can be estimated by multiplying by 1x109 to convert to ng and then multiplying 
by the amount of template (in ng). The formula used was:  number of copies = 
(amount x 6.022x1023) / (length x 1x109 x 650). This was done using an online tool 
at http://cels.uri.edu/gsc/cndna.html. 
2.2.18 Bacterial transformation 
Bacterial plasmid glycerol stocks are important for long-term storage of plasmids. The 
preparation of plasmid constructs will be described in details in chapter 5. The 
addition of glycerol stabilizes the frozen bacteria, preventing damage to the cell 
membranes and keeping the cells alive. The bacterial plasmids were used to generate 
standard curves for QPCR or as positive control in standard PCR. Once the bacterial 
glycerol stock is made, the process of generating plasmid DNA would be a lot easier 
without the need for bacterial transformation. Experimental plasmids DNA used in the 
experiment (mouse Arp/ Gpdh and human APRT/ LPL) were stored at -20°C and 
glycerol stocks were stored at -80°C which could last for many years.  
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The first process to amplify plasmid stocks is via bacterial transformation. Luria 
Bertani (LB) Agar (Sigma L3147) 40 g/L was prepared by suspending 40 g of the agar 
powder in 1 L of distilled water. This was boiled in the microwave to dissolve it then 
autoclaved for 15 minutes at 121°C. It was cooled to 50°C prior to addition of 400 µl 
of ampicillin (stock 100 mg/ml) to give a final concentration of 100 µg/ml and 
dispensed into sterile petri dishes. Once solidified, the plate was dried further by 
turning upside down in a sterile laminar flow hood. 
LB broth (USB Affymetrix Luria Broth 758541) 25 g/L was prepared by adding 12.5 g 
of the powder with 500 ml distilled water. This was autoclaved and allowed to cool to 
55°C prior to addition of antibiotic if needed.  
This bacteria transformation was achieved by using One Shot® TOP10 Chemically 
Competent E.coli (Thermo Fisher C4040-10). For blue/white screening selection, 40 
μl of 40 mg/mL X-Gal in dimethylformamide was spread on top of the agar and left to 
diffuse into the agar for approximately 1 hour. This was done on the principle that if 
β-galactosidase is produced, X-gal is hydrolysed to form 5-bromo-4-chloro-indoxyl, 
which spontaneously dimerizes to produce an insoluble blue pigment called 5,5’-
dibromo-4,4’-dichloro-indigo. The colonies formed by non-recombinant cells, 
therefore appear blue in colour while the recombinant ones appear white. The desired 
recombinant colonies then can be easily picked and cultured. 
The vial(s) containing the plasmid/ligation reaction(s) was centrifuged briefly and 
placed on ice. The cloning process will be described in details in chapter 5.  On ice, 
one 50 μl vial of One Shot® cells was thawed. This can be divided into 2X25 µl in 1.5 
ml Eppendorf. 2 μl of each plasmid/ligation reaction was added directly into the vial 
of competent cells and mixed by tapping gently. The vial(s) was incubated on ice for 
30 minutes. Then this was further incubated for exactly 30 seconds in the 42°C water 
bath before placing them back on ice. 250 μl of pre-warmed 37°C Super Optimal broth 
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with Catabolite repression (SOC) medium was added to each vial. SOC is a rich 
medium (see Table 16). The vial(s) was then placed in a microcentrifuge rack on its 
side, secured with tape to avoid loss of the vial(s) at 37°C for exactly 1 hour at 225 
rpm in a shaking incubator. 70 μl from each transformation vial was spread on 
separate, labelled LB agar plates. The remaining transformation mix may be stored 
at 4°C and plated out the next day, if desired. The plate(s) was inverted and incubated 
at 37°C overnight. Approximately 5-10 colonies were selected and each transferred 
into 5 ml of LB broth. This was then cultured overnight again prior to miniprep. The 
remaining cultures then stored at 4°C. 
 
Table 16: SOC medium components 
SOC medium components 
2% tryptone 
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
 
2.2.18.1 Miniprep 
The miniprep was performed using GenElute™ Plasmid Miniprep Kit (Sigma PLN70) 
according to the manufacturer’s instructions. Two ml of LB Broth were harvested and 
centrifuged at 13000 rpm for 1 minute. The supernatant was discarded. The pellet 
was then resuspended with 200 µl of resuspension solution. The cells then lysed with 
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200 µl lysis solution by gentle inversion 6-8 times. This was neutralised with 350 µl of 
neutralising solution by inverting 5 times and centrifuged at 13000 rpm for 10 minutes.  
The column was then prepared by adding 500 µl column preparation solution and 
centrifuged at 13000 rpm for 1 minute. The lysate was then loaded into the column 
and centrifuged at 1300 rpm for 1 minute. The column was then washed with 750 µl 
of wash solution, centrifuged as before and the DNA was eluted into new vial with 
100 µl elution solution. 
2.2.18.2 Plasmid digestion 
To confirm the identity of the amplified plasmid, the plasmid was digested by using 
the following digestion reaction mix (see Table 17): 
 
Table 17: Component of enzyme digestion 
Components Volume (µl) 
Plasmid 1 
Xbal1 (restriction enzyme) 0.5 
10X Buffer 1.5 
H2O 12 
Final volume 15 
 
Xba1 enzyme was an example of the restriction enzyme used. Initially master mix 
was prepared, vortexed and centrifuged. Fourteen µl of the master mix was added to 
each vial containing 1 µl of plasmid and was again vortexed and centrifuged. The 
reaction was incubated 1-4 hour in the shaking incubator (37°C) and analysed by 
agarose gel electrophoresis. If the digest generated restriction fragments of the 
expected sizes, the plasmid was also verified by sequencing as described in section 
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2.2.16) 
2.2.19 Statistical analysis 
For statistical analysis, we used SPSS 18.0 software. Where appropriate, data were 
analysed using Student’s t test for parametric and Mann-Whitney for non-parametric; 
in all cases, p<0.05 was considered significant. Multiple comparisons of group means 
were analysed using one-way ANOVA with post hoc Tukey HSD. The statistical 
analysis applied is indicated in the tables and figure legends. All parametric data are 
presented as mean ± standard deviations and median ± interquartile range for non-
parametric. 
2.3 RESULTS  
2.3.1 Morphology of 3T3-L1 in complete and differentiation medium 
Upon plating after a rapid thawing process from liquid nitrogen, 3T3-L1 cells in 
complete medium had a round appearance and would attach to the plate in 
approximately 10-15 minutes. The higher the cell numbers being plated the more 
likely they would be to clump in the centre of the well. Therefore, the culture had to 
be shaken sideways to encourage the cells to spread out in the well. By the next day, 
it would adopt a phenotypic appearance of fibroblast-like cells with an elongated 
shape (see Figure 14A). It grew rapidly with doubling time of 1 day. Once subjected 
to adipogenic medium, by day 7 the cells turn into a very rounded adipocyte-like cell 
with multiple lipid droplets in each cell (see Figure 14B). Some of these cells’ lipid 
droplets coalesce to form slightly larger size droplets but none have a large single 
droplet typical of mature adipocytes (see Figure 15). These cells were easily 
detachable and float easily. Approximately 70-90% of the 3T3-L1 cells could be 
induced into adipocyte-like cells.  
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Figure 14: Phase contrast photomicrograph of undifferentiated 3T3-L1 in complete medium 
(A) and differentiation medium (B). After 7 days, lipid droplet accumulation in differentiated 
cells is clearly visible in 70-90% of the cells. Magnification 100x. 
 
Figure 15: Higher magnification (400x) of phase contrast photomicrograph of differentiating 
3T3-L1 in differentiation medium showing ring formation of lipid droplets.  
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2.3.2 Validation of the QPCR assay 
In order to confirm that the QPCR assays generated the intended products with high 
efficiency, the experimental data was validated by confirming that:  
(a) A single peak for the melting curve indicating single product has been 
amplified. 
(b) High PCR reaction efficiency. 
(c) A single band of the appropriate size on gel electrophoresis. 
(d) Identity of the intended DNA sequence. 
 
The reaction efficiency was calculated by running a standard curve using a serial 10-
fold dilution of plasmid DNA. I normally performed a standard curve having 108 copies 
in the highest and then 10-fold dilutions to 101. Example of optimization of Arp QPCR 
showing agarose gel electrophoresis (see Figure 16) and melt curve analysis (see 
Figure 17B) confirming that the Arp QPCR assay produced a single product of the 
correct size which was 72bp and correct sequence on Sanger sequencing analysis. 
Analysis of serial dilutions of Arp plasmid DNA (see Figure 17) was used to determine 
the efficiency of the assay. This can be calculated from Efficiency (E) formula, E = 
10(-1/slope). The slope was obtained by plotting the Ct values against serial plasmid DNA 
concentration using the MxPro software (Stratagene). This showed that the reaction 
has linear standard curve (r²>0.999), consistency across replicates and high 
amplification efficiency of 111.3%. 
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Figure 16: Agarose gel (2%) in 1xTris-acetate-EDTA confirming the size of the Arp QPCR 
product of 72bp. Lanes (L) DNA 100bp ladder and samples tested lane 1-7. Lane 1-7 
represents day 0, 1, 2, 3, 5, 8 and 10 during differentiation protocol of the 3T3-L1 cell line. 
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Figure 17: Validation of Arp QPCR assay performed on serial dilutions of plasmid DNA 
producing the standard curve (A) and single melting peak curve analysis (B). 
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2.3.3 PGF2α reduces 3T3-L1 cell proliferation by prolonging the G2/M phase 
In the 3T3-L1 cell line, the population doubling time (PDT) of untreated cells was 27.3 
± 4.4 (mean ± standard deviations) hours. The DMSO control at 0.02% significantly 
increased the PDT to a mean of 44.6 ± 14.4 hours (p=0.007 compared to the 
untreated cells). PGF2α at 10-8 M concentration significantly reduced 3T3-L1 cell 
proliferation with PDT of 93.6 ± 15.0 hours (p=0.049 compared to DMSO control). 
However, the limited half-life of the compound resulted in recovery of cell proliferation, 
with cell numbers returning towards untreated levels by day 3. In contrast, daily 
administration of PGF2α produced a sustained significant reduction in proliferation 
(see Figure 18).  
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Figure 18: Direct cell counting to assess the effects of PGF2α on proliferation of 3T3-L1 cells 
cultured alone (black bars, DMSO control), with addition of 10-8M PGF2α on day 0 (stippled 
bars) or with daily addition of PGF2α (grey bars). Results are expressed as the mean ± SD of 
2 individual experiments all performed in triplicate. *p<0.05, **p<0.01 and ***p<0.001 
compared with the control on the respective days. 
 
To exclude simple toxicity as the cause of reduced growth, trypan blue exclusion was 
performed and indicated >90% survival across three concentration of PGF2α (10-8M 
to 10-6M), suggesting that this is not the case (see Figure 19). In the same experiment, 
we also obtained a dose-dependent decrease in proliferation. 
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Figure 19: Trypan blue exclusion study on 3T3-L1 showing more than 90% survival across 
three concentration of PGF2α (10-8M to 10-6M). Results are expressed as the mean ± SD of 
individual experiments (n=3) all performed in triplicate. 
 
To determine whether an increase in apoptosis or cell cycle disruption was 
responsible for the increased PDT, cell cycle analysis was undertaken. Our results 
illustrate that PGF2α significantly increased the percentage of cells in the G2/M phase 
from 23.97 ± 2.87% in untreated to 35.65 ± 1.29% in treated cells, p = 0.04 (see 
Figure 20), indicating prolongation of this stage, but did not increase the proportion of 
cells undergoing apoptosis (as defined by the pre-G1 peak). The cell cycle analysis 
histogram reports DNA content with the G1 peak representing normal diploid DNA 
content and the G2+M peak representing double this amount as the cells prepare for 
mitosis. Therefore, the pre-G1 peak indicates less than the diploid DNA content as 
occurs in cells undergoing apoptosis. 
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Figure 20: Cell cycle analysis of 3T3-L1, to assess PGF2α effects, presented as scatter plots 
(A & C) and histograms  (B & D) in control (A & B) and 10-6M PGF2α (C & D) treated cells. The 
x axis on the scatter plot represents cell size where the arbitrary box was drawn to gate single 
cells and the y axis represents fluorescence intensity of DNA dye (propidium iodide). The 
histograms show the G1, S and G2/M phases (figures above = percentage of cells) in (B) 
control (+ DMSO) medium or (D) treated with PGF2α. The histogram report DNA content (x 
axis) and cell number (y axis). The figure is a representative experiment of 2 performed, both 
in duplicate. 
  
2.3.4 PGF2α reduced in vitro-induced adipogenesis in 3T3-L1 
In DM 3T3-L1 cells were induced to undergo adipogenesis with more than 70% of the 
cells acquiring a rounded appearance and intracellular lipid droplet accumulation. In 
our system, we managed to induce an approximately 14-fold increase in the terminal 
marker of differentiation, Glycerol-3-phosphate-dehydrogenase (Gpdh) transcript by 
day 7 as compared to day 0 (p=0.002). To hypothesise that the effect observed in this 
experiment was mediated by PGF2α via its receptor (PTGFR), we have to show that 
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Ptgfr transcript is present. Ptgfr transcripts were detected in the 3T3-L1 at baseline 
and after differentiation with no apparent change during adipogenesis (Figure 21). In 
view of the proliferation results, which indicated that PGF2α has a short half-life, the 
drug was added at every medium change throughout the period of differentiation. 
When assessing adipogenesis morphologically, in both treated and control groups, 
by day 3, adipogenic changes were seen but with no difference in the number of 
adipogenic foci. At day 7, the increase in numbers of lipid droplets was similar in 
PGF2α treated cells and controls. I found that the adipogenesis process in 3T3-L1 was 
very rapid and diffuse hence difficult for us to show the morphological difference 
between treated and untreated cells. When using QPCR measurement of markers of 
differentiation, the presence of 10-8M PGF2α reduced transcripts for Gpdh by about 
12-fold (p=0.01) with a dose dependent response (see Figure 22).  
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Figure 21: Agarose gel (2%) in 1xTris-acetate-EDTA confirming the size of the Ptgfr QPCR 
product of 330bp. Lanes (L) DNA 100bp ladder and samples tested on day 0 and 8 during 
differentiation protocol of the 3T3-L1 cell line. 
L							Day	0			Day	8
330	bp
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Figure 22: In vitro induced adipogenesis of 3T3-L1 cells assessed by QPCR measurement of 
glycerol-3-phosphate dehydrogenase (Gpdh) transcripts expressed as transcript copy number 
(TCN) per 1000 copies of acidic ribophosphoprotein (Arp) housekeeper gene following 7 days 
exposure to control (DM+DMSO) and treatment (DM+PGF2α). Data shown (mean ± SD) are 
from a representative experiment of two performed in duplicate. Error bar represents ± SD; 
**p< 0.01. 
 
2.3.5 PGF2α had no effect on lipolysis on differentiating 3T3-L1 
In order to study the effects of PGF2α on 3T3-L1 lipolysis, we induced adipogenesis 
by culturing confluent cells in DM for 7 days. As noted above, at this point >70% of 
the cells had undergone differentiation and contained large lipid droplets although 
none were fully mature adipocytes with a single lipid vacuole, since these cells are 
not adherent and are removed during manipulations. 
The effects of 10-8M to 10-6M PGF2α on lipolysis were assessed in unstimulated in 
vitro differentiated cells and also in cells in which lipolysis was induced using 10-8M 
to10-6M norepinephrine (produced a dose-dependent increase in free glycerol 
peaking at 300%). PGF2α alone did not induce lipolysis and had no effect on 
norepinephrine mediated lipolysis (see Figure 23). 
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Figure 23: The lipolysis effect of PGF2α was studied by inducing 3T3-L1 into adipogenesis for 
7 days in unstimulated and stimulated conditions. The control contained DSMO 0.02% only 
whilst the stimulated contains PGF2α at the concentrations of 10-8M to 10-6M and 
Norepinephrine at similar concentration ranges. The experiments were performed twice. 
Norepinephrine showed dose dependent effect on lipolysis but not PGF2α. Error bar represents 
median ± IQR. 
  
2.3.6 Morphology of primary orbital fibroblast in complete and differentiation 
medium 
After a few days in complete medium, primary human orbital fibroblasts (OF) 
proliferated out from explanted orbital fat piece as a very elongated cell with very long 
string like processes at both ends (see Figure 24). It would take approximately 1 
month to obtain confluent cells in 6 well plates and few weeks longer if it was from 
normal/non-GO orbital fat explant. Similar duration was noted upon thawing and re-
inoculating in the 75 ml flask. As the OFs became more confluent, they realign along 
themselves with their long processes interlacing with each other (see Figure 25 A and 
C). After 2-3 weeks in differentiation medium primary human OFs underwent 
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morphological changes characteristic of conversion from a fibroblast to adipocyte 
morphology. They appeared more rounded in shape filled with lipid droplets. These 
observations only happened in 30-40% of the primary OFs from GO samples and to 
a lesser degree (<5%) in normal OFs (see Figure 25 B and D).  
 
 
Figure 24: Orbital fat explant culture showing very narrow and elongated fibroblasts 
proliferated out from the fat (black shadow on the top left corner) after 3 days.  
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Figure 25: Phase contrast photomicrographs show various stages of adipocyte differentiation. 
Undifferentiated normal human orbital OFs at day 0 (A) and after 15 days in differentiation 
medium (B) stained with Oil Red O. Figure C (day 0) and D (day 15) representing OFs from 
GO patients indicating higher degree of lipid droplet accumulation. Magnification 100x. 
 
2.3.7 Validation of the QPCR assay 
Example of optimization of APRT genes showing agarose gel electrophoresis (see 
Figure 26) and melt curve analysis (see Figure 27B) confirming that the APRT QPCR 
assay produced a single product of the correct size which was 247bp and had the 
correct sequence. Analysis of serial dilutions of APRT plasmid DNA (see Figure 27) 
was used to determine the efficiency of the assay. The slope was obtained by plotting 
the Ct values against serial plasmid DNA concentration dilutions using the MxPro 
software (Stratagene). This showed that the reaction has linear standard curve 
(r²>0.999), consistency across replicates and amplification efficiency of 83.9%. 
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Figure 26: Example of agarose gel (2%) in 1xTAE confirming the size of the APRT QPCR 
product of 247bp. Lanes (L) DNA 100bp ladder, samples tested lane 1 & 2 and negative 
template control (NTC). 
  
 105 
 
 
 
Figure 27: Validation of APRT QPCR assay performed on serial dilutions of plasmid DNA 
resulting the standard curve (A) and single melting peak curve analysis (B). 
 
2.3.8 PGF2α reduced cell proliferation in GO and non-GO orbital preadipocytes 
We subsequently performed the experiments in primary OF obtained from patients 
with GO and individuals free of thyroid or other inflammatory eye disease. The 
average PDT for orbital cells from GO patients (n=3) was 5.36 ± 0.88 days but for 
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non-GO orbits (n=3) was 6.63 ± 0.69 days, the difference was significant (p=0.035) 
with GO orbital cells proliferating more rapidly. In view of the longer PDT of primary 
orbital cells, the effects of PGF2α on proliferation were assessed by cell counting 5 
days after plating in CM. Similar results to those for 3T3-L1 were obtained, in that 
PGF2α reduced orbital cell proliferation both in GO and non-GO patients compared to 
control (Figure 28). Cell-cycle analysis of the primary OF also demonstrated G2/M 
phase arrest in both GO and non-GO populations. In non-GO OF the percentage of 
cells in G2/M in control was 17.14 ± 0.72 and increased to 22.43 ± 0.89 (p=0.003); 
whilst in GO OF, PGF2α increased the percentage to 18.57 ± 0.17 from 12.49 ± 0.30 
in the DMSO control (p<0.001) (Figure 29). 
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Figure 28: Direct cell counting to assess the effects of PGF2α on proliferation of human orbital 
fibroblasts (OF) cultured for 5 days alone (DMSO control) or with 10-8M to 10-6M PGF2α added 
on day 1 and 3. Stippled bars are Graves’ OF (n=3) and grey bars non-GO (n=3). Results are 
presented as mean ± SD; *p value <0.05 compared to control on each respective day. 
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Figure 29: Cell cycle analysis was performed in orbital fibroblasts, to assess PGF2α effects, 
presented as scatter plots (A & C) and histograms (B & D) in control (A & B) and 10-6 M PGF2α 
(C & D) treated cells. The x axis on the scatter plot represents cell size where the arbitrary 
box was drawn to gate single cells and the y axis represents fluorescence intensity of DNA 
dye (propidium iodide). The histograms show the G1, S and G2/M (figures above = percent of 
cells) phases in (B) control (+ DMSO) medium or (D) treated with PGF2α. The histogram report 
DNA content (x axis) and cell number (y axis). The figure presents data from Graves’ OF and 
is a representative experiment of 2 performed (using OF from different donors), both in 
duplicate. 
  
2.3.9 PGF2α reduced in vitro-induced adipogenesis in GO and non-GO 
preadipocytes 
After 15 days incubation in DM, preadipocytes from GO and non-GO orbits were seen 
to be undergoing adipogenesis. Compared with the 3T3-L1 cell line, only a small 
proportion (up to 30-40%) of the primary cells differentiate by assuming a rounded 
appearance and forming lipid vacuoles. In our in vitro model, the addition of DM 
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induced at least a 500-fold increase in the terminal marker of differentiation LPL 
transcripts in GO orbital cells and an approximately 150-fold increase in those from 
non-GO orbits compared to day 0 (p<0.001). The increased adipogenic potential of 
the GO cells was further supported by their significantly higher colony count (p=0.013) 
and Oil Red O absorbance data (p=0.008), shown Figure 31.  
PGF2α receptor transcripts (PTGFR) were present in both normal and GO OF at 
baseline and after differentiation protocol with no apparent change during 
adipogenesis. (Figure 30). The addition of PGF2α significantly inhibited adipogenesis 
in GO and non-GO OF when assessed by all 3 measures of differentiation (Figure 31 
A-C). The drug produced visible signs of reduced adipocyte colony formation and Oil 
Red O staining, but its effects on adipogenesis were most apparent when comparing 
transcript levels for LPL. I have used LPL transcript marker in human study and Gpdh 
transcript marker for the mouse as the primers for both genes have been fully 
optimised in our lab for PCR use and also we have cloned the respective gene into a 
plasmid to allow absolute gene number quantification. A significant reduction in LPL 
transcripts was observed in cells from GO and non-GO orbits at all concentrations of 
PGF2α from 10-8M to 10-6M, p<0.01. The effects were partly reversible as illustrated in 
Figure 32, in which OF exposed to the drug for 3 days had no significant reduction in 
adipogenesis, cells exposed for 6, 9, 12 or 15 days all demonstrated a significant 
reduction in differentiation but with no significant difference when comparing cells 
exposed for 15 days with those for 6, 9 or 12.  
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Figure 30: Agarose gel (2%) in 1xTAE confirming the size of the PTGFR QPCR product of 
304bp. Lanes (L) DNA 100bp ladder, samples tested lane 1 & 2 were from normal OF on day 
0 and after 15 days differentiation respectively and lane 3 and 4 were from GO OF on day 0 
and after 15 days differentiation respectively.  
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Figure 31: In vitro induced adipogenesis (15 days in DM) in orbital preadipocytes in control 
(DMSO) and PGF2α treated cells was assessed by (A) counting foci of differentiation, (B) 
QPCR measurement of LPL transcripts and (C) quantification of Oil Red O staining. (A) Colony 
counts (n=3) are expressed as the mean ± SD from 4 representative quadrants of the well. 
(B) QPCR results (n=5) expressed as mean ± SD of transcript copy number (TCN) per 1000 
copies of housekeeper gene (adenosine phosphoribosyl transferase, APRT). (C) Oil Red O 
staining (n=2) expressed as the mean ± SD of the OD490 absorbance. Stippled bars are 
Graves’ OF and grey bars non-GO. In all cases, the bar above the control represents statistical 
comparison between GO and non-GO orbital cells, other comparisons are between treated 
and control, *p<0.05; **p<0.01; ***p<0.001. 
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Figure 32: The effects of PGF2α on adipogenesis are reversible; confluent Graves’ OF (n=2) 
were treated with differentiation medium alone or supplemented with PGF2α 10-6M for varying 
periods during differentiation as indicated in the graph. Lipoprotein Lipase transcripts were 
measured on day 15 expressed as mean ± SD of transcript copy number (TCN) per 1000 
copies of housekeeper gene (adenosine phosphoribosyl transferase, APRT). OF exposed to 
the drug for 3 days had no significant reduction in adipogenesis when LPL was measured 15 
days later, indicating cell recovery; cells exposed for 6, 9, 12 or 15 days all demonstrated a 
significant reduction in adipogenesis. In all cases, comparisons are between treated and 
control, **p<0.01; ***p<0.001. 
 
2.3.10 PGF2α had no effect on lipolysis on mature orbital adipocytes 
We obtained mature adipocytes from 2 GO patients and treated them with PGF2α 
alone or in the presence of norepinephrine, as described above for the 3T3-L1 cell 
line. No concentration of PGF2α induced lipolysis in basal conditions. Norepinephrine 
produced a dose-dependent increase in glycerol with a maximum of 260% of 
unstimulated, but as with the cell-line, this was not altered by PGF2α (Figure 33). 
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Figure 33: Mature adipocytes obtained from GO patients (n=2) via collagenase digest of orbital 
fat tissue tested in varying conditions. SFM: serum free media, NE: Norepinephrine (10-6M), 
PGF: Prostaglandin F2α (10-6M), DMSO: Dimethyl sulfoxide (0.02% v/v). Experiments were 
performed in triplicates. Results were expressed as median ± interquartile range. 
  
0
50
100
150
200
250
300
SFM NE PGF PG/NE DMSO DMSO/NE
G
ly
ce
ro
l c
o
n
ce
n
tr
at
io
n
 (
u
g/
m
l)
 114 
2.4 DISCUSSION 
The study was designed to find out whether the observed enophthalmos in patients 
treated with PGF2α is secondary to reductions in orbital tissue proliferation, 
adipogenesis and/or increased lipolysis using the well-established 3T3-L1 cell line 
and also human primary orbital fibroblasts from normal and patients with GO. The 
results presented in this study demonstrate that PGF2α agonists could be a potential 
treatment for GO. 
In the 3T3-L1 cell-line, proliferation was inhibited by PGF2α in a dose-dependent 
manner, from 10-8M (physiological concentration) to 10-6M (pharmaceutical 
concentration). We are unaware of any studies investigating whether proliferation of 
3T3-L1 is modified by PGF2α. The process appears to be mediated by prolongation 
of the G2/M phase of the cell cycle and not by cytotoxicity. This could potentially be 
mediated by downstream pathways of phospholipase C either via IP3 or 
diacylglycerol-PKC route but would require further investigation [305]. Direct cell 
counting and toxicity was performed by using an automatic counter (Cellometer®) 
which is based on image analysis of the disposable counting chamber. Even though 
it is an automated counter, the process itself was labour intensive and highly variable 
especially at low cell numbers. This was mainly due to loss of cells during preparation 
and the presence of remaining volume of media on the cell pellet. As the 
resuspension volume is small (50 µl), any remaining media can potentially dilute the 
sample. To overcome this, the cells were centrifuged at 2000 rpm instead at 1000 
rpm without causing cell rupture and each vial of the cells has to be manually 
aspirated to ensure that minimal residual media before resuspension in HBSS. 
Trypan blue analysis at 0.2% and 0.4% was found to be too concentrated for 
Cellometer® to read hence this was performed at 0.1% final concentration. For further 
reassurance, each set of experiments was performed in triplicates. The automated 
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counter is easy to use and reduces the amount of effort required to count cells 
compared to a traditional haemocytometer. Despite this, we found the technique has 
difficulty obtaining accurate measurements of cells that are extremely small (unable 
to distinguish the debris) or extremely dilute.  We were surprised to note that the 
vehicle, DMSO, exerted significant inhibition of proliferation, even at very low 
concentrations. DMSO is a widely used reagent in cell biology. It is commonly used 
as a solvent due to its efficiency as a carrier for a wide range of chemicals. It is also 
used to differentiate cells and its mode of action includes cell cycle arrest [321] but it 
should be noted that PGF2α exerted an additional significant reduction in proliferation. 
The inhibitory effects of PGF2α on adipogenesis are in agreement with those of 
several other authors [310, 322, 323].  This is despite using different adipogenic 
cocktails than us (3-isobutyl-1-methylxanthine instead of pioglitazone and T3) which 
might be due to a common inhibitory pathway by the PGF2α. Prostaglandins are 
known to exert their effects either via surface or nuclear receptors (Majority are via 
surface G-protein coupled receptors) and different prostaglandin molecules have 
different potency in inhibiting adipogenesis. This suggests that the process might be 
mediated by binding to FP receptor [324]. Membranes prepared from either 
undifferentiated or differentiated 3T3-L1 exhibited similar specific binding for [3H] 
PGF2α suggesting that FP receptors are present throughout differentiation [324].  It is 
proposed that stimulation of FP receptor leads to increase in intracellular calcium via 
activation of phospholipase C [305] and the release of calcium. This in turn leads to 
activation of calmodulin-dependent protein kinase (CaMK) [324], calcineurin-
dependent signalling pathway [310] and activation of mitogen-activated protein 
kinase resulting in phosphorylation of PPARγ [325] which is the main regulator of 
adipogenesis. Casimir et al [323] reported that endogenous PGF2α production is 
higher in undifferentiated then differentiated cells and postulated that its release from 
preadipocytes provides a control mechanism to limit adipogenesis. This could be via 
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reduction in the substrate arachidonic acid which moves towards eicosatrienoic acid 
production during adipogenesis process [326]. 
We were unable to demonstrate any modification of lipolysis, either basal or 
norepinephrine induced, by PGF2α. Other studies using different PGF2α analogues 
(latanoprost and travoprost) also did not show the effect of PGF2α on lipolysis [322]. 
We found that DMSO has no effect on lipolysis. We used in vitro differentiated 3T3-
L1, which displayed abundant lipid accumulation but these had not coalesced into the 
single vacuole which typifies a mature adipocyte (MA). Since MA cells are non-
adherent, they are lost from the culture well during media changes, but the immaturity 
of the cells used might provide some explanation for the absence of any effect. Using 
in vitro differentiated human adipocytes for studying lipolysis was not performed 
because the adipogenesis process happens in patches, and even remarkably less so 
in normal OFs cultures, making the comparison even more difficult. However, the fact 
that we did not observe any effect of PGF2α on lipolysis, when using freshly isolated 
MA from human orbital adipose tissues, albeit both samples are from GO patients, 
suggests that this limitation had minimal impact on the interpretation of the results. 
We were unable to use normal fat sample as the sample received is too small for 
collagenase digest. 
Experiments using OF from human orbits revealed disease-associated differences, 
e.g. significantly higher proliferation and adipogenic potential in cells from GO patients 
compared with those from donors free of any inflammatory eye problem or thyroid 
disease; even though the GO tissues were obtained from patients with apparently 
inactive disease. The increased proliferation in GO has been reported previously 
[327] and the enhanced adipogenesis agrees with previous ex vivo data from 
ourselves [120] and others [328].  
PGF2α significantly inhibited the proliferation of OFs, originating in GO and non-GO 
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orbits and agree with the results of Seibold et al [329] but using human subcutaneous 
preadipocytes. This is consistent with previous clinical reports and MRI studies 
regarding PGF2α causing upper eyelid sulcus deepening and reduced infraorbital fat 
combined with enophthalmos [281, 298, 301]. Similarly, in cell cycle analyses, in 
common with the 3T3-L1 cell line, there was an accumulation of OFs in the G2/M 
phase, with GO and non-GO cells being similarly affected. 
In agreement with Choi and colleagues [330] we showed that PGF2α also inhibited 
adipogenesis in OF. Although these authors only investigated cells from normal 
orbits, our studies illustrate that the GO OFs remain highly responsive to the drug and 
have not become resistant e.g. by losing FP receptors. This is in contrast with the 
result from Silvestri et al which suggested that FP receptor is down regulated during 
adipogenesis using commercially available human subcutaneous preadipocytes 
[331].  
We recognise that this study has limitations, including the use of in vitro models 
devoid of the inflammatory cytokines and cell-cell interactions operating in GO orbits. 
The differences observed also could be due to differences of the donors’ age and 
sites of the biopsy (blepharoplasty procedures from controls and orbital 
decompression from GO). The model of adipogenesis itself is using 
supraphysiological concentration of dexamethasone, insulin, PPARγ and T3. 
However the models have been used by ourselves [332] and others [245, 328] to 
provide valuable insights into the tissue remodelling leading to GO, and in the 
absence of a robust animal model is the best currently available. Current case reports 
of PGF2α causing enophthalmos are small. However, since most patients receive 
treatment to both eyes it is possible that the incidence of enophthalmos in PGF2α 
treated patients has been underestimated.  
The results obtained are encouraging, since they indicate that several of the 
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mechanisms which contribute to the expansion of the orbital volume, and responsible 
for the exophthalmos in GO, are inhibited by PGF2α. The inhibitory actions on 
proliferation and differentiation were obtained in the range of 10-8M to10-6M PGF2α 
and even the most concentrated is 3 orders of magnitude less than the 0.03% used 
in eye drops; although this is a prodrug.  The prodrug, 17-phenyl trinor PGF2α ethyl 
amide needs to be converted by an amidase enzyme present in human cornea, to 
the corresponding free acid, 17-phenyl trinor PGF2α [333, 334]. The latter free acid 
compound, which we used in these experiments to negate the requirement of the 
amidase enzyme, is a potent FP receptor agonist but has a short half-life, as 
illustrated by the rapid recovery of 3T3-L1 proliferation and OF adipogenesis when 
the agent was withdrawn, and indicates that daily administration would be required.  
We would predict that the drug will reach the retro-orbital space to exert its intended 
effect, since topical ocular administration of PGF2α leads to its detection in the 
aqueous humor and systemic circulation [335, 336];  the existence of reduced 
periorbital fat in Bimatoprost treated patients also supports the prediction [301]. 
Fortunately, drug formulations containing PGF2α have been in regular use for 
glaucoma for more than a decade, and indeed nowadays PGF2α preparations are 
available over-the-counter for cosmetic application, thus their safety is well 
established.  
About 1 in 5 of patients with Graves’ disease suffer with disfiguring eye disease or 
GO [149]. The majority of these patients have inactive disease in which the 
disfigurement persists, but there is no longer active inflammation. Rehabilitative 
surgery and symptomatic treatment is the mainstay of treatment for the late disease 
phase. However, surgery is not always successful in reducing proptosis. Here we 
suggest PGF2α agonists may thus be particularly useful in the late-phase of GO, a 
disease stage in which disfigurement and impairment of ocular function persists after 
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resolution of the initial inflammatory process and which affects 5-10 times as many 
people as the early active phase. Stable inactive patients also mean that the true 
effect PGF2α can be measured and not due to natural progress of the disease itself. 
We conclude that randomised clinical trials of PGF2α and/or associated products are 
warranted in GO. 
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Chapter Three 
 
3 PROSTAGLANDIN F2-ALPHA EYE DROPS 
(BIMATOPROST) IN GRAVES’ ORBITOPATHY: A 
RANDOMISED CONTROLLED DOUBLE BLIND 
CROSSOVER TRIAL 
3.1 INTRODUCTION 
Graves’ orbitopathy (GO) is the commonest extra thyroidal manifestation of Graves’ 
hyperthyroidism. A key mechanism underlying GO is an increase in adipogenesis in 
the orbit resulting in orbital volume expansion and proptosis (eye protrusion). 
Proptosis may persist after inflammation has subsided in the late “burnt out” phase of 
GO and the persistent disfigured appearance of the eyes is a source of significant 
psychological distress and impaired quality of life for sufferers. Despite the negative 
impact of the condition, however, there are no specific medical treatments that target 
orbital volume reduction in late stage disease. Furthermore, a UK nationwide survey 
of patients with GO revealed low satisfaction levels with existing therapies [337]. In 
this study, we propose to take advantage of the observation that enophthalmos 
(recession of the eye into the orbit) occurs in some patients treated with prostaglandin 
analogue eye drops like Bimatoprost (PGF2α) for glaucoma as well as our in vitro 
findings reported in Chapter 2, that prostaglandin analogues reduce fat expansion. 
We hypothesise that topical treatment with Bimatoprost may reduce orbital tissue 
volume in non-inflamed orbits and thereby improve quality of life in patients with GO. 
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3.1.1 Current management 
The natural history of GO comprises an early active inflammatory phase followed by 
a late or “burnt out” disease phase. For the majority of patients these treatments are 
supportive but in 5-10% of cases the disease is severe enough to merit major 
immunosuppressive therapy (e.g. high dose steroids or ciclosporin) and orbital 
radiotherapy during the inflamed "active" phase of the disease, or surgical 
decompression and rehabilitative surgery at a later stage [338]. Each of these 
treatment modalities has significant drawbacks in terms of side effects. Surgical 
decompression carries the risk of worsening double vision and local complications, 
while high dose steroid therapy may be complicated by weight gain, diabetes mellitus, 
depression, or life threatening liver dysfunction and is not effective in "burnt-out" 
disease; orbital radiotherapy is not always effective and carries the potential risk of a 
tumour developing at the treatment site [339].  
As mentioned above, most available non-surgical treatments are targeted towards 
control of inflammation during the active stage whereas rehabilitative surgery is the 
mainstay of treatment for the late disease phase. However, surgery is not always 
successful in reducing proptosis and carries the attendant risks of anaesthesia and 
local complications, (decompression surgery is highly skilled and involves removal of 
one, two or three orbital walls). PGF2α agonists may thus be particularly useful in the 
late-phase of GO, a disease stage in which disfigurement and impairment of ocular 
function persists after resolution of the initial inflammatory process and which affects 
5-10 times as many people as the early active phase. If PGF2α is confirmed to be 
effective in reducing proptosis in this study, it would indicate that PGF2α could 
represent a safe, locally acting agent in the management of GO, reducing the need 
for potentially high risk therapies such as surgical rehabilitation. 
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3.1.2 Pathophysiology 
The main pathological features of GO include expansion of orbital tissue fat, 
mononuclear cell infiltration of orbital connective tissue and extra ocular muscle, and 
tissue remodelling, a process that can culminate in fibrosis and diminished eye 
motility [278]. A key mechanism underlying GO is an increase in adipogenesis and 
associated secretion of glycosaminoglycans in the orbit, resulting in an increase in 
orbital volume and exophthalmos (protrusion of the eye) [247, 262]. The opposite 
effect, enophthalmos (recession of the eye into the orbit), has been described in 
patients with glaucoma treated with daily Bimatoprost (PGF2α), a prostaglandin 
analogue used topically in the management of intraocular hypertension (glaucoma). 
Cases of enophthalmos developing in patients treated with Bimatoprost have been 
reported worldwide, albeit in small numbers [280-282]. This side effect is more 
noticeable if only one eye is exposed to treatment as the treated eye is easily 
comparable with the unexposed eye. However, since most patients receive treatment 
to both eyes it is possible that the incidence of enophthalmos in Bimatoprost treated 
patients has been underestimated. 
3.1.3 Mechanism of action and trial rationale 
A possible mechanism by which PGF2α agonists might produce enophthalmos is 
through reduction of orbital fat volume [280]. A PGF2α receptor agonist has been 
shown to be a potent inhibitor of adipose differentiation in new-born rat precursor cells 
[340]. This raises the possibility that PGF2α exerts direct effects on adipose tissue 
precursors. We have confirmed this finding in in-vitro studies in our laboratory using 
3T3-L1 cell lines and human primary orbital fibroblast cultures. Thus, PGF2α agonists 
may be effective in reducing orbital fat expansion, ameliorating proptosis, and thus 
improving quality of life in patients with GO. There has been no clinical trial of PGF2α 
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agonists in patients with GO. We hypothesize that in order for Bimatoprost to work, 
patients must have active adipogenesis in vivo. In our in vitro model, most GO 
samples were from inactive or burnt out GO who underwent orbital decompression. 
Despite this, the tissues still have higher proliferation and adipogenesis potential than 
cells from normal orbits. This was shown in Chapter 2. 
3.2 METHODS 
3.2.1 Conduct of trial 
The trial was conducted according to the protocol and in compliance with the 
principles of the Declaration of Helsinki (1996), the principles of Good Clinical Practice 
(GCP) and in accordance with Medicines for Human Use (Clinical Trials) Regulations 
2004, as amended in 2006, the Research Governance Framework for Health and 
Social Care, the Data Protection Act 1998 and other regulatory requirements as 
appropriate. The trial has been approved by a local NHS Research Ethics Committee 
(REC, registration number: 14/WA/0081), the Medicines and Healthcare Products 
Regulatory Agency (MHRA, registration number: 21323/0043/001-0001) and is 
registered with ClinicalTrials.gov (registration number: NCT02059655) and 
International standard randomized controlled trial network (ISRCTN, registration 
number: ISRCTN46696624). 
3.2.2 Trial design 
3.2.2.1 Cross-over design 
The study was a randomised placebo controlled double blind cross over design, which 
was chosen for several reasons. First each participant serves as his or her own 
control thus reducing the influence of confounding variables (e.g. smoking status). 
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Second, each patient is exposed to both control and treatment and thus the design is 
highly efficient in that it reduces the actual number of participants required for the 
study. This is particularly useful for conditions like GO in which the prevalence of the 
condition is relatively low. Lastly the quick onset and short duration of action of 
Bimatoprost eye drops (reversible in 3 days in vitro cell cultures [18]) makes this a 
feasible design to study its effects. The drawback of this study design was that the 
long term effect of the treatment on patient outcomes, side effects and costs cannot 
be estimated, however short term efficacy could be assessed with good value for 
money. 
We had carefully considered the risk of carry over and discussed this with our 
advisory statisticians. As a result, we had extended the wash-out period from 1 month 
in our initial plans to 2 months, since the evidence suggested that carryover effect is 
likely to be negligible with the 2 months wash out period, allowing us to take 
advantage of the crossover design. In human studies, the elimination half-life of 
topical Bimatoprost is 45 minutes and the intra ocular pharmacological effect is not 
known to exceed 24 hours [17]. By one month the drug is completely washed out and 
we have allowed an extra one month of recovery period for any tissue changes to 
stabilise. Clinical case reports [13-15] suggest that effects wear off in 4-6 weeks so 
that a 2-month washout period will allow subjects to experience both treatment and 
placebo equally. Therefore, the two-month washout period should be adequate for 
complete elimination of the drug and for its biological effect to have worn off. Analysis 
of any treatment order effect will confirm this was the case at the end of the study. 
3.2.2.2 Patients recruitment 
This was a randomised controlled double blind crossover trial of Bimatoprost in GO. 
Thirty-one patients with stable late inactive disease were enrolled. Patients was 
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allocated either Bimatoprost or placebo for 3 months, followed by 2 months wash out 
period before crossing over to the opposite treatment. Follow-up continued for 10 
months’ duration. The key eligibility criteria were patients with stable proptosis of at 
least 6 months’ duration.  
Patients were recruited from the multidisciplinary thyroid eye disease clinic at 
University Hospital of Wales. There is a database of 200 patients with inactive 
(previously treated) thyroid eye disease of which we expected 60% to be ineligible 
such as due to patient refusal, current treatment with glaucoma eye drops, recent 
steroid usage or disease reactivation. This would leave 80 patients available for 
recruitment in the 6 months available; assuming a 60% recruitment rate we should 
achieve the target of 31 by contacting 50 patients. We intended to consent 31 patients 
with a diagnosis of GO in the late inactive disease stage and meeting the inclusion 
and exclusion criteria. The diagnosis of GO was made by a consultant 
ophthalmologist on the basis of clinical assessment. GO was diagnosed clinically 
in the presence of one or more of the following features: soft tissue changes in 
the eye, proptosis, extra ocular muscle dysfunction, corneal abnormalities, and 
optic nerve involvement. Allocation of subjects was by randomisation and 
minimisation to ensure balance between the 2 trial arms.  This service was provided 
by remote computerised web-based allocation of treatment arm 
(https://trials.cardiff.ac.uk/BIMA) and was supported by telephone service during 
working hours should network failure occur.  
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Figure 34: Expected participant flow  
Trial participants were randomised to receive Bimatoprost or placebo (illustrated 
above (n=expected number of participants)).  
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3.2.3 Selection of subjects 
3.2.3.1 Inclusion criteria 
1. Stable GO with no reported change in proptosis for at least 6 months. See 
section 3.2.2.2 for GO definition; 
2. Clinical activity score <3 (Appendix 4); 
3. Proptosis (subjective unilateral proptosis confirmed by asymmetry in 
exophthalmometry of >2mm OR greater than 20 mm on exophthalmometry 
measurement in one eye); 
4. Euthyroid (FT3 and FT4 in the reference range); 
5. If female, must be using a reliable form of contraception during the trial, e.g. 
oral contraceptive and condom, intra-uterine device (IUD) and condom, 
diaphragm with spermicide and condom. 
 
3.2.3.2 Exclusion criteria 
1. Age <18 yrs; 
2. Dysthyroid optic neuropathy unless previously treated; 
3. Pregnancy or lactation; 
4. Previous Corneal Herpes Simplex infection; 
5. On therapy for glaucoma or intraocular hypertension; 
6. Less than 6 months from prior systemic steroid use; 
7. Aphakia, pseudophakia with torn posterior lens capsule or anterior chamber 
lenses; 
8. Patient with risk factors for cystoid macular oedema, iritis or uveitis; 
9. Severe Asthma (risk of severe allergic reaction to medication); 
10. Previous allergy to Bimatoprost or preservative.  
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3.2.3.3 Baseline assessment 
Potentially eligible patients were assessed by one of the Clinical Investigators. 
Patients received a patient information sheet at least 24 hours before this visit. Any 
questions related to the trial was answered prior to signing informed consent. 
Subjects fitting the clinical eligibility criteria were invited to enter the trial. 
The purpose of the baseline visit was to confirm eligibility, further discuss the pros 
and cons of taking part in the study, obtain consent in patient agreeing to participate 
and conduct the trial baseline assessments. A case record form (CRF) was used to 
record the information and a modified version of the Initial Assessment Proforma 
published in 2002 by the European Group on Graves Orbitopathy (EUGOGO) was 
used. The key components of the baseline visit were to document: 
Medical History 
a. Duration and severity of GO symptoms 
b. GO treatment to date 
c. Prior and current thyroid status and treatments 
d. Ocular Co-morbidity 
e. General Past Medical History 
f. Current medications 
g. Smoking History 
h. Weight and Height 
Ophthalmological assessment 
a. Proptosis (using an Oculus© exophthalmometer) 
b. Intraocular pressure in primary position and up gaze 
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c. logMAR Visual Acuity 
d. Clinical activity score (CAS)*  
e. Palpebral aperture* 
f. Gorman’s diplopia score 
g.   Corneal integrity (Defined as healthy/dry (staining)/ulcerated) * 
(*Please see appendix 4) 
Photographs 
Colour photographs of the eye in the lateral and anterior views according 
to standard operating procedure. 
Blood tests 
Thyroid Function Tests (TSH, FT3, FT4). These was analysed in 
endocrinology laboratory University Hospital of Wales, as per standard 
practice. See appendix 4 or management of abnormal thyroid function 
test. 
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3.2.4 Trial treatments 
3.2.4.1 Bimatoprost 0.03% 
Bimatoprost (Lumigan®) was administered at a strength of 0.03%. This was 
purchased from the manufacturer (Allergan) and is the strength used in the treatment 
of intraocular hypertension and glaucoma. It was administered at a dose of one drop 
in the eye once daily between 6:00 - 00:00 pm starting from the day of allocation. It 
was self-applied to the affected eye in unilateral involvement or in case of bilateral 
involvement, to both eyes.  
3.2.4.2 Placebo  
The placebo was an artificial tear purchased from the manufacturer (Blumont 
Healthcare). To enhance masking the placebo contained artificial tears with similar 
preservative (Benzalkonium chloride) which replicated any mild stinging sensation 
experienced with Bimatoprost. It was administered at a dose of one drop in the eye 
once daily between 6:00 - 00:00 pm starting from the day of allocation. It was self-
applied as per Bimatoprost eye drops.  
3.2.4.3 Concomitant medication 
Patients were allowed to use preservative free eye drops during the trial which had to 
be applied at least 30 minutes before/after IMP application. No other eye drops were 
allowed during the trial period. Patients were asked during each visit regarding any 
change in their regular medication especially recent steroid exposure. 
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3.2.5 Follow up assessment 
The primary outcome measure for the trial was based on exophthalmometry readings 
of proptosis measured using a Hertel exophthalmometer, according to a standard 
operating procedure. This was assessed by the lead ophthalmology investigator at 
each follow-up visit and their measurement recorded on the trial’s Clinical Report 
Form. Please refer to visit schedule in Appendix 4 for more details. 
The key components of the follow-up visits were:  
1. Ophthalmological assessments 
2. Adverse events  
3. Any Changes in medications (including thyroid treatments) 
4. Any Changes in smoking habit 
5. Weight 
6. Colour photographs of the eye in the lateral and anterior views according to 
standard operating procedure 
7. GO-QOL (Appendix 4) done at clinic visits 
8. EQ-5D-5L (Appendix 4 done at clinic visits 
9. Review of clinical blood tests 
3.2.6 Objectives 
The overall objective was to determine whether Bimatoprost eye drops can reduce 
proptosis in inactive thyroid eye disease. 
3.2.6.1 Primary endpoint 
The primary endpoint of the study was to compare the change in exophthalmometry 
readings over the two 3-month treatment periods. A treatment effect of reducing 
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proptosis by 2 mm for treatment compared to placebo would be considered clinically 
relevant.  
3.2.6.2 Secondary endpoints 
1. Change in quality of life scores on the GO quality of life questionnaire (GO-QOL). 
The GO-QOL measures two different aspects of health related quality of life: 
(1) visual functioning as a consequence of double vision and decreased visual 
acuity (question 1-7) and (2) psychosocial functioning as a consequence of a 
changed appearance (question 8-15). A score of 1, 2, or 3 was assigned to 
each of the questions in each subscale to indicate whether the limitation was 
marked, mild, or absent, respectively. The scores were added to obtain a raw 
score. The final score was calculated as follows: [(raw score-7)/14x100]. In 
case one item has to be excluded (no answer to one question) the final score 
is calculated as follows: [(raw score-6)/12x100. The scores range from a 
minimum of 0 (marked limitation) to 100 (no limitation). A change of at least 6 
points was considered a minimal clinically important difference (MCID). This 
cut-off value was derived from a previous study in which the MCID, defined 
as the smallest difference in score on the domain of interest which patients 
perceived as of benefit and which would mandate, in the absence of 
troublesome side effects and costs, a change in the patient’s management in 
either GO-QOL subscales appeared to be 6 points. The change was 
measured during the 2 treatment periods and 2 two-month wash out periods 
(between treatment and at the end of the trial). This would indicate whether 
QOL is improved or worsened once the effect of medication wears off during 
the washout phase. 
 
2. Change in intraocular pressures (IOP) 
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IOP during primary gaze and chin forward position: 
a) Treatment versus placebo and  
b) Primary gaze versus chin forward pressure. 
 
3. Side effect profiles of Bimatoprost in GO patients during the study. 
Safety was evaluated with a summary of adverse events. All trial subjects 
were asked about co-morbidities, medications and new or unexpected 
symptoms at each follow-up visit (collected via patient’s diary), as well as an 
ophthalmic and general examination. Patient’s photographic assessment by 
a blinded assessor also was performed. 
 Common side effects 
I. Conjunctival redness  
II. Lengthening of eyelashes 
III. Darkening of eye lashes  
IV. Peri-ocular skin pigmentation  
V. Darkening of the iris  
 
Rare side effects 
I. Iris cysts 
II. Cystoid macular oedema 
III. Anterior uveitis 
IV. Reactivation of herpes simplex virus infection. 
 
4. Health economic evaluation 
The primary intention of the economic evaluation was to explore the cost 
associated with GO treatment. It was measured from the perspective of 
the NHS, the patient and society using the client service receipt inventory 
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(CSRI) which had been modified under the guidance of a health economist 
to capture the cost associated with Graves’ disease and GO. In theory, 
Bimatoprost intervention would lead to the net cost savings to NHS in 
comparison to surgical rehabilitation that the patient otherwise would go 
through. We were aware of limitations in the trial design as its primary 
intention is to evaluate efficacy of Bimatoprost in GO, not to follow up 
patients until they might need surgery. However, it would be useful to 
collect the resource use and quality of life data during this trial period on a 
pilot basis which may lead to a larger health economic focus study in the 
future. It was not envisaged that the crossover design would yield data 
that could allow a meaningful incremental cost-effectiveness ratio (ICER) 
to be calculated for Bimatoprost against placebo, as the duration of effects 
on perceived quality of life cannot be predicted in advance. 
 
3.2.6.3 Other outcomes  
1. Generic (EQ-5D-5L) Health Questionnaire 
2. Clinical activity score  
3. Total eye score  
4. Palpebral aperture 
5. Subjective eye changes 
6. Patients’ satisfaction with the treatments 
7. Blinding success (assessor and patient) 
8. Photographic assessments 
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3.2.7 Statistical analysis 
3.2.7.1 Determination of sample size 
The primary outcome of interest was the change in proptosis with Bimatoprost 
treatment and a reduction of 2 mm or more was regarded as clinically relevant. 
Previous studies have shown a standard deviation of 2.5 mm in proptosis 
measurements in patients with GO [19, 20]. We calculated that 16 participants would 
be needed to be able to identify a treatment effect of 2 mm as statistically different 
(p=0.05, two-sided, power 0.84) and 26 participants would be needed to be able to 
identify a treatment effect of 1.6 mm as statistically significant (p=0.05, two-sided, 
power 0.88) (Figure 35). We have opted for the latter which meant we would have 
more data (26 participants) but a smaller treatment effect than originally intended.  
Allowing for a 15% dropout rate and/or incomplete datasets, we intended to recruit 31 
participants. If the number of participants with incomplete datasets reached 30% there 
would still be 80% power to detect an effect of this size.  
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Figure 35: Graph plot of power calculation. Total sample size (N) was plotted against size 
effect in millimetres (Mean1) with standard deviation of the differences is 2.5 mm using a 
significance level (alpha) of 0.05 and two-sided paired t-test. It shows that that sample size 
drops as effect size increases. Red dot indicates power of approximately 91% and green dot 
indicates power of 82%. 
3.2.7.2 Data preparation 
Data cleaning and preparation were carried out prior to analysis. The process 
involved monitoring the following: 
1. Naming and labelling of all variables and values 
2. Presence of duplicates in the file; 
3. Presence of non-existent patients;  
4. Compulsory completion of a variable;  
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5. Out-of-range values; 
6. Logical inconsistencies between variables; 
7. Missing data investigated and data imputation 
considered where missing is not considered to be 
at random; 
8. Data set preparation for multilevel modelling to 
include both eyes and both phases where 
appropriate; 
9. Normality of outcome variables investigated. 
 
Data analysis was proceeded according to CONSORT guidelines for randomised 
controlled trials. 
3.2.7.3 Demographic and Baseline Characteristics 
Descriptive statistics were used to describe the group of individuals recruited to the 
trial in relation to those eligible, and to investigate comparability of the trial arms at 
baseline.  A tabulation of demographic and clinical variables was carried out to identify 
any chance imbalances at baseline between the two treatment groups.  
3.2.7.4 Primary outcome analysis 
1. The mean change in proptosis measurement in the treated phase and 
control phase was compared with a paired t-test and displayed visually 
using Box plots. This was carried out using the mean improvement of 
the two eyes where both have been treated.   
2.  Proptosis for patients with both eyes treated and the one eye for 
patients with only one treated eye was analysed using a multilevel 
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model in STATA. This would also enable us to use one data point for 
those patients who were unwilling or unable to proceed to the second 
phase of the protocol, thus using all available data as efficiently as 
possible. 
Demographic and clinical variables (including baseline, the order of 
treatment and carryover effects) were used in this multilevel model 
regression model to reduce the unexplained variance and obtain better 
estimates of effect size with tighter confidence intervals. The results 
were expressed as millimetres effect from the treatment arm 
controlling for the placebo effect with 95% confidence intervals and p-
values. 
3. Phase effects and carry over effects were also reported in this way, but 
the study had not been designed to be powered to detect these effects 
as statistically significant unless they are as large as the treatment 
effect. 
3.2.7.5 Secondary outcome and other analysis 
Secondary and other outcomes were summarized with descriptive statistics. 
Continuous variables were summarized with n, mean and standard deviation for 
normally distributed data and with n, median and interquartile range for non-
parametric data. Frequency counts and percentage of subjects within each category 
were provided for categorical data. 
These secondary outcome variables were tested for differences by treatment phase 
using Wilcoxon signed rank tests and McNemar’s tests for non-normally distributed 
data and categorical data respectively for significance testing. To provide statistics on 
the strength of differences between the two phases, mean differences with 95% 
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confidence intervals were produced for normally distributed variables, and similar 
95% confidence intervals were provided where possible for other types of statistic. 
The frequency of adverse effects was compared in the treatment and control phases 
by observation of data tables and where appropriate use of the McNemar X2 for 
paired samples. 
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3.3 RESULTS 
3.3.1 Trial process 
Seventy-two patients were invited initially of which 33 agreed for the trial enrolment. 
One patient was ineligible on screening and one patient chose not to take part due to 
fear that Bimatoprost might change her pupil colour. Thirty-one patients were 
subsequently randomised and underwent the first phase of the trial successfully. 
Unfortunately, one patient died at the end of wash out period due to pulmonary 
embolism which was not considered to be related to the investigational product. 
Therefore, 30 patients were entered into the second phase of the trial. One patient 
did not return for visit 4 (end of second phase assessment) due to withdrawal of 
consent. Twenty-nine patients entered second washout phase and completed the 
trial.  
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Figure 36: Study consort diagram 
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3.3.2 Demographic and baseline characteristics 
Out of 31 patients, we have female preponderance with 5:1 ratio and mean age of 55 
(SD 11). Patients had a median symptom duration of 4.0 (IQR 5.0) months before the 
diagnosis was made. As we were looking at late phase ‘burnt out’ GO, the median 
duration of GO was 7.6 (IQR 8.7) years. As expected the majority were smokers at 
diagnosis (74.2%) but this reduced to 38.7% after the diagnosis. The majority are still 
suffering from diplopia (61.3%) with bilateral involvement (61.3%). There was a good 
balance between the 2 treatment allocations with some differences on smoking 
history but not at trial entry and more patients with constant diplopia (Table 18).  
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Table 18: Demographics of all the trial patients and then split into treated with Bimatoprost 
first or placebo first phases. Data presented as means (standard deviation or range) unless 
stated otherwise or % (patient number/total).  
Treatment allocations All patients Bimatoprost Placebo 
F:M (ratio) 26:5 14:2 12:3 
Caucasian: Others (ratio) 29:2 14:2 15 
Age (years) 55 (11) 55 (9) 55 (12) 
BMI (kg/m2) 29.0 (6.5) 28.8 (6.3) 29.2 (7.0) 
Symptom duration before diagnosis 
(months), median (IQR) 
4.0 (5.0) 3.5 (4.5) 4.0 (5.0) 
GO Duration (years), median (IQR) 7.6 (8.7) 8.8 (10.9) 7.1 (8.0) 
Smokers at diagnosis (%) 74.2 (23/31) 81.2 (13/16) 66.7 (10/15) 
Current smoking (%) 38.7 (12/31) 37.5 (6/16) 40.0 (6/15) 
No. cigarettes/week 84 (0-280) 82 (0-280) 86 (5-210) 
FT4 (pmol/L) 16.1 (3.5) 17.2 (3.4) 14.8 (3.4) 
TSH (mU/L), median (IQR) 0.87 (2.48) 0.76 (1.07)  1.45 (5.21) 
Total Diplopia (%) 
Intermittent 
Inconstant (gaze-evoked) 
Constant 
61.3 (19/31) 
25.8 (8/31) 
16.1 (5/31) 
19.4 (6/31) 
62.5 (10/16) 
18.8 (3/16) 
12.5 (2/16) 
31.3 (5/16) 
60.0 (9/15) 
33.3 (5/15) 
20.0 (3/15) 
6.7 (1/15) 
% Eyes treated 
Both 
Right or Left 
 
61.3 (19/31) 
38.7 (12/31) 
 
62.5 (10/16) 
37.6 (6/16) 
 
60.0 (9/15) 
40.0(6/15) 
Clinical activity score, median (IQR) 0 (1) 0 (1) 0 (1) 
GO severity at enrolment 
Mild 31/31 16/16 15/15 
Palpebral aperture (mm) 11.1 (2.0) 11.8 (2.0) 10.4 (1.7) 
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Previous treatments of GO (%) 
Selenium  
Steroid 
Other immunosuppressant 
Radiotherapy 
Decompression 
Blepharoplasty 
 
29.0 (9/31) 
51.6 (16/31) 
22.6 (7/31) 
35.5 (11/31) 
19.4 (6/31) 
35.5 (11/31) 
 
25.0 (4/16) 
37.5 (6/16) 
31.3 (5/16) 
37.5 (6/16) 
18.8 (3/16) 
25.0 (4/16) 
 
33.3 (5/15) 
66.7 (10/15) 
13.3 (2/15) 
33.3 (5/15) 
20.0 (3/15) 
46.7 (7/15) 
The diplopia severity was assessed by Gorman score and GO severity according to 
EUGOGO. GO, Graves’ orbitopathy; BMI, body mass index; IQR, interquartile range; FT4 
(9.0-19.1 pmol/l); TSH (0.30-4.4 mU/l).  
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3.3.3 Primary outcome analysis 
The mean exophthalmometer readings of the treated eyes throughout the trial was 
around 23 mm (range 18 – 31.5) (see Table 19 and Figure 37). 
 
Table 19: The mean exophthalmometer readings of the treated eyes throughout trial visits. 
“Obs” indicates number of observations. 
Visit  Obs Mean (mm) Std. Dev. Min Max 
1 31 23.6 2.5 20 30.5 
2 31 23.4 2.7 18 30 
3 30 23.1 2.7 19 29 
4 29 23.7  2.9 19 31 
5 29 23.9 2.6 20 31.5 
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Figure 37: The mean exophthalmometer readings of all treated eyes throughout the trial. The 
box represents interquartile range (IQR) with median line and the whiskers represent all data 
points within 1.5 IQR.  
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The mean change in measurement was calculated by subtracting the baseline 
measurement from that following treatment. Therefore, negative values indicate an 
improvement in the treatment. The mean change in proptosis measurement in the 
placebo phase and Bimatoprost phase was compared with a paired t-test and 
displayed using dot plots (Figure 38). This was carried out using the mean 
improvement of the two eyes where both have been treated. The mean changes in 
Bimatoprost phase were 0.17 mm (95% CI -0.35 to 0.69) versus 0.26 mm (95% CI -
0.51 to 1.03) in the placebo phase. These were not statistically different with p value 
= 0.8455.  
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Figure 38: Dot plot of the mean change in proptosis measurement in the placebo phase and 
Bimatoprost phase expressed in millimetres. The mean change in measurement was 
calculated by subtracting the baseline measurement from that following treatment. Therefore, 
negative value indicates an improvement in the treatment. The ++ represents mean and the -
- represents standard deviation. Paired t-test p value=0.8455. 
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There were 3 patients who were deemed to be protocol non-compliant with inclusion 
criteria who had FT4 levels above the reference range with normal FT3 during the 
screening period. This was due to missed interpretation of the inclusion criteria: 
Euthyroid (FT3 and FT4 in the reference range), instead FT3 or FT4 results were 
used. It should be stressed that all of these patients were clinically euthyroid during 
randomisation. A sensitivity analysis was done after exclusion of these three subjects 
to determine any effect on the study conclusions. There was no difference between 
the 2 groups with Bimatoprost mean change of 0.17 mm (95% CI -0.40 to 0.75) versus 
placebo mean change 0.02 mm (95% CI -0.75 to 0.79) p=0.727 (Figure 39).  
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Figure 39: Dot plot of the mean change in proptosis measurement in the placebo phase and 
Bimatoprost phase expressed in millimetres excluding 3 patients with protocol non-
compliance. The mean change in measurement was calculated by subtracting the baseline 
measurement from that following treatment. Therefore, negative value indicates an 
improvement in the treatment. The ++ represents mean and the -- represents standard 
deviation. Paired t-test p value=0.727. 
 
Using pkcross function on the STATA version 12 program, there were no period 
(p=0.38) or carryover (p=0.46) effects observed.  
3.3.3.1 Multilevel modelling 
Data from patients with both eyes affected/treated and patients with one eye 
affected/treated were analysed using a multilevel model in STATA which will also give 
us the ability to use one data point for those patients who were unwilling or unable to 
proceed to the second phase of the protocol thus using all available data as efficiently 
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as possible. In this process, each patient’s eye outcome measured was nested within 
each individual patient. 
Crude analysis (model 1) did not show any treatment effect on the exophthalmometer 
readings with coefficient of -0.27 mm (95% CI -1.43 to 0.89, p=0.648). Adding 
multilevel modelling correcting for baseline and phase of treatment (model 2) 
improved the model with treatment coefficient of -0.17 mm (95% CI -0.67 to 0.32) but 
not statistically significant p=0.490. Carryover adjustment was omitted because of 
collinearity with the phase of treatment. Adding the assessors to the model did not 
improve the model with treatment effect of -0.16 mm (95% CI -0.65 to 0.33, p=0.531) 
and assessor coefficient of -0.34 (95% CI -0.96 to 0.27, p= 0.274). Removing 3 
patients with protocol deviation to the model 2 and 3 resulted in a worsening of 
treatment effect with model 2 treatment coefficient of -0.06 mm (905% CI -0.56 to 
0.45, p=0.827) and model 3 treatment coefficient of -0.04 mm (95% CI -0.55 to 0.46, 
p= 0.861). Using response to any drop in IOP as a surrogate marker for compliance 
improved the model but with no statistically significant treatment effect on proptosis 
as measured on the exophthalmometer (Table 20).  
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Table 20: Beta coefficient of Bimatoprost effect on exophthalmometer readings using 
multilevel modelling with each treated patient’s eye within the patient. Minus protocol deviation 
indicated 3 patients removed from the analysis due to the stated reason. Minus IOP non-
responder indicated removal of eyes with no reduction in intraocular pressure (surrogate 
marker to compliance). 
Model N  coefficient 95% CI p value 
All patients 
Model 1 96 -0.27 -1.43, 0.89 0.648 
Model 2 96 -0.17 -0.67, 0.32 0.490 
Model 3 96 -0.16 -0.64, 0.33 0.531 
Minus protocol deviation 
Model 1 88 -0.20 -1.44, 1.03 0.745 
Model 2 88 -0.05 -0.56, 0.45 0.827 
Model 3 88 -0.04 -0.55, 0.46 0.861 
Minus IOP non-responder 
Model 1 88 -0.34 -1.59, 0.91 0.593 
Model 2 88 -0.29 -0.81, 0.24 0.283 
Model 3 88 -0.26 -0.78, 0.25 0.313 
 
Model 1 Crude. 
Model 2 Adjusted for baseline, phase and carryover. 
Model 3 Adjusted for baseline phase, carryover and assessors. 
  
 153 
3.3.4 Exophthalmometer change in patients with unilateral proptosis 
There were 12 patients with unilateral proptosis. In these patients, only the eye with 
proptosis was treated whilst the other untreated eye served as a control. Analysis of 
the exophthalmometer reading revealed predicted baseline exophthalmometer 
difference with higher exophthalmometer mean of 22.17 mm in the treated (95% CI 
21.16 to 23.17) compared with 20.33 mm (95% CI 19.14 to 21.52) p=0.0032 in the 
untreated eye (Figure 40). Interestingly, treatment with Bimatoprost produced a 
statistically significant reduction in exophthalmometry in treated eyes, with a mean 
change of -1.17 mm (95% CI -2.62 to 0.29) compared to the untreated eye of 1.92 
mm (95% CI 0.60 to 3.23) p=0.0067 (Figure 41). In this case 9 patients had a 
reduction in their exophthalmometer reading whilst 3 patients did not. 
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Figure 40: Box plot of the baseline proptosis measurement in the untreated and treated eyes 
expressed in millimetres in patients with unilateral proptosis (n=12). Paired t-test p 
value=0.0032. 
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Figure 41: Box plot of the mean change in proptosis measurement in the untreated and treated 
eyes expressed in millimetres in patients with unilateral proptosis (n=12). The mean change 
in measurement was calculated by subtracting the baseline measurement from that treatment. 
Therefore, negative value indicates an improvement in the treatment. Paired t-test p 
value=0.0067. 
 
3.3.5 Secondary outcome analysis 
3.3.5.1 Change in quality of life scores on the GO quality of life questionnaire (GO-
QOL) [341] 
3.3.5.1.1 Total visual score 
In general patients scored highly on total visual score throughout trial visits with the 
range of mean total visual scores of 79 to 85 (see Table 21 and Figure 42). Test for 
downward trend for total visual score mean with time was not significant (p=0.2816). 
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Table 21: Total visual score of GO-QOL throughout trial visits. “Obs” indicates observation 
numbers. 
Visit  Obs Mean Std. Dev. Min Max 
1 31 84.5 20.6 8.3 100 
2 31 85.0 24.6 0 100 
3 30 81.3 24.9 8.3 100 
4 29 79.4 24.9 14.3 100 
5 29 79.4 24.9 14.3 100 
 
 
 
Figure 42: Box plot of total visual score of GO-QOL throughout trial visits. The box represents 
interquartile range (IQR) with median line and the whiskers represent all data points within 1.5 
IQR. 
 
With regard to treatment, we did not see any change in total visual scores using GO-
QOL questionnaire. The change was calculated by subtracting post treatment score 
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against baseline score. A positive value would indicate an improvement in quality of 
life and a change of at least 6 points was considered a minimal clinically important 
difference. The mean changes for Bimatoprost was 0.8 (95% -7.1 to 8.7) versus 
placebo -0.6 (95% CI -6.5 to 5.2) p=0.7933. There was a moderate negative 
correlation between Gorman diplopia score and total visual score (Spearman’s rho -
0.5118, p<0.0001). This negative correlation persisted even after removing patients 
treated with prism (Spearman rho -0.5111, p<0.0001). 
 
Figure 43: Total visual score change of GO-QOL 3 months after each treatment. The change 
was calculated by subtracting post treatment score against baseline score. A positive value 
would indicate an improvement in quality of life and a change of at least 6 points was 
considered a minimal clinically important difference. Paired t-test p=0.7933. 
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3.3.5.1.2 Total appearance score 
Patients scored moderately throughout trial visits with regard to total appearance 
score with the mean ranging from 52 to 58 (see Table 22 and Figure 44). 
 
Table 22: Total appearance score of GO-QOL throughout trial visits. “Obs” indicates 
observation numbers. 
Visit  Obs Mean Std. Dev. Min Max 
1 31 52.2 26.2 0 100 
2 31 55.6 28.7 0 100 
3 30 57.9 30.1 0 100 
4 29 55.4 29.7 0 100 
5 29 55.0 29.8 0 100 
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Figure 44: Box plot of total appearance score of GO-QOL throughout trial visits. The box 
represents interquartile range (IQR) with median line and the whiskers represent all data 
points within 1.5 IQR. 
 
Similarly, we did not see any change in total appearance score at 3 months after 
Bimatoprost treatment with the mean of 0.4 (95% CI -3.6 to 4.5) versus placebo 2.2 
(95% CI -5.2 to 9.5) p=0.6897 (Figure 45). There was no correlation between Gorman 
diplopia score and total appearance score (Spearman’s rho –0.0785, p=0.3396). This 
negative correlation became significant after removing patients treated with prism 
albeit rather weak association (Spearman rho -0.2282, p<0.0115). 
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Figure 45: Total appearance score change of GO-QOL 3 months after each treatment. The 
change was calculated by subtracting post treatment score against baseline score. A positive 
value would indicate an improvement in quality of life and a change of at least 6 points was 
considered a minimal clinically important difference. The box represents interquartile range 
(IQR) with median line and the whiskers represent all data points within 1.5 IQR. Paired t-test 
p=0.6897. 
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3.3.5.2 Change in intraocular pressures (IOP) 
3.3.5.2.1 IOP during trial visits 
During trial visits, the mean intraocular pressures measured in primary position were 
between 16-18 mmHg (Table 23 and Figure 46). 
 
Table 23: Intraocular pressure measurements (mmHg) during trial visits. 
Visit  Obs Mean 
(mmHg) 
Std. Dev. Min Max 
1 31 18.2 4.0 10 25 
2 31 17.3 3.6 11.5 25 
3 30 17.8 3.5 11 24 
4 29 16.2 3.5 10.5 22 
5 29 17.3 3.6 11.5 22.5 
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Figure 46: Box plot of intraocular pressure measurements (mmHg) during trial visits. The box 
represents interquartile range (IQR) with median line and the whiskers represent all data 
points within 1.5 IQR. 
 
3.3.5.2.2 IOP Treatment versus placebo in primary position 
As expected Bimatoprost caused reduction in IOP pressure by the mean change of -
2.7 mmHg (95% CI -4.0 to -1.4) compared to placebo with the mean change of 0.3 
mmHg (95% CI -1.4 to 2.1) p=0.0070 (Figure 47).  
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Figure 47: Mean change of intraocular pressure (mmHg) in placebo compared to Bimatoprost 
(*Paired t-test p=0.0070). The box represents interquartile range (IQR) with median line and 
the whiskers represent all data points within 1.5 IQR. 
 
3.3.5.2.3 IOP in primary versus chin forward position 
We found chin forward position did not alter intraocular pressure significantly. On 
Bimatoprost the mean change in primary position was -2.7 mmHg (95% CI -3.9 to -
1.4) compared to chin forward position mean -2.2 mmHg (95% CI -3.8 to -0.9) 
p=0.5208. The mean change in primary position in placebo group was 0.4 mmHg 
(95% CI -1.3 to 2.1) compared to chin forward position 1.4 mmHg (95% CI -0.5 to 3.3) 
p=0.1249 (Figure 48). 
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Figure 48: Box plot of intraocular pressure change in placebo and Bimatoprost in primary 
position versus chin forward position. The box represents interquartile range (IQR) with 
median line and the whiskers represent all data points within 1.5 IQR. 
 
3.3.5.3  Side effect profiles of Bimatoprost in GO patients during the study 
Bimatoprost was associated with more patient reported ocular side effects in 
particular conjunctival hyperaemia in 10 patients (32.3%) versus 3 patients (9.7%) in 
placebo and eye pruritus 4 patients (12.9%) versus 1 patients (3.2%) in placebo 
(Table 24). There was also higher incidence of headache in Bimatoprost group 9 
patients (29%) compared to 2 patients (6.5%) in placebo (Table 25). 
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Table 24: Patient reported ocular side effects. 
Ocular side effects 
 
Bimatoprost 
n (%) 
Placebo 
n (%) 
Trial total 
n (%) 
Conjunctival 
hyperaemia 10 (32.3) 3 (9.7) 16 (51.6) 
Eye pruritus 4 (12.9) 1 (3.2) 5 (16.1) 
Eyelid swelling 3 (9.7) 2 (6.5) 5 (16.1) 
Visual disturbance 2 (6.5) 0 2 (6.5) 
Meibomian cyst  2 (6.5) 2 (6.5) 5 (16.5) 
Burning sensation 1 (3.2) 1 (3.2) 3 (9.7) 
Eye dryness 1 (3.2) 1 (3.2) 2 (6.5) 
Eyelid 
pigmentation 1 (3.2) 0 1 (3.2) 
Conjunctivitis 1 (3.2) 0 2 (6.5) 
Foreign body 
sensation 0 1 (3.2) 1 (3.2) 
Eye pain 0 1 (3.2) 1 (3.2) 
Ptosis 0 1 (3.2) 1 (3.2) 
Difficulty eye 
opening 0 1 (3.2) 2 (6.5) 
Sub total  25 (80.6) 14 (45.2) 46 (148.4) 
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Table 25: Patient reported non-ocular side effects. 
Non-ocular side effects 
 
Bimatoprost 
n (%) 
Placebo 
n (%) 
Trial total 
n (%) 
Pain (total) 16 (51.6) 2 (6.5) 22 (71.0) 
Pain headache 9 (29.0) 2 (6.5) 11 (35.5) 
Infection 3 (9.7) 1 (3.2) 6 (19.4) 
Sinus 3 (9.7) 4 (12.9) 9 (29.0) 
Flu-like syndrome 1 (3.2) 1 (3.2) 6 (19.4) 
Urticarial 1 (3.2) 1 (3.2) 4 (12.9) 
Bronchospasm 1 (3.2) 0 1 (3.2) 
Osteoarthritis 1 (3.2) 0 1 (3.2) 
Dizziness 0 1 (3.2) 1 (3.2) 
Heartburn 2 (6.5) 0 2 (6.5) 
Musculoskeletal 1 (3.2) 0 1 (3.2) 
Polydipsia 0 1 (3.2) 1 (3.2) 
Tooth ache 1 (3.2) 0 1 (3.2) 
Urine colour change 0 1 (3.2) 1 (3.2) 
D&V 1 (3.2) 0 2 (6.5) 
Joint function 0 2 (6.5) 2 (6.5) 
Ear wax 0 0 1 (3.2) 
Pulmonary Embolism 0 0 1 (3.2) 
Osteoporosis 0 0 1 (3.2) 
Middle ear surgery 0 0 1 (3.2) 
Total 31 (100.0) 16 (45.2) 64 (206.5) 
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3.3.5.4 Health economics consumption 
The primary intention of health economic evaluation was to explore the cost 
associated with GO treatment. In theory, Bimatoprost intervention would lead to the 
net cost savings to NHS in comparison to surgical rehabilitation that the patient 
otherwise will go through. However it would be useful to collect the resource use on 
a pilot basis which may lead to a larger health economic focus study in the future. As 
expected there was no difference in NHS health economics consumption between 
Bimatoprost and placebo period. The median thyroid and GO related drugs cost 4 
months’ post Bimatoprost treatment was £12.36 (range £0.00-£136.04) compared to 
placebo treatment £10.85 (£0.00-£131.84) and the NHS encounter median cost 
during similar period was £86.60 (£0.00-£528.80) compared to placebo £67.80 
(£0.00-£995.40) (Table 26). 
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Table 26: Health economics consumption comparison 
 2 months period 2 months period All (4 months period) 
Post Bimatoprost  Placebo  Bimatoprost 
washout 
Placebo 
washout  
Bimatoprost  Placebo  
Total drug cost 
Median/mean 
(range) 
£6.14/£9.71 
(0.00-70.12) 
£5.68/£11.81 
(0.00-65.92) 
£6.14/£12.93 
(0.00- 65.92) 
£6.02/£9.42 
(0.00-65.92) 
£12.36/£22.41 
(0.00-136.04) 
£10.85/£21.24 
(0.00-131.84) 
Total NHS 
encounter cost 
Median/mean 
(range) 
£0.00/£57.49 
(0.00-253.20) 
£7.80/£79.12 
(0.00-567.00) 
£7.80/£66.93 
(0.00-275.60) 
£4.30/£75.09 
(0.00-428.40) 
£86.60/£124.59 
(0.00-528.80) 
£67.80/£154.21 
(0.00-995.40) 
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3.3.6 Other outcomes  
3.3.6.1 Generic (EQ-5D-5L) Health Questionnaire 
There was no change with regard to generic EQ-5D-5L general well-being questionnaires with 
median total utility score 0.796 (IQR 0.479-0.837) in Bimatoprost versus placebo 0.826 (IQR 
0.696 to 1.000) p=0.9652 (Figure 49). There was a positive correlation between EQ-5D-5L 
utility score and GO-QOL total visual score (Figure 50, Spearman rho 0.6515, p<0.0001). 
Similar but weaker correlation was found between EQ-5D-5L utility score and total appearance 
score (Figure 51, Spearman rho 0.1997, p=0.0143).  
 
Figure 49: EQ5D-5L total utility score in placebo compared to Bimatoprost. The box represents 
interquartile range (IQR) with median line and the whiskers represent all data points within 1.5 IQR. 
Wilcoxon signed-rank test p=0.9652. 
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Figure 50: Scatter plot of total visual score (GO-QOL) against utility score questionnaires with fitted 
values (red line) showing a positive correlation with Spearman rho 0.6515, p<0.0001. 
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Figure 51: Scatter plot of total appearance score (GO-QOL) against utility score questionnaires with 
fitted values (red line) showing a positive correlation with Spearman rho 0.1997, p=0.0143. 
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3.3.6.2 Clinical activity score (CAS) 
Patient thyroid eye disease remained inactive throughout trial period with median CAS score 
of 0 as depicted in Figure 52. 
 
 
Figure 52: Clinical activity score during trial visits. The box represents interquartile range (IQR) with 
median line and the whiskers represent all data points within 1.5 IQR. 
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There was no evidence that Bimatoprost can induce GO disease activity in this patient group 
(p=0.7179) (Figure 53). 
 
 
Figure 53: Clinical activity score in placebo versus Bimatoprost. The box represents interquartile range 
(IQR) with median line and the whiskers represent all data points within 1.5 IQR. Wilcoxon signed-rank 
test p=0.7179. 
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3.3.6.3 Total eye score (TES) 
There was no change with regard to total eye score. Bimatoprost median TES was 6 (IQR 2-
11) compared to placebo median TES of 8 (IQR 5-11) p=0.2089 (Figure 54). 
 
 
Figure 54: Box plot of total eye score at the end of each treatment period. The box represents 
interquartile range (IQR) with median line and the whiskers represent all data points within 1.5 IQR. 
Wilcoxon signed-rank test p=0.2089. 
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3.3.6.4 Palpebral aperture 
There was no change with regard to palpebral aperture measurements with Bimatoprost mean 
change of 0.16 mm (95% CI -0.36 to 0.67) compared to placebo -0.60 (95% CI -1.27 to 0.06) 
p=0.1043 (Figure 55). 
 
 
Figure 55: Box plot palpebral aperture change in placebo compared to Bimatoprost. The box represents 
interquartile range (IQR) with median line and the whiskers represent all data points within 1.5 IQR. 
Paired t-test p=0.1043. 
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3.3.6.5 Subjective eye changes 
There were 13 patients (41.94%) who thought that their eye prominence had changed with 
the Bimatoprost and 8 patients (26.67%) in the placebo group (Table 27). Remarkably in both 
groups, if there was a change this was most likely to be an improvement (less prominence) 
(Table 28). 
 
Table 27: Patients’ response to question ‘As the result of last 3 months treatment, has the prominence 
of your eyes changed?’ in placebo and Bimatoprost. 
Response Placebo n (%) Bimatoprost n (%) 
Yes 8 (26.67) 13 (41.94) 
No 22 (73.33) 18 (58.06) 
 
Table 28: Patients’ response to question ‘If so, is the prominence more or less?’. 
Response Placebo n (%) Bimatoprost n (%) 
More 1 (12.50) 3 (23.08) 
Less 7 (87.50) 10 (76.92) 
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3.3.6.6 Patients’ satisfaction with the treatment 
Only 13 patients (41.94%) preferred Bimatoprost treatment. Fourteen (46.47%) patients 
preferred placebo eye drops (Table 29). 
 
Table 29: Patients’ preference with the treatment. 
Response Placebo n (%) Bimatoprost n (%) 
Yes 14 (46.67) 13 (41.94) 
No 12 (40.00) 10 (32.26) 
Not sure 4 (13.33) 8 (25.81) 
 
3.3.6.7 Treatment masking success (assessor and patient) 
Sixteen patients (53.33%) in placebo group thought that either they are on Bimatoprost or 
unsure of their treatment allocation. Nineteen patients (51.29%) in Bimatoprost group thought 
they either on placebo or unsure of their treatment allocation (Table 30). 
 
Table 30: Patients’ treatment masking response. The question asked was ‘Do you think you have been 
on treatment or placebo?’. 
Response Placebo n (%) Bimatoprost n (%) 
Treatment 3 (10.00) 12 (38.71) 
Placebo 14 (46.67) 10 (32.26) 
Don’t know 13 (43.33) 9 (29.03) 
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Assessors have guessed correctly that patient on placebo in 22 cases (73.33%) but only in 13 
cases (43.33%) for Bimatoprost allocation (Table 31). 
Table 31: Assessors’ treatment masking response. The question asked was ‘Do you think patient has 
been on treatment or placebo?’. 
Response Placebo n (%) Bimatoprost n (%) 
Treatment 7 (23.33) 13 (43.33) 
Placebo 22 (73.33) 14 (46.67) 
Don’t know 1 (3.33) 3 (10.00) 
 
3.3.6.8 Photo assessment 
Proptosis measurements were also made by photographic assessment of the patient photos 
taken during the trial. The measurements were taken either from lateral canthus or nasal 
bridge to the corneal apex by a masked assessor. 
3.3.6.8.1 Lateral canthus to corneal apex measurement 
There was no different between placebo and Bimatoprost with placebo mean change of 1.30 
mm (95% CI -0.74 to 3.35) compared to Bimatoprost 0.98 mm (95% CI -1.25 to 3.20) p=0.8160 
(Figure 56). 
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Figure 56: Box plot mean lateral canthus to corneal apex measurement change in placebo compared 
to Bimatoprost. The box represents interquartile range (IQR) with median line and the whiskers 
represent all data points within 1.5 IQR. Paired t-test p=0.8160. 
 
3.3.6.8.2 Nasal bridge to corneal apex measurement 
There was no different between placebo and Bimatoprost with placebo mean change of -0.50 
mm (95% CI -4.18 to 4.08) compared to Bimatoprost 1.30 mm (95% CI -5.65 to 8.25) p=0.6870 
(Figure 57). 
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Figure 57: Box plot mean nasal bridge to corneal apex measurement change in placebo compared to 
Bimatoprost. The box represents interquartile range (IQR) with median line and the whiskers represent 
all data points within 1.5 IQR. Paired T-test p=0.6870. 
3.3.6.8.3 Exophthalmometry and photo assessment correlations  
All data from 5 visits were used for this analysis. There was a moderate positive correlation 
Spearman rho 0.609 p<0.0001 for exophthalmometer and lateral canthus to corneal apex 
measurement and weaker negative correlation (which was expected negative correlation as 
the measurement was taken from nasal bridge to corneal apex i.e. the more proptosis the 
lesser the distance to the nasal bridge) Spearman rho -0.396, p<0.0001. See Figure 58 and 
Figure 59. 
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Figure 58: Scatter plot of clinical exophthalmometer against lateral canthus to corneal apex 
measurements by photograph with fitted values (blue line) showing a positive correlation with Spearman 
rho 0.609 and p<0.001. 
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Figure 59: Scatter plot of clinical exophthalmometer against nasal bridge to corneal apex measurements 
by photograph with fitted values (blue line) showing a negative correlation with Spearman rho -0.396 
and p<0.001. 
 
3.3.6.8.4 Detectable side effects 
Apart from patients’ reported side effects, subjective assessments were also made by an 
independent masked assessor. Patients treated with Bimatoprost have higher detectable side 
effects including skin discoloration and eye lashes prolongation (Table 32). Majority 14 /16 
(87.50%) of the patients experienced at least 1 side effect compared to placebo 3/15 (20.00%) 
after the first phase of treatment (Fisher’s exact p <0.0001). Only 3 patients (18.75%) 
developed periorbital fat atrophy which was a desired effect in this trial. 
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Table 32: Frequency of detectable side effects (percentage) recorded by masked assessor on 
photographic assessment after 1st phase of treatment 
Phase 1 
Treatment Fisher’s p 
value Placebo Bimatoprost 
Iris colour changes  0 (0) 1 (6.25) 1.00 
Skin colour changes  0 (0) 7 (43.75) 0.007 
 
Eye lashes elongation  
 
2 (13.33) 11 (68.75) 0.003 
Redness  Conjunctival 1 (6.67) 6 (37.50) 0.083 
Upper lid 
2 (13.33) 6 (37.50) 0.220 
Lower lid 
1 (6.67) 5 (31.25) 0.172 
Fat atrophy  Upper lid 
0 (0) 1 (6.25) 1.00 
Lower lid 
0 (0) 2 (12.50) 0.484 
 
After the second phase of treatment, there were no detectable differences in side effects 
between the 2 groups (Table 33) and with no statistically different number of patients with any 
side effects between the 2 groups (Bimatoprost 7/16 (43.75%) versus 8/15 (53.33%), Fisher’s 
exact p=0. 724). 
  
 184 
Table 33: Frequency of detectable side effects (percentage) recorded by masked assessor by 
photographic assessment after 2nd phase of treatment 
Phase 2 
Treatment Fisher’s p 
value Placebo Bimatoprost 
Iris colour changes  1 (6.67) 0 (0) 1.00 
Skin colour changes  2 (13.33) 2 (16.67) 1.00 
 
Eye lashes elongation  
 
3 (20.00) 7 (58.33) 0.057 
Redness  Conjunctival 2 (13.33) 2 (16.67) 1.00 
Upper lid 
3 (20.00) 4 (33.33) 0.662 
Lower lid 
1 (6.67) 2 (16.67) 0.569 
Fat atrophy  Upper lid 
1 (6.67) 1 (8.33) 1.00 
Lower lid 
0 (0) 0 (0) na 
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3.3.6.8.5 Persistent side effects after washout period 
Some of side effects persist and some improved after the 2 months’ washout period. These 
include skin colour changes and eye lashes elongation (Table 34 and Table 35). 
 
Table 34: Frequency of detectable side effects (percentage) after 2 months wash out phase 1 period 
recorded by a masked assessor by photographic assessment 
Two months’ post 
Phase 1 
persist/improved/new 
Treatment 
Fisher’s 
p value Placebo Bimatoprost 
Iris colour changes 0 (0) 1 (6.67)/0/0 1.00 
Skin colour changes 0(0) 2 (13.33)/4 (26.67)/0 0.017 
 
Eye lashes elongation 
 
1 (6.67)/1(6.67)/0 8 (53.33)/2(13.33)/0 0.004 
Redness 
Conjunctival 0 (0)/1(6.67)/1(6.67) 0 (0)/6(40.00)/1(6.67) 0.080 
Upper lid 1 (6.67)/1(6.67)/1(6.67) 3(20.00)/2(13.33)/0 0.577 
Lower lid 1 (6.67)/0/0 
2 
(13.33)/3(20.00)/1(6.67) 
0.115 
Fat atrophy 
Upper lid 0 (0) 1 (8.33)/0/0 1.00 
Lower lid 0 (0) 2 (13.33)/0/0 0.483 
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Table 35: Frequency of detectable side effects (percentage) after 2 months wash out phase 2 period 
recorded by a masked assessor by photographic assessment. 
Two months’ post 
Phase 2 
persist/improved/new 
Treatment 
Fisher’s 
p value Placebo Bimatoprost 
Iris colour changes  1(6.67)/0/0 0/0/1(8.33) 0.701 
Skin colour changes  2(13.33)/0/0 1 (8.33)/1(8.33)/1(8.33) 0.543 
 
Eye lashes elongation 
 
2 
(13.33)/1(6.67)/2(13.33) 
6 
(50.00)/1(8.33)/3(25.00) 
0.045 
Redness 
Conjunctival 2 (13.33)/0/0 1 (8.33)/1(8.33)/1(8.33) 0.543 
Upper lid 0/3 (20.00)/0 2(16.67)/2(16.67)/0 0.353 
Lower lid 0/1(6.67)/0 1 (8.33)/1(8.33)/0 0.713 
Fat atrophy 
Upper lid 1(6.67)/0/1(6.67) 0/1(8.33)/1(8.33) 0.844 
Lower lid 0/0/1(6.67) 0/0/1(8.33) 1.00 
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3.3.6.8.6 Eyes similarity 
As eye symmetry is very important to the patients, we asked the masked assessor: ‘At the end 
of treatment do the right and left eye looks similar?’ There were no different between the 2 
groups (Fisher’s exact p=1.000) (Table 36) 
 
Table 36: Frequency of eyes symmetry by a masked assessor by photographic assessment. Fisher’s 
exact p=1.00 in both phases. 
  Phase 1 Phase 2 
Eyes symmetry Placebo Bimatoprost Placebo Bimatoprost 
Yes 15 (100) 15 (93.75) 14 (93.33) 12(100) 
No 0 1 (6.35) 1(6.67) 0 
 
3.3.6.8.7 Treatment masking success (photographic assessment) 
The assessor has guessed correctly that patient on placebo in 8 cases (61.54%) and in 10 
cases (66.67%) for Bimatoprost allocation. The assessor also has guessed incorrectly or 
unsure of treatment allocation in 10 patients (35.71%). 
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Table 37: Assessors’ treatment masking response by photographic assessment. The question asked 
was ‘Which phase do you think is the treatment phase?’. 
Response Placebo n (%) Bimatoprost n (%) 
Treatment 1 (7.69) 10 (66.67) 
Placebo 8 (61.54) 3 (20.00) 
Don’t know 4 (30.77) 2 (13.33) 
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3.4 DISCUSSION 
In this study, we showed that treatment with Bimatoprost for 3 months was not effective in 
reducing proptosis in late phase GO patients. At baseline, we found that up to 75% of our 
patients were smokers prior to the diagnosis which came down close to 40% after the 
diagnosis. This is lower than the findings from Prummel et al of in a case control study with 
prevalence of 81% compared to control of 38% [59] in Netherlands and above that of Bartalena 
64.2% in GO and other thyroid conditions of 30% [170] in Italy. Although there was a 35% 
prevalence reduction after the diagnosis in our trial population, this is still at least double to 
that of national Wales smoking prevalence which was approximately 20% in 2014 
(http://www.ash.org.uk/files/documents/ASH_93.pdf). Our diplopia rate is lower at 61.3% than 
that of 75% in moderate to severe GO measured by motility assessment [342]. The difference 
might be explained as the subjective nature of our assessment using Gorman diplopia score 
which might be more relevant from patient perspective and also the late burnt out stage of the 
disease process where patients have been treated initially. Our figure includes all types of 
diplopia from untreated intermittent to constant diplopia inclusive of those treated with prisms 
(19.35% of total patients). Although there was a high prevalence of diplopia, visual function in 
GO-QOL was well preserved in our patients with mean total visual scores throughout trial visits 
between 79 and 85 whilst appearance score was poor with means of 52 to 58. Despite this 
finding, there was a negative correlation between diplopia score and visual function in GO-
QOL but not with appearance score which is consistent with the original finding of Terwee et. 
al [343]. The findings of persistent high rates of untreated diplopia raise a significant question 
regarding the management or treatment effectiveness in acute stage in reducing diplopia. 
This is the first clinical trial assessing the effects of PGF2α in GO. Using multilevel modelling 
this trial failed to show that Bimatoprost is capable of reducing proptosis. This is in contrast 
with the in vitro findings [344, 345] and anecdotal case reports in people without GO [280-282] 
suggesting adipocytes differentiation inhibition and orbital fat atrophy. Interestingly, we found 
a statistically significant reduction in proptosis in patients treated for unilateral disease. The 
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lack of the effects in the primary analysis might be due to several explanations. There was 
considerable ‘noise’ in the exophthalmometer measurements with standard deviation between 
visits ranging from 2.5 mm to 2.9 mm. However, this negative result does not rule out the 
possibility of Bimatoprost having an effect. This is illustrated by the statistically significant 
reduction we observed in patients with unilateral disease in which the unaffected (and hence 
untreated) eye served as a control hence reducing overall ‘noise’.  Although type 1 error is a 
possibility, these patients are phenotypically different possibly suggesting a different 
predominant disease process which might be susceptible to Bimatoprost. Not all glaucoma 
patients develop enophthalmos. Some patients with GO have predominantly fat excess whilst 
the others have muscle predominant disease. This suggests a subgroup of subjects that are 
more susceptible to the effect of Bimatoprost who could be identified by screening using orbital 
imaging. We did consider orbital imaging in our study but was prohibited by its cost.  We are 
fully aware that the 2 main mechanisms of GO are adipogenesis and hyaluronan accumulation 
[346]. In the burnt out stage, this will be fibrosis in nature. In the search for stable disease in 
order to show the effect of PGF2α, we might have chosen the wrong stage of the disease where 
the disease state is predominantly caused by hyaluronan or fibrosis rather than adipogenesis. 
PGF2α inhibits adipogenesis per se but does not affect lipolysis and hence has no impact on 
an already fully mature adipocyte [344]. Although the aforementioned case reports described 
periorbital fat atrophy, our photo assessment showed only 3 patients with this effect which 
lasted for at least 2 months after treatment had been stopped. There was no prevalence fat 
available on periorbital fat atrophy. Perhaps 3 months’ duration is not long enough to see the 
intended reduction in proptosis. Compliance also might be an issue although we did not find 
statistically significant treatment effect after adjustment made for compliance using a reduction 
in IOP as a surrogate marker (p=0.593).  
Exophthalmometer readings are filled with its own caveat in terms of variability of readings 
with parallax error and pressure of the exophthalmometer against the orbital rim. In 
experienced hands it will deliver consistent results. For practical reason we did have 2 
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assessors in order to deliver the project in time. Both assessors were randomly assigned to 
the trial patients at each trial visit and also pending assessors’ availability. Our assessors were 
calibrated by multiple exophthalmometer readings on the same non trial subjects in the clinic 
and adjustments were made to ensure their readings were comparable. This negative finding 
was further supported by our photographic assessment of proptosis conducted by an assessor 
who was blinded to the treatment phase. We found there were good correlations of proptosis 
measurement between exophthalmometer and photographic assessments suggesting that the 
later could be used as an alternative tool for proptosis measurement provided that there is 
standardisation to its process. 
In general, our patient scored reassuringly high on total visual score throughout trial visits with 
the mean total visual score ranging from 79 to 85 and moderately with regard to total 
appearance score with the mean ranging from 52 to 58. This is in contrast to the original study 
of GO-QOL development by Terwee et al with visual means of 54.7 (standard deviation 22.8) 
and 60.1 (24.8) for appearance [347]. The latter group was from unselected GO patients 
attending endocrine clinic, 6 years younger than our group (mean 49.1 years old) and shorter 
duration of the disease (3,7 years) with similar CAS (less than 2) and TES (median of 6) score 
to our study population. As there was no impact on primary outcome with the Bimatoprost we 
did not expect to see any improvement with their GO-QOL. Measuring IOP in the clinic is 
normally performed with the head in primary position. Any deviation from this might stretch the 
neck muscles which in turns impede the venous return and change the intra ocular pressure. 
Here we did not show that stretching the head forward alters the IOP. In health economic 
consumption analysis, we found that there was no difference between Bimatoprost and 
placebo in terms of total drug and NHS encounter costs for up to 4 months after treatment. 
Our placebo all-inclusive direct NHS mean cost (including total drug cost) was £526.35 per 
annum. This was considerably high comparing to Kahaly’s group data from Germany quoting 
£285±736 (€332 ± 857) per annum for their mild GO patients [348]. 
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We found higher rates of visible side effects on photographic assessment skin colour changes 
(43.7%), eye lashes elongation (68.75%) and conjunctival redness 37.50% compare to what 
patients were complaining 3.2%, 0 and 32.3% respectively. Other main complaint was eye 
pruritus at 12.9%. The side effects are comparable to the findings of a 12-month randomized 
double-blind trial of Bimatoprost in glaucoma with conjunctival redness of 45%, eye lashes 
elongation (43%), eye pruritus (14.6%) but lower skin colour pigmentation at 5.5% [349]. 
Interestingly, there were more headaches symptoms in Bimatoprost phase (29%) compared 
to placebo (6.5%). The rate was higher than of Bimatoprost summary product characteristics 
which quoted the headache incidence around 1-10%. We found Bimatoprost has no effects 
on other outcomes measured including palpebral aperture, generic (EQ-5D-5L) Health 
Questionnaire, clinical activity scores (CAS) and total eye scores (TES). 
The success of masking process was analysed by asking patients and assessors directly and 
also by independent masked assessor on photographic assessment. Approximately 27% of 
the patients on placebo thought that the prominence of their eyes improved compared to 42% 
in Bimatoprost. Just above 40% of the patients in both groups preferred the treatment. Majority 
patients guessed incorrectly or unsure treatment allocation by 53% in placebo group and 61% 
in Bimatoprost group. The figures were bettered by the assessors, whereby they guessed 
incorrectly or unsure by 26% in placebo group and 57% in Bimatoprost group. Even though a 
masked assessor was asked to assess specific side effects on the patients’ photograph, these 
figures improved to 38% in placebo groups and decreased to 33% in Bimatoprost group.  
In summary, the questions of whether Bimatoprost can reduced proptosis in inactive thyroid 
eye disease has been answered in a robust, randomised clinical trial: Bimatoprost does not 
result in improvement and this information will prevent clinicians trialling this approach and 
causing side-effects unnecessarily. The BIMA study has demonstrated that crossover studies 
can be performed reliably in patients with persistent proptosis due to thyroid eye disease and 
that this study design is acceptable to patients. The BIMA study also has shown that over 60% 
 193 
of patients with residual proptosis in thyroid eye disease also have double vision (diplopia), 
confirming the unmet clinical need in this patient group. 
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Chapter Four 
3 MODULATION OF TSHR SIGNALLING BY PUTATIVE 
LIGAND BINDING PROTEINS 
4.1 INTRODUCTION  
Graves’ orbitopathy (GO) is the commonest extra thyroidal manifestation of Graves’ 
disease (GD) affecting around 30-50% of patients [165, 350-352]. Approximately 5% 
will have severe disease which may lead to blindness. There is a close clinical and 
temporal association between GD and GO suggesting an autoimmune response to 
common antigen/s in the orbit and thyroid gland. Since the thyrotropin receptor 
(TSHR) is expressed in orbital fat [114, 118, 328, 353] and virtually all patients with 
hyperthyroid GO have thyroid stimulating antibodies (TSAB), the receptor is the most 
logical candidate. As with other autoimmune conditions there is female 
preponderance towards the condition with 6:1 female to male ratio, although in GO 
the ratio is less skewed. Extensive orbital tissue remodelling (increased adipogenesis 
& hyaluronan production) produces disfiguring proptosis and underpins all GO signs 
and symptoms. This was discussed in details in chapter one. In addition most patients 
with GO have reduced quality of life [153] and suffer long-term psychological distress 
due to the disfiguring appearance of the proptosis, also known as exophthalmos 
[154]. Available treatments for GO are unsatisfactory and research is needed to 
address the pathophysiology of the disease which may lead to early pre-clinical 
diagnosis promoting preventative/early interventions. This in turn will improve long-
term morbidity and socioeconomic impact. As described in the introduction, the TSHR 
is the target of TSH, a member of the glycoprotein hormone family. In recent years, 
novel members of this hormone group have been identified the most notable being 
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thyrostimulin. 
4.1.1 Thyrostimulin 
The anterior pituitary gland and placenta are known to secrete members of the family 
of heterodimeric glycoproteins namely thyroid stimulating hormone (TSH), luteinizing 
hormone (LH), follicular stimulating hormone (FSH) and human choriogonadotropic 
hormone (HCG). These are composed of a common α subunit and specific β subunits 
for each hormone type and which thus confer specificity. Thyrostimulin was 
discovered by Nakabayashi et al in 2002 by the process of GenBank data mining 
[283]. It was named thyrostimulin because of its ability to stimulate the TSHR and 
promote thyroid hormone production. It is also known as corticotroph-derived 
glycoprotein as both subunits are co-localised in corticotroph cells in the anterior 
pituitary gland [284]. It belongs to the above described heterodimeric glycoprotein 
hormone family and consists of 2 subunits; α2 subunit (GPHA2, accession no. 
AF403384) - named due to its structural similarity to the common glycoprotein α-
subunit and β5 (GPHB5, accession no. AF403430) - being the fifth member of the 
glycoprotein hormone β subunit. The alpha 2 gene is located on chromosome 
11q13.1 and β5 is located on chromosome 14q23.2. 
4.1.1.1 Thyrostimulin structure 
GPHA2 is encoded by 4 exons and GPHB5 by 3 exons [354]. The 2 subunits form a 
heterodimer with non-covalent bonds although this assumption was based on SDS-
PAGE only after chemical crosslinking of co-expressed recombinant GPHA2 and 
GPHB5 with disuccinimidyl suberate [283]. The yeast two hybrid assay suggested 
that GPHA2 can also interact with FSH-β and HCG-β and to a lesser extent with TSH-
β and LH-β [283]. Please see Figure 60 and Figure 62 for comparisons of the 
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sequence and 3D models of human GPHA2 with common α and GPHB5 with TSHβ 
subunits. GPHB5 sequence lacks the C-Terminal seat belt region but contains all the 
cysteine residues important for the generation of disulphide bonds and cysteine knot 
formation [283, 355, 356]. 
 
Figure 60: Protein sequence alignment between (upper panel) human GPHA2 (Refseq 
NP_570125.1) and common α subunit (Refseq NP_000726.1) (lower panel) GPHB5 subunit 
(Refseq NP_660154) and TSH-β subunit (Refseq NP_000540). 
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
 
The consensus sequence for the cysteine knot structure is: 
C1-(X)n-C2-X-G-X-C3-(X)n-C4-(X)n-C5-X-C6. G, glycine is the residue most 
conserved in this polypeptide. In these proteins, three disulphide (SS) bonds are 
arranged in such a way that one SS bond passes through the ring formed by 8 amino 
acids completed by the two other SS bridges [357]. The six cysteine residues forming 
three knotted SS bonds are numbered C1 to C6 from the N to C-terminus along the 
polypeptide sequence of these proteins. The disulphide bonds between cysteine 
residues 2 and 5 as well as 3 and 6 form part of the ring whilst cysteine residues 1 
and 4 SS penetrates the ring forming a ‘knot’ (Figure 61 and Figure 62). 
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Figure 61: Schematic view of the structure of thyrostimulin protein with six cysteines belonging 
to the cysteine knot are shown in red with the remaining 4 shown in yellow. The ring is made 
up of 8 amino acids partly contributed by 2 interconnecting disulphide bridges (SS). G, glycine 
is the residue that is conserved and typical of an 8 amino-acid ring cysteine knot protein. The 
yellow lines with black stripes represent SS; yellow triangular with black stripes represents SS 
bond penetrating through the ring. Adapted from Alvarez et al 2009 [358]. 
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Figure 62: Comparison of protein 3D structures of the GPHA2 (α2), GPHB5 (β5), common α 
and TSHβ subunits. http://www.proteinmodelportal.org 
 
As the glycoprotein name suggests, thyrostimulin has multiple N-linked glycosylation 
motifs. GPHA2 glycosylation motifs are located at position 14 and 58 and GPHB5 at 
location 63. Using site directed mutagenesis, disruption of either of the 
oligosaccharides in GPHA2 significantly decreased receptor activation. The 
disruption of either GPHA2 (at both position 14 and 58) or GPHB5 glycosylation motifs 
are associated with reduced expression and secretion of both subunits in the cell 
lysate and conditioned medium respectively [355].  
4.1.1.2 Human thyrostimulin tissue expression 
Similar to other β subunits, GPHB5 subunit transcripts have restricted tissue 
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expression, and are found mainly in the pituitary, brain, testes, retina and skin. In 
contrast, GPHA2 transcripts are found in diverse tissues [354] [284]. 
Immunocytochemistry studies have shown that both GPHA2 and GPHB5 are co-
localised in the same cell in the pituitary gland [284]. Glycoprotein hormones are 
normally stabilised by the presence of the seatbelt region. Because of the absence of 
seatbelt, heterodimerization of GPHA2 and GPHB5 should not require reducing redox 
potential (to permit opening of the seatbelt SS buckle) but necessitates higher 
concentrations compatible with a Kd of more than 10-7M [359]. Current evidence 
would indicate that thyrostimulin would have a short-term paracrine role but not with 
an endocrine role after dilution in circulation [358] as supported by the recent work of 
the Williams group in bone [21]. Efforts to find it in the circulation have not succeeded. 
The only study from human orbital retroorbital fat tissue was from Lantz et al where 
they were unable to show the present of thyrostimulin GPHB5 subunit but GPHA2 
subunit was not tested [360]. Transgenic mice over-expressing the GPHA2 subunit 
had no overt phenotype but overexpression of GPHB5 in mice is associated with 
hyperthyroidism, weight loss and proptosis [17]. These facts suggest it is a potential 
major contributor to the GD and GO disease processes. In order to exert its effects, 
thyrostimulin or any other ligands have to bind to appropriate receptors-TSHR or 
potentially to their cognate binding proteins such as TSHR variant. 
4.1.2 Thyrotropin receptor variant 
As described in Chapter 1, TSHR consists of two subunits. After protein translation, 
the TSHR is split into two subunits (A and B subunits) which are linked to each other 
by disulphide bonds. The split results in the loss of an intervening C peptide segment 
corresponding to approximately 50 amino acids [93, 100]. Of interest, these 50 amino 
acids segments are found only in the TSHR, not LHR or other glycoprotein receptors. 
The A subunit is the extracellular domain and encoded by exons 1-9 and the B subunit 
 200 
is the transmembrane domain responsible for G-protein coupled receptor signalling, 
mainly via cAMP, and encoded by exon 10 [90].  
We and others have shown that activation of the TSHR in orbital preadipocyte-
fibroblasts (OF) leads to increase in hyaluronan production and early stages of 
adipogenesis [247, 262]. TSHR expression has been shown to increase during 
adipogenesis [118] but little is known about the effects of TSHR activation at various 
stages during differentiation. G protein signalling will depend on the types and 
abundance of G proteins available in the cell [219]. Denis-Henriot et al has reported 
that rat subcutaneous preadipocytes have higher capacity to differentiate than 
epididymal preadipocytes that seems to be correlated with the decrease in Gq/11 
alpha expression and the decreased Gq/11 mediated PKC activation [361]. 
Several TSHR variants have been described which lack the transmembrane domain 
and if expressed as protein would lead to soluble receptor products which could serve 
as TSH/TSAB/Thyrostimulin binding proteins (Figure 63). Variants which have been 
described are TSHR isoform 2 precursor (TSHR_v2) with 1281 base pairs amino 
acids which codes for amino acid residues 21-253 (NM_001018036.1) [112] and 
TSHR isoform 3 precursor with 1089 base pairs which code for 21-274 amino acids 
(NM_001142626.2) [113]. The isoform 3 is similar to isoform 2 with some unknown 
sequence between the expected exonic sequences. The isoform 2 1.3 kb variant 
encodes exons 1-8 and has a unique tail sequence (PCR amplification and southern 
blotting) in the thyroid and also in OF [112] [362]. Paschke et al also found presence 
of this transcript in the extra ocular muscle, peripheral blood mononuclear cells and 
cervical fat [362]. Of interest, the exon 1-8 variant is similar in structure to the TSHR 
A subunit which is generated following cleavage of the full length receptor [363, 364]. 
TSHR variants can potentially act as TSH binding protein, autoantigen or biomarker 
of GO. The role as potential autoantigen is further supported by success in GD mouse 
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model using recombinant adenovirus vector expressing TSHR into the muscle by 
Nagayama et al [365] and GD/GO model by Banga’s group using in vivo 
electroporation of TSHR A-subunit plasmid into female BALB/c mice [80]. The latter 
has been reproduced successfully in Essen [366]. 
 
Figure 63: Thyroid binding protein illustration with 2 possible sources: TSHR A subunit 
shedding and TSHR variant generation. Adapted from Rapoport et al [100]. 
 
Taken together and as explained in Chapter 1, the animal models provide evidence 
that full length TSHR or more likely extra cellular domain TSHR subunit are easily 
recognisable by immune cells and also that the TSHR is probably the antigen in GO. 
We hypothesize that thyrostimulin; probably locally produced, may contribute to 
TSHR activation and that TSHR_v2 may modulate TSHR activation, whether due to 
TSH, TSAB or thyrostimulin. We have chosen this variant and not other isoforms as 
this variant has almost complete extra cellular domain sequence which is needed to 
exert its function and the most studied variant compares to other isoforms. The aim 
of this chapter is to apply in vitro models to determine transcript expression levels of 
 202 
these molecules and to determine whether these are functional using primary human 
orbital fibroblasts (OF) from GO patients and people free of GO supported by ex vivo 
analysis of orbital tissues derived from people with GO and unaffected controls. 
Several laboratory methods are used in this chapter including western blot analysis. 
4.1.3 Western blot analysis 
Western blotting is a method for detecting specific proteins in a given sample of tissue 
lysate or supernatant. The technique was developed by Dr W. Neal Burnette at Fred 
Hutchinson Cancer Research Centre in Seattle in 1979 [48]. The ‘Western blot’ is a 
play on the name of Southern blot, a DNA detection technique developed by Edwin 
Southern [49]. The process uses gel electrophoresis to separate denatured proteins 
according to molecular weight. The choice of percentage gel concentration depends 
on the size of protein of interest. A low percentage of acrylamide will allow separation 
of proteins with high molecular weight, whilst a higher percentage is suitable for the 
separation of the proteins that have a lower molecular weight. The protein is then 
transferred to a nitrocellulose membrane and followed by detection using specific 
antibodies. Details for each step are outlined below in section 4.2.7. 
In order to detect meaningful differences in protein expression equal protein loading 
from each sample must be performed. Several methods exist such as bicinchoninic 
acid (BCA), Bradford assay and Folin-Lowry. The Bradford reaction is fast and stable 
for up to an hour but unlike the BCA, it is sensitive to detergents like SDS and Triton 
X-100. It is using the principle that negatively-charged Coomassie brilliant blue dye 
binds to positively-charged proteins. When the dye is in solution, it is red (absorbs 
465 nm wavelength). Upon binding to basic amino acids in the protein, it becomes 
blue and absorbs at 595 nm. The absorption in the sample can then be compared to 
a standard curve. In Lowry assay, copper forms a complex with nitrogen in the protein 
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followed by reaction of tyrosine and tryptophan with Folin-Ciocalteau phenol reagent 
to give an intense, blue-green colour which absorbs at 650–750 nm. The downside 
of this assay is that it is not compatible with lots of common chemicals such as EDTA, 
Tris and carbohydrates, reducing agents (e.g., DTT, 2-mercaptoethanol). While 
slower than the Bradford, the BCA assay is an option to choose if the protein samples 
contain more than 5% detergent. ‘This method utilises a known reduction of Cu2+ to 
Cu+ by protein in an alkaline medium (the Biuret reaction) with the highly sensitive 
and selective colorimetric detection of the cuprous cation (Cu+) using a unique 
reagent containing bicinchoninic acid. The purple-coloured reaction product of this 
assay is formed by the chelation of two molecules of BCA with one cuprous ion. This 
water-soluble complex exhibits a strong absorbance at 562nm that is nearly linear 
with increasing protein concentrations over a broad working range (20-2000 µg/mL)’. 
 
4.2 MATERIALS AND METHODS 
All reagents were obtained from Sigma-Aldrich (St. Louis, MO) and tissue culture 
components were obtained from Lonza (Verviers, Belgium) unless otherwise stated.  
4.2.1 Cells and tissues studied; in vitro culture & ex vivo samples 
The 3T3-L1 preadipocytes and orbital tissue samples were collected and cultured in 
complete medium as described in chapter 2, section 2.2.1-2.2.5). Briefly, the orbital 
samples are from 5 GO patients (2 males and 3 females), median age of 50 years 
(range 39-54 years) who were diagnosed on clinical grounds based on the presence 
of typical clinical features and positive TSHR antibody by TBII and luciferase 
bioassay. 
Samples for ex vivo transcript analysis comprised intact samples of orbital fat from 9 
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GO patients (3 males and 6 females), median age of 45 years (range 32-71 years) 
and 5 unaffected controls (All females), median age of 66 years (range 52-86 years). 
The tissue was snap frozen in liquid nitrogen directly following surgical removal.  
4.2.2 In vitro adipogenesis  
The various cell populations were plated in 6 well plates or 75 cm2 flasks in CM. 
Adipogenesis was induced in confluent cells by replacing with differentiation medium 
(DM) as previously described in chapter 2 section 2.2.5. Adipogenesis was quantified 
by measuring transcripts for terminal markers of differentiation lipoprotein lipase 
(LPL) for OF and Glyceraldehyde-3-Phosphate Dehydrogenase (Gpdh) for 3T3-L1 by 
quantitative PCR (QPCR). 
4.2.3 QPCR 
RNA was extracted using Tri Reagent (Sigma) from the OF (See chapter 2, section 
2.2.10) and ex vivo samples using RNA easy lipid tissue mini kit (Qiagen cat. no. 
74804) and treated with DNAse as described below. 
4.2.4 RNA extraction for orbital fat ex vivo samples 
Frozen tissues were homogenised using Tissue Ruptor (Qiagen cat. no. 9061273) in 
1 ml lysis reagent then incubated for 5 minutes at room temperature. Two hundred 
microliters of chloroform was added followed by 15 seconds vigorous shaking then 
left for 3 minutes to settle. This was then centrifuged at 13000 rpm for 15 minutes at 
4°C. The upper aqueous layer was transferred to a fresh Eppendorf tube with an 
equal amount of 70% ethanol, vortexed and transferred to a spin column and 
centrifuged at 13000 rpm for 15 seconds. Seven hundred microliters of buffer RW1 
was added and centrifuged briefly as above to wash the column followed by a further 
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wash with 500 µl of the same buffer. The column was transferred to a new Eppendorf 
tube, spun 1 minute to dry any remaining ethanol. Finally, this was transferred into a 
fresh Eppendorf tube with 30 µl of RNAse free water, centrifuged at 13000 rpm for 1 
minute to collect the RNA. 
4.2.5 DNAse treatment protocol 
For 1 µg RNA, the following were mixed in a 1.5 ml Eppendorf tube on ice: 
 
Table 38: DNase reaction components 
Components Mass or Volume 
RNA 1 µg 
10X reaction buffer 1 µl 
DNase I (1U/µl) 1 µl 
H2O To 10 µl 
 
This was incubated at 37°C for 15 minutes and terminated by addition of 1 µl 25 mM 
EDTA for 15 minutes incubation at 65°C. The reaction was subsequently used for 
reverse transcription.  
One µg RNA was reverse transcribed using oligo-dT and M-MLV reverse 
transcriptase (Promega) (See chapter 2, section 2.2.11-13). cDNA was PCR 
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amplified using primers in Table 39: for TSHR, TSHR_v2 and thyrostimulin. TSHR 
(human NM_000369, mouse NM_011648 (Tshr)) could be distinguished from 
TSHR_v2 isoforms (human NM_001018036, mouse NM_001113404 (Tshr_v2) by 
using exon 9 & 10 primers that are not present in the truncated isoforms and using 
the unique sequence in intron 8 of the isoforms that are not present in full length 
TSHR. Sequencing of the amplicons produced confirmed the specificity of the primers 
for the different types of TSHR. QPCR was carried out using Brilliant II SYBR green 
master mix (Agilent Technologies, Stockport, UK) and a Stratagene (La Jolla, CA) 
MX3000 light cycler. Levels were normalised against adenosine phosphatylribosome 
transferase (APRT). Standard curves were created using the relevant PCR product 
cloned into pGEM T-easy (Promega, Southampton, UK) except for human TSHR_v2, 
mouse Tshr and Tshr_v2 (serial dilutions of quantified PCR amplicon were used) to 
calculate the copy number/1000 APRT copies for human and Arp for mouse. 
APRT/Arp expression has been previously shown to be unaffected by differentiation). 
In a single QPCR experiment, all measurements were made in duplicate.  
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Table 39: Primers for the TSHR isoforms and thyrostimulin subunits 
 
Accession 
number 
Forward  Reverse  
Amplicon 
size (bp) 
Tshr 
(mouse) 
NM_011648 TCTCTTACCCGAGCCACT
GC (exon 9) 
CCCAACACTGTTGTCACC
CG (exon 10) 
180 
Tshr_v2 
(mouse) 
NM_001113404 ACGCATTCCAGGGCCTA
TGC (exon 6) 
TCCTAGATTTGTGCCTGG
TGG (exon 8) 
232 
TSHR NM_000369 
GTGTCACTGCCCTTCCAT
CCA (exon 9) 
GGGGCTATTCAAGGCAT
TCACAGA (exon 10) 
254 
TSHR_v2 NM_001018036 
CCTCCTAAAGTTCCTTGG
CATT (exon 7) 
AGGACTTTCTTCCAAGAG
GTAG (exon 8) 
338 
GPHA2 NM_130769.3 
CTCGGAAGTGATGCCTAT
GGC (exon 1) 
CTAGTAGCGAGAGAGGC
GAC (exon 4) 
400 
GPHB5 NM_145171.3 
ATGAAGCTGGCATTCCTC
TTC (exon 2) 
CAGTTGGGCAGCTTGAC
AGTC (exon 3) 
296 
 
4.2.5 Agarose gel electrophoresis analysis of PCR product 
If multiple peaks were observed on the QPCR melting curve (indicating multiple PCR 
products), the samples were analysed on a 2% agarose gel containing 400 ng/ml 
ethidium bromide (Promega) and visualised on an UV transilluminator, and 
photographed using Alpha Innotech MultiImage II (Alpha Imager HP) as previously 
described in chapter 2 section 2.2.14. To confirm that the PCR amplicon was the 
intended product, the DNA sample was sequenced as described in chapter 2 section 
2.2.16. The confirmed gel bands were analysed using densitometry (AlphaView 
Software) for semi-quantification and corrected with respective house keeper bands.  
4.2.6 Production of antibody specific for TSHR_v2 
We have used the 21 amino acid sequence (Figure 64) derived from intron 8 of the 
TSHR which is unique to the TSHR_v2 to generate a polyclonal antibody using a 
commercial company (Generon, Maidenhead, UK). Briefly, the unique peptide 
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sequence NH2-cLPLGRKSLSFETQKAP-CONH2 (Antigen ID 140626002) was 
conjugated to highly immunogenic Keyhole limpet hemocyanin (KLH) via terminal 
Cysteine residues. Two New Zealand rabbits were subjected to a 69-day 
immunization schedule and bleed production. The rabbits were vaccinated with 200 
µg of antigen in Complete Freund's Adjuvant (CFA) twice 2 weeks apart. The injection 
of antigen in CFA (heat-killed Mycobacterium tuberculosis) induces a Th1-dominated 
response to create intense inflammatory reaction at the site of antigen deposition. 
Further two 100 µg of antigen injection in Incomplete Freund's Adjuvant (IFA) 2 weeks 
apart were given to induce a Th2-dominated response. The rabbits were bled before 
and after IFA immunizations. The resulting polyclonal antibodies were affinity purified 
on the immunizing peptide. Using ELISA, approximately 29.73 mg antibodies were 
produced. We verified the specificity of each antibody using western blots (described 
below) on the immunizing peptide. 
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MRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLIET
HLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPDALKE
LPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETLTLKLYN
NGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLLPLGRKSLSFETQKAPR
SSMPS 
Figure 64: TSHR_v2 253 amino acid peptide sequence. Peptide sequence used for antibody 
production is indicated by underlined letters in italics which is where the sequence difference 
between full length and variant starts. Blue highlighting indicates alternate exons. Red 
highlighting indicates amino acids encoded across a splice junction. (Adapted from CCDS 
sequence data, ID number P16473-2).  
 
4.2.7 Western blot analysis 
4.2.7.1 Cell lysate and supernatant preparation 
OF were cultured in 6 well plates as described previously. Cell lysates from OF at 
various time points before and during adipogenesis were obtained by scraping the 
cells with 150 µl of lysis buffer, LB (see Table 40), spun at 13000 rpm for 5 minutes 
and collection of the supernatant. For culture supernatant preparation, the cells were 
cultured in 75 cm2 flask. Following culture medium aspiration, 5 ml serum free media 
(SFM) without phenol (GIBCO cat no. 11039-021) was added and collected the next 
day. This was then concentrated by using Amicon Ultra-15 spin columns (Merck 
Millipore cat no. UFC901024). Twenty ml of SFM was concentrated down to 250 µl 
(80 fold) by centrifugation at 4°C 3000 rpm for 30 minutes. 
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Table 40: Lysis buffer component was made to 100 ml and adjusted to pH 7.6. One ml of 
CompleteTM protease inhibitor was added to 10 ml of lysis buffer prior to use. 
Component (Final 
concentration) 
Mass or volume  
Trizma Base (50 nM) 600 mg 
NaCl (150 mM) 875 mg 
EGTA (5 mM) 190 mg 
Triton x100 (1%) 1 ml 
H2O Add up to 100 ml 
 
4.2.7.2 Protein concentration determination 
Protein concentrations of the cell lysates/supernatants were determined using 
bicinchoninic acid (BCA) protein assay kit (Pierce cat no. 23225). The protein assay 
was performed with cell lysate in LB and concentrated supernatant. These were 
diluted 1: 1000 in PBS before the measurement. The standard curve of 5-250 µg/ml 
was prepared from supplied bovine serum albumin stock in LB. Twenty-five µl of each 
standard or unknown sample were pipetted in duplicate into a microplate well. 200 µl 
of the working reagent was added to each well and mixed thoroughly on a plate 
shaker for 30 seconds followed by incubation at 37°C for 30 minutes. The protein 
concentration was measured by reading the absorbance at 562 nm in a plate reader 
(Dynex Technologies Inc, USA). A standard curve was constructed allowing the 
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protein concentrations for each cell sample to be calculated. One µg protein from 
each sample was used for final loading. 
4.2.7.3 SDS-PAGE gel preparation 
The running gel was prepared as per Table 41. Ten percent running gels were used 
as it has a separation range of 30-80 kDa. Fifteen percent gel was used to separate 
the designed TSHR_v2 peptide (1.7 kDa). Seven ml of running gel was added to 1.5 
mm gel casting plates. Polymerization of the gel was initiated by ammonium 
persulphate in the presence of TEMED (N,N,N’,N’,-tetramethylethylenediamine). One 
ml water-saturated N-butanol was added on top of gel and the gel was allowed to set. 
When set, the N-butanol was removed and the gel washed three times with water. 
Stacking gel mixture (see Table 42) was added to the top of the running gel. Combs 
were placed to ensure that there are no trapped air bubbles under the comb fingers. 
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Table 41: Components of running gel 
Components 10% Running gel 15% Running gel 
30% acrylamide 3.3 ml 9.2 ml 
Water 2.92 ml 3.8 ml 
1M Tris (pH8.8) 3.75 ml 4.5 ml 
10% SDS 100 µl 135 µl 
10% ammonium 
persulfate (APS)* 
100 µl 270 µl 
TEMED* 5 µl 10 µl 
* APS is made up fresh and TEMED added immediately prior to use. 
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Table 42: Components of stacking gel 4% 
Components Volume 
30% acrylamide 1.3 ml 
Water 6.1 ml 
0.5M Tris (pH 6.8) 2.5 ml 
10% SDS 100 µl 
10% ammonium persulfate (APS)* 100 µl 
TEMED* 10 µl 
* APS is made up fresh and TEMED added immediately prior to use 
 
4.2.7.4 Sample loading and gel running 
Samples were added to an equal volume of loading buffer (Table 43). Ten µl of 
molecular weight marker (10-250 kDa) (New England Biolabs cat no. 7703S) was 
added to 10 µl loading buffer. The samples were boiled for 5 minutes then centrifuged 
for 5 minutes at 13,000 rpm. The samples which contained 1 µg protein were loaded 
into each wells and separated at 200v for 30-45 minutes in running buffer (Table 44) 
until the tracking dye band had reached the bottom of the gel. 
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Table 43: Loading Buffer 
Component Volume 
10% SDS 2 ml 
Glycerol 1 ml 
0.5M Tris (pH 6.8) 1 ml 
cOmplete™, Mini protease inhibitor 0.8 ml 
0.2% Pyronin Y 0.1 ml 
β-mercaptoethanol 0.1 ml 
PMSF (100mM) 10 µl/ml 
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Table 44: Running buffer 
Components Weight 
Tris 15 g 
Glycine 72 g 
SDS 5 g 
H2O Made up to 1 litre 
4.2.7.5 Electroblotting using PVDF membrane 
The resulting SDS-PAGE gel was placed in blotting buffer (Table 45) for 20 minutes 
on an orbital shaker. PVDF membrane was cut to fit the gel 5.5 cm x 8.5 cm, briefly 
soaked in 100% methanol and rinsed twice in distilled H2O. The membrane was then 
allowed to equilibrate in blotting buffer for 15 minutes by gently shaking. Two pieces 
of filter paper (cut to similar size to fibre pad) and two fibre pads were soaked in 
blotting buffer for 10 minutes ensuring no air was trapped in the fibre pad. The 
gel/membrane sandwich was prepared as depicted in Figure 65. 
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Figure 65: Electroblotting using gel/PVDF membrane sandwich illustration. The figure was 
adapted from http://www.bio-rad.com/en-uk/category/western-blotting-membranes-filter-
paper. 
 
After the second piece of filter was placed on the gel, a Pasteur pipette was rolled 
over the stack to remove any air bubbles. The cassette was inserted into the tank 
containing blotting buffer and an ice pack. Protein transfer was achieved by running 
at 350 mA for one hour while stirring. 
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Table 45: Components of blotting buffer 
Components Weight/Volume 
Tris (0.025M) 3.025 g 
Glycine (0.182M) 13.66 g 
H2O 800 ml 
Methanol 200 ml 
The mixture was cooled at -20°C for an hour prior to use. 
4.2.7.6 Blot development 
All washes/incubations steps were performed on an orbital shaker. This is to ensure 
that the blot moves freely and is not stuck to the bottom of the dish. After blotting the 
membrane was transferred and washed for 5 minutes in TBS-T (see Table 46: and 
Table 47:). The membrane was blocked with 50 ml blocking buffer (Table 48) 
overnight at 4°C then placed in a square Petri dish in10 ml blocking buffer containing 
primary antibody at optimal dilution. The membranes were probed using antibodies 
to the full length TSHR (2C11, Santa Cruz Biotechnology) and TSHR_v2 antibody, at 
dilutions of 1:200 and 1:50 respectively at 4°C overnight. After incubation step, 
primary antibody was removed and membrane washed 3X for 5 minutes with TBS-T. 
This was followed by a sheep anti-mouse IgG-HRP (1:5000, room temperature for 1 
h, GE Healthcare) or donkey anti-rabbit IgG-HRP conjugate (1:5000, room 
temperature for 1 h, GE Healthcare).  
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Table 46: TBS (10X) 
Components Weight 
Tris (0.2M) 24.2 g 
NaCl (0.137M) 80 g 
H2O Made up to 1 litre 
TBS was pH to 7.6 with HCl and stock kept in the fridge 
Table 47: TBS-T 
Components Volume 
TBS (10X) 100 ml 
H2O 900 ml 
Tween 20 1 ml 
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Table 48: Blocking buffer  
Components Weight/volume 
TBS-T 100 ml 
Marvel 5 g 
 
4.2.7.7 Stripping and reprobing PVDF membrane 
Membranes were re-probed by stripping antibodies off the membrane using stripping 
buffer (Table 49) which were then probed with housekeeping antibodies. The stripping 
buffer was prepared and warmed to 60°C in a hybridization oven. If the blot dries out 
the membrane would be re-wetted with methanol for 30 seconds and washed 3X for 
5 minutes with TBS-T, if the membrane still wet this step would be omitted. Blots were 
then incubated with 50 ml stripping buffer in the hybridization oven (GE Healthcare 
Life Sciences, UK) at 60˚C 30 minutes with gentle mixing. After stripping blots were 
washed 3X for 10 minutes with 50 ml of TBS-T. These blots were blocked with 
blocking buffer for 1 hour at room temperature and re-probed with antibodies to 
housekeeping protein, actin at dilution of 1:1000 4°C overnight with secondary anti-
rabbit as above. 
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Table 49: Stripping buffer (50 ml) 
Components Volume 
Tris 0.5M (pH 6.8) 6.25 ml 
10% SDS 10 ml 
Mercaptoethanol 0.35 ml 
H2O 33.5 ml 
 
4.2.7.8 TSHR_v2 antibody verification 
TSHR_v2 antibodies supplied were verified against the immunization peptide (1.7 
kDa). The following adjustments were made- 20 microliters of peptide was diluted 
with 180 µl SFM and mixed with an equal amount of loading buffer. The comb was 
taped to give a single well in a 15% gel to accommodate peptide loading. The peptide 
was run half way down the gel and blotted for 30 minutes instead of 1 hour. The 
membrane was cut into strips of equal size for immunoblotting. 
4.2.7.9 Detection of protein 
Membrane-bound proteins labelled with HRP conjugate were detected via 
chemiluminescence (ECL Plus, GE Healthcare) by exposing PVDF membrane with 
antigen–antibody complex to film in a dark room. After a series of washings with TBS-
T (2X for 30 seconds, 1X for 15 minutes and 3X for 5 minutes), the membrane was 
removed and excess TBS-T drained. ECL Plus reagent was prepared (1:1 ratio of 
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solution A: solution B) and 2 ml pipetted onto the protein side of the membrane and 
incubated at room temperature for 5 minutes. Excess solution was drained before 
wrapping in saran wrap and placed in a film cassette with the protein side up. A film 
sheet (HyperflimTM ECL, GE Healthcare, UK) was cut to size and placed on top of 
the membrane. The film cassette was closed to allow exposure time from 5 seconds 
to 15 minutes depending on signal strength. Exposed film was placed into the 
developer solution (Kodak D-19, Kodak, UK) until bands appear and then placed in 
fixer (Polymax T, Kodak, UK) for a few minutes. The developed film was washed with 
running water for 15 minutes then dried. Film was aligned with blot in the cassette to 
mark position of the standards. 
4.2.8 Measurement of TSHR activation 
TSHR activation was measured in two different contexts. cAMP induced by TSH / 
TSAB (M22) was measured directly in OF using radioimmunoassay and indirectly 
using luciferase bioassay to determine whether the TSHR_v2 is secreted as a TSHR-
BP (see below). 
4.2.8.1 cAMP Radioimmunoassay 
4.2.8.1.1 Sample preparation 
In the direct assay, 5 x104 OF in 1 ml per well were plated in triplicates and cultured 
in 12 well plates at various time points before and during adipogenesis. Prior to the 
assay they were switched to 500 µl/well serum free medium for 24 hour and then 
treated with IBMX 10-4M alone or combined with bovine TSH 5 mu/ml or monoclonal 
TSAB (m22, RSR) 0.2 ng/µl 37°C for 4 hours. These were then washed with 1ml 
PBS/well. The cAMP was extracted using 500 µl 0.1M HCl and frozen until further 
analysis. The day prior to performing RIA, the HCl extracts were evaporated to 
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dryness using speedvac. The residue was resuspended in 300 µl of acetate buffer 
and 100 µl was used to measure cAMP.  
4.2.8.1.2 Sample analysis 
 
cAMP in the lysate was measured using cAMP [125I] RIA Kit (PerkinElmer Life 
Sciences). The cAMP stock standard reagent (50,000 pmol/ml) was diluted by fifty-
fold by adding 100 µl of the stock solution to 4.9 ml of assay buffer resulting 1,000 
pmol/ml standard solution. Further dilution was made down to 40 pmol/ml (by adding 
0.1 ml of the 1,000 pmol/ml solution to 2.4 ml of assay buffer). The samples were 
prepared for acetylation as follows: 100 µl of the sample was pipetted into 400 µl of 
assay buffer (1:5 dilutions). 150 µl of acetylation reagent was prepared by mixing 
together in a glass test tube 100 µl of Triethylamine and 50 µl of Acetic Anhydride 
and vortexed. 10 ml of modified assay buffer was prepared by adding 50 µl of the 
acetylation reagent to 10 mL of assay buffer. The modified assay buffer was used for 
the preparation of the cAMP standards and in the “blank” and “zero standard” tubes. 
The 40 pmol/ml standard was acetylated by adding to it 10 µL of the freshly prepared 
acetylation reagent and 1.8 ml of assay buffer and further diluted to create a range of 
concentration from 0.05 to 4 pmol/ml. The samples were acetylated by adding 5 µl of 
acetylation reagent to each 100 µl diluted samples and vortexed, followed by an 
addition of 900 µl of assay buffer to each tube (Final sample dilution of 1:50). The 
working tracer solution was prepared by adding one volume of diluted cAMP [125I]-
Tracer to one volume of the reconstituted cAMP carrier serum. 100 µl of working 
tracer and antiserum complex were added to all tubes and vortexed. These were 
incubated overnight at 4°C. The following day 500 µl of 4°C cAMP precipitator was 
added, centrifuged at 4°C for 15 minutes 1,200 x g and decanted before counting in 
a gamma counter for 50 seconds. The average net counts for each standard and 
sample were expressed as a percentage of the average net counts for the zero 
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standard (termed “normalized” percent bound or % B/Bo). 
% B/Bo =  Average Net Counts of Standard or Sample x 100 
                                              Average Net Counts of Zero Standard 
 
4.2.8.2 Luciferase bioassay  
In the indirect assay, culture supernatants from OF before and at various time points 
during adipogenesis were collected as described above. The supernatants were then 
added to TSH or M22 whilst they were assayed using an in-house luciferase bioassay 
as previously described [367]. Clone lulu* cells are CHO cells expressing the full-
length human TSHR and a cAMP-responsive luciferase reporter and clone zulu cells 
are CHO cells expressing cAMP-responsive luciferase reporter without the full-length 
human TSHR. Initially lulu* cells have been shown to display a dose dependent TSH 
response detectable from 10 µU/ml and maximal at 10 mU/ml when a >25 fold 
increase in light output was obtained [367]. Zulu cell serves as control for non-specific 
binding.  
4.2.8.2.1 Maintenance of lulu* and zulu cell line. 
Lulu*/zulu cells were maintained in 75 cm2 flasks at 37°C in 5% CO2 in Ham’s F12 
medium containing 10% FCS and G418 antibiotic (see Table 50). The cells were 
found to be very sensitive needing medium replacement every second day. 
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Table 50: Hams F12 medium components 
Component Volume (ml) 
Hams F12 171 
Sodium Bicarbonate 5 
FCS 20 
Penicillin/Streptomycin 4 
G418 (40mg/ml) 2 
TOTAL 200 
 
Once confluent cells were trypsinised and resuspended in fresh medium and 
aliquotted into new culture vessels at a split ratio of 1:10. The cell stocks were frozen 
in the liquid nitrogen as described in chapter 2 section 2.2.2. 
4.2.8.2.2 Preparation of bioassay 
A confluent 75 cm2 flask of cells were trypsinised and resuspended in 20 ml of Hams 
F12 medium. 2 x 104 lulu* and zulu 200 µl/well were plated in triplicates in 96 well 
plates in Hams F12 medium for 24 hours.  The next day the medium was replaced 
with Hams F12 containing 10% charcoal stripped serum. On the second day of assay, 
the cells were washed with 100 µl serum free media and 100 µl culture supernatants 
added with or without (control) TSH or M22. These were incubated at 37°C for 5 hours 
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prior to 100 µl saline wash and addition of 55 µl passive lysis buffer (Promega) and 
frozen at -80°C prior to analysis. The analysis was performed using 50 µl of the cell 
extracts with luciferase assay reagent (Promega) using Glomax Multidetection 
System (Promega). Stimulation index was calculated by dividing the mean of 
stimulated/unstimulated lulu* light unit ratio for each sample by the mean of 
stimulated/unstimulated zulu light unit ratio. 
4.3 STATISTICAL ANALYSIS 
For statistical analysis, we used SPSS 18.0 software. Where appropriate, data were 
analysed using Student’s t test for parametric and Mann-Whitney for non-parametric. 
A paired t-test and One- way ANOVA with post-hoc Tukey analysis were carried out 
where indicated. In all cases, p<0.05 was considered significant. The statistical 
analysis applied is indicated in the tables and figure legends. All parametric data are 
presented as mean ± standard deviation and median ± interquartile range for non-
parametric. 
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4.4 RESULTS 
4.4.1 3T3-L1 in vitro adipogenesis  
3T3-L1 was successfully induced to undergo adipogenesis. This was confirmed 
morphologically and by terminal marker of differentiation glycerol-3-phosphate 
dehydrogenase (Gpdh) transcript levels. Morphologically, the maximum adipogenesis 
process was noted by day 6-7 but by Gpdh transcripts the maximum adipogenesis 
was achieved by day 8 (Figure 66). 
 
Figure 66: In vitro induced adipogenesis of 3T3-L1 cells assessed by QPCR measurement of 
glycerol-3-phosphate dehydrogenase (Gpdh) transcripts expressed as transcript copy number 
(TCN) per 1000 copies of acidic ribophosphoprotein (Arp) housekeeper gene. Data shown 
(mean ± SD) are from a representative experiment of two performed in duplicate. **p< 0.01. 
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4.4.2 3T3-L1 Tshr/Tshr_v2 transcripts increase with adipogenesis 
Similar to Gpdh data, 3T3-L1 Tshr full length and Tshr_v2 transcript levels were 
highest on day 8 for Tshr and day 10 for Tshr_v2 (Figure 67). Despite multiple 
attempts to optimize primers for Tshr_v2, we were unable to produce primer pair that 
works for QPCR reaction. The designed primers produced multiple peaks on 
dissociation curve (Figure 68). These were separated on electrophoresis gel to reveal 
2 bands, Tshr_v2 (232bp) and additional bands around 75bp which might represent 
primer dimer (Figure 69). Therefore, the results for Tshr_v2 were obtained by 
densitometry and not QPCR. 
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Figure 67: Transcripts for A; the full length Tshr and B; the Tshr_v2 were measured in 3T3-L1 
by densitometry of QPCR products at various time points before (Day 0) and during 
adipogenesis (Day 1-10). Results are expressed as transcript copy number of Tshr per 1000 
copies of the housekeeper Arp (A) and Tshr_v2 corrected to Arp by densitometry. Results are 
presented as mean ± SD. p value ** <0.01 compared to day 0 on each respective day. 
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Figure 68: Dissociation curve for Tshr_v2 QPCR showing multiple peaks suggesting multiple 
band sizes.  
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Figure 69: Representative densitometry of Tshr_v2 QPCR showing Tshr_v2 bands (232bp) 
and additional bands around 75bp (A) and corresponding to housekeeping Arp bands (72bp) 
(B). 
 
4.4.3 GO orbital fibroblast had higher adipogenic potential than normal 
Human OF adipogenesis was induced in about 30% of cells and we noted that cells 
obtained from GO patients had higher adipogenic potential than those from 
unaffected orbits (Figure 70). 
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Figure 70: Transcripts for the terminal marker of adipogenesis Lipoprotein lipase (LPL) were 
measured in orbital preadipocyte-fibroblasts from patients with Graves’ orbitopathy, GO 
(Stippled bar, n=5) and unaffected (Grey bar, n=5) at various time points before (Day 0) and 
during adipogenesis (Day 5, 10, 15). Results are expressed as transcript copy number of LPL 
per 1000 copies of the housekeeper APRT. Results are presented as mean ± SD; **p value 
<0.01 compared to day 0 on each respective day. Horizontal bar represent comparison 
between normal and GO. 
 
4.4.4 Thyrostimulin is unlikely to have a role in GO 
We measured transcripts for both thyrostimulin subunits. As shown in Figure 71, 
GPHA2 transcripts were present at baseline but a significant reduction in transcript 
levels was observed during adipogenesis (p<0.05) but with some recovery by day 15. 
This might suggest some factor(s) secreted during early adipogenesis, but not later 
in differentiation, which inhibits GPHA2 transcription. No difference was observed 
between normal and GO OF. In contrast GPHB5 transcripts were at the limit of 
detection at all-time points (data not shown). 
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Figure 71: Transcripts for the thyrostimulin GPHA2 subunit were measured in orbital 
preadipocyte-fibroblasts from patients with Graves’ orbitopathy (Stippled bar, n=5) and 
unaffected (Grey bar, n=5) at various time points before (Day 0) and during adipogenesis (Day 
5, 10, 15). Results are expressed as transcript copy number of α2 per 1000 copies of the 
housekeeper APRT). Results are presented as mean ± SD; *p value <0.05 compared to day 
0 on each respective day for GO and non-GO. 
 
4.4.5 TSHR_v2 transcripts are more abundant than full-length TSHR 
We confirmed others and our previous finding that expression of full-length TSHR 
increases during adipogenesis. In this experiment we found there was no significant 
difference noted between GO and unaffected cells as shown in Figure 72A. The 
TSHR_v2 was more abundant than the complete receptor and again its expression 
increased during differentiation, as shown in Figure 72B. However, the TSHR_v2 was 
significantly more abundant in GO than unaffected, possibly reflecting the higher 
adipogenic potential of these cells. Consequently, the ratio of TSHR_v2 to TSHR 
differed significantly at various time points when comparing GO and unaffected, as 
shown in Figure 72C. The fact that TSHR_v2 upregulation was no longer shown when 
corrected with TSHR might suggest that TSHR_v2 expression regulation is related to 
TSHR expression. 
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Figure 72: Transcripts for A; the full length TSHR and B; the TSHR_v2 were measured in 
orbital preadipocyte-fibroblasts from patients with Graves’ orbitopathy, GO (Stippled bar, n=5) 
and unaffected (Grey bar, n=5) at various time points before (Day 0) and during adipogenesis 
(Day 5, 10, 15). Results are expressed as transcript copy number of TSHR or TSHR_v2 per 
1000 copies of the housekeeper APRT. C; the ratio of TSHR_v2:TSHR in GO patients 
(Stippled bar, n=5) and in unaffected orbits (Grey bar, n=5). ). Results are presented as mean 
± SD except C presented as median ± interquartile range; *p value <0.05, ** <0.01 compared 
to day 0 on each respective day. Horizontal bars represent comparison between normal and 
GO. 
 
4.4.6 Thyrostimulin & TSHR_v2 in ex vivo samples 
Analysis of orbital fat directly after surgical removal and without any modification due 
to in vitro culture was also performed. As the sample sizes are small, the results are 
presented as dot plots instead of histograms to show the value for each patient.  We 
confirmed results of in vitro cultures in that GPHA2 transcripts of the thyrostimulin 
was present in the ex vivo samples with no difference between GO and unaffected. 
GPHB5 were undetectable. Transcripts for the TSHR_v2 were also present but we 
did not observe differential effect between GO and unaffected. We did however 
confirm results in vitro cultures that TSHR_v2 was more abundant than full length 
TSHR (Figure 73). Similar to in vitro transcripts data the TSHR_v2:TSHR ratio was 
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no different. 
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Figure 73: Ex vivo analysis of orbital preadipocyte-fibroblasts from unaffected individuals (NO, 
n=5) and patients with Graves’ orbitopathy, (GO, n=9 except figure B and C n=8) for transcripts 
of A; GPHA2 subunit, B; TSHR, C; the TSHR_v2, D; the TSHR_v2:TSHR transcripts ratio. 
Results are expressed as transcript copy number per 1000 copies of the housekeeper APRT. 
Results are presented as median ± interquartile range. 
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4.4.7 Human TSHR_v2 antibodies were successfully generated 
The TSHR_v2 antibodies were successfully generated to detect the intended peptide 
sequence as shown in Figure 74 as dark bands on the lower part of the figure with 
calculated molecular weight of 1.7 kDa. Higher titre antibodies were produced from 
rabbit 1 (Figure 74). 
 
 
Figure 74: Western blot analysis of immunizing peptide showing stronger band from rabbit 1 
sera than rabbit 2. Second immunisation produced a stronger band with higher specificity than 
1st immunisation. Pre: Pre immune serum; 1st and 2nd: first and second immunisation; P1 and 
P2: post affinity column purification. 
 
The antibody was then blotted against GO and normal OF lysates and 
unconcentrated supernatants. Using 1:50 TSHR_v2 antibodies dilution in PBS 
resulted stronger signal at an apparent molecular mass of 46 kDa than 1:200 dilutions 
but at the expense of some other higher molecular mass bands. The TSHR_v2 was 
not detectable in unconcentrated supernatants either from GO or normal OF (Figure 
75). As previously discussed, to ensure the specificity of TSHR_v2 antibodies, the 
immunisation peptide was designed based on 8th intronic sequence of full length 
TSHR which was unique to TSHR_v2. This was supported by the absence of TSHR 
band (expected molecular weight 62 kDa) on the blot indicating specificity of the 
TSHR_v2 antibodies (Figure 75). 
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Figure 75: Western blot analysis of preadipocyte-fibroblast lysates and unconcentrated 
supernatants 15 days after adipogenesis from a patient affected (GO) and not (NO) with 
Graves’ orbitopathy showing protein with an apparent molecular mass of 46 kDa. There were 
other bands detected at 56, 80 and in between 80-175 kDa by using 1:50 anti TSHR_v2 
antibodies dilution. 2nd: secondary antibody only; Lx: lysate; SN: supernatant. 
 
4.4.8 TSHR_v2 and TSHR protein are detectable in orbital preadipocyte-
fibroblasts 
We then performed western blots on cell lysates and concentrated culture 
supernatants from GO and unaffected OF. One µg protein was loaded into each well. 
This was calculated from standard curve of bovine serum albumin by BCA assay 
(Figure 76). Equal loading was confirmed on western blot of housekeeping protein 
actin (Figure 77). As shown in Figure 77A, a protein with an apparent molecular mass 
of 46 kDa was present in the cell lysates and culture supernatants from OF. This is 
consistent with the TSHR_v2, which comprises 253 amino acids and retains 5 of the 
6 putative N-linked glycosylation sites present in the full-length TSHR. The doublet 
may reflect differing amounts of glycosylation. Its presence in the conditioned culture 
medium indicates that it can be secreted from cells which express it. 
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Of note, the protein levels increased when comparing cells before and after 
adipogenesis and there was a substantially stronger signal in the GO samples, when 
compared with unaffected, both in the cell lysates and conditioned culture medium 
(n=3 GO and 3 Normal). Using 2C11 antibody, we also showed that TSHR protein 
with an apparent molecular mass of 62 kDa was present in the lysates after 
adipogenesis and higher in GO than normal. This is consistent with the shed TSHR 
A subunit (Figure 77B). 
 
 
Figure 76: BCA assay standard curve for protein quantifications. 
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Figure 77: Representative western blot analysis of preadipocyte-fibroblast lysates and 
supernatants before (D0) and after adipogenesis (DM15) from a patient affected (GO) and not 
(NO) with Graves’ orbitopathy showing higher TSHR_v2 protein concentration (A) as the cells 
undergoing adipogenesis and higher TSHR protein (B) using 2C11 antibody. Neg; negative 
control. 
 
4.4.9 Is the TSHR_v2 functional? 
We measured cAMP production in response to TSH or a human monoclonal TSAB 
(M22) at various time points before and after differentiation of OF. This was calculated 
from a standard curve of acetylated cAMP by radioimmunoassay (Figure 78). We 
observed a decrease in cAMP from basal levels when OF were stimulated with TSH 
or M22 before differentiation compared to unstimulated (p value <0.05). In contrast a 
robust increase in cAMP was induced by both agents in differentiated cells, as shown 
in Figure 79 and Figure 80. The difference between GO and NO was not significant. 
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Figure 78: Acetylated cAMP radioimmunoassay standard curve expressed as “normalized” 
percent bound or % B/Bo plotted against cAMP concentration. 
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Figure 79: Radioimmunoassay results of cAMP response in Graves’ orbitopathy (GO) and 
normal (NO) OF pre and post-adipogenesis in response to TSH 5 mU/ml and M22 0.2 ng/µl 
presented as normalised percentage bound and converted cAMP concentration (n=2). The 
concentrations of TSH and M22 chosen were shown to stimulate the most cAMP in our 
luciferase assay. CM 15; undifferentiated OF in CM on day 15. The results presented were 
median (interquartile values) of duplicate readings from experiment performed in triplicate. 
Kruskal–Wallis one way ANOVA with post hoc Dunns test within each day comparing to 
unstimulated*, TSHᵠ; p value */ᵠ<0.05, **/ᵠᵠ<0.01. 
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Day of 
culture 
Treatment 
cAMP Stimulation Index (SI) 
GO NO 
Day 0 
TSH 0.29 ± 0.08* 1.30 ± 0.22 
M22 0.75 ± 0.02* 0.84 ± 0.05 
Day 5 
TSH 1.58 ± 0.40 1.19 ± 0.11 
M22 2.00 ± 0.05* 0.63 ± 0.40 
Day 15 
TSH 1.55 ± 0.90 2.61 ± 1.31 
M22 1.05 ± 0.57 1.89 ± 0.30 
CM 15 
TSH 0.52 ± 0.24* 1.20 ± 0.03 
M22 1.63 ± 0.46 1.19 ± 0.22 
 
Figure 80: cAMP response (expressed in fold changes from unstimulated samples, 
Stimulation Index (SI)) in OF pre and post-adipogenesis in response to TSH 5 mU/ml and M22 
0.2 ng/µl. Noted that there were reductions in TSH and M22 stimulated cAMP responses in 
day 0.  Results are expressed as median ± interquartile range. NO, Normal; GO, Graves’ 
Orbitopathy. *Mann-Whitney p value <0.05 compared to normal. 
  
Of note, there was a strong negative association in the amount of cAMP generated 
and the TSHR_v2:TSHR  transcripts ratio, as demonstrated in Figure 81 but this 
achieved significance only for M22 (Spearman correlation: TSH r=-0.55, p=0.23, M22 
r=-0.87, p=0.03). 
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Figure 81: Negative association between cAMP, expressed as a stimulation index (SI) on the 
x axis and the ratio of TSHR_v2:TSHR transcripts on the y axis.  
 
We also assessed the ability of conditioned medium from OF before and after 
differentiation to interfere with TSH or M22 induced TSHR activation in a luminescent 
bioassay. In the standard assay performed in serum-free medium, both TSH and M22 
induce a dose-responsive stimulation index (S.I.); e.g. TSH 5 mU/ml S.I. = 8.1, 0.5 
mU/ml S.I. = 4.4; M22, 0.2 ng/µl S.I. = 9.5, 0.01 ng/ µl S.I. =1.1 (Figure 82).  
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Figure 82: Dose-responsive stimulation index (SI) of TSH and M22 in serum free media. 
 
We used unconcentrated conditioned medium (serum-free) from confluent cells just 
prior to addition of differentiation medium as the baseline S.I. The value was 
decreased relative to non-conditioned medium but we observed no significant 
difference in S.I. between GO and unaffected conditioned medium. At the end of 
differentiation, the TSH-induced S.I. was significantly lower in GO conditioned 
medium but not in unaffected, in keeping with the abundance of TSHR_v2 in GO. In 
M22 experiment we observed that S.I was lower in GO than unaffected at day 0 and 
after differentiation (Figure 83).  
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Figure 83: Indirect assays were performed using conditioned medium from OF at various 
stages of differentiation in the presence of TSH/M22 in a TSHR/cAMP luciferase bioassay. 
Grey bar represents normal and stripped bar are of Graves’ OF. Results are presented as 
mean ± SD; *p value <0.05, ** <0.01. Horizontal bars represent comparison between normal 
and GO 
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4.5 DISCUSSION 
Our results do not confirm a role for thyrostimulin in the orbit although we cannot rule 
out production of this high-affinity TSHR ligand [283] by other orbital components not 
studied. We did find difficulties in designing GPHA2 primers as these were picking up 
genomic DNA. Electrophoretic band analysis and sequencing revealed that our 
forward and reverse primer sequences were also found to be present in the intronic 
region i.e. we were amplifying the intronic region. Despite careful attention in 
designing the second set of the primers, we were still picking up genomic DNA which 
was resolved by treating the RNA with DNAse. We found cDNAs obtained from RNAs 
extracted using standard Tri-reagent for our orbital fat ex vivo analyses were 
producing poor CT values for the house keeping genes despite good A260/A280 ratio. 
The problem was overcome by using commercial specific RNA extraction kit which 
was optimized for use with fatty tissues.  
Our results confirm those of Lantz et al who also investigated orbital tissues [360]. 
Both orbital studies contrast with the work of Sun et al who identified thyrostimulin as 
a paracrine regulator in the ovary [368] and also of Bassett and colleagues who 
reported that thyrostimulin regulates osteoblast formation in bone but only in early life 
[369]. Analysis of tissue distributions showed that GPHA2 subunit exhibits a wider 
distribution than GPHB5 subunit but both transcripts have been found to 
be expressed in human pituitary, retina, testis and skin [284, 370]. Here we show 
that GPHA2 is present in abundance in the retroorbital adipose tissue but not 
GPHB5 which is needed to form the functional heterodimer thyrostimulin. Whilst 
it is still possible that GPHA2 can act as monomer or heteromerize with 
unknown partner, current animal model data does not support this is the case [284, 
371]. 
We confirmed our previous findings and that of others that TSHR expression was very 
low in undifferentiated OF and increased with adipogenesis. We did not find any 
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differential expression of TSHR between GO and normal in contrast to previous 
findings [118, 120, 328, 372]. This discrepancy might be explained by different 
techniques and housekeeping gene used to quantify TSHR. We used QPCR in which 
absolute numbers of TSHR transcripts are reported per APRT housekeeping gene; 
this contrasts with Kumar et al who applied relative quantification of the TSHR 
compared to the 18S RNA [328]. It is well known that different housekeeping gene 
used will affect the results of gene expressed. However our protein expression 
analysis of TSHR using 2C11 antibodies by western blot were in agreement with 
others albeit different techniques used (immunocytochemistry and flow cytometry 
methods) to show the presence of TSHR protein [118, 120, 372, 373].  
Our data suggest that TSHR activation may be further regulated by a variant isoform 
which can be secreted from cells which express it. Early northern blot analysis of 
thyroid tissue identified the expected full-length transcript plus 2 additional transcripts 
at 1.3 and 1.7 kb [362]. We have demonstrated that the more abundant of these 
isoforms is also present in extra-thyroidal locations where TSHR activation 
contributes to pathology, i.e. Graves’ orbitopathy. 
We observed that TSHR activation of non-differentiated orbital fibroblasts, i.e. prior to 
adipogenesis, leads to a reduction in cAMP suggesting that the receptor is coupled 
to Gi in these cells. Others have reported that TSHR activation of orbital fibroblasts 
signals via p70s6 kinase [374], which may result from Gq or Gs-beta/gamma 
signalling, but to our knowledge this is the first report of the receptor coupling to an 
inhibitory G protein. The finding may explain our lack of success when using gain-of-
function mutants of the TSHR to stimulate adipogenesis [247] and concurs with the 
study from van Ziejl et al who investigated TSH/TSAB induced hyaluronan production 
[264].  
The TSHR_v2 we have studied comprises 253 amino acids and is predicted to retain 
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5 of the 6 N-linked glycosylation sites. Previous work by Rapoport and colleagues 
demonstrated that a TSHR truncated to 229 amino acids was unable to bind TSH. 
The holoreceptor contains 9 leucine rich repeats (LRR) which have been reported to 
act as the binding site for both TSH and TSAB [375]. Two of the LRR reside in exon 
9 but the unique sequence of 22 amino acids contributed by intron 8 are likely to be 
sufficient to complete the 8th LRR and thus enable this variant to bind TSH and TSAB. 
The variant could function in several ways; (i) A TSH or TSAB binding protein would 
neutralize their effects and thus prevent the consequences of TSHR activation in the 
orbit (ii) A potent autoantigenic stimulus could have a positive influence on T cell 
homing to the orbit and thus exacerbate GO pathology. Studying TSH binding 
protein/s possess their own challenges. We found cAMP radioimmunoassay was a 
cumbersome, protracted and expensive assay to perform. With luciferase assays, we 
were unable to find perfect negative control for the experiment. We tried conditioned 
medium from HEK293 cells and HCA2 but later found these cells also express 
TSHR_v2. Adsorption tests of TSH and M22 using CHO cells with TSHR extra cellular 
domain were not successful for unexplained reasons. In fact the S.I. indexes in these 
cells were much higher than empty CHO cells. It is possible that these GPI cells were 
secreting TSH ECD forming a complex with TSH and M22 which enhanced TSHR 
stimulation in the assay.  
Relatively little is known about the regulation of alternative splicing of the TSHR. 
Some single-nucleotide polymorphisms in the proximal TSHR promoter or intron 1 
have been associated with increased levels of the variant in thyroid tissue and also 
of receptor expression in the thymus with consequent impact on central tolerance 
mechanisms [376]. However, GD patients who develop GO do not have a higher 
prevalence of the disease-associated TSHR intronic SNP than GD patients who do 
not develop GO. 
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In conclusion, we found no evidence that thyrostimulin presents in the orbital adipose 
tissue.  Both TSHR and TSHR_v2 are present in the orbit. In vitro data supports that 
TSHR_v2 are more abundant than full length TSHR in OF and during adipogenesis 
are significantly higher in GO than non-GO. TSHR_v2 is secreted and may alter 
intracellular TSHR signalling. 
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Chapter Five 
4 DISSECTING THE ROLES OF TSHR ACTIVATION AND 
THYROID HORMONE IN REGULATING ADIPOSE 
PHENOTYPE 
5.1 INTRODUCTION 
Excess thyrotropin receptor (TSHR) activation occurs in two common conditions, 
Graves’ disease (GD) in which thyroid stimulating antibodies (TSAB) mimic thyroid 
stimulating hormone (TSH) causing hyperthyroidism, and primary hypothyroidism 
when elevated circulating TSH compensates for low thyroid hormone (T4/T3) levels 
resulting from the failing gland [377]. Both confer alterations in body composition e.g. 
more than 90% of people with GD lose weight, mainly muscle mass and fat [378] 
whilst hypothyroidism increases fat and bone mineral density (BMD). The opposing 
differences of thyroid hormone levels have been traditionally suggested for these 
changes of body compositions, e.g. impact on white adipose tissue (WAT) or brown 
adipose tissue (BAT) metabolism which will be discussed later in this chapter [379, 
380]. 
There is still considerable controversy regarding the best modality of treatment for 
hyperthyroidism in Graves’ disease. Treatment options include thionamide drugs that 
block thyroid hormone biosynthesis, radioiodine therapy or thyroidectomy. 
Radioiodine and/or thyroidectomy might be associated with more weight gain 
compared to those on anti-thyroid drugs and patients who underwent ablative therapy 
for thyroid cancer [288, 381, 382]. This suggests that there are some factors 
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associated with Graves’ disease that influence post therapy weight gain. Furthermore 
analysis has suggested that a diagnosis of Graves’ disease (as opposed to another 
cause of thyroid over-activity), is an independent predictor of weight gain [288] 
separately from thyroid dysfunction, raising the possibility that the anti-TSH receptor 
antibodies that alter fat biology in the orbit, might also have long-term effects on 
peripheral adipose tissue composition; contrary to a study by Rotondi et al which failed 
to find this association [383]. 
5.1.1 Adipose tissue 
Adipose tissue is a connective tissue system consisting mainly of adipocytes within a 
structural network of fibres. The main function of the adipose tissue is for fat storage, 
which could originate from either dietary intakes or intracellular synthesis. The 
adipose tissue depots are found mainly under the skin (known as subcutaneous fat) 
but also in the omentum (known as visceral fat), in other locations such as bone 
marrow, heart, kidneys and elsewhere around the body. It is the largest tissue 
accounting for about 10-15% of total body weight in the normal population. As 
mentioned above, adipose tissue is distributed in different anatomical locations and 
divided into subcutaneous and visceral fat. This division is largely based on the fact 
that they both have different cellular properties and association with insulin resistance 
and cardiovascular diseases [384]. There is also different distribution of adipose 
tissue according to sex. In general, men tend to accumulate adipose tissue around 
the waist, and women tend to accumulate the adipose tissue around the hips. 
Majority of these adipose tissues are consisting of WAT. It is composed of cells 
containing a single large fat droplet with the nucleus located within a thin rim of 
cytoplasm at the periphery. Previously believed to be only involved in energy storage, 
now WAT is thought to be involved in many other functions including glucose 
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homeostasis, lipid metabolism, vascular homeostasis and inflammatory processes. 
Many of these roles are achieved via production of signalling proteins also known as 
adipokines such as adiponectin. Despite being produced solely by adipocytes, its 
level has been found negatively associated with obesity. In an animal model, the 
administration of adiponectin has been accompanied by a reduction in plasma 
glucose and an increase in insulin sensitivity [385]. In contrast to this, a different 
adipokine called resistin is found positively correlated with obesity.  It was named 
after the discovery that it caused insulin resistance in mice [386]. Other adipokines 
include leptin, tumour necrosis factor , interleukin 6, plasminogen activator inhibitor-
1, tissue factor angiotensinogen, adipsin, acylation-stimulating protein, and retinol-
binding protein. Some of these are also produced by cells other than adipocytes. 
Mature adipocytes do not divide and new fat cells can be generated only by 
differentiation of precursor preadipocytes i.e. adipogenesis. Although originally it was 
thought that all adipocytes originate from a common mesodermal precursor, the origin 
of these adipocyte precursors is now being questioned [387]. Lineage tracing studies, 
indicated that WAT originates from a Myf5-negative precursors although some 
subsets of white adipocytes also can arise from Myf5 expressing precursors [388]. 
The description of preadipocytes and adipogenesis were described in detail in chapter 
one. 
Until recently, brown adipose tissue was thought to be essentially nonexistent in 
human adults and only found primarily in infants and young children [389]. With 
advances in imaging techniques, it is now possible to visualize brown adipose tissue 
via positron emission tomography (PET) scanning. Work by Cypess and others using 
a combination of PET scan, ex vivo and in vitro analysis have proven that functional 
brown fat tissue does exist in human adults [390, 391]. Another interesting finding 
from Cypess et al in a different study, is that fat tissue becomes more brown (using 
uncoupling protein1 (UCP1) as brown marker) as one moves from subcutaneous to 
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deeper paravertebral adipose compartment and with the reverse finding with LEPTIN 
(WAT marker) [392].  
Two types of brown adipose tissues (BAT) have been identified. They are described 
as ‘classical’ and ‘inducible (also known as brite/beige)’ BAT and as will be described 
below, lose energy as heat. Classical BAT is found in the interscapular BAT depot 
and perirenal regions of rodents. In vivo fate mapping showed that this brown fat 
arose from precursors that express Myf5, a gene previously thought to be expressed 
only in the myogenic lineage [393]. These Myf5 derived precursors can differentiate 
into brown adipocytes through the action of PRDM16 and C/EBP-β although it 
remains unknown whether the Myf5 positive cells clonally give rise to brown 
adipocytes and myocytes [394]. The inducible type of brown adipocytes is found 
sporadically as clusters in the white adipose of adult animals that have been 
chronically exposed to cold or to PPARγ ligands. They possess the morphological 
(multilocular lipid droplets) and biochemical characteristics (e.g. UCP1) of classical 
brown adipocytes but not of a Myf5 lineage [393, 395].  Study in mice suggested there 
is bi-directional interconversion of beige and white adipocytes [396]. Here that the 
beige adipocyte can be induced by cold temperature into brown fat and conversely 
can return back into white fat type by heat. Similarly, Lee et al also found that these 
cells can be turned into brown or white by adrenergic stimulation and high calorie diet, 
respectively [397]. 
Human BAT deposits are located in supraclavicular and neck region, but beige 
adipocytes have been described in WAT and BAT depots including subcutaneous 
[398, 399]. GD patients display heat intolerance, which has been attributed to excess 
thyroid hormone increasing metabolic rate. The results from this study indicate that 
TSHR activation may contribute to this symptom. This concept is supported by studies 
in the hyt/hyt mouse, which lacks a functional TSHR and deals poorly with low 
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temperature, a characteristic which can be overcome by transfecting WT TSHR into 
the animals [400]. High thyroid hormone levels are also known to induce brown fat 
activity in brown and beige fat [379, 380, 401]. 
In general, all types of brown fat have specific signature genes (which will be 
discussed below) such as UCP1 and peroxisome proliferator-activated receptor 
gamma coactivator -1 alpha (PGC1). Whilst zinc finger of cerebellum 1 (ZIC1) is 
found selectively in brown adipose tissues and not detectable in white (commonly 
used gene markers TCF21 or LEPTIN) and beige adipose tissues. On the other hand, 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain 1 
(CITED1) was found uniquely in beige fat tissues. One of the unique features of brown 
fat is that it contains a very high number of mitochondria, which gives its brown 
appearance. Through its uncoupling proteins, it is responsible for generating heat by 
non-shivering thermogenesis. 
5.1.1.1 Mitochondrial uncoupling proteins 
Mitochondria are essential organelles in cells and involved in cell survival and 
functioning. One of the main functions of the mitochondria is involved in energy 
production via ATP generation. Historically by studying oxygen consumption 
(respiration) in mitochondria suspensions, the trace of oxygen can be recorded with 
an oxygen-sensitive electrode. In the absence of ADP, oxygen consumption of 
mitochondria is slow but its rate is increased rapidly by addition of ADP, which leads 
to ATP accumulation in the suspension. The reaction is temporary until another bolus 
of ADP is added to the mitochondrial suspension. This experiment indicates that 
respiration of mitochondria is ‘coupled’ to the oxidative phosphorylation of ADP [402]. 
In the modern era, this knowledge has been expanded to a process involving a 
spontaneous electron transfer through complexes I (NADH Dehydrogenase), III (bc1 
complex), and IV (Cytochrome Oxidase) which is coupled to active H+ ejection from 
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the mitochondrial matrix into intermembrane space of the mitochondria. H+ ejection 
creates a membrane potential and a pH gradient (negative charge and alkaline pH in 
the inner membrane or matrix). The ATP synthesis is coupled to spontaneous H+ 
transport via the ATP-synthase into the matrix compartment driven by the pH and 
electrical gradients created.  The term ‘uncoupling’ refers to the loss of this coupling 
process between electron transport in the respiratory chain and ATP production. 
Compounds capable of stimulating oxygen consumption (respiration) without a 
concomitant increase in ATP production were termed ‘uncouplers’. An uncoupling 
protein (UCP) is a mitochondrial inner membrane protein that is a proton transporter 
or a channel thus capable of dissipating the proton gradient generated by the 
mechanism. This process in turn stimulates respiration, which leads to dissipation of 
heat.  It is estimated that the energy generated by uncoupling constitutes a 
considerable part of the basal energy expenditure i.e. approximately 20%-50% of total 
energy expenditure [403]. 
There are five types of UCP known in mammals namely UCP1 (also known as 
thermogenin), UCP2, UCP3, UCP4 and UCP5. Although these proteins are similar in 
their structures, they have different tissue expression in mammals. UCP1, is mainly 
expressed in BAT, UCP2 is widely distributed, whereas UCP3 is mainly expressed in 
skeletal muscle, and UCP4 and 5 are mainly expressed in the brain [403, 404]. Thus 
their roles are also different namely UCP1 is for thermogenesis or energy, UCP 2 and 
3 are for regulation of free-fatty acids, all UCPs except 4 are involved in reduction of 
reactive oxygen species formation. The UCP1 gene is located on chromosome 4 
containing 6 exons [403] and mainly found in BAT. Its expression is increased by 
adrenergic stimulation, cold temperature, -agonists, retinoid, non-esterified fatty 
acids, thyroid hormones, and cAMP [403, 405]. Contrary to the expectation, UCP1-
knockout mice did not become obese but only sensitive to cold. The transgenic mice 
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overexpressing UCP1 expression in WAT were resistant to weight gain by high fat 
diet [403].  
5.1.1.2 PGC1 
The PGC-1 is a family of coactivators consisting of PGC-1α, PGC-1β and PRC (PGC-
1-related coactivator). They play a central role in mitochondrial biogenesis and 
respiratory function. PGC-1α is a protein that in humans is encoded by the 
PPARGC1A gene on chromosome 4 (4p15.2) [406]. As the name suggests, this 
protein interacts with the nuclear receptor PPAR-γ which is an important regulator of 
adipocyte differentiation and enhances UCP1 expression. It is also known to be 
activated by reactive oxygen species (ROS), cold exposure, cAMP response 
element-binding (CREB) proteins and AKT pathways [407]. It is expressed in brown 
adipose tissue, brain, heart, kidney, skeletal muscle [408]. 
5.1.1.3 ZIC1 
The first member of the zinc finger of cerebellum family was identified during a screen 
for cDNAs enriched in the murine cerebellum [409]. It acts as a transcriptional 
activator and is mainly involved in neurogenesis. The gene is located on chromosome 
3 and contains only 3 exons. There are currently 5 known members namely ZIC1 to 
5. Samples taken from the interscapular area of mice and human neck (classical 
brown fat depots) were found to express high levels of ZIC1 suggesting it to be the 
gene that best discriminates it as a classical brown fat from other types of fat [395, 
399].  
5.1.1.4 CITED1 
CITED1 was initially identified in a murine melanoma cell line [410]. Its gene is located 
on chromosome 3 (Xq13.1). This gene encodes a member of the CITED family of 
proteins. The encoded protein, also known as melanocyte-specific gene 1, may 
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function as a transcriptional coactivator and may play a role in pigmentation of 
melanocytes and acts as a transcriptional co-activator for oestrogen receptor [411].  
CITED1 was found selectively expressed in the UCP1-positive beige cells in the mice 
inguinal WAT treated with a β3 agonist and UCP1-positive brown adipocytes in 
human BAT indicating that CITED1 can serves as a marker for beige cells both in 
mice as well as in humans [412]. 
5.1.1.5 HOXC9 
This gene belongs to the homeobox family of genes that encode a highly conserved 
family of transcription factors that play an important role in morphogenesis. It provides 
cells with specific positional identities on the anterior-posterior axis. Humans possess 
four similar homeobox gene clusters, HOXA, HOXB, HOXC and HOXD, which are 
located on different chromosomes. HOXC genes are located on chromosome 12. The 
transcripts have been found to be expressed mainly in skeletal muscle, adipose 
tissues, skin, small intestine and fallopian tube. HOXC9 was originally described as 
a WAT marker [392] but later was found to be significantly upregulated by PPAR 
treatment (suggesting beige quality) [413]. It was found in the beige depots [412], but 
it was not increased by cold exposure. It was less expressed in white depots and not 
at all in brown depots [414]. 
5.1.2 Graves’ disease and body composition 
TSHR activation occurs in most people with thyroid dysfunction; either due to elevated 
TSH in hypothyroidism or TSAB in GD. Hypothyroidism is associated with increased 
body fat and BMD, which revert with treatment – but seldom reach pre-disease levels. 
Despite restoration of euthyroid status, many GD patients complain of substantial 
weight gain post treatment [285, 286] with potential negative impact on their future 
cardiovascular risk. This suggests a role of TSHR activation through the presenting 
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TSAB after therapeutic treatment of GD [415]. Indeed, the presence of functional 
extrathyroidal TSHR has been demonstrated in e.g. adipose tissue [117, 247] and 
bone [416]. This was further supported by Marcus et al, who demonstrated that TSH 
has a predominant lipolytic effect on isolated neonatal adipose tissue at physiological 
concentration. Similar but reduced effects were also seen up to adulthood but only at 
supra-physiological concentrations of TSH [417]. Activation of TSHR in adipose 
tissues has been shown to be positively correlated with obesity in some recent studies 
[418-420], and reports using animal models suggest a role for the TSHR in BAT and 
WAT function [400, 421, 422].  Taken together, there is a clear need for greater 
understanding of the effect of thyroid auto-antibodies on subcutaneous and visceral 
fat, which may have key implications for the treatment options offered in managing 
Graves’ disease.  
The above evidence led us to hypothesize that TSHR activation per se may contribute 
to changes in body composition separately from the effects of thyroid hormone levels, 
e.g. impact on adipose tissues metabolism [423]. We would hope to delineate this by 
studying GD neck fat samples with 2 different controls. We recognised the limitation 
that all patients were euthyroid during surgery. However, we would envisage that GD 
fat samples would experience a period of hyperthyroidism and TSAB stimulation 
whilst the controls, toxic multinodular goitre - the tissues experienced hyperthyroid 
state without TSAB stimulation and normal who were euthyroid with negative TSAB. 
Our aim was to investigate the effect of TSHR activation on brown, beige and white 
adipose tissue formation in ex vivo human neck fat tissues recognised as a BAT 
inducible region [390]. Where possible analyses were also extended to investigate 
the differential expression of these markers between subcutaneous and perithyroidal 
fat locations.   
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5.2 MATERIALS AND METHODS  
All reagents were obtained from Sigma-Aldrich and tissue culture components from 
Lonza unless otherwise stated. 
5.2.1 Adipose tissue collection  
All fat samples were collected with informed consent and local research ethics 
committee approval. Perithyroidal neck fat samples were obtained from GD (n=14), 
multinodular goitre (MNG) (n=6) and normal patients (n=11) undergoing thyroid 
surgery. The perithyroidal fat samples will be referred to as ‘deep’ fat samples from 
here on. Where possible paired neck subcutaneous and deep samples were obtained 
and all patients were euthyroid prior to surgery. Euthyroid is defined as FT4 and/or 
FT3 in normal reference range. It was acceptable that TSH may remained suppressed 
many months later after normalisation of thyroid hormones. All GD patients have 
positive TSHR antibodies measured by thyroid binding inhibiting immunoglobulin 
(TBII) assays at diagnosis and TSAB luciferase reporter assay [367] measured from 
serum sample on the day of surgery. There were 2 controls with borderline TSAB. 
There were kept in their respective groups as none of their TSAB levels 
reached that of GD TSAB and the cut off TSAB was based on the 97th 
percentile of normal TSAB levels. One GD patient without TSAB had clinical 
evidence of GD with marked GO. Furthermore, analysis excluding 2 controls 
with borderline positive TSAB and the GD patient did not alter the findings of 
this chapter. 
5.2.2 Primer design 
Primers were designed using primer3 software as described previously (Chapter 2, 
section 2.2.12). Please see Table 51 for primer pairs used in this chapter. 
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Table 51: PCR primers used indicating exon location and size of amplicon. 
 
Accession 
number 
Forward  Reverse  
Amplicon 
size (bp) 
UCP1 NM_021833.4 
GGGGCTTCAGCGGCAA
ATCAG (Exon 2) 
TATAAGTCCCCGTGTAGCGAG
GTT (Exon 3) 
236 
PGC1 NM_013261.3 
GAAGAGCGCCGTGTGA
TTTA (Exon 10-11) 
 
CGCTGTCCCATGAGGTATTC 
(Exon 13) 
 
433 
ZIC1 NM_003412.3 
CCCTTCAAGTGCGAGTT
TGA (Exon 2) 
 
TGGACCTTCATGTGTTTGCG 
(Exon 3) 
 
161 
CITED1 NM_004143.3 
CTCACCTGCGAAGGAG
GATG (Exon 2) 
CCATTTGAGGCTACCCCAGG 
(Exon 3) 
117 
HOXC9 NM_130769.3 
CTGGACCCCAGCAACC
C (Exon 1-2) 
CTCCTTCTCCAGTTCCAGCG  
(Exon 2) 
98 
 
5.2.3 RNA extraction  
We used Trizol reagent initially (See chapter 2, section 2.2.10) to extract the RNA 
from the frozen tissue. Despite having good A260/280 absorbance (e.g. A260/280 of 
2.0), the resulting cDNA housekeeping gene was very poor with CT values around 
27-39. Subsequently, RNA was extracted as described previously in chapter 4 
(section 4.2.4) using RNAeasy lipid tissue minikit (QIAGEN). 
5.2.4 PCR analysis of markers for white, beige or brown adipose tissues 
Standard PCR was performed for 35 cycles, followed by agarose gel electrophoresis 
analysis and sequencing to confirm that the PCR amplicon was the intended product 
(see Chapter 2, section 2.2.12-2.2.16). QPCR was conducted using SYBR Green 
incorporation measured on a Stratagene MX 3000. As the samples were quite small 
in amount, only small numbers of PCR studies could be performed on any one 
sample. The comparative, also known as delta delta CT method was used to calculate 
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relative gene expression to the same normal control throughout the experiment. This 
involved comparing the CT values of the samples of interest with average normal 
control. The CT values of both the calibrator and the samples of interest were 
normalized to adenine phosphoribosyltransferase (APRT) housekeeping gene. The 
formula used was:  
ΔΔCt = ΔCT sample - ΔCT reference 
If multiple products were detected on the dissociation curve, a densitometry technique 
was used to express the results. The PCR products were separated on 2% agarose 
gel for 35 minutes. The confirmed densitometry gel bands were analysed using 
AlphaView Software for semi-quantification and corrected with respective 
housekeeper bands as previously described (Chapter 4 section 4.2.6). 
5.2.5 Luciferase bioassay 
Patients’ sera collected on the day of surgery was tested for the presence of TSAB 
using in-house luciferase bioassay as described in Chapter 4 (section 4.2.9.2). Salt 
free buffer (Table 52 and Table 53) was used instead of serum free medium due to 
failure in generating meaningful stimulation index with the latter. The working assay 
buffer was obtained by diluting sterile PEG (20 ml of pure water added to 5 g) with 
salt free assay buffer (1 in 5 solution) i.e. 5 ml PEG: 20 ml buffer (sufficient for one 
full plate). 
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Table 52: Salt free buffer composition made up to 50 ml with pure water and placed in 37°C 
water bath for 20 minutes and pH to 7.4 using KOH. 
Component Volume or weight 
Solution A 12.5 ml 
Glucose  0.05 g 
Hepes 20 mM 1 ml 
CaCl2 stock 50 l 
BSA 20.75 g 
Sucrose 280 mM 4.8 g 
CaCl2 stock was made with 1.85 g in 10 ml water. 
Table 53: Solution A made up to 250 ml with pure water and stored at 4°C. 
Component Weight 
KCL 0.4 g 
KH2PO4  0.06 g 
MgSO4 0.1 g 
NaHCO3 0.35 g 
Na2HPO4 0.48 g 
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5.2.6 Statistical analysis 
Parametric data were analysed using Student’s t test, paired t test and one-way 
ANOVA with post hoc Tukey’s test for multiple group comparisons where appropriate. 
Similarly, Mann-Whitney U test, Wilcoxon signed rank test and Kruskal-Wallis H test 
with post hoc Dunn’s test were used for non-parametric data. Chi-square test was 
used for categorical variables. All analyses employed 2 tailed tests. Parametric data 
were presented as mean ± standard deviation and median ± interquartile range for 
non-parametric data. In all cases p<0.05 was considered significant.  
  
 266 
5.3 RESULTS 
5.3.1 Patient demographics 
Please see Table 54 below for demographics of the patients. Patients whose thyroid 
histology indicated malignancy were excluded. Two patients with histology of 
multinodular goitre (MNG) but positive TSAB were included in the Graves’ disease 
(GD) group. There was no difference in patients’ age (p=0.1322), FT4 (Kruskal-Wallis 
H p=0.577), TSH (Kruskal-Wallis H p=0.1679) and sex distribution (Chi square 
p=0.379) between the 3 groups. Patients in GD group had a high level of TSAB 
compared to TMNG and normal (Kruskal-Wallis H p<0.0001 with Dunn’s post hoc test 
p<0.001 against both TMNG and normal).  
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Table 54: Patients demographic. F=female, M=male, GD=Graves’ disease, TMNG=Toxic 
Multinodular goitre, EMNG=Euthyroid multinodular goitre, TA=Toxic Adenoma, CN=Colloid 
nodules, HN=Hyperplastic nodules, BC=Benign cyst. Normal reference: FT3 (2.6-5.7 pmol/l), 
FT4 (9.2-22 pmol/l), TSH (0.30-4.40 mU/l), Thyroid receptor antibodies (TRAB; <1 negative, 
1-1.4, borderline >1.4 u/l positive), Thyroid peroxidase antibodies (TPO) (<32 kU/l is negative), 
Thyroid stimulating antibodies (TSAB; stimulation index 97.5th SD of normal <1.4 is negative). 
  
Patient ID Sex Age Histology FT3 FT4 TSH TRAB  TPO  TSAB 
 
Graves’ Disease 
 
  
     
GD1 M 47 GD  13.0 2.06 32 
 
2.6 
GD2 F 71 GD 4.7 11.4 6.83 4.7 <2 2.9 
GD3 F 23 GD  7.1 7.84 <1 1059 3.0 
GD4 M 48 GD 4.3 14.9 0.04 11.7 <2 2.4 
GD5 F 63 GD  22.4 <0.02 6.7 
 
2.5 
GD6 F 39 GD 5.6 17.5 <0.02 
  
3.1 
GD7 F 52 GD 5.6 9.3 0.29 15.8 >1000 3.0 
GD8 F 38 GD  13.2 0.43 
  
2.9 
GD9 M 31 GD  12.3 2.34 
   
GD10 F 57 TMNG 4.5 12.9 <0.02 19.3 648 2.7 
GD11 F 27 TMNG 4.6 14.1 <0.02 
  
3.3 
 
Toxic MNG 
  
  
     
MNG1 F 43 TMNG 5.3 17.8 <0.02 
  
1.6 
MNG2 M 76 TMNG  13.0 0.1 <1 
 
1.1 
MNG3 F 61 TMNG  14.3 0.92 
 
50 1.2 
MNG4 F 70 TA  13.0 1.22 <1 12.5 1.2 
MNG5 M 61 TMNG  13.5 0.21 
  
1.2 
MNG6 M 89 TMNG  14.1 0.25 
  
1.1 
   
  
     
Normal 
  
  
     
NO1 F 21 CN  13.5 1.56 
  
1.4 
NO2 F 78 HN  13.0 3.26 
  
1.1 
NO3 F 46 BC  12.6 1.46 
  
1.2 
NO4 F 71 EMNG  16.7 1.79 
  
1.3 
NO5 M 50 EMNG  12.2 0.61 
  
1.1 
NO6 F 27 EMNG  14.0 2.58 
 
<2 1.2 
NO7 F 78 EMNG  13.7 0.11 
  
1.8 
NO8 F 27 EMNG  14.6 1.09 
  
1.2 
NO9 F 61 EMNG  14.0 0.57 
 
<2 1.3 
NO10 M 45 EMNG  16.5 0.83 
 
<2 1.4 
NO11 F 71 EMNG  13.0 0.65 
 
300 1.2 
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5.3.2 TSHR transcript in the neck adipose tissue 
To hypothesise that the browning effect of euthyroid adipose tissue was driven by 
TSAB, we have to show that TSHR transcript is present. TSHR transcripts were 
detected in the neck adipose tissues but at a very low level with a mean CT value of 
27.8 (range 23.5 -31.5). There was no difference detected between the 3 patient 
groups (Kruskal-Wallis test, p=0.1155) (Figure 84). 
 
 
Figure 84: Scatter dot plot showing median ± interquartile range of thyrotropin receptor 
(TSHR) expression in fold change (Normalized against housekeeping gene adenine 
phosphoribosyltransferase (APRT)) to average control normal in ex vivo analysis of deep neck 
adipose tissues of Graves’ disease (GD), multinodular goitre (MNG) and normal subjects. Fold 
change in expression was calculated using the ΔΔCT method assuming 100% efficiency. 
There was no difference detected between 3 groups (Kruskal-Wallis test, p=0.1155).  
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5.3.3 UCP1 and PGC1 - General brown adipose tissue markers 
No differences were detected in transcript levels from deep neck adipose tissue for 
UCP1 (Figure 85); Kruskal-Wallis test, p=0.7273) and peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1) (Figure 86; Kruskal-Wallis 
test, p=0.3462) between the 3 groups. The mean of UCP1 CT value of all samples 
was 26.5 (range 17.4-29.6) and PGC1 was 25.9 (range 20.2-33.0). 
 
 
Figure 85: Scatter dot plot showing median ± interquartile range of uncoupling protein 1 
(UCP1) expression in fold change (Normalized against housekeeping gene adenine 
phosphoribosyltransferase (APRT)) to average control normal in ex vivo analysis of deep neck 
adipose tissues of Graves’ disease (GD), multinodular goitre (MNG) and normal subjects. Fold 
change in expression was calculated using the ΔΔCT method assuming 100% efficiency. 
There was no difference detected between 3 groups (Kruskal-Wallis test, p=0.7273). 
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Figure 86: Scatter dot plot showing median ± interquartile range of peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1) expression in fold change 
(Normalized against housekeeping gene adenine phosphoribosyltransferase (APRT)) to 
average control normal in ex vivo analysis of deep neck adipose tissues of Graves’ disease 
(GD), multinodular goitre (MNG) and normal subjects. Fold change in expression was 
calculated using the ΔΔCT method assuming 100% efficiency. There was no difference 
detected between 3 groups (Kruskal-Wallis test, p=0.3462). 
 
5.3.4 ZIC1 - True brown adipose tissue specific marker  
There was no difference in ZIC1 expression in deep neck fat between the 3 groups 
(Kruskal Wallis, p=0.4158), lowest levels were present in GD samples but this did not 
reach significance (Figure 87).  
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Figure 87: Scatter dot plot showing median ± interquartile range of zinc finger of cerebellum 1 
(ZIC1) expression in fold change (Normalized against housekeeping gene adenine 
phosphoribosyltransferase (APRT)) to average control normal in ex vivo analysis of deep neck 
adipose tissues of Graves’ disease (GD), multinodular goitre (MNG) and normal subjects. Fold 
change in expression was calculated using the ΔΔCT method assuming 100% efficiency. 
There was no difference detected between 3 groups (Kruskal-Wallis test, p=0.4158). 
 
There was no statistical difference in ZIC1 expression between deep and 
subcutaneous adipose tissue although 3 out of 5 normal samples showed the 
expected higher transcript level in deep compared to subcutaneous depot (Wilcoxon 
signed rank test of all the samples, p=0.4258; normal samples only, p=0.125) (Figure 
88). 
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Figure 88: Differential expression of zinc finger of cerebellum 1 (ZIC1) in fold change 
(Normalized against housekeeping gene adenine phosphoribosyltransferase (APRT)) to 
average control normal in ex vivo analysis of deep and subcutaneous neck adipose tissues of 
Graves’ disease (GD-short interrupted line), multinodular goitre (MNG-dotted line) and normal 
subjects (continuous line). Fold change in expression was calculated using the ΔΔCT 
assuming 100% efficiency. Wilcoxon signed rank test of all the samples, p=0.4258; normal 
samples only, p=0.125. 
 
5.3.5 CITED1 - Beige adipose tissue specific marker 
Due to the detection of multiple peaks on the dissociation curve in the QPCR 
experiment, gene quantifications from here on were analysed semi quantitatively 
using the densitometry method. In contrast to the prior findings, the beige marker 
CITED1 was lower in GD samples compared to normal (ANOVA p=0.0045, post hoc 
Tukey GD versus normal <0.01, GD versus MNG and MNG versus normal p>0.05) 
and test for trend p=0.0013 (Figure 89 and Figure 90).  
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Figure 89: Representative agarose gel (2%) in 1xTAE confirming the size of the CITED1 PCR 
product of 117bp with 100bp DNA ladder and primer dimers as the lower bands. Samples 
tested: G#s represent Graves’ disease patient with #=number, s=subcutaneous sample, M 
represents multinodular goitre and N represent normal individual. 
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Figure 90: Relative expression of Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain 1 (CITED1) measured by densitometry corrected to housekeeping 
gene adenine phosphoribosyltransferase (APRT) in ex vivo analysis of the deep neck adipose 
tissues of Graves’ disease (GD), multinodular goitre (MNG) and normal subjects. CITED1 
transcripts lower in GD than normal. ANOVA p=0.0045, post hoc Tukey GD versus normal 
<0.01; GD versus MNG and normal versus MNG p>0.05. Test for trend p=0.0013. Scatter dot 
plot indicates the standard deviation (lower and upper lines), mean (middle line). 
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There was no difference between deep and subcutaneous CITED1 expression 
(Wilcoxon signed rank test of all the samples, p=0.6953; normal samples only, 
p=0.6250) (Figure 91). 
 
Figure 91: Differential expression between deep and subcutaneous neck adipose tissues of 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain 1 (CITED1) 
measured by densitometry corrected to housekeeping gene adenine 
phosphoribosyltransferase (APRT) in ex vivo analysis of the neck adipose tissues of Graves’ 
disease (GD-short interrupted line), multinodular goitre (MNG-dotted line) and normal subjects 
(continuous line). Wilcoxon signed rank test of all the samples, p=0.6953; normal samples 
only, p=0.6250. 
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5.3.6 HOXC9 - Mixed Beige/white adipose tissue marker 
There was a reduction in HOXC9 transcripts in samples from GD patients when 
compared to MNG and normal subjects (Kruskal-Wallis p=0.0002, Dunn’s post hoc 
GD versus MNG p<0.0001, GD versus normal p<0.01, MNG versus normal p>0.05) 
(Figure 92 and Figure 93). In normal individuals, HOXC9 levels were lower in deep 
compared to subcutaneous adipose tissue samples. The reverse happened in MNG 
(higher HOXC9 levels in deep compared to subcutaneous adipose tissue samples). 
In GD HOXC9 levels were equally low in both deep and subcutaneous adipose 
tissues (Wilcoxon signed rank test of all the samples, p=0.4513; normal samples only, 
p=0.0021) (Figure 94). 
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Figure 92: Representative agarose gel (2%) in 1xTAE confirming the size of the HOXC9 PCR 
product of 98bp with 100bp DNA ladder and primer dimers as the lower bands. Samples 
tested: G#s represent Graves’ disease patient with #=number, s=subcutaneous sample, M 
represents multinodular goitre and N represent normal individual. 
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Figure 93: Relative expression of homeobox C9 (HOXC9) measured by densitometry 
corrected to housekeeping adenine phosphoribosyltransferase (APRT) in ex vivo analysis of 
the deep neck adipose tissues of Graves’ disease (GD), multinodular goitre (MNG) and normal 
subjects. HOXC9 transcripts were more abundant in MNG compared to GD and normal 
(Kruskal-Wallis p=0.0002, Dunn’s post hoc GD versus MNG p<0.0001, GD versus normal 
p<0.01, MNG versus normal p>0.05). Scatter dot plot indicates the interquartile range (lower 
and upper lines), median (middle line). 
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Figure 94: Differential expression between deep and subcutaneous neck adipose tissues of 
homeobox C9 (HOXC9) measured by densitometry corrected to housekeeping gene adenine 
phosphoribosyltransferase (APRT) in ex vivo analysis of the neck adipose tissues of Graves’ 
disease (GD-short interrupted line), multinodular goitre (MNG-dotted line) and normal 
subjects (continuous line). Wilcoxon signed rank test of all the samples, p=0.4513; normal 
samples only, p=0.0021. 
5.3.7 LEPTIN - White adipose tissue specific marker 
LEPTIN, a marker of white adipose tissue, was lower in GD samples (Figure 95 and 
Figure 96) compared to normal (Kruskal Wallis p=0.0031, Dunn’s post hoc GD versus 
normal p<0.01, GD versus MNG and MNG versus normal p>0.05). There was no 
differential effect on gene expression with regard to location of the fat samples, only 
2 out of 5 normal samples indicated the expected higher transcript levels in 
subcutaneous than deep samples (Wilcoxon signed rank test of all the samples, 
p=1.0000; normal samples only, p=0.6250).  
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Figure 95: Agarose gel (2%) in 1xTAE confirming the size of the LEPTIN PCR product of 
158bp with 100bp DNA ladder and primer dimers as the lower bands. Samples tested: G#s 
represent Graves’ disease patient with #=number, s=subcutaneous sample, M represents 
multinodular goitre and N represent normal individual. 
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Figure 96: Relative expression of LEPTIN transcripts measured by densitometry corrected to 
housekeeping gene adenine phosphoribosyltransferase (APRT) in ex vivo analysis of the 
deep neck adipose tissues of Graves’ disease (GD), multinodular goitre (MNG) and normal 
subjects. LEPTIN transcript levels were lower in GD compared to other normal (Kruskal Wallis 
p =0.0031, Dunn’s post hoc GD versus normal p<0.01, GD versus MNG and MNG versus 
normal p>0.05). Scatter dot plot indicates the interquartile range (lower and upper lines), 
median (middle line).  
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Figure 97: Differential expression between deep and subcutaneous neck adipose tissues of 
LEPTIN measured by densitometry corrected to housekeeping gene adenine 
phosphoribosyltransferase (APRT) in ex vivo analysis of the deep neck adipose tissues of 
Graves’ disease (GD-short interrupted line), multinodular goitre (MNG-dotted line) and normal 
subjects (continuous line). Wilcoxon signed rank test of all the samples, p=1.0000; normal 
samples only, p=0.6250. 
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5.4 DISCUSSION  
This pilot study demonstrated that there were lower levels of CITED1 (beige marker), 
HOXC9 (mixed marker) and LEPTIN (WAT marker) transcripts in deep neck fat of 
euthyroid GD patients with positive TSAB compared to MNG and normal individuals. 
The ZIC1 (true BAT) expression was low in GD but did not reach statistical significant 
comparing to other groups. I found that there was no difference in expression of 
general BAT markers, UCP1 and PGC1α between the 3 groups.  
These findings are in contrast to in vitro findings of Zhang et al. using human orbital 
adipocytes transfected with gain of function mutants of the TSHR, he showed that 
TSHR activation seems to favour the development of brown adipose tissue in this 
case UCP1 expression [247]. TSH also has been shown to increase basal and T3-
stimulated Ucp1 and Dio2 expression and D2 activity but inhibit Leptin expression in 
the presence of T3 in rat brown adipose tissue but not in the concomitant presence 
of norepinephrine and T3 [422]. The contrasting findings might be explained by the 
difference in the in vitro nature of the experiment, fat depot studied, the mechanism 
of TSHR stimulation and species differences. The general suppression in brown 
markers suggests that the BAT in GD has reached a ‘burnt out’ state explaining the 
lack of difference in general BAT markers (UCP1 and PGC1α). It is possible that the 
adipose tissue already underwent a ‘browning’ process during the hyperthyroid 
phase.  
In this study, I was hoping to delineate the effect of TSAB and T3 on adipose tissue 
using GD and MNG samples. GD patients experienced high T3 and TSAB stimulation 
and MNG patients experience T3 stimulation only without TSAB. This aspiration was 
limited by the fact that all patients were euthyroid during the surgery although the GD 
and TMNG had been hyperthyroid before. Therefore, the changes detected in the 
adipose tissues only reflect the ‘residual’ effect of T3, which could be delineated by 
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comparing TMNG with normal individuals who were always euthyroid and with both 
groups being negative for TSAB. I found that there was a trend that CITED1 and 
LEPTIN levels were highest in the normal. The levels were lower in MNG than normal 
suggesting residual effect of hyperthyroidism on MNG adipose tissue biology. Both 
levels were lowest in GD suggesting an additive effect of TSAB or other unmeasured 
factors in GD, above of that T3.  
HOXC9 levels were proposed as a brown marker in one study [412] but white marker 
in other studies [392, 414]. In these analyses, I found HOXC9 levels were highest in 
the MNG group, followed by normal samples with GD samples having the lowest 
transcript levels. This might imply residual T3 positive effect on HOXC9 expression. 
This effect was negated in GD adipose tissues suggesting the effect may be mediated 
by the presence of TSAB. I also found that the level was higher in the subcutaneous 
compared to deep adipose tissue in normal individuals, which adds weight to its being 
more of a marker for WAT than BAT. It is interesting to see the reverse was observed 
in MNG samples and also GD HOXC9 levels were flat with no gradient at all between 
subcutaneous and deep samples. It is possible that T3 alone has some effects on 
converting deep adipose tissue to more WAT phenotype. Again, the low level of both 
subcutaneous and deep HOXC9 suggest the ‘burnt out’ phenomenon experienced by 
the 2 depots suggesting a role of TSAB in adipocyte biology. 
Similar to Cypess’ findings [392], I observed a differential gradient of subcutaneous 
and deep adipose tissue in normal individual samples with regard to HOXC9 
transcripts (higher in subcutaneous compared to deep samples) and ZIC1 transcripts 
which was higher in deep samples compared to subcutaneous although not reaching 
statistical significant. However, I could not replicate the LEPTIN gradient. This might 
be due to variability in sample location from different patients. There was no gradient 
with regard to beige marker again similar to Cypess’ finding. I did not analyse UCP1 
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and PGC1 in the subcutaneous samples as at the start of the study, I could not get 
any paired subcutaneous samples from the patients due to lack of patients’ consent. 
Some of the discordant findings might reflect a very small sample size in our study. 
Despite small sample size, HOXC9 levels showed 3 distinctive groupings suggesting 
a differential effect of T3 and TSAB on adipose tissues. 
The finding of low LEPTIN  transcript levels was in agreement with low serum LEPTIN 
levels reported in treated euthyroid GD patients [424]. Leptin function is to suppress 
appetite by stimulating its receptor in the arcuate nucleus of the hypothalamus. 
Although  rare, congenital leptin deficiency has been described and presented with 
morbid obesity, which is reversible with daily recombinant Leptin administration [425]. 
Patients with severe forms of obesity and metabolic syndrome were also found to 
have a relatively low levels of leptin [426]. This finding might explain an increase in 
appetite level leading to the weight gain experienced upon reaching normal thyroid 
function in GD patients [288, 381].  
The study is not without difficulties. The results might be cofounded by the disease 
process itself i.e. Hyperthyroidism tends to be far greater and of shorter duration 
in patients with GD than in toxic nodular goitre; also iatrogenic hypothyroidism 
is commoner in patients treated for GD than other causes, which may have a 
carryover effect. I found it very hard to recruit MNG patients as most of these patients 
were having radioactive iodine as a definitive treatment rather than surgery. Although 
most patients have been shown to have positive TRAB, we were very keen to show 
that this TRAB was indeed TSAB. We were unable to produce consistent stimulatory 
index in GD group in order to differentiate it from other groups using serum free media, 
however the problem was overcame by using salt free buffer in the assay as 
recommended in the original establishment of the assay [367].  
I experienced many problems in generating working primers to amplify the BAT-
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specific gene ZIC1. This included absence of an amplicon and excessive primer dimer 
formation, despite multiple optimisation attempts e.g. primer concentration matrix, Q 
solution and gradient temperature PCR. The primers were successfully generated 
after the third attempt and cloned into pGEM®-T easy plasmid. However, I 
experienced issues with inconsistent standard curves between the experiments and 
double peaks in the dissociation curves in QPCR analysis, forcing me to abandon 
calculating QPCR by transcript copy numbers. Instead I applied the widely-used 
∆∆CT method, which gave me more consistent readings throughout the experiments. 
The double peaks encountered in some PCR amplifications also meant that I could 
quantify gene expression only semi quantitatively using densitometry. There was no 
differential effect noted when UCP1 and PGC1α were analysed based on either APRT 
or GAPDH housekeeping genes using transcript copy numbers and ∆∆CT methods. 
However, by densitometry it appears that GAPDH was expressed in abundance 
limiting its use in the densitometry calculation. Limited tissue sample size meant that 
I had to abandon GAPDH as a housekeeping marker. 
In conclusion, I found unexpectedly low levels of BAT and WAT markers in GD. I also 
found unexplained high levels of HOXC9 in MNG that merits further investigation. 
Whether the latter finding suggests an effect of the previous hyperthyroid state, whose 
effect in GD is reversed by TSAB remains purely speculative. The low level of ZIC, 
CITED1 and HOXC9 in euthyroid GD patients with positive TSAB suggests the 
inhibitory effect of TSAB on beige fat and WAT respectively. But this also can be 
explained by prior stimulatory effect of TSAB on BAT and WAT in the presence of T3 
which is now ‘burnt out’. The low level of LEPTIN might explain the weight gain 
experienced upon reaching normal thyroid function in GD patients. Further in vitro 
study is needed to unravel the mechanistic processes behind these findings. 
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Chapter Six 
 
6 GENERAL DISCUSSION AND FUTURE WORK 
 
I started my investigation with an in vitro study following clinical observations of 
enophthalmos in patients treated with PGF2α for glaucoma and trying to dissect the 
pathophysiology behind it. The work was performed using the well-established 3T3-
L1 cell line and also human primary orbital fibroblasts (OF) from normal and patients 
with GO. The finding was that PGF2α reduced proliferation and adipogenesis of both 
3T3-L1 cell line and human OF from normal and GO. I also found that there was 
higher proliferation rate in GO OF compared to normal and PGF2α has no effect on 
lipolysis. 
Cell counting is essential to evaluate the kinetics of cell growth. In this study, direct 
cell counting and toxicity was performed by using an automatic counter (Cellometer®) 
which is based on image analysis of the disposable counting chamber. Even though 
it is an automated counter, the process itself was labour intensive and highly variable 
especially at low cell numbers. One way of getting around this issue is perhaps by 
using a larger number of cells to start with or more dedicated sensitive automated 
machine such as Beckman Coulter instrument.  
Despite the limitations of the method used, the observed increased proliferation in 
GO deserves more attention as it might shed light on mechanisms central to GO 
pathophysiology. Further cell cycle analysis is needed to compare any differential 
process between GO and normal OF. An in vitro analysis of human OF with regard 
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to local production of PGF2α and cell surface expression of the receptor (FP) or its 
splice variant (FPS) should help to delineate any differences. Candidate pathways 
involved such as phospholipase C or other pathways should be investigated using 
PCR and Western blot analysis with or without relevant pathway inhibitors.  
The cell cycle is regulated by 2 key classes of regulatory molecules, cyclins and 
cyclin-dependent kinases (CDKs). Cell cycle checkpoints are used by the cell to 
monitor and regulate the progress of the cell cycle [427]. There are 3 main 
checkpoints namely G1/S checkpoint (rate-limiting step), the G2/M checkpoint and 
the metaphase (mitotic) checkpoint. These checkpoints consist of a network of 
regulatory proteins that monitor and dictate the progression of the cell through the 
different stages of the cell cycle. Studying kinetics of cell cycle in GO OF would be 
fundamental to better understanding the pathophysiology of GO. This could be 
achieved by PCR analysis of the relevant genes or using commercially available cell 
cycle profiler such as Human Cell Cycle RT² Profiler™ PCR Array which profiles the 
expression of 84 genes key to cell cycle regulation. The array contains genes that 
both positively and negatively regulate the cell cycle, the transitions between the each 
of the phases, DNA replication, checkpoints and arrest.  
The inhibitory effects of PGF2α on adipogenesis are consistent with those of several 
other authors [310, 322, 323].  Using 3T3-L1, Casimir et al reported that endogenous 
PGF2α production is higher in undifferentiated then differentiated cells and postulated 
that its release from preadipocytes provides a control mechanism to limit 
adipogenesis [323]. The mechanism could be via reduction in the substrate 
arachidonic acid which moves towards eicosatrienoic acid production during 
adipogenesis  [326]. It would be interesting to determine whether GO OF are unable 
or less able to produce endogenous PGF2α and/or experience down-regulated FP 
receptor expression and hence display enhanced adipogenesis compared with 
 289 
normal.  Measuring arachidonic acids (AA) from OF using mass spectroscopy also 
would be useful. If there is reduction in AA in OF, the rescue experiment could be 
performed by supplementing the OF with AA as this could prove one way of treating 
early-stage GO. Another main mechanism in GO pathophysiology is hyaluronan (HA) 
production. Understanding the effect of PGF2α on HA and subtypes of HA would be 
useful. This can be achieved by PCR, western blots and ELISA (enzyme-linked 
immunosorbent assay) of the products involved. I did consider HA analysis but since 
Bimatoprost induced enophthalmos seemed due to fat atrophy, it was decided then 
to focus on this aspect of the investigation. 
Based on the in vitro findings, I subsequently conducted a randomised controlled 
double blind crossover trial clinical trial of PGF2α in late phase GO (BIMA study). The 
primary outcome was a reduction in proptosis. As mentioned in chapter 3, the choice 
of late phase or burnt out GO was to ensure that the proptosis was stable and the 
effect seen was due to the PGF2α and not part of the natural disease recovery itself. 
The trial showed that treatment with PGF2α in this case Bimatoprost for 3 months was 
not effective in reducing proptosis in late phase GO patients. At baseline, there was 
high smoking rate (75%) which reduced close to 40% after the diagnosis. Although 
there was a 35% prevalence reduction after the diagnosis in our trial population, this 
is still at least double that of national Wales’s smoking prevalence which was 
approximately 20% in 2014. This finding should lead to more smoking cessation 
intervention strategies complemented by pre and post intervention audits to measure 
the effectiveness of the strategy utilised. The observed high diplopia rate (61.3%) 
many years after initial diagnosis also raises a significant question regarding the 
management or treatment effectiveness in the acute stage in reducing diplopia. 
Perhaps greater attention should be placed on diplopia as primary or secondary 
outcome in any GO related trial, rather than part of a composite outcome which may 
mask the effect of the intervention on diplopia.  
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The lack of anticipated PGF2α effects might be due to several explanations. The 
choice of late stage of the disease where the disease state is predominantly caused 
by hyaluronan or fibrosis rather than adipogenesis might explain the lack of impact 
and perhaps 3 months’ duration is not long enough to see the intended reduction in 
proptosis. With 5% drop out rate, the BIMA study has also demonstrated that 
crossover studies can be performed reliably in patients with persistent proptosis due 
to GO and that this study design is acceptable to patients. Future trial should be done 
on early stage GO and active disease. This can be performed on top of standard 
proven treatment such as selenium for mild GO or IV methylprednisolone in active 
GO. The issue with lack of trial participants can be negated by multicentre design.  
Unfortunately, cross over trial cannot be performed for active GO trial due to the 
natural disease process as per Rundle’s curve. The lack of response could also be 
due to genetic polymorphisms in the FP receptor. Using <10% drop in IOP as a cut 
off for a low responder, single nuclear polymorphism (SNP) rs12093097 C/T of the 
FP receptor gene has been associated with lack of IOP response in such trial patients 
[428]. 
Exophthalmometer readings have their own caveat in terms of variability of readings 
with parallax error and pressure of the exophthalmometer against the orbital rim.  With 
the right support, a new device could be invented with a simple pressure sensor to 
ensure constant pressure is applied to all patients at different visits. To ensure the 
measurement is parallax free, ultra sound techniques could be used to measure the 
proptosis distance. There was consistency in terms of clinical exophthalmometer 
measurement throughout the trial and the negative finding was further supported by 
photographic assessment of proptosis conducted by an assessor who was masked 
to the treatment phase. Further analysis should be performed on the data on the 
correlation and reproducibility of the clinical exophthalmometry measurements versus 
photo measurements as the data can provide an important basis to design and power 
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future studies to address the unmet need in this patient group. There is also a 
possibility to use 3D volumetric assessment analysis of the orbit in particular looking 
at the fat pad in the eye lid.  
The in vitro study of thyrostimulin in OF did not confirm its role in the orbit although I 
cannot rule out production of this high-affinity TSHR ligand [283] by other orbital 
components not studied. GPHB5 was at the limit of detection. GPHA2 was detected 
but with no differential effect at baseline and during adipogenesis between GO and 
normal, limiting its usefulness as GO marker.  
The study also suggests that TSHR activation may be further regulated by a variant 
isoform TSHR_v2 which can be secreted from cells which express it. The variant 
could function in several ways (1) as a TSH or TSAB binding protein it would 
neutralize their effects and thus prevent the consequences of TSHR activation in the 
orbit (2) as a potent autoantigenic stimulus it could have a positive influence on T cell 
homing to the orbit. 
The truncated TSHR_v2 was detected in both cell layer lysates and medium from 
orbital fibroblast cultures and appears to increase during adipogenesis. There is also 
indirect evidence that TSHR_v2 might modulate TSH and M22 activity from direct 
cAMP RIA assay and indirectly via bioassay. Detection of the TSHR_v2 protein was 
achieved using a rabbit polyclonal antibody. To confirm that the protein binding the 
antibody in the western blot is indeed TSHR_v2 would require targeted proteomic 
analysis of the band detected in order to confirm its sequence. There was indirect 
evidence that TSHR_v2 might be binding with TSH and M22 hence reducing its effect. 
I realised that the effects seen might be due to other unmeasured factors in the 
medium studied. Even though serum free media was used, other factors could be 
generated during the overnight incubation period. To prove that the factor is indeed 
TSHR_v2 further experiments are needed whereby TSHR_v2 is depleted from the 
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conditioned medium using one of several specific strategies to immune-adsorb or 
immunoprecipitate out the TSHR_v2. 
I observed that TSHR activation of non-differentiated OF, i.e. prior to adipogenesis, 
leads to a reduction in cAMP suggesting that the receptor is coupled to Gi in these 
cells. This is in contrast to the situation in differentiating adipocytes in which TSH and 
TSAB induce an increase in cAMP. If my findings are confirmed it is unknown when 
and what factors are associated with the conversion to coupling to Gs protein. To 
confirm the results and investigate further the study could be expanded by measuring 
cAMP via RIA daily in a bigger sample cohort which should indicate the Gi and Gs 
switching period. G protein coupled receptors are known to exist in oligomeric 
structures but whether TSHR abundance dictates the conversion to Gs utilisation is 
unknown. The fact that TSHR expression increases during adipogenesis which is 
paralleled by TSHR activation signalling via Gs tends to support this concept. 
However to address the point I would propose an in vitro model whereby TSHR 
numbers could be controlled by transfecting increasing amounts of TSHR expression 
plasmid into OF and measuring cAMP. Furthermore, knock-down using TSHR siRNA 
could be performed to see if the reverse is true. More sophisticated ways to dissect 
the issue include fluorescence resonance energy transfer (FRET) and 
coimmunoprecipitation (COIP) techniques whereby TSHR is tagged with green (GFP) 
or red fluorescent protein (Myc) as described by Latif et al [107]. 
If the above study confirmed that TSHR_v2 could modulate TSHR or M22, further 
study could be performed to understand its regulation. The fact that its production is 
higher during adipogenesis suggests that it might be a marker for patients who will or 
will not develop GO. Therefore, TSHR_v2 assay can be tested on serum sample of 
GO patients, GD patients without GO and MNG patients (control) using ELISA 
technique. Going forward, one could envisage to use TSHR_v2 in generating mouse 
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model of GO. 
Despite restoration of euthyroid status, many GD patients complain of substantial 
weight gain post treatment [285, 286] with potential negative impact on their future 
cardiovascular risk. Indeed, the BIMA study cohort confirmed this finding with an 
average BMI of 29. I performed a pilot study of brown and white fat markers in GD, 
MNG and normal ex vivo samples. The study demonstrated that there were lower 
levels of CITED1 (beige marker), HOXC9 (mixed marker) and LEPTIN (WAT marker) 
transcripts in deep neck fat of euthyroid GD patients with positive TSAB compared to 
MNG and normal individuals. The ZIC1 (true BAT) expression was low in GD but did 
not reach statistical significant compared with other groups. There was also no 
difference in expression of general BAT markers, UCP1 and PGC1α between the 3 
groups.  
One of the key weaknesses of this ex vivo study is the lack of MNG control samples 
and paired subcutaneous samples amongst the 3 groups. Therefore, further ex vivo 
study, with increased numbers and sample size, is needed to confirm the findings. 
The transcript data also needs to be supported by immunohistological analysis to 
confirm the presence of the corresponding protein. It could also be useful to analyse 
different depots such as abdominal, visceral and subcutaneous fat to see whether 
there are any depot specific differences. Admittedly, it would be difficult to find GD or 
MNG patients undergoing abdominal surgery although it is possible. Further in vitro 
experiment is needed in order to understand the mechanism of the difference in BAT 
and WAT markers in GD. To investigate the role of TSAB and T3 on the BAT and 
WAT markers, an in vitro model could be performed on OF and also abdominal 
visceral/subcutaneous fat obtained via collagenase digest. These cells would then be 
subjected to culture with or without T3 and/or TSH/M22 followed by QPCR 
measurement of BAT and WAT markers. In this study, I found that HOXC9 transcripts 
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behave as a WAT marker; furthermore it displayed 3 unique expression patterns 
corresponding to the GD, MNG and normal groups suggesting it may be useful in 
dissecting the role of TRAB above and beyond that of T3.  
TSHR signals mainly through Gs, although other cascades may also be involved. One 
of the main downstream pathways for Gs is cAMP responsive element binding protein 
(CREB) which binds to its response element (CRE) on the promoter region of the 
DNA exerting various gene transcription processes, whilst T3 exert its effect via its 
nuclear receptor which then binds thyroid response elements (TRE). Analysis of 
promoters for WAT and BAT markers should identify any functional CREs and TREs 
in this region and gain insight into their influence on adipose tissue marker 
expression.  
The finding of low LEPTIN levels was in agreement with low serum LEPTIN levels 
found in treated euthyroid GD patients [424]. Leptin function is to supress appetite. 
Patients with metabolic syndrome also found to have a relatively low levels of leptin 
[426]. It is not known whether hyperphagia experienced by the patient when 
hyperthyroid is correlated with the LEPTIN level or whether its low concentration post 
treatment contribute to the weight gain experience by GD patients [288, 381]. Further 
study of serum LEPTIN level in GD/MNG is needed to confirm this finding and validate 
previous work by Sera et al [424]. If this is the case, LEPTIN regulation by 
T3/TSH/M22 is needed to be dissected through in vitro model and whether LEPTIN 
rescue is beneficial in this condition.  
Current data on weight gain in GD post treatment is gathered after clinical diagnosis 
of hyperthyroidism. It is possible to investigate the GD weight prior to and after the 
diagnosis by using available database such as Clinical Practice Research Datalink 
(CPRD) previously known as The General Practice Research Database (GPRD) 
which contains computerized medical records of over 5,000,000 people from 508 
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primary care practices throughout the UK (http://www.CRPD.com). This also can be 
gathered from Secure Anonymised Information linkage (SAIL) databank, which is a 
nationwide dataset covering the entire population of Welsh residents treated in 
National Health Service (NHS) hospitals (http://www.saildatabank.com).  
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8 APPENDICES 
8.1 Appendix 1: Supplier list  
Fisher    https://www.fishersci.co.uk/ 
Promega   https://www.promega.com/b/uk/ 
Star lab   http://www.starlab.de/ 
Stratagene   http://www.genomics.agilent.com/ 
Melford   htpp://www.melford.co.uk 
Sigma    http://www.sigmaaldrich.com/ 
Invitrogen   https://www.thermofisher.com/ 
Abcam    http://www.abcam.com/ 
Cell signalling   https://www.cellsignal.com/ 
Santa Cruz Biotechnology https://www3.scbt.com/ 
Qiagen   https://www.qiagen.com/ 
New England Biolab  http://www.neb.uk.com/ 
GE Healthcare  http://www3.gehealthcare.com/ 
Cayman chemical  http://www.caymaneurope.com/ 
Cambridge Bioscience http://www.bioscience.co.uk/ 
Allergan   http://www.allergan.co.uk/ 
Blumont healthcare  http://www.blumonthealthcare.com/ 
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8.2 Appendix 2: Stock components 
 
Pioglitazone stock (100nM-Takeda) 
Dilute the stock 1 in 10 in DMSO (working solution 10 mM, e.g. 80 ul in 720 ul of DMSO). 
Aliquot 25 ul volume. Use 20 ul/200ml DM to give final concentration of 1 uM. 
Insulin (100mg, I1882-Sigma) 
Dissolve 100mg in 10 ml ultra-pure water and few drops glacial acetic acid, Filter sterilised. 
Mix 1ml of 0.01% BSA with 99 ml of HBSS. Add 90 ml of HBSS/0.01% BSA to 10 ml filtered 
insulin. Aliquot 600 ul each and freeze. 
BSA (100mg, A7906-Sigma) 
1% BSA was made by adding 100mg of BSA in 10 ml of ultra-pure water and filter sterilised. 
0.01% concentration was achieved by adding 100 ul of 1% BSA to 9.9 ml of ultra-pure water. 
Hydrocortisone (100mg, H2270-Sigma) 
100mg was dissolved in 20 ml of ultra-pure water. Aliquot 200 ul and freeze -20 C. Use 20 ul 
of stock into 200 ml of DM. 
Pantothenate (100g, P5155-Sigma)  
100mg in 25ml of complete medium (4mg/ml). Aliquot 210 ul. Use 200 ul per 200 ml medium. 
Biotin (500mg B4639-Sigma) 
Dissolve 500mg in 20 mls of 1 M NaOH (25mg/ml). Aliquot 200 ul and freeze. 
NaOH (100ml of 10M, 72068-Sigma) 
Dilute 1:10 of water to get 1M NaOH. 
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T3 (1mg,T-5516-Sigma) 
10x stock is prepared in 1M NaOH.1ml of 1M NaOH was added to 1mg T3 and gently swirled 
to dissolve. To this 49 ml of complete medium was added to give a stock solution of 20 ug/ul. 
Aliquots 200 ul and freeze. 
OligodT (500ug/ml, C110A-Promega) 
Dilute 1:5 (e.g. 40 ul in 160 ul of RNAse free water to give working solution 100 ug/ml) 
dNTPs 
dGTP (100nM, U121A- Promega), dATP (100nM, U120A- Promega), dCTP (100nM, U122A- 
Promega), dTTP (100nM, U123A- Promega). 
Dilute 20 ul of each in 120 ul of water (1:10) to give working concentration of 10 nM. 
PMSF (phenylmethylsulfonyl fluoride) 
To prepare a 100 mM solution, add 17.4 mg of PMSF per millilitre of isopropanol. Store at 
−20°C. 
 
Phosphate buffered saline (PBS) 
NaCl 16g 
Na2HPO4 2.9g 
KH2PO4   0.5g 
KCL 0.4g 
Distilled water                            2 l 
 
Adjusted to pH 7.2 using 10N sodium hydroxide.  
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TAE 50x 
  242g  TRIS 
  100ml 0.5M pH8 EDTA 
  57.1 ml glacial acetic acid 
Make up to 1L with distilled water + autoclave this solution to give 50x solution. 
100mls of TAE 50x in 4.9 Litre of distilled water = TAE x1 
Stock pH 8.5 
Ampicillin 100mg/ml  
1g in 10 ml of distilled water and filtered sterilised. 1ml Aliquots was prepared. 
X-Gal 
100mg was dissolved in 2.5ml of Dimethylformamide and filtered sterilised, 40 ul per plate, 
spread over and left for 1 hour to diffuse. 
Glycerol stock solution 
67% Glycerol and 13 mM MgCl2 
 
Components Amount 
Glycerol 6.7 ml 
MgCl2 anhydrous 12.38 mg 
H2O 3.3 ml 
Use 500 ul of the solution and mix with 200 ul of overnight E. coli culture.  
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8.3 Appendix 3: Websites 
Genome restriction map 
http://db.yeastgenome.org/cgi-bin/seqTools 
 
Human genome database 
http://genatlas.medecine.univ-paris5.fr/ 
http://www.ncbi.nlm.nih.gov/nucleotide 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
 
Mouse genome database 
http://www.informatics.jax.org/ 
http://vega.sanger.ac.uk/index.html 
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8.4 Appendix 4: BIMA Study 
8.4.1 Protocol
 
Prostaglandin F2-alpha eye drops 
(Bimatoprost) in thyroid eye disease: a 
randomised controlled double blind crossover 
trial 
Protocol V2 
 
Confidential 
Short title: Bimatoprost Eye Drops in Thyroid Eye Disease (BIMA Study) 
 
Sponsor Number: SPON1266-14 
EudraCT Number:   2014-000540-15
Bima Study 
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7 BACKGROUND INFORMATION 
Thyroid eye disease (TED) is the commonest extra thyroidal manifestation of Graves’ 
hyperthyroidism. A key mechanism underlying TED is an increase in adipogenesis in the orbit 
resulting in orbital volume expansion and proptosis (eye protrusion). Proptosis may persist 
after inflammation has subsided in the late “burnt out” phase of TED and the persistent 
disfigured appearance of the eyes is a source of significant psychological distress and 
impaired quality of life for sufferers. Despite the negative impact of the condition, however, 
there are no specific medical treatments that target orbital volume reduction in late stage 
disease.  Furthermore, a UK nationwide survey of patients with TED revealed low satisfaction 
levels with existing therapies [1].  In this study we propose to take advantage of the observation 
that enophthalmos (recession of the eye into the orbit) occurs in some patients treated with 
prostaglandin analogue eye drops like Bimatoprost (PGF2α) for glaucoma as well as the 
finding in in-vitro studies that prostaglandin analogues reduce fat expansion. We hypothesise 
that topical treatment with Bimatoprost may reduce orbital tissue volume in non-inflamed orbits 
and thereby improve quality of life in patients with TED. 
 
3.9 BACKGROUND 
Graves’ disease affects about 1% of the general population and is the commonest cause of 
hyperthyroidism in iodine sufficient countries [2, 3]. Affected individuals suffer considerable 
morbidity and untreated disease may be complicated by multiple systemic manifestations 
including cardiac rhythm disorders, osteoporosis, and strokes [2, 3]. About 10-20% of patients 
with Graves’ disease suffer with disfiguring eye disease or thyroid eye disease (TED) [4], 
equating to around 5,000 people in Wales. The majority of these patients have “burnt-out” or 
inactive disease in which the disfigurement persists, but there is no longer active inflammation. 
Women in the age range 30-50 are the group most commonly affected. The annual incidence 
of new TED is estimated at about 16 per 100,000 in women and 3 per 100,000 in men [5].  
 
3.10 SYMPTOMS 
In its mildest form TED causes marked irritation of the eye with excessive tearing, discomfort, 
and redness of the conjunctiva. Severe eye disease however leads to double vision and 
protrusion of the eyes, and in 3-5% of cases to sight loss [2, 3]. In addition most patients with 
TED have reduced quality of life [6] and suffer long-term psychological distress due to the 
disfiguring appearance resulting from the eye ball protrusion [7], an effect that is often 
underestimated by health care professionals. The course of the disease is highly unpredictable 
and treatment options are limited.  
 
3.11 CURRENT TED MANAGEMENT 
The natural history of TED comprises an early active inflammatory phase followed by a late or 
“burnt out” disease phase.  For the majority of patients these treatments are supportive but in 
5-10% of cases the disease is severe enough to merit major immunosuppressive therapy (e.g. 
high dose steroids or ciclosporin) and orbital radiotherapy during the inflamed "active" phase 
of the disease, or surgical decompression and rehabilitative surgery at a later stage [8]. Each 
of these treatment modalities has significant drawbacks in terms of side effects. Surgical 
decompression carries the risk of worsening double vision and local complications while high 
dose steroid therapy may be complicated by weight gain, diabetes mellitus, depression, or life 
threatening liver dysfunction and is not effective in "burnt-out" disease; orbital radiotherapy is 
not always effective and carries the potential risk of a tumour developing at the treatment site 
[9].  
As mentioned above, most available non-surgical treatments are targeted towards control of 
inflammation during the active stage whereas rehabilitative surgery is the mainstay of 
treatment for the late disease phase. However, surgery is not always successful in reducing 
 332 
proptosis and carries the attendant risks of anaesthesia and local complications, 
(decompression surgery is highly skilled and involves removal of bone around all three orbital 
walls). PGF2α agonists may thus be particularly useful in the late-phase of TED, a disease 
stage in which disfigurement and impairment of ocular function persists after resolution of the 
initial inflammatory process and which affects 5-10 times as many people as the early active 
phase. If PGF2α is confirmed to be effective in reducing proptosis in this study, it would 
indicate that PGF2α could represent a safe, locally acting agent in the management of TED, 
reducing the need for potentially high risk therapies such as surgical rehabilitation. 
 
3.12 PATHOPHYSIOLOGY 
The main pathological features of TED include expansion of orbital tissue fat, mononuclear 
cell infiltration of orbital connective tissue and extra ocular muscle, and tissue remodelling, a 
process that can culminate in fibrosis and diminished eye motility [10]. A key mechanism 
underlying TED is an increase in adipogenesis and associated secretion of 
glycosaminoglycans in the orbit, resulting in an increase in orbital volume and exophthalmos 
(protrusion of the eye) [11, 12]. The opposite effect, enophthalmos (recession of the eye into 
the orbit), has been described in patients with glaucoma treated with Bimatoprost (PGF2α), a 
prostaglandin analogue used topically in the management of intraocular hypertension 
(glaucoma). Cases of enophthalmos developing in patients treated with Bimatoprost have 
been reported worldwide, albeit in small numbers [13-15]. This side effect is more noticeable 
if only one eye is exposed to treatment as the treated eye is easily comparable with the 
unexposed eye. However, since most patients receive treatment to both eyes it is possible 
that the incidence of enophthalmos in Bimatoprost treated patients has been underestimated. 
 
3.13 MECHANISM OF ACTION AND TRIAL RATIONALE 
A possible mechanism by which PGF2α agonists might produce enophthalmos is through 
reduction of orbital fat volume [13]. A PGF2α receptor agonist has been shown to be a potent 
inhibitor of adipose differentiation in new-born rat precursor cells [16]. This raises the 
possibility that PGF2α exerts direct effects on adipose tissue precursors. We have confirmed 
this finding in in-vitro studies in our laboratory using 3T3L1 cell lines and human primary orbital 
fibroblast cultures [17, 18]. Thus, PGF2α agonists may be effective in reducing orbital fat 
expansion, ameliorating proptosis, and thus improving patient quality of life in patients with 
TED. There has been no clinical trial of PGF2α agonists in patients with TED.  
 
3.14 TRIAL SUMMARY 
This randomised controlled double blind crossover trial of Bimatoprost in TED will be the first 
to explore the role of a PGF2α agonist as a topical agent for TED. Only patients with stable 
late inactive disease will be enrolled and follow-up will continue for a minimum of 10 months 
with 2 months wash out period in between treatment. A cross over design is used to allow 
efficient use of patients. 
 
2.7   CONDUCT OF TRIAL 
The trial will be conducted according to the protocol and in compliance with the principles of 
the Declaration of Helsinki (1996), the principles of Good Clinical Practice (GCP) and in 
accordance with Medicines for Human Use (Clinical Trials) Regulations 2004, as amended in 
2006, the Research Governance Framework for Health and Social Care, the Data Protection 
Act 1998 and other regulatory requirements as appropriate. The Protocol has been submitted 
for approval to an NHS Research Ethics Committee (REC) and to Medicines and Healthcare 
Products Regulatory Agency (MHRA) 
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8 OBJECTIVES 
The overall objective is to determine if PGF2α eye drops can reduce proptosis in inactive 
thyroid eye disease. 
 
3.15 PRIMARY ENDPOINT 
The primary endpoint of this study will be comparison of the change in exophthalmometry 
readings over the two 3-month treatment periods. A treatment effect of reducing proptosis by 
2mm for treatment compared to placebo will be considered clinically relevant.  
 
3.16 SECONDARY ENDPOINTS 
1. Change in quality of life scores on the TED quality of life questionnaire (GO-QOL) [19] 
2. Change in intraocular pressures 
3. Side effect profiles of Bimatoprost in TED patients during the study 
4. Health economics consumption 
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9 TRIAL DESIGN 
 
3.17 CROSS-OVER DESIGN 
The study design is a randomised placebo controlled double blind cross over design. We have 
chosen this design for several reasons. First each participant serves as his or her own control 
thus reducing the influence of confounding variables (e.g. smoking status). Second, each 
patient is exposed to both control and treatment and thus the design is highly efficient in that 
it reduces the actual number of participants required for the study. This is particularly useful 
for conditions like thyroid eye disease (TED) in which the prevalence of the condition is 
relatively low. Lastly the quick onset and short duration of action of Bimatoprost eye drops 
(reversible in 3 days in vitro cell cultures [18]) makes this a feasible design to study its effects. 
The drawback of this study design is that the long term effect of the treatment on patient 
outcomes, side effects and costs cannot be estimated, however short term efficacy can be 
assessed with good value for money. 
 
We have carefully considered the risk of carry over and discussed this with our advisory 
statisticians. As a result we have extended the wash-out period from 1 month in our initial 
plans to 2 months, since the evidence suggests that carryover effect is likely to be negligible 
with the 2 months wash out period, allowing us to take advantage of the crossover design.  In 
human studies, the elimination half-life of topical Bimatoprost is 45 minutes and the intra ocular 
pharmacological effect is not known to exceed 24 hours [17]. By one month the drug is 
completely washed out and we have allowed an extra one month of recovery period for any 
tissue changes to stabilise. Clinical case reports [13-15] suggest that effects wear off in 4-6 
weeks so that a 2 month washout period will allow subjects to experience both treatment and 
placebo equally. Therefore, the two month washout period should be adequate for complete 
elimination of the drug and for its biological effect to have worn off. Analysis of any treatment 
order effect will confirm this was the case at the end of the study. 
 
3.17.1 TRIAL OVERVIEW 
This is a randomised controlled double blind crossover trial of Bimatoprost in TED. Thirty one 
patients with stable late inactive disease will be enrolled. Patients will be allocated either 
Bimatoprost or placebo for 3 months, followed by 2 months wash out period before crossing 
over to the opposite treatment. Follow-up will continue for 10 months duration. The key 
eligibility criteria are patients with stable proptosis for at least 6 months duration. The primary 
outcome measured is the reduction in proptosis at the end of treatment period. The secondary 
outcome measured includes quality of life score, intraocular pressure reduction and side effect 
profile of Bimatoprost. 
 
Patients will be recruited from the multidisciplinary thyroid eye disease clinic at University 
Hospital Wales.  There is a database of 200 patients with inactive (previously treated) thyroid 
eye disease of which we expect 60% to be ineligible.  This will leave 80 patients available for 
recruitment in the 6 months available for recruitment.  If these patients can be consented with 
a recruitment rate of 60%, it will be possible to consent 31 by contacting just 50 of these 
patients. We intend to consent 31 patients with a diagnosis of TED in the late inactive disease 
stage meeting the inclusion and exclusion criteria. The diagnosis of TED will be made by a 
consultant ophthalmologist on the basis of clinical assessment. TED will be diagnosed 
clinically in the presence of one or more of the following features: soft tissue changes 
in the eye, proptosis, extra ocular muscle dysfunction, corneal abnormalities, and optic 
nerve involvement. To avoid inter-rater variability the same examiner, Mr Dan Morris, will 
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conduct the ophthalmological assessments. Each participant will be enrolled in the trial for 
approximately 10 months. Participants will receive either treatment or placebo for the first three 
months, followed by a two month washout phase before being crossed over to the opposite 
treatment. Patients will be followed for a further 2 months after treatment completion to allow 
us to determine reversibility of the treatment and to collect health economic data. We will 
randomly assign patients to start with either intervention or placebo such that the order of 
treatment is random.  
 
3.17.2 Figure 1: Expected participant flow (Also see activity chart appendix 2) 
 
 
 
Review Clinic Database (n=200) 
Invite for screening (n=80) 
Complete follow up (n=26) 
(2 months) 
Ineligible on screening (n=19) 
Ineligible on records (n=120) 
Consent & screen (n=50) 
No response/not keen to take 
part (n=30) 
Randomise (n=31) 
End of study 
Washout (2 months) 
Allocation to Bimatoprost 
Assessments: 
Visit 1 & 2 (3 months) 
Allocation to Placebo 
Assessments: 
Visit 3 & 4 (3 months) 
Allocation to Bimatoprost 
Assessments: 
Visit 3 & 4 (3 months) 
Allocation to Placebo 
Assessments: 
Visit 1 & 2 (3 months) 
Analysis 
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Trial participants will be randomised to receive Bimatoprost or placebo (illustrated above 
(n=expected number of participants)).  
 
3.18 RANDOMISATION AND CODE BREAK SERVICE 
Allocation of subjects will be by randomisation and minimisation to ensure balance between 2 
trial arms.  This service will be provided by remote computerised web-based allocation of 
treatment arm and will be supported by telephone service during working hours should 
network failure occur.  
 
All investigators, trial staff, and participants will be blinded to the allocations. The trial 
pharmacist will use a web based format and receive treatment allocation from a Cardiff 
University validated randomisation system.  A code of the allocations will be held by the 
pharmacist who will remain independent of the study and also by the clinical trials unit 
conducting the randomisation process. Code break during office hours will be via senior trial 
manager according to SOP. Out of hours code break service will be provided by UHW on-call 
pharmacist contactable via the hospital switchboard according to SOP agreed with pharmacy. 
The randomization information will be kept in the Bimatoprost trial pharmacy folder in the 
clinical trials room in the pharmacy. If a patient needs unmasking, this information will only be 
given to a doctor who is treating the patient.  The pharmacist would say that the patient is 
receiving either Bimatoprost or placebo.  If the doctor then needs to know whether the patient 
is receiving active or placebo, only then will the pharmacist reveal the treatment allocation. 
The PI will need to inform the senior trial manager within 24 hours of the code breaking.  
 
3.19 MEASURE TO AVOID BIAS 
3.19.1 Treatment Allocation  
Allocation of patients to the 2 arms of the study will be done using minimisation. This is a 
process that allocates patients based on (a) their own characteristics, and (b) the allocations 
of patients with the same characteristics already in the trial. The process gains its name by 
minimising the imbalance in numbers in each of the trial arms with respect to a range of 
important prognostic variables simultaneously. It is a dynamic process and a randomisation 
schedule is therefore not drawn up in advance. The variables used to minimise patients are: 
 
1. Degree of proptosis (Mild to moderate ≤ 22mm/Severe >23mm)  
2. Eye involvement (Unilateral/bilateral) 
 
The 2 trial arms to which minimisation will be applied in this study are:  
(A) Starting Bimatoprost first  
(B) Starting placebo first. 
 
3.19.2 Masking 
The placebo will be an artificial tear. To enhance masking the placebo will contain artificial 
tears with similar preservative (Benzalkonium chloride – marketed preparation) which will 
replicate any mild stinging sensation experienced with Bimatoprost. Both products (see 
section 6.1 for more details) will be relabelled by the trial pharmacist in accordance with EU 
Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use 
Annex 13. The relabelled product will be kept in an opaque medicine vial. However, it should 
be noted that the treatment and placebo bottles will be different sizes (3mls vs. 10mls), to 
avoid the need to repackage the agents. In an early proof of concept trial such as this, this 
lack of perfect placebo matching is justified to reduce costs – later confirmatory study will 
require this element to be addressed.  However, in order not to unmask trial staff, the patients 
will be instructed not to bring their eye drop bottles to the eye clinic, but only to the hospital 
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pharmacy at the end of each treatment phase for disposal.    Patients will be given a treatment 
log/diary to ensure compliance (Section 4.6.2).  The PI and Consultant Ophthalmologists will 
not know the treatment allocation and will not have access to the eye drop bottles prescribed 
to patients – this will ensure maintenance of masking.  Participants will be informed that the 
two treatments are in different sized vials, but with no indication of which is which.  
 
3.19.3 OTHER MEASURES FOR MASKING AND PROTECTING AGAINST BIAS 
Concealment of allocation as described above is very important. However, Bimatoprost eye 
drops do in some cases cause redness and irritation of the eyes, as well as iris colour and 
eyelash changes. We recognise that this may result in inadvertent unmasking during the trial 
of either the patient or the ophthalmologist. In addition only affected eyes will be treated (see 
section 6.1). This may mean that differences become apparent between the eye colours or 
eye lashes between the eyes.  This will unavoidably have the potential to reduce masking 
amongst participants as well as trial staff and assessors. To minimise and evaluate this risk to 
concealment the following measures will be taken:  
1. Participants will be asked to record any changes or adverse events in a 
standardised questionnaire, which will be designed to (a) not draw 
excessive attention to known unmasking effects of the treatment, (b) to 
allow this information to be collected prior to contact with trial staff, so that 
any influence of trial staff is minimised; 
2. Only objective findings will be recorded by the assessor (e.g. proptosis 
measurements); 
3. Assessor will have no access to prior assessment records/photos to 
compare with current measurement; 
4. The success of blinding will be assessed at the 3-month and 8-month visits 
by asking patients and investigators to state whether they believe they know 
which treatment individual patients are receiving and assessing whether they 
can correctly identify this treatment.  This will provide a degree of assessment 
of unmasking. Importantly, the quality of masking will be reported in the final 
trial report. 
5. At the end of study, the masked photograph will be assessed by an 
independent ophthalmologist for treatment allocation. This will give 
information whether assessor/patients perception on treatment allocation is 
real.       
 
3.19.3.1 Masked individuals 
1. Patients 
2. Clinical Investigators  
3. Ophthalmologists 
4. Endocrinologists 
5. Clinical research fellow 
6. Trial Coordinator 
7. Data Analysts 
 
  
3.19.3.2 Un-masked individuals: 
1. Senior Trial Manager 
2. Clinical Trial Pharmacists 
 
Patients and the ophthalmic/endocrine clinical teams responsible for their care may request 
their treatment allocation which will be provided after the trial is completed (after last patient 
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completes follow up), unless unmasking is required for clinical reasons.    
 
3.20 DETERMINATION OF SAMPLE SIZE 
3.20.1 Primary outcome measure 
The primary outcome of interest is the change in proptosis with Bimatoprost treatment and a 
reduction of 2mm or more is regarded as clinically relevant. Previous studies have shown a 
standard deviation of 2.5mm in proptosis measurements in patients with TED [19, 20]. We 
calculated that 26 participants (complete datasets) would be needed to be able identify a 
treatment effect of 1.6mm as statistically significant (p=0.05, two-sided, power 0.88). Allowing 
for a 15% dropout rate/incomplete datasets, we intend to recruit 31 participants.  If the number 
of participants with incomplete datasets reaches 30% however there will still be 80% power to 
detect an effect of this size. 
 
3.20.2 Secondary outcome measures 
 Change in quality of life scores on the TED quality of life questionnaire (GO-
QOL) [18] 
 Change in intraocular pressures 
 Side effect profiles of Bimatoprost in TED patients during the study 
 Health economic consumption 
 
3.21 TIMESCALES 
3.21.1 Proposed Trial Start: January 2014 
 
3.21.2 Projected Trial Completion: Feb 2016 
 
3.21.3 Trial Duration: 26 months 
 
3.21.4 Duration of Each Patient’s Participation: 10 months 
 
3.21.5 Follow up visits:  
Following a baseline assessment (visit 1) follow up visits will be undertaken at 3 months (visit 
2), 5 months (visit 3), 8 months (visit 4) and 10 months (visit 5). See appendix 2. 
 
 
3.22 QUALITY CONTROL  
3.22.1 Accountability for Investigational Products 
Active Bimatoprost 0.03% and placebo artificial tear drop are being sourced via the St Mary's 
Pharmaceutical Unit. Both products will be relabelled by the trial pharmacist. The relabelled 
product will be kept in an opaque medicine vial. See section 6.1.  Accountability logs will be 
kept in the Pharmacy Department and collected by the trial team at the end of the study. 
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3.22.2 Procedures for monitoring subject compliance 
Each participant will be provided with a pre-designed log-book and asked to record each time 
the drug is taken. Compliance will be assessed at each visit by interviewing the participant 
and reviewing the log book (Appendix 9 - Patient Diary).  
 
3.22.3 Site Monitoring 
The Sponsor will delegate this responsibility to HCTU, who will have direct access to source 
data. 
 
 
3.23 SAFETY 
The safety of Bimatoprost is already established in its use in other indications. However, 
preliminary risk assessments will be conducted and the TMG will routinely review blinded 
adverse events on a three monthly basis. Since significant new adverse event information is 
not anticipated, a formal data safety monitoring board (DSMB) will not be established. 
However, if an unexpected rate of adverse event is observed, this will be discussed with the 
TSC and an independent DSMB able to review unmasked data will be convened if considered 
appropriate.  
 
3.23.1 Interim analyses 
No formal interim analyses are planned unless requested by the TSC. 
 
3.23.2 Adverse Events 
A list of adverse events will be compiled by the clinical research fellow and the trial coordinator 
and discussed at each TMG meeting along with a review of any early withdrawals from the 
protocol. All serious adverse events will be reported immediately to the sponsor who will 
manage these and report to the MHRA according to agreed procedures. See section 8.0 for 
adverse events classification. 
 
3.23.3 Procedures for breaking randomisation codes 
Randomisation codes may be broken prior to trial completion at the request of the patient’s 
responsible clinician. Randomisation codes for individual patients may be broken for safety 
reasons and if clinically indicated. See section 4.2. 
 
 
3.23.4 Criteria for termination of the trial 
It is unlikely that the trial will be terminated prematurely due to safety issues, given the known 
safety record of the IMPs (active product and placebo). Should there be any unusual side 
effects detected, this will be discussed at TMG and reported to TSG. The trial can be 
terminated at the request of the TSG.  
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10 SELECTION AND WITHDRAWAL OF SUBJECTS 
3.24 STUDY POPULATION 
3.24.1 Inclusion criteria 
1. Stable TED with no reported change in proptosis for at least 6 months. See 
section 4.1.1 for TED definition; 
2. Clinical activity score <3  (Appendix 1); 
3. Proptosis (subjective unilateral proptosis confirmed by asymmetry in 
exophthalmometry of >2mm OR greater than 20 mm on exophthalmometry 
measurement in one eye); 
4. Euthyroid (FT3 and FT4 in the reference range); 
5. If female, must be using a reliable form of contraception during the trial, e.g. 
oral contraceptive and condom, intra-uterine device (IUD) and condom, 
diaphragm with spermicide and condom. 
 
3.24.2 Exclusion criteria 
1. Age <18 yrs; 
2. Dysthyroid optic neuropathy unless previously treated; 
3. Pregnancy or lactation; 
4. Previous Corneal Herpes Simplex infection; 
5. On therapy for glaucoma or intraocular hypertension; 
6. Less than 6 months from prior systemic steroid use; 
7. Aphakia, pseudophakia with torn posterior lens capsule or anterior chamber 
lenses; 
8. Patient with risk factors for cystoid macular oedema, iritis or uveitis; 
9. Severe Asthma (risk of severe allergic reaction to medication); 
10. Previous allergy to Bimatoprost or preservative.  
 
3.25 RECRUITMENT AND IDENTIFICATION OF ELIGIBLE SUBJECTS 
3.25.1 Advertising 
Referrals will be from patients under the TED clinic at UHW and no specific advertising is 
planned.  
 
3.25.2 Screening 
Trial participants will be identified from the database of the multidisciplinary TED clinic in 
University Hospital Wales (UHW), Cardiff. The clinic database currently holds about 200 
patients with TED who could potentially fulfil the study inclusion criteria. Potential participants 
meeting the inclusion criteria will be sent a letter informing them of the study and inviting their 
participation in the study. Patients who have been discharged from the clinic will be invited to 
re-attend the clinic. 
 
3.25.3 Recruitment 
Individuals who are clinically considered to have stable late stage TED, meeting the 
inclusion/exclusion criteria will be provided with an information sheet explaining the nature of 
the study in simple non-technical language. Participants will be recruited from current or 
previous attendees at the UHW TED clinic. In the unlikely event that adequate participant 
recruitment cannot be achieved from the multidisciplinary TED clinic in Cardiff and Vale Health 
Board, additional participants would be sought from other specialist eye clinics in neighbouring 
trusts including Aneurin Bevan Health Board, Cwm Taf Health Board and Abertawe 
Morgannwg University Health Board.  Such sites will be added as Participant Identification 
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Sites (PICs) to identify and refer patients to C&V UHB. To our knowledge there are no major 
competing studies in this area which might impact our recruitment process.  
 
REC and MHRA will be notified of end of study within 30 days of the last visit of the last 
participant taking part in the trial. 
 
3.25.3.1 Screening and enrolment visit-Baseline assessment 
Potentially eligible patients will be assessed by one of the Clinical Investigators. Patients will 
have received already a patient information sheet at least 24 hours before this visit. Any 
questions related to the trial will be answered prior to signing inform consent. Subjects fitting 
the clinical eligibility criteria will be invited to enter the trial. 
 
The purpose of the baseline visit is to confirm eligibility, further discuss the pros and cons of 
taking part in the study, obtain consent if the patient wishes to take part and conduct the trial 
baseline assessments. A case record form (CRF) will be used to record the information and a 
modified version of the Initial Assessment Proforma published in 2002 by the European Group 
on Graves Orbitopathy (EUGOGO) will be used. The key components of the baseline visit are 
to document: 
a) Medical history 
 Duration and severity of TED symptoms 
 TED treatment to date 
 Prior and current thyroid status and treatments 
 Ocular Co-morbidity 
 General Past Medical History 
 Current medications 
 Smoking History 
 Weight and Height (BMI) 
b) Ophthalmological assessment:  
 Proptosis (using an Oculus© exophthalmometer) 
 Intraocular pressure in primary position and upgaze 
 logMAR Visual Acuity 
 Clinical activity score (CAS)* see appendix 1 
 Palpebral aperture* 
 Gorman’s diplopia score 
 Corneal integrity (Defined as healthy/dry (staining)/ulcerated)* 
 Fundoscopy 
 (*As per EUGOGO ATLAS) 
c) Photograph 
Colour photographs of the eye in the lateral and anterior views according to 
standard operating procedure. 
d) Blood tests: 
Thyroid Function Tests (TSH, FT3, FT4). These will be analysed in chemical 
pathology lab University Hospital of Wales, as per standard practice. See appendix 
6 for management of abnormal thyroid function test. 
 
3.26 RANDOMISATION 
Allocation of subjects will be by randomisation by minimisation. This is done to minimise the 
imbalance between the numbers of patients in each treatment group over 2 identified factors 
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(Degree of proptosis and uni/bilateral eyes involvement: See section 4.3.1). The service will 
be provided by a Cardiff University validated randomisation system.  This is a remote 
computerised web-based allocation of treatment arm and will be supported by telephone 
service during working hours should network failure occurs.  After a subject is deemed eligible, 
the trial coordinator will assign the patient a study number (1001-10xx) and fill an eligibility 
check list form which will include minimisation criteria.  
 
Trial prescription will be written by clinical research fellow. The details will be entered into a 
randomisation web form by the trial coordinator. Treatment arm allocation will then be provided 
and confirmed via email to the clinical trial pharmacist.  On receipt of the trial prescription, the 
pharmacist will provide the appropriate treatment materials for that subject at each visit. 
 
3.27 WITHDRAWAL 
3.27.1 Exit Criteria 
 
AT ANY TIME  
 Patient withdrawal of consent 
 
AFTER RANDOMISATION 
 Reactivation of TED  
o Increasing Clinical Activity Score (CAS) by ≥2 points, confirmed on repeat 
examination (within 14 days). 
 Potential Serious Adverse Event attributable to Bimatoprost. 
o Iris cysts 
o Cystoid macular oedema 
o Anterior uveitis 
o Reactivation of herpes simplex virus infection 
 
3.27.2 Treatment of Withdrawn Subjects 
 
The patient, Consultant Ophthalmologist and Consultant Endocrinologist responsible for their 
care, will be informed of their treatment allocation on withdrawal from the trial. 
 
Withdrawn subjects will be followed up as per standard care. 
 
3.27.3 Follow-up of Withdrawn Subjects 
Care for withdrawn subjects will return to their referring ophthalmologist, however they will 
also be invited to attend assessment visits at 3, 5, 8 and 10 months, to obtain outcome data 
in accordance with the planned intention-to-treat analysis. 
 
3.27.4 Management of Data from Withdrawn Subjects 
All withdrawn patients will be invited to produce outcome data for the purposes of the planned 
intention-to-treat analysis.  
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11 TRIAL TREATMENTS 
3.28 Trial Interventions 
Bimatoprost will be administered to affected eyes only. If both eyes are affected, both 
will be treated hence no comparison can be made between the 2 eyes. If one eye is 
affected, only the affected eye will be treated. The changes in the effected eyes could 
only be due to treatment (either placebo or Bimatoprost) or part of disease process 
itself. Treating only the affected eye will be acceptable to patients as treatment may 
restore normality.  
 
3.28.1 Bimatoprost 0.03% 
Bimatoprost (Lumigan®) will be administered at a strength of 0.03%.  This will be purchased 
from the manufacture (Allergan). This is the strength used in the treatment of intraocular 
hypertension and glaucoma. It will be administered at a dose of one drop in the eye once daily 
between 6:00 - 00:00 pm starting from the day of allocation. It will be self-applied to the 
affected eye in unilateral involvement or in case of bilateral involvement, to both eyes.  
Treating both eyes will help to restore towards normality. Treating only affected eye in 
unilateral disease will be acceptable to patients as treatment may restore symmetry.  
 
3.28.2 Placebo 
The placebo will be an artificial tear purchased from manufacturer. To enhance masking the 
placebo will contain artificial tears with similar preservative (Benzalkonium chloride) which will 
replicate any mild stinging sensation experienced with Bimatoprost. It will be administered at 
a dose of one drop in the eye once daily between 6:00 - 00:00 pm starting from the day of 
allocation. It will be self-applied as per Bimatoprost eye drops.  
 
3.28.3 Concomitant medication 
Patients will be allowed to use preservative free eye drops during the trial. This has to be 
applied at least 30 minutes before/after IMP application. No other eye drops will be allowed 
during the trial period. Patients will be asked during each visit regarding any change in their 
regular medication especially recent steroid exposure. 
 
3.28.4 Order of treatments and washout period 
The order of treatment is by randomisation. Patient will be treated over 3 month period 
followed by 2 months washout period. Subsequently patient will cross over to the opposite 
treatment and continue further treatment for 3 month period.  
 
3.28.5 Responsibility for Endocrine Care 
Patients will either transfer responsibility for their Endocrine care to the trial team (under the 
supervision of the Endocrine Chief Investigator) for the duration of their participation in the 
study, or if they prefer to remain under the care of their own Endocrinologist the trial team will 
liaise closely with them in order to ensure that the patient is rendered euthyroid and maintained 
euthyroid for the duration of the trial.  
 
3.28.6 Smoking advice 
All trial subjects will be advised to stop smoking. We will monitor changes in smoking habits. 
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12 FOLLOW UP ASSESSMENT 
 
3.28.7 STANDARD CLINICAL ASSESSMENTS AT EACH FOLLOW-UP VISIT 
The primary outcome measure for the trial is based on exophthalmometry readings of 
proptosis measured using a Hertel exophthalmometer, according to a standard operating 
procedure by the same observer (as far as possible). These will be assessed by the lead 
ophthalmology investigator at each follow-up visit and their measurement recorded on the 
trial’s Clinical Report Form. Please refer to visit schedule in Appendix 2 for more details. 
The key components of the follow-up visits are:  
10. Ophthalmological assessments; 
11. Adverse events (Refer to Section 9 and Appendix 3); 
12. Any Changes in medications (including thyroid treatments); 
13. Any Changes in smoking habit; 
14. Weight; 
15. Colour photographs of the eye in the lateral and anterior views according to 
standard operating procedure; 
16. GO-QOL (Appendix 4) done at clinic visits; 
17. EQ-5D-5L (Appendix 5) done at clinic visits; 
18. Review of clinical blood tests: 
 
Thyroid Function Tests (TSH, FT4 & FT3) at visit 1, 2 and 4. See Appendix 6 for management 
of abnormal thyroid blood test.  
 
 
13 HEALTH ECONOMIC EVALUATION 
 
The primary intention of the economic evaluation is to explore the cost associated with TED 
treatment. In theory, Bimatoprost intervention would lead to the net cost savings to NHS in 
comparison to surgical rehabilitation that the patient otherwise would go through. We are 
aware of limitation in the trial design as this trial primary intention is to evaluate efficacy of 
Bimatoprost in TED, not to follow up patients until they might need surgery. However it would 
be useful to collect the resource use and quality of life data during this trial period on a pilot 
basis which may lead to a larger health economic focus study in the future. It is not envisaged 
that the crossover design will yield data that could allow a meaningful incremental cost-
effectiveness ratio (ICER) to be calculated for Bimatoprost against placebo, as the duration of 
effects on perceived quality of life cannot be predicted in advance. 
 
The different methods of patient care will be evaluated from the viewpoint of the National 
Health Service (NHS) and patients/carers. The data will be collected using Client Service 
Receipt Inventory (CSRI). Please see Appendix 7 and 
http://www.kcl.ac.uk/iop/depts/hspr/research/cemph/tools/csri.aspx. This is a questionnaire 
for collecting retrospective information about study participants’ use of health and social care 
services, accommodation and living situation, income, employment and benefits.   We have 
modified the CSRI in line with services used by our patient population. The questionnaire will 
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be filled by the patient at 0, 3, 5, 8 and 10 months. 
 
The key domains and variables of the Client Service Receipt Inventory are: 
 Socio-demographics:  Age, gender, marital status, ethnicity, mother tongue, 
years of schooling, educational level   
 Usual living situation:  Living situation (alone, with relatives, etc.), type of 
accommodation, household composition   
 Employment and income:  Employment status, occupational category, days of 
work lost, state benefits, source/level of income   
 Service receipt:  Hospital in-patient days, out-patient attendances (e.g. 
endocrine & eye attendances) and community-based service contacts (private 
medical, counsellor, primary care etc.) 
 Medication profile:  Name/type of drug, dosage level and frequency   
 
Quality of life 
Participants will be asked to complete both a generic (EQ-5D-5L) and an eye-specific (GO-
QOL) questionnaire concerning their quality of life (See appendix 4 and 5).  Both 
questionnaires will be completed at 0, 3, 5, 8 & 10 months from recruitment, i.e. at baseline, 
at the end of the first treatment period and two months later, and at the end of the second 
treatment period. 
 
Valuation of resource use 
Analysis will be performed under the guidance of health economist. 
 
National data sets such as the Unit Costs of Health and Social Care 
(http://www.kent.ac.uk/PSSRU/) will be used to value primary care contacts. 
 
Visits to Walk-in Centres and calls to NHS Direct will be valued using information in the 
National Evaluations (http://www.epi.bris.ac.uk/wic/pdf/WIC%20Evaluation%20Report%20-
%20Final.pdf and http://www.shef.ac.uk/scharr/mcru/reports/nhsd3.pdf) 
 
The British National Formulary (http://bnf.vhn.net/bnf) will be used to value prescribed 
medication. 
 
Secondary care use will be valued using the Department of Health National Reference Costs 
(http://www.doh.gov.uk/nhsexec/refcosts.htm).  
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14 PHARMACOVIGILANCE 
There is established clinical experience of both trial interventions (Bimatoprost and placebo), 
and it is unlikely that this trial will contribute significantly to published safety data. However, 
Bimatoprost has not been used in this particular group of patients before. Adverse events will 
be monitored, reported in the trial publications and to the Trial Sponsor, Research Ethics 
Committee (REC) and Medicines and Healthcare products Regulatory Agency (MHRA) if 
appropriate. 
 
SAE collection will start when the first participant is recruited and end at each patient’s last 
visit.   
 
3.29 PROCEDURES FOR RECORDING AND REPORTING ADVERSE EVENTS 
Definitions used will be those under the Medicines for Human Use (Clinical Trials) Regulations 
2004 and Amended Regulations 2006 as follows. 
 
3.29.1 Definitions 
An Adverse Event (AE) is any untoward medical occurrence in a participant to whom an 
investigational medicinal product (IMP) has been administered, including occurrences which 
are not necessarily caused by or related to that product. 
 
An Adverse Reaction (AR) is any untoward and unintended response, in a participant, to an 
IMP which is related to any dose administered to that participant. An Adverse Reaction is an 
Adverse Event with a causal relationship to the IMP. 
 
Serious Adverse Event (SAE), Serious Adverse Reaction (SAR) or Serious Unexpected 
Suspected Adverse Reaction (SUSAR) is defined as an Adverse Event, Adverse Reaction or 
unexpected Adverse Reaction that: 
 
 results in death; 
 is life-threatening; 
The term “life-threatening” in the definition of serious refers to an event in which 
the participant was at risk of death at the time of the event; it does not refer to 
an event which hypothetically might have caused death if it were more severe; 
 requires hospitalisation or prolongation of existing hospitalisation.  
Hospitalization is defined as an inpatient admission, regardless of the length of 
stay, even if the hospitalization is a precautionary measure, for continued 
observation. Pre-planned hospitalisation e.g. for pre-existing conditions which 
have not worsened or elective procedures does not constitute an adverse 
event; 
 results in persistent or significant disability or incapacity; 
 consists of a congenital anomaly or birth defect; or 
 is medically significant; 
Other events that may not result in death are not life-threatening, or do not 
require hospitalisation may be considered as a serious adverse event when, 
based upon appropriate medical judgement, the event may jeopardise the 
participant and may require medical or surgical intervention to prevent one of 
the outcomes listed above. 
 
Pregnancy in either a participant or the partner of a participant taking trial medication should 
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be reported as a SAE. 
 
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is an adverse reaction that is 
both serious and unexpected (i.e. the nature and severity of which is not consistent with the 
information about the IMP in question set out in the Summary of Products Characteristics 
(SPC)). 
 
Expected Adverse Reactions to the trial treatment(s) are detailed below: 
a) Commonly occurring cosmetic effects (approximate incidence) 
 Conjunctival redness (0.5%); 
 Lengthening of eyelashes – (average elongation 0.7mm); 
 Darkening of eye lashes (45-57%); 
 Peri-ocular skin pigmentation (3%); 
 Darkening of the iris (10.1%). 
 
b) Rare but potentially serious side effects (limited information available)  
 Iris cysts; 
 Cystoid macular oedema; 
 Anterior uveitis; 
 Reactivation of herpes simplex virus infection. 
 
The above list should not be relied upon. Always refer to the current Summary of Product 
Characteristics (SPC) when assessing the expectedness of an Adverse Reaction. 
 
3.29.2 Prevention of Adverse Events 
The trial exclusion criteria prevent patients especially at risk of developing adverse events 
from participating in the trial. In particular, patient with risk factors for cystoid macular oedema, 
iritis or uveitis is excluded. Also patient with corneal Herpes Simplex infection history is 
excluded to prevent potential reactivation of herpes simplex virus infection. 
 
3.29.3 Eliciting Adverse Events 
All trial subjects will have an enquiry about co-morbidities, medications and new or unexpected 
symptoms at each follow-up visit, as well as an ophthalmic and general examination. 
 
3.29.4 Principal Investigator/Trial Centre Responsibilities 
The lead ophthalmologist will be required to report all AEs/SAEs which occur during the Trial 
on an Adverse Event Form and keep a record in the case report form (CRF). AEs will be 
collected from the time the participant signs the trial consent form until one month after the 
last trial visit. The AEs will be reported monthly to TMG. TMG will report at least every 6 
monthly to TSC and if there is any concern a DSMB will be convened.  
 
3.29.5 Assessing AEs 
The lead ophthalmologist should assess the AE for seriousness and causality. The lead 
ophthalmologist should exercise medical judgement in deciding whether an Adverse 
Event/Reaction is serious in other situations. All SAEs should be reported to the HCTU by the 
lead ophthalmologist immediately (within 24hrs) of becoming aware of the event. The lead 
ophthalmologist will be asked to grade all AEs in relationship to the study treatment according 
to their clinical judgement as follows: 
 
Causality: 
• Not related – temporal relationship of the onset of the event, relative to administration 
of the product, is not reasonable or another cause can by itself explain the occurrence of the 
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event. 
• Unlikely to be related – temporal relationship of the onset of the event, relative to 
administration of the product, is likely to have another cause which can by itself explain the 
occurrence of the event. 
• Possibly related – temporal relationship of the onset of the event, relative to 
administration of the product, is reasonable but the event could have been due to another, 
equally likely cause. 
• Probably related – temporal relationship of the onset of the event, relative to 
administration of the product, is reasonable and the event is more likely explained by the 
product than any other cause. 
• Very likely – temporal relationship of the onset of the event, relative to administration 
of the product, is reasonable and there is no other cause to explain the event, or a re-challenge 
is positive 
 
Expectedness 
No events other than those listed in section 9.1.1 and appendix 3 (SPC) are expected. 
 
3.29.6 Reporting procedures 
All SAEs must be reported immediately (within 24 hrs of being made aware of the event) by 
the lead ophthalmologist to HCTU. 
Initial reports should be submitted as soon as the following minimum criteria are met: 
 A suspected SAE is identified; 
 An identifiable participant (e.g. trial participant code number); 
 An AE assessed as serious and unexpected, and for which there is a 
reasonable suspected causal relationship; 
 An identifiable reporting source (e.g. Clinical research fellow). 
 
Following the Initial Report, all SAEs should be followed to resolution. Following the initial 
report the lead ophthalmologist may be requested to provide further information. The 
participant should only be identified by trial number, date of birth and initials. The participant’s 
name should not be used on any correspondence. The lead ophthalmologist is also 
responsible for reporting AEs to their NHS Trust as per their local NHS Trust procedures. 
 
3.29.7 Sponsor and Chief Investigator Responsibilities 
The Sponsor (or delegate – HCTU) is responsible for ensuring all SAEs, SARs and SUSARs 
(except those specified in this protocol as not requiring reporting) will be reported in the 
appropriate timescale to the MHRA and REC. 
 
HCTU is responsible for ensuring all SUSARs (except those specified in this protocol as not 
requiring reporting) will be reported in the appropriate timescale to the MHRA and REC. 
Once an SAE is received by HCTU, the SAE will be sent to the CI (or appropriate delegate) 
for clinical review (assessment of causality and expectedness).  Fatal and life threatening 
SAEs should be assessed by the CI within 24 hours of receipt.  Non fatal or non life-threatening 
SAEs should be assessed by the CI within 4 days of receipt. 
Only SUSARs should be reported immediately to MHRA and REC.   HCTU will report 
according to the following timelines: 
Fatal and life threatening SUSARs not later than 7 days  after receipt at HCTU;  Non fatal or 
non life-threatening SUSARs not later than 15 days after  receipt at HCTU. Follow up 
information should be reported within 8 days of receipt of the follow up information. A copy of 
the SUSAR report should be provided to RIES.  
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In addition to reporting to the relevant REC and the MHRA, SUSARs will also be reported 
within 3 working days to all members of the TSC.  The CI shall ensure that all co-investigators 
receive regular safety updates of SUSARs that occur in relation to the IMP in the trial. 
 
 
15 PLANNED ANALYSES 
3.30 INTERIM 
No interim analysis is planned. See sections 4.7.1. 
 
3.31 FINAL 
Data cleaning and preparation process will be carried out prior to analysis. The process will 
involve monitoring the following:   
1. Presence of duplicates in the file; 
2. Presence non-existent patients;  
3. Compulsory completion of a variable;  
4. Out-of-range values; 
5. Logical inconsistencies between variables; 
6. Missing data investigated and data imputation considered 
where missing is not considered to be at random; 
7. Data set preparation for multilevel modelling to include 
both eyes and both phases where appropriate; 
8. Normality of outcome variables investigated. 
 
Data analysis will proceed according to CONSORT guidelines for randomised controlled trials. 
This will be conducted under guidance of senior statistician. The first stage of the analysis will 
be to use descriptive statistics to describe the group of individuals recruited to the trial in 
relation to those eligible, and to investigate comparability of the trial arms at baseline.  
 
A tabulation of demographic and clinical variables will be carried out to identify any chance 
imbalances at baseline between the two treatment groups 
 
The mean change in proptosis measurement in the treated phase and control phase will be 
compared with a paired t-test in the first instance.  In order to protect the independence of the 
data points, this will be carried out using the mean improvement of the two eyes where both 
have been treated.  In addition to this proptosis both eyes for patients with both eyes treated 
and the one eye for patients with only one treated eye will be analysed using a multilevel 
model in STATA which will also give us the ability to use one data point for those patients who 
were unwilling or unable to proceed to the second phase of the protocol.  Demographic and 
clinical variables (including baseline, the order of treatment and carryover effects) may be 
used in this multilevel model regression model to reduce the unexplained variance and obtain 
better estimates of effect size with tighter confidence intervals. The results will be expressed 
as millimetres effect from the treatment arm controlling for the placebo effect with 95% 
confidence intervals and p-values. Phase effects and carry over effects can be reported in this 
way also, but the study has not been designed to be powered to detect these effects as 
statistically significant unless they are as large as the treatment effect.  The frequency of 
adverse effects will be compared in the treatment and control phases by observation of data 
tables and where appropriate use of the McNemar X2 for paired samples. 
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16 DATA HANDLING AND RECORD KEEPING 
Source documents produced for this trial will be kept in the patient’s hospital records and 
source data will be transcribed into trial-specific Clinical Record Forms (CRFs) at the end of 
each patient visit. These CRFs will be coded with the study number and will not include 
patients’ names and addresses.  
 
The paper CRFs will be maintained in the trial office at the Diabetes & Thyroid Research 
Group, C2 Link Corridor, University Hospital of Wales. Selected anonymised data will also be 
stored in electronic format. Paper records will be kept in a locked cabinet in secure premises 
within the Department at all times when the record is not in use for a study visit. Access to the 
records will be restricted to researchers working on the study, Sponsor representatives and 
representatives of regulatory authorities required to audit the conduct of the research study.  
 
Photographs will be held electronically on University Health Board system. 
 
Relevant data will be transferred (with double data entry/data checking) from the paper record 
in the trial office to an electronic database which will be stored and regularly backed up on a 
Cardiff University server. Identifiable data including the link between the patients’ names and 
the study number will be stored separately from other data. All files will be password protected. 
Electronic data containing personalised information will be saved on Cardiff University 
computers only in password protected files and backed up regularly to hard copy on secure 
remote Cardiff University servers. Participant data will be anonymised by the use of study 
numbers. A copy of the study number code identifying subjects will be kept in a secure cabinet 
at local study sites accessible to the investigators at all times. Analysis will be conducted by 
the study team. Analysis will only be conducted on anonymised data.  
 
The Chief Investigator, Professor Colin Dayan will act as custodian of the data, however for 
practical purposes this role will be delegated to HCTU. Personal data will be stored for a 
minimum of 15 years. Access will be controlled by Professor Dayan who will continue to act 
as custodian for all data held by the co-sponsors and will permit trial related monitoring, audits, 
REC review, and regulatory inspections (where appropriate) by providing direct access to 
source data and all other documents (i.e. patients’ case sheets, blood test reports, etc). 
 
17 FINANCIAL AND INSURANCE DETAILS 
Support for this trial has been granted by the following charitable bodies: 
 
 NISCHR Research for Patient and Public Benefit Wales  
For administrative and clinical research support; Investigational Medicinal Product (IMP) 
(Bimatoprost and placebo) and research related costs. 
 
 Cardiff and Vale LHB (University Hospital of Wales) 
For NHS treatment excess cost and grant award administration; pharmacy and media 
supports. 
 
Cardiff University has arranged clinical research insurance to cover the legal liability of the 
University for negligent harm. In addition the study doctors hold substantive or honorary NHS 
contracts, giving them the protection of the NHS clinical negligence arrangements. 
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18 PATIENT INVOLVEMENT 
 
Our research group has a long tradition of involvement with the thyroid eye disease charitable 
trust (TEDct). This is a registered charity which provides information and support to individuals 
affected by thyroid eye disease. TEDct is associated with the British Thyroid Foundation and 
the British Thyroid Association and produces health information leaflets to promote awareness 
and understanding of the disease. The Chief Investigator has been working with TEDct for 
over 10 years, is Chairman of Trustees and Honorary Consultant Advisor to TEDct.  
 
The current therapeutic options for patients with thyroid eye disease are unsatisfactory and 
the need for novel therapies which improve disfigurement and reduce the risk of sight loss has 
been a fundamental concern for most patients and clinicians. The current research question 
has thus evolved from discussions and feedback at past TEDct forum meetings as well as 
extensive patient surveys.  
 
A UK nationwide survey of patients with thyroid eye disease revealed low satisfaction levels 
with existing therapies [1]. A "Thyroid Eye Disease Day", a workshop of patients and clinicians 
with the goal of advancing thyroid eye disease research, was held in December 2012, under 
the auspices of the NIHR Moorfields Biomedical Research Centre. The Chief investigator was 
present at the meeting and a consultation on the current research was held and received 
favourable feedback as to its relevance from the patient perspective.  
 
We have been fortunate to have two patients who have very keen to be involved in the 
development of the study protocol and trial set up. Involving patients with TED from the outset 
strengthens the application by showing that the research is patient-centred and that patient 
participation has been welcomed, encouraged and facilitated. Our patient representatives 
have and will be involved in: 
 Information leaflets design (participant information leaflets, patient invitation 
letter, consent form and GP letter); 
 Protocol development; 
 Trial management meetings; 
 Trouble shooting to support recruitment and retention of participants; 
 Reporting the final results to the trial participants; 
 Preparing information for web site inclusion. 
 
The study will be registered on the NIHR INVOLVE and NISCHR CRC Involving People 
(Cynnwys Pobl) databases once ethical approval is granted. These are national advisory 
groups that support greater public involvement in NHS, public health and social care research. 
INVOLVE provides a public information pack, newsletters and public networking to facilitate 
pubic involvement. Locally, Involving People provides excellent training and support for public 
involvement via local conferences, newsletters and public network.  
 
Patient involvement, involvement of TEDct, and INVOLVE/Involving people will also facilitate 
dissemination of the study findings to as wide an audience as possible and will help set the 
agenda for future research in this field. Training and support for our patient representatives 
will be flexible and tailored to their individual needs. It will include training on the study 
background, methods and outcomes and where indicated IT training will be provided. Patients 
will be reimbursed in line with NISCHR’s AcoRD guidance (Attributing the costs of Health and 
Social Care Research & Development).  
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19 PUBLICATION AND DESSIMINATION POLICY 
It is intended that the results of the study will be reported and disseminated at local and 
international conferences and in peer-reviewed scientific journals. The result will be published 
further in eyes charity newsletter (e.g. TEDct). Written feedback will also be made available to 
the study participants. 
 
 
20 TRIAL MANAGEMENT 
 
1. Trial Steering Committee [TSC] 
An independent Trial steering committee (TSC) will be convened (See membership 
section 1.4.1). The TSC will meet in person or by teleconference at a minimum of 6 monthly 
intervals during the trial. The TSC principal responsibilities will be to: 
1. Review the protocol and comment on any major concerns in the trial design that 
they feel would prevent it addressing the primary objectives. 
2. Review progress reports on the trial and provide advice if problems arise. 
3. Comment on protocol amendments. 
4. Ensure that any new information on the trial interventions which becomes available 
after the start of the trial is properly considered. 
5. Protect the interests of patients should safety issues arise.  
6. Ensure the integrity of the data as far as they are able. 
 
2. Trial Management Group[TMG] 
The project will be run by a Trial Management Group comprising trial coordinator, clinical 
research fellow, statistician, lead ophthalmology investigator and chief investigator and patient 
representatives. The TMG will oversee the day to day trial management and will meet in 
person or by teleconference at a minimum 2 monthly for the duration of the study. The TMG 
will overview and provide guidance on all aspects of regulatory approval, set-up, recruitment, 
protocol deviations, adverse events, data management, data analysis and dissemination. The 
TMG will report 6 monthly to the TSC and to the study sponsor as required. 
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24 Appendices  
 
 Appendix 1 
 
Clinical Activity Score in TED 
The Clinical Activity Score (CAS) [19] is calculated by assessing the presence or absence of 
each of the following clinical features using the trial’s Standard Operating Procedures. 
 
1. Pain 
 Pain on eye movement in the last 4 weeks 
 Painful, oppressive feeling on or behind globe in the last 4 weeks 
 
2. Redness 
 Conjunctival redness 
 Eyelid redness 
 
3. Swelling 
 Chemosis 
 Swollen caruncle 
 Eyelid oedema 
 Increasing proptosis of > 2mm  
 
4. Impaired Function 
 Decreasing visual acuity of > 1 snellen line 
 Decreasing eye movement of ≥ 8o [20] 
 
Each feature = one point. The maximum score is 10 at each visit.  
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Appendix 2 
Bima study activity chart 
 Baseline Randomisation Follow-up 
       
Visit Number -1 1 2 3 4 5 
       
Study month Week 
-2 
Month 
0 
 
3 
 
5 
 
8 
 
10 
       
Activity       
Ophthalmologist assessment X  X X X X 
Blood test X  X  X  
Pregnancy test X  X X X X X 
Weight  X X X X X 
Height  X     
Photograph  X X X X X 
Adverse Event Assessment    X X X X 
Send standard GP letter  X     
Sign Informed consent X      
Complete GO-QOL &  EQ5D-5L 
Questionnaire 
 X X X X X 
Complete CSRI questionnaire  X X X X X 
Start Treatment  X  X   
Stop Treatment   X  X  
Fill minimisation form and online 
randomisation service 
X      
Transcribe CRF X X X X X X 
If eligible to proceed, issue trial 
IMP prescription (Bimatoprost or 
placebo) 
X   X   
Patient to return used eye drop 
bottles to pharmacy 
  X  X  
If eligible to proceed, issue trial 
diary 
 X     
Ask coordinator to chase blood 
results for this visit 
X  X  X  
Masking Questionnaire (Dr and 
Patient) 
  X  X  
Trial Completion Summary 
Letter to inform post-exit clinic 
consult (cc GP +/- referring 
endocrinologist and 
ophthalmologist) 
     X 
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Appendix 3  
ANNEX I 
SUMMARY OF PRODUCT CHARACTERISTICS 
 
 
1. NAME OF THE MEDICINAL PRODUCT  
LUMIGAN 0.3 mg/ml eye drops, solution 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION  
One ml of solution contains 0.3 mg Bimatoprost. 
 
Excipient: 
One ml of solution contains 0.05 mg benzalkonium chloride. 
 
For the full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM  
Eye drops, solution. 
 
Colourless solution. 
 
 
4. CLINICAL PARTICULARS  
4.1 Therapeutic indications  
 
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular 
hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers). 
 
4.2 Posology and method of administration  
Posology 
 
The recommended dose is one drop in the affected eye(s) once daily, administered in the 
evening. The dose should not exceed once daily as more frequent administration may lessen the 
intraocular pressure lowering effect. 
 
Paediatric population 
The safety and efficacy of LUMIGAN in children aged 0 to 18 years has not yet been established. 
 
Use in hepatic and renal impairment 
LUMIGAN has not been studied in patients with renal or moderate to severe hepatic impairment 
and should therefore be used with caution in such patients. In patients with a history of mild 
liver disease or abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
and/or bilirubin at baseline, bimatoprost 0.3 mg/ml eye drops, solution had no adverse effect 
on liver function over 24 months. 
 
 
Method of Administration 
If more than one topical ophthalmic medicinal product is being used, each one should be 
administered at least 5 minutes apart. 
 
4.3 Contraindications  
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Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
 
4.4 Special warnings and precautions for use  
Ocular 
Before treatment is initiated, patients should be informed of the possibility of eyelash growth, 
darkening of the eyelid skin and increased iris pigmentation since these have been observed 
during treatment with LUMIGAN. Some of these changes may be permanent, and may lead to 
differences in appearance between the eyes when only one eye is treated. Increased iris 
pigmentation is likely to be permanent. The pigmentation change is due to increased melanin 
content in the melanocytes rather than to an increase in the number of melanocytes. The long 
term effects of increased iris pigmentation are not known. Iris colour changes seen with 
ophthalmic administration of Bimatoprost may not be noticeable for several months to years. 
Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery 
of the iris and the entire iris or parts become more brownish. Neither naevi nor freckles of the 
iris appears to be affected by the treatment. At 12 months, the incidence of iris pigmentation with 
Bimatoprost 0.3mg/ml was 1.5% (see section 4.8) and did not increase following 3 years 
treatment. Periorbital tissue pigmentation has been reported to be reversible in some patients. 
 
Cystoid macular oedema has been uncommonly reported (≥1/1000 to <1/100) following 
treatment with Bimatoprost 0.3 mg/ml eye drops. Therefore, LUMIGAN should be used with 
caution in patients with known risk factors for macular oedema (e.g. aphakic patients, 
pseudophakic patients with a torn posterior lens capsule). 
 
There have been rare spontaneous reports of reactivation of previous corneal infiltrates or ocular 
infections with Bimatoprost 0.3 mg/ml eye drops, solution. LUMIGAN should be used with caution 
in patients with a prior history of significant ocular viral infections (e.g. herpes simplex) or 
uveitis/iritis. 
 
LUMIGAN has not been studied in patients with inflammatory ocular conditions, 
neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-
angle glaucoma. 
 
Skin 
There is a potential for hair growth to occur in areas where LUMIGAN solution comes 
repeatedly in contact with the skin surface. Thus, it is important to apply LUMIGAN as 
instructed and avoid it running onto the cheek or other skin areas. 
 
Respiratory 
LUMIGAN has not been studied in patients with compromised respiratory function and should 
therefore be used with caution in such patients. In clinical studies, in those patients with a history 
of a compromised respiratory function, no significant untoward respiratory effects have been 
seen. 
 
Cardiovascular 
LUMIGAN has not been studied in patients with heart block more severe than first degree or 
uncontrolled congestive heart failure. There have been a limited number of spontaneous 
reports of bradycardia or hypotension with Bimatoprost 0.3 mg/ml eye drops, solution. 
LUMIGAN should be used with caution in patients predisposed to low heart rate or low blood 
pressure 
 
Other Information 
In studies of Bimatoprost 0.3 mg/ml in patients with glaucoma or ocular hypertension, it has 
been shown that the more frequent exposure of the eye to more than one dose of 
Bimatoprost daily may decrease the IOP-lowering effect (see section 4.5). Patients using 
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LUMIGAN with other prostanglandim analogues should be monitored for changes to their 
intraocular pressure. 
 
Bimatoprost 0.3 mg/ml eye drops, solution contains the preservative benzalkonium chloride, 
which may be absorbed by soft contact lenses. Eye irritation and discolouration of the soft 
contact lenses may also occur because of the presence of benzalkonium chloride. Contact 
lenses should be removed prior to instillation and may be reinserted 15 minutes following 
administration. Benzalkonium chloride, which is commonly used as a preservative in ophthalmic 
products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. 
Since LUMIGAN contains benzalkonium chloride, monitoring is required with frequent or 
prolonged use in dry eye patients or where the cornea is compromised. 
 
There have been reports of bacterial keratitis associated with the use of multiple dose 
containers of topical ophthalmic products. These containers had been inadvertently 
contaminated by patients who, in most cases, had a concurrent ocular disease. Patients with 
a disruption of the ocular epithelial surface are at greater risk of developing bacterial keratitis. 
 
The tip of the bottle should not be allowed to contact the eye, surrounding structures, fingers 
or any other surface in order to avoid contamination of the solution. 
 
 
4.5 Interaction with other medicinal products and other forms of interaction  
No interaction studies have been performed. 
 
No interactions are anticipated in humans, since systemic concentrations of Bimatoprost are 
extremely low (less than 0.2 ng/ml) following ocular dosing with Bimatoprost 0.3 mg/ml eye 
drops, solution. Bimatoprost is biotransformed by any of multiple enzymes and pathways, and 
no effects on hepatic drug metabolising enzymes were observed in preclinical studies. 
 
In clinical studies, LUMIGAN was used concomitantly with a number of different 
ophthalmic beta-blocking agents without evidence of interactions. 
 
Concomitant use of LUMIGAN and antiglaucomatous agents other than topical beta-blockers 
has not been evaluated during adjunctive glaucoma therapy. 
 
There is a potential for the IOP-lowering effect of prostaglandin analogues (e.g. LUMIGAN) 
to be reduced in patients with glaucoma or ocular hypertension when used with other 
prostaglandin analogues (see section 4.4). 
 
 
4.6 Pregnancy and lactation  
Pregnancy 
There are no adequate data from the use of Bimatoprost in pregnant women. Animal studies 
have shown reproductive toxicity at high maternotoxic doses (see section 5.3). 
 
LUMIGAN should not be used during pregnancy unless clearly necessary. 
 
Breast-feeding 
It is unknown whether Bimatoprost is excreted in human breast milk. Animal studies have shown 
excretion of Bimatoprost in breast milk. A decision must be made whether to discontinue breast-
feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast feeding 
for the child and the benefit of therapy for the woman. 
 
Fertility 
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There are no data on the effects of Bimatoprost on human fertility. 
 
 
4.7 Effects on ability to drive and use machines  
LUMIGAN has negligible influence on the ability to drive and use machines. As with any ocular 
treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision 
clears before driving or using machines. 
 
Undesirable effects  
In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/ml eye drops, 
solution. On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/ml 
eye drops, solution usage, the most frequently reported treatment-related adverse events were: 
growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing 
to 7% at 2 years and 2% at 3 years, conjunctival hyperaemia (mostly trace to mild and thought 
to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports 
decreasing to 13% at 2 years and 12% at 3 years and ocular pruritus in up to 14% of patients in 
the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years. 
Less than 9% of patients discontinued due to any adverse event in the first year with the incidence 
of additional patient discontinuations being 3% at both 2 and 3 years. 
 
The following adverse reactions were reported during clinical trials with LUMIGAN 0.3 mg/ml 
eye drops, solution or in the post-marketing period. Most were ocular, mild to moderate, and 
none was serious: 
 
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare 
(≥1/10,000  
to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data) 
adverse reactions are presented according to System Organ Class in Table 1. Within each 
frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
 
 
System Organ class Frequency Adverse reaction 
Nervous system disorders common headache 
   
 uncommon dizziness 
Eye disorders very common conjunctival hyperaemia, 
  ocular pruritus, growth of 
  eyelashes 
 common superficial punctate keratitis, 
  corneal erosion, ocular 
  burning, ocular irritation, 
  allergic conjunctivitis, 
  blepharitis, worsening of 
  visual acuity, asthenopia, 
  conjunctival oedema, foreign 
  body sensation, ocular 
  dryness, eye pain, 
  photophobia, tearing, eye 
  discharge, visual 
  disturbance/blurred vision, 
  increased iris pigmentation, 
  eyelash darkening. 
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 uncommon retinal haemorrhage, uveitis, 
  cystoid macular oedema, iritis, 
  blepharospasm, eyelid 
  retraction, periorbital erythema 
 not known enophthalmos 
Vascular disorders common hypertension 
Gastrointestinal disorders uncommon nausea 
   
Skin and subcutaneous tissue common 
eyelid erythema, eyelid 
pruritus, 
disorders  pigmentation of periocular skin 
   
 uncommon eyelid oedema, hirsutism 
General disorders and uncommon asthenia 
administration site conditions   
   
Investigations common liver function test abnormal 
 
4.8 Overdose 
No case of overdose has been reported, and is unlikely to occur after ocular administration. 
 
If overdose occurs, treatment should be symptomatic and supportive. If LUMIGAN is 
accidentally ingested, the following information may be useful: in two-week oral rat and mouse 
studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 
is at least 70-times higher than the accidental dose of one bottle of LUMIGAN 0.3 mg/ml eye 
drops, solution in a 10 kg child. 
 
5. PHARMACOLOGICAL PROPERTIES  
5.1 Pharmacodynamic properties  
Pharmacotherapeutic group: Ophthalmologicals, prostaglandin analogues, ATC code: S01EE03. 
 
Mechanism of action 
 
The mechanism of action by which Bimatoprost reduces intraocular pressure in humans is by 
increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral 
outflow. Reduction of the intraocular pressure starts approximately 4 hours after the first 
administration and maximum effect is reached within approximately 8 to 12 hours. The duration 
of effect is maintained for at least 24 hours. 
 
Bimatoprost is a potent ocular hypotensive agent. It is a synthetic prostamide, structurally related 
to 
 
prostaglandin F2α (PGF2α), that does not act through any known prostaglandin receptors. 
Bimatoprost selectively mimics the effects of newly discovered biosynthesised substances called 
prostamides. The prostamide receptor, however, has not yet been structurally identified. 
 
During 12 months’ monotherapy treatment with LUMIGAN 0.3 mg/ml in adults, versus timolol, 
mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm 
Hg. At any visit, the mean diurnal IOP values measured over the 12-month study period differed 
by no more than 1.3 mmHg throughout the day and were never greater than 18.0 mmHg. 
 
In a 6-month clinical study with LUMIGAN 0.3 mg/ml, versus latanoprost, a statistically superior 
reduction in morning mean IOP (ranging from -7.6 to -8.2 mmHg for bimatoprost versus –6.0 to 
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-7.2 mmHg for latanoprost) was observed at all visits throughout the study. Conjunctival 
hyperaemia, growth of eyelashes, and eye pruritus were statistically significantly higher with 
Bimatoprost than with latanoprost, however, the discontinuation rates due to adverse events 
were low with no statistically significant difference. 
 
Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and 
LUMIGAN 0.3 mg/ml lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg. 
 
Limited experience is available in patients with open-angle glaucoma with pseudoexfoliative and 
pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy. 
 
No clinically relevant effects on heart rate and blood pressure have been observed in clinical 
trials. 
 
Paediatric population 
The safety and efficacy of LUMIGAN in children aged 0 to less than 18 years has not been 
established. 
 
 
5.2 Pharmacokinetic properties  
Absorption 
Bimatoprost penetrates the human cornea and sclera well in vitro.  After ocular administration in 
adults, the systemic exposure of Bimatoprost is very low with no accumulation over time. After 
once daily ocular administration of one drop of LUMIGAN 0.3 mg/ml to both eyes for two weeks, 
blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit 
of detection (0.025 ng/ml) within 1.5 hours after dosing. Mean Cmax and AUC 0-24hrs values 
were similar on days 7 and 14 at approximately 0.08 ng/ml and 0.09 ng•hr/ml respectively, 
indicating that a steady Bimatoprost concentration was reached during the first week of ocular 
dosing. 
 
Distribution 
Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution 
in humans at steady-state was 0.67 l/kg. In human blood, Bimatoprost resides mainly in the 
plasma. The plasma protein binding of Bimatoprost is approximately 88%. 
 
Biotransformation 
Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation 
following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and 
glucuronidation to form a diverse variety of metabolites. 
 
Elimination 
Bimatoprost is eliminated primarily by renal excretion, up to 67% of an intravenous dose 
administered to healthy adult volunteers was excreted in the urine, 25% of the dose was excreted 
via the faeces. The elimination half-life, determined after intravenous administration, was 
approximately 45 minutes; the total blood clearance was 1.5 l/hr/kg. 
 
Characteristics in elderly patients 
After twice daily dosing of LUMIGAN 0.3 mg/ml, the mean AUC0-24hr value of 0.0634 ng•hr/ml 
 
Bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 
ng•hr/ml in young healthy adults. However, this finding is not clinically relevant as systemic 
exposure for both elderly and young subjects remained very low from ocular dosing. There was 
no accumulation of Bimatoprost in the blood over time and the safety profile was similar in elderly 
and young patients. 
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5.3 Preclinical safety data  
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess 
of the maximum human exposure indicating little relevance to clinical use. 
 
Monkeys administered ocular Bimatoprost concentrations of ≥0.3 mg/ml daily for 1 year had an 
increase in iris pigmentation and reversible dose-related periocular effects characterised by a 
prominent upper and/or lower sulcus and widening of the palpebral fissure. The increased iris 
pigmentation appears to be caused by increased stimulation of melanin production in 
melanocytes and not by an increase in melanocyte number. No functional or microscopic 
changes related to the periocular effects have been observed, and the mechanism of action for 
the periocular changes is unknown. 
 
Bimatoprost was not mutagenic or carcinogenic in a series of in vitro and in vivo studies. 
 
Bimatoprost did not impair fertility in rats up to doses of 0.6 mg/kg/day (at least 103 -times the 
intended human exposure). In embryo/foetal developmental studies abortion, but no 
developmental effects were seen in mice and rats at doses that were at least 860-times or 1700-
times higher than the dose in humans, respectively. These doses resulted in systemic exposures 
of at least 33- or 97 -times higher, respectively, than the intended human exposure. In rat 
peri/postnatal studies, maternal toxicity caused reduced gestation time, foetal death, and 
decreased pup body weights at ≥0.3 mg/kg/day (at least 41-times the intended human exposure). 
Neurobehavioural functions of offspring were not affected. 
 
6. PHARMACEUTICAL PARTICULARS  
6.1 List of excipients  
Benzalkonium chloride 
Sodium chloride 
Sodium phosphate dibasic heptahydrate 
Citric acid monohydrate 
Hydrochloric acid or sodium hydroxide (to adjust pH) 
Purified water 
 
6.2 Incompatibilities  
Not applicable. 
 
6.3 Shelf life  
2 years. 4 weeks after first opening. 
 
6.4 Special precautions for storage  
This medicinal product does not require any special storage conditions. 
 
6.5 Nature and contents of container  
White opaque low density polyethylene bottles with polystyrene screw cap. Each bottle has a fill 
volume of 3 ml. 
 
The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml solution. Not all 
pack sizes may be marketed. 
 
6.6 Special precautions for disposal  
No special requirements for disposal. 
 
7. MARKETING AUTHORISATION HOLDER  
Allergan Pharmaceuticals Ireland 
 365 
Castlebar Road 
Westport 
Co. Mayo 
Ireland 
 
8. MARKETING AUTHORISATION NUMBER  
EU/1/02/205/001-002 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION  
8 March 2002 / 20 February 2007 
 
 
10. DATE OF REVISION OF THE TEXT  
Detailed information on this product is available on the website of the European Medicines 
Agency (EMEA): http://www.emea.europa.eu 
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Health Questionnaire 
 
 
 
English version for the UK 
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Under each heading, please tick the ONE box that best describes your health TODAY  
 
MOBILITY 
I have no problems in walking about      
I have slight problems in walking about     
I have moderate problems in walking about     
I have severe problems in walking about      
I am unable to walk about        
 
SELF-CARE 
I have no problems washing or dressing myself    
I have slight problems washing or dressing myself    
I have moderate problems washing or dressing myself    
I have severe problems washing or dressing myself    
I am unable to wash or dress myself     
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities) 
I have no problems doing my usual activities    
I have slight problems doing my usual activities    
I have moderate problems doing my usual activities    
I have severe problems doing my usual activities     
I am unable to do my usual activities      
 
PAIN / DISCOMFORT 
I have no pain or discomfort        
I have slight pain or discomfort       
I have moderate pain or discomfort       
I have severe pain or discomfort       
I have extreme pain or discomfort       
 
ANXIETY / DEPRESSION 
I am not anxious or depressed       
I am slightly anxious or depressed       
I am moderately anxious or depressed     
I am severely anxious or depressed       
I am extremely anxious or depressed      
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10 
0 
20 
30 
40 
50 
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100 
5 
15 
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55 
75 
65 
85 
95 
The worst health        
 you can imagine 
The best health        
 you can imagine 
 
 We would like to know how good or bad your health is 
TODAY. 
 
 This scale is numbered from 0 to 100. 
 
 100 means the best health you can imagine. 
 0 means the worst health you can imagine. 
 
 Mark an X on the scale to indicate how your health is TODAY. 
 
 Now, please write the number you marked on the scale in the 
box below. 
 
YOUR HEALTH TODAY  =    
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Appendix 6 Endocrine Management 
Hyperthyroid patients will be treated with Carbimazole 40mg daily until euthyroid and then 
transferred to block-replace treatment (Carbimazole 40mg and Thyroxine 100µg daily) prior 
to study entry if recruitment time allowing.  
Hypothyroid patients will be treated with Thyroxine, and the dose adjusted to normalise TSH 
levels. Previously controlled hyperthyroid patients (treated in the last 1 year) will remain on 
current treatment.  If unstable, patient will be placed on block-replace treatment. Previously 
hypothyroid patients will have their dose adjusted (if required) according to their TSH levels. 
Euthyroid patients (5% of patients with TED have normal thyroid hormone levels) will not 
require any treatment for thyroid disease, but their Thyroid Function Tests (TSH, FT3, FT4) 
will be monitored at 3 month intervals and treated (as above) if changes develop. 
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Appendix 7 
Study Number              
Date    / /  
 
      Assessment  0 3 5 8 10 
         
Firstly, please tell us about the health care you have received for your  
Thyroid Eye Disease 
1) In the last 2 months, have you been to hospital because of your thyroid or thyroid eye disease?  
 
Please tick 'yes' or 'no' for each line. If you answer 'yes' to any of them, please tell us how many times you used the service. 
 No    Yes  
Had a hospital outpatient appointment        Total number of appointment                ..…......…....... 
Been to accident and emergency (casualty)        Total number of visits:    ........................ 
Stayed in hospital overnight        Total number of nights:                     ........................ 
 
2) In the last 2 months, have you used any of the services below because of your thyroid 
or thyroid eye disease?  
 
Please tick 'yes' or 'no' for each line. If you answer 'yes' to any of them, please tell us how many times you used the service, how long 
your contact with that person lasted (on average if more than once) and when applicable tick if the service was private. 
 
GP and practice nurse 
No    Yes Number of 
times 
On average, how many minutes 
did you see/talk to them for? 
Cost (£) 
Saw GP at the surgery        ............... .....................  
Phoned GP for advice         ............... .....................  
Saw practice nurse         ............... .....................  
Phoned practice nurse for advice        ............... .....................  
Got a repeat prescription (without seeing doctor)        ............... .....................  
Blood test         ............... .....................  
Other NHS Services     
NHS direct            ...................                     ………….  
Other phone call (details) …………………        ............... .....................  
Other (details) ……………………………..        ............... .....................  
Non-NHS Services  
 
   
Private Medical        ............... ..................... ……... 
Acupuncture        ............... ..................... ……….. 
Counsellor        ............... ..................... ……... 
Support Group         ............... ..................... ……... 
Other services     
University Hospital of Wales 
Bima Study 
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Others (e.g. alternative therapies) 
…………………………………………..… 
       ............... ..................... ……... 
 
We would now like to know about what thyroid eye disease has cost you and 
others 
 
3) In the last 2 months, what medicines have you used for your thyroid & thyroid eye disease 
and how did you pay for them altogether? (Include homeopathic/herbal medicines) 
    
  Name of drug Dosage  
(if known) 
Dosage 
frequency (e.g. 
twice daily) 
1.   
2.   
3.   
4.   
5.   
   
4) In the last 2 months, how did you pay for the above medicines (Include homeopathic/herbal 
medicines) altogether? 
Please tick all that apply  
 I did not have any medicines   
 I got free prescriptions  
 I have to pay for my private prescription 
 
5) In the last 2 months, have you, your relatives/friends, the NHS or social services paid for any 
of the following because of your thyroid or thyroid eye disease?  
 
Please tick 'yes' or 'no' for each line and tell us how much it cost 
 No    Yes How much has this 
cost altogether 
in the last 2 
months? 
Who paid for 
this? 
Employing extra help (e.g. childcare or cleaning)      ................... ................... 
Transport to get healthcare (e.g. to go to your GP surgery or hospital)      ................... ................... 
Glasses      ................... ................... 
Cosmetics      ................... ................... 
Sunglasses      ................... ................... 
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Any other costs due to thyroid eye 
disease........................…..............................................................
. 
     ................... 
 
................... 
 
 
 
 
 
 
5) In the last 2 months, have you taken any time off work because of your thyroid or thyroid eye 
disease?  
Note: Include any time taken off because you were suffering with thyroid eye disease or using any health services 
such as those listed in questions 1 & 2. 
 
Yes         If yes: Please give details below 
No         
I have not been employed in the last 2 months   
 
   Please tell us either the number of days or the number of hours you 
took off in the last 2 months 
 No       Yes Number of whole working days Number of hours 
Took sick leave from work        ....................... .......................... 
Used your paid holiday time from work        ........................ ....................... 
Took unpaid leave from work        ....................... ....................... 
Just made up the time at work        ...................... ....................... 
Other arrangement (please describe below) 
......................................................................... 
       ....................... ........................ 
 
Have you lost any pay because of this time off work?     
 
Yes    If yes: How much gross income you have lost in the last 2 months £...............                            
No   
 
6) In the last 2 months, have friends and relatives helped you with tasks at home which you 
couldn't do because of your thyroid or thyroid eye disease? 
 
Yes   If yes: Please tick below the tasks they helped you with and for how many 
hours per week. 
No   
 
Did anyone help you with this task? 
 
No                    Yes Typically, how many hours per week? 
Personal care (e.g. bathing, dressing)                   .......................... 
Child care                   .......................... 
Housework / laundry                   .......................... 
Providing transport/taking you out                   .......................... 
Preparing meals                   .......................... 
Gardening                   .......................... 
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Shopping                   .......................... 
Looking after pets                   .......................... 
Generally providing support                   .......................... 
Other (Please describe below)                    .......................... 
..........................................................   
 
7) In the last 2 months, have friends and relatives stayed off work to help you because of your 
thyroid eye disease? 
 
Yes  If yes: How many days did they take off work in the last 2 months?   ………………. 
        
No      
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Now please tell us something about yourself 
 
8)  Which of the following best describes your current situation? 
 
Please read the whole list first and then write '1' in the box that applies. If other categories apply, write '2' , '3' etc. to indicate the 
order that best describes your situation. 
 
Working full time (30 hours or more per week)      
Working part time (less than 30 hours per week)   
Unemployed and looking for work    
Volunteer       
Job training/apprentice      
Student        
At home and not looking for work     
(e.g. looking after home and/or family) 
Unable to work        What is the reason for this?  
            
      Thyroid eye   Other illness  Other reason   
 
Made redundant/took early retirement     What is the reason for this?  
  
      Thyroid eye   Other illness  Other reason  
 
Retired        
Other          Please describe .............................................. 
 
 
 
9)  Do you receive any state benefits?  
 
Yes   If yes: Please tick below which benefits you get and tell us how much you get altogether 
No  
 
 Income support    Invalidity allowance     
 Jobseeker's allowance   Disability living allowance   
  
 Housing benefit    Incapacity benefit    
 Attendance allowance  
  Others (please describe) 
......................................................................…........................................................................................ 
   
How much do you receive altogether in benefits each week?                   
£........................... 
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10)  What is the total income of your household per week from all sources before taxes and 
deductions? 
 (Exclude housing benefit and council tax rebate) 
Note: a household is either one person living alone, or a group of people (who may or may not be related) 
living, or staying  temporarily, at the same address, with common housekeeping.   
          
           
Please tick one 
 £0 - £99    (£0 - £5199  per year)   £350 - £449  (£18,200 - 23,399 per 
year) 
 £100 - £149  (£5,200 - £7,799 per year)   £450 - £599  (£23,400 - £31,199 per 
year)  
 £150 - £249  (£7,800 - £12,999 per year)   £600 - £749  (£31,200 - £38,999 per 
year)  
 £250 - £349  (£13,000 - £18,199 per year)  £750 or more (£39,000 or more per 
year)   
  
  
11) What kind of accommodation do you live in at the moment?  
 
Please tick one  
 Domestic housing (e.g. house, flat)      Residential home 
 Sheltered housing        Nursing home 
  
 
 
12)  If you live in domestic housing, how many people are there in your household?  
Number of adults (including yourself)  ………………. 
Number of children under the age of 16  ………………. 
 
 
13)  Which ethnic group do you consider yourself to belong to? 
   
Please tick one  
 White       Indian    
  
 Chinese       Pakistani    
  
 Black African      Bangladeshi    
   
 Black Caribbean      None of these    
  
 Black other          
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 Thank you for completing this questionnaire  
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Appendix 8 
 
Patient Diary 
            
                        
BIMA Study Subject Diary 
Screening No. / Study ID Subject Initials 
 
  
 
 
  
 
            
Investigator: Prof Dayan/Mr Morris/Mrs Lane Eye  Unit Secretary: 029 20742083   
Trial Doctor:  Dr Shazli Draman: Tel: 029 20 748481 Mob: 07446624212   
Trial Coordinator: 
Julie Pell: Tel: 029 744370 
         
            
Date of next scheduled visit:      Time of visit:       
            
Study Reminders  
1 
Please bring this study diary with you to all clinic visits or have it to hand in case you need to call your study 
team 
2 Please notify your study doctor or nurse IMMEDIATELY if you are admitted to hospital for any reason 
           
            
            
            
            
BIMA Study 
 
 
Subject Diary 
 
 
            
Instructions on how to complete your diary 
            
1 
Please apply 1 drop of the eye drops into one or both eyes as instructed by your doctor daily anytime between 06:00 pm 
to 00:00 midnight. 
2 Record the time you have administered the eye drops in provided box.    
3 Please tick the appropriate box for the eye you have applied the eye drops.     
4 If you notice any side effects please fill the Side Effect log      
5 Record any illness or new medication used in the Illness and Medication log    
            
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Date Time 
Right 
Eye 
Left 
Eye 
Other Date Time Right Eye Left Eye Other 
01.01.2014 example 
10:00 
pm √               
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                      
                      
                        
 
 
 
         
BIMA Study Subject Diary-Side Effects 
      
 
     
Side Effects - Instructions 
1In this section, please record any side effects you are experiencing from the trial medication 
EXAMPLE  
Side effect 
Start   
Date 
Stop   
Date 
Side effect 
Start   
Date 
Stop   
Date 
Comment 
 Example: Redness in right eye  01.01.14           
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Side effect 
Start   
Date 
Stop   
Date 
Side effect 
Start   
Date 
Stop   
Date 
Comment 
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Patient Diary  Version 1.0 18-Sep-2011 
        
            
BIMA Study Subject Diary-Illness and Medication Log 
                        
Illness and Medication Log - Instructions 
1 In this section, new medication other than your prescribed eye drops should be recorded  
2 Please record any new illnesses and medications (or medication changes) since your last study visit (include any vitamins 
and herbal remedies).  Please bring medication packaging for doses if you are unsure.   
3 Please record the date the new illness and medication STARTED and/or the date of medication (dose) change. 
4 Please record the date the illness/ medication STOPPED and/or the stop date of medication (dose) change 
5 If you are still taking the same medication(s) without any dose change at the time of your next study visit, record a dash 
(--) in the STOP DATE column  (see example below) 
 
EXAMPLE:           
Illness 
Start   
Date 
Stop   
Date 
Medication Name 
Start   
Date 
Stop   
Date 
Total Daily Dose 
(Change) 
headcold 15.7.11 20.7.11 paracetamol 15.7.11 18.7.11 4gms 
headcold 15.7.11 21.7.11 paracetamol 19.7.11 21.7.11 2gms 
ankle sprain 23.7.11 _ _ _ Ibuprofen 23.7.11 _ _ _  600mgs 
  
    
 
383 
        
Illness 
Start   
Date 
Stop   
Date 
Medication Name 
Start   
Date 
Stop   
Date 
Total Daily Dose 
(Change) 
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8.4.2 Patient information sheet (summary) 
 
 
 
 
 
 
 
 
 
 
 
 
Chief Investigator:   Professor Colin Dayan 
Address:  Thyroid Research Group, Cardiff University School of Medicine, 
University Hospital of Wales, Heath Park, Cardiff CF14 4XW 
Telephone:    029 20 742182 / Clinical Trials Office: 029 20 744370 
Fax:    029 20744671 
Email:    DayanCM@cardiff.ac.uk 
Researchers:   Mr Dan Morris / Mrs Carol Lane 
Telephone:    029 20 747747 (secretary extension: 2083) 
 
SUMMARY PATIENT INFORMATION SHEET 
1. What is the purpose of the study? 
To establish whether Bimatoprost eye drops, which are routinely used to treat 
glaucoma, are effective in making the eyes less prominent in Thyroid Eye Disease 
(TED). 
 
2. Why have I been sent this information sheet? 
Because you are currently attending, have previously attended or have been 
referred to the eye clinic involved in this trial for the treatment of prominent (‘starey’) 
eyes due to Thyroid Eye Disease.  
 
3. Do I have to take part in this study? 
No. It is up to you to decide whether or not to take part.   
 
4. What will happen to me if I take part? 
You will be given two courses of treatment each of 3 months with a two month gap 
in between. One course will be with once daily eye drops containing Bimatoprost 
and the other will be with dummy (called a placebo) eye drops.  
 
5. Will I be asked to give any blood samples? 
Yes. You will be asked to give blood samples on 3 occasions, 3 months apart.  
 
6. Will I (or my doctor) know what treatments I am taking? 
Eich cyf/Your ref:   
Ein cyf/Our ref:  
Rhwydwaith Ffôn Iechyd Cymru/ 
Welsh Health Telephone Network:  
Llinell uniongyrchol/Direct Line: 
Ysbyty Athrofaol Cymru 
University Hospital of Wales 
 
Parc y Mynydd Bychan Heath Park 
Caerdydd CF14 4XW  Cardiff CF14 4XW 
Ffôn 029 2074 7747 Phone 029 2074 7747 
Ffacs 029 20743838  Fax 029 2074 3838  
Minicom 029 2074 3632 Minicom 029 2074 3632 
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To ensure the study is well designed, neither you nor the doctors will know which 
treatment you receive first or second (Bimatoprost or placebo) until all patients 
have completed the study.  
 
7. How will the decision about which treatments I receive be made? 
This will be selected by a computer on the basis of chance, like flipping a coin. 
 
8. How long will I be in the study? 
10 months – 2 treatment periods of 3 months and 2 rest periods of 2 months each. 
 
9. What are the possible benefits of taking part? 
If the treatment you receive is found to be better than the current standard treatment used 
at your Eye Hospital, you will benefit from participating in this study. Otherwise, taking part 
may not be of direct benefit to you. It should, however, help us to develop better care for 
TED patients in the future.  
 
10. What safety assurances will I have if I take part? 
If your TED gets worse at any stage you will be withdrawn from the study and given 
standard treatment.  
 
11. Who is organising and funding the research? 
This research has been organised by a group of doctors (Ophthalmologists and 
Endocrinologists) who are specialists in the treatment of Thyroid Eye Disease. It has been 
funded by National Institute for Social Care and Health Research (NISCHR) which is a 
Welsh government body. 
 
12. What do I do if I want more information? 
For more information please contact: 
Mr Dan Morris and Mrs Carol Lane, Consultant Ophthalmologists, University Hospital of 
Wales, Heath Park, Cardiff CF14 4XW 
Tel:   029 20 747747 (secretary extension: 2083) 
 
Or 
 
Professor Colin Dayan, Professor Clinical Diabetes and Metabolism, School of Medicine 
Centre for Endocrine and Diabetes Science, Cardiff University, Heath Park, Cardiff CF14 
4XW 
Tel:   029 20 742182 (secretary) 
 
Or 
 
Trials Office: 
Julie Pell, Trials Coordinator: 029 21847942, pelljc@cardiff.ac.uk 
Dr Draman, Study Doctor:   02920 748481, Dramanyusofms@cardiff.ac.uk 
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8.4.3 Patient information sheet (detailed) 
 
 
 
 
 
Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: A randomised 
controlled double blind crossover trial 
(BIMA Study) 
 
Principal Investigator:  Professor Colin Dayan 
Address:  Thyroid Research Group, Cardiff University School of Medicine, 
University Hospital of Wales, Heath Park, Cardiff CF14 4XW 
Telephone:    029 20 742182 / Clinical Trials Office: 029 20 744370 
Fax:    029 20744671 
Email:    DayanCM@cardiff.ac.uk 
 
Researchers:   Mr Dan Morris/ Mrs Carol Lane 
Telephone:    029 20 747747 (secretary extension: 2083) 
 
DETAILED PATIENT INFORMATION SHEET 
Part 1 
1. Invitation to take part in this research project 
You have been sent this information because you are currently attending or have been 
referred to the eye clinic involved in this trial for the treatment of prominent (‘starey’) eyes 
due to Thyroid Eye Disease (TED). If we confirm at your outpatient visit that you still have 
prominent and inactive TED for at least 6 month duration prior to the visit, you will be 
invited to take part.   
2. What is the purpose of the study? 
 To establish whether Bimatoprost eye drops are effective in making the eyes less (‘starey’) 
in thyroid eye disease and improving quality of life in patients with TED. 
3. Do I have to take part in this study? 
 It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be asked to sign a consent form.  
 If you decide to take part you are still free to withdraw at any time and without giving a 
reason. If you change your mind and withdraw, this will not affect the standard of care that 
Eich cyf/Your ref:   
Ein cyf/Our ref:  
Rhwydwaith Ffôn Iechyd Cymru/ 
Welsh Health Telephone Network:  
Llinell uniongyrchol/Direct Line: 
Ysbyty Athrofaol Cymru 
University Hospital of Wales 
 
Parc y Mynydd Bychan Heath Park 
Caerdydd CF14 4XW  Cardiff CF14 4XW 
Ffôn 029 2074 7747 Phone 029 2074 7747 
Ffacs 029 20743838  Fax 029 2074 3838  
Minicom 029 2074 3632 Minicom 029 2074 3632 
    
 
387 
you receive. 
4. What are Bimatoprost eye drops and are they safe? 
Bimatoprost eye drops are normally being used to treat people with glaucoma (this is a 
condition that increases the pressure in the eye. Bimatoprost eye drops work by increasing 
the amount of fluid that drains out of your eye, which reduces the pressure. We will be 
using the dose that is regularly prescribed for glaucoma. The expected benefit may not 
last after you stop the treatment. This medication has been used since 2002 with an 
excellent safety profile. Its role in TED has not been studied yet. 
5. What other medicines could I have instead? 
There is currently no other eye drop licenced for this purpose.  The majority of the patients 
will be on some form of artificial tears. 
6. What are its side-effects? 
The most common side effects after using Bimatoprost eye drops are an itching sensation 
in the eyes and/or eye redness. This was reported in approximately 4% of patients. 
Bimatoprost may cause other less common side effects which typically occur on the skin 
close to where it is applied, or in the eyes. These include skin darkening, longer or thicker 
eyelashes, dryness of the eyes and redness of the eyelids. Any eyelid skin darkening or 
eye lashes thickening/elongation are expected to reverse after several weeks to months 
after stopping the eye drops. Bimatoprost use may also cause increased brown 
pigmentation (reported in approximately 1% of patients) of the coloured part of the eye 
known as iris which may be permanent. If you develop any other eye problems with your 
eyes you can contact your eye specialist for advice.  
7. What will happen to me if I take part? 
 You will have 6 visits in total as part of clinical assessments in the outpatient clinic.  At the 
start of the trial you will be given either Bimatoprost eye drops or dummy eye drops (called 
a placebo). You will be on 3 month course of either eye drops. You then will have 2 month 
break before commencing the eye drops that you have not used at the start of the trial.  At 
all visits, apart from the first, we will take photographs of your eyes.  We will ask you to 
consent separately for publication of any photographs.  Although you have the right to 
withdraw consent, it would not be possible to withdraw published material. 
You also will be asked to fill in a short questionnaire regarding your thyroid eye condition 
throughout the study period.  
 
 
8. Will I know what treatments I am taking? 
 
No, not until the end of the study. It is an important part in the design to ensure that neither 
you nor your doctor will know what treatments you receive (a procedure called ‘masking’). 
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This is because it is well known that if patients receive what they and / or their doctor 
believes is the ‘best’ or ‘worst’ treatment; it influences the way they measure the benefit of 
the treatment.  
 
9. How will I be prevented from knowing what treatments I am taking? 
 
All patients enrolled in the study will be given the eye drops to take once a day. Half will 
receive Bimatoprost eye drops and half will receive a dummy eye drops (placebo), which 
looks like the real thing but is not. Both products will be relabelled by the trial pharmacist. 
The relabelled product will be kept in an opaque medicine vial. You will be asked to not 
bring your eye drop bottles to the hospital when you come for your trial visits, but ONLY 
to return your eye drop bottles to the pharmacy department at the end of each 3 month 
course of treatment.   
   
10. In an emergency, can I find out what treatments I am taking? 
 
Yes. Your doctor can contact our trial pharmacist or on-call pharmacist (outside working 
hours) via the hospital switchboard (029 2074 7747). However, if you find out which 
treatments you have been given you will no longer be able to continue on treatment, but 
you would be invited to attend for the remaining follow up visits.  
 
11. How will the decision about which order I receive the treatment be made? 
 
Everyone in the study will receive both treatments (Bimatoprost and placebo). Neither you 
nor the study staff will have any influence over which treatments you receive first. This will 
be selected by a computer on the basis of chance, like flipping a coin. You have an equal 
chance of being allocated to either treatment first.  
 
12. How long will I be in the study? 
 
10 months. 
 
13. If I take part in the study will I be asked to give any extra blood samples (apart from 
routine check), or have any other tests?  
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No.  You will only have routine blood tests for your thyroid gland that would be carried out 
even if you were not taking part in the study and may normally be done by your GP.  If you 
take part in the study, the blood tests would be carried out here in the hospital as part of 
your study visits or with your GP whichever is more convenient for you.  
 
14. What will happen at each of the follow-up visits? 
 
You will be seen by an Eye Specialist and a Clinical Research Fellow at each visit. The 
clinic visit will last as your routine clinic visit. 
They will conduct a detailed examination of your eyes (like a routine eye clinic visit) and 
ask questions about your Thyroid Eye Disease, general health, and medications. In 
addition photographs of your eyes will be undertaken. You also will be asked to complete 
a short quality of life questionnaire and a health related cost questionnaire at each visit. 
 
15. What if my Thyroid Eye Disease gets worse during this research, or if I receive 
Bimatoprost eye drops and do not tolerate it? 
 
If your Thyroid Eye Disease gets worse at one of your follow-up visits you will be recalled 
2 weeks later to double check the measurements. If these have not improved at the second 
visit you will be withdrawn from the trial (we will stop your study eye drops and treat you 
accordingly). 
 
If you are concerned that your Thyroid Eye Disease is getting worse you can contact your 
research doctor at any time and they can arrange to review you before your planned 
appointment. If they confirm that your condition is deteriorating (as above) you will be 
withdrawn from the trial. 
16. Expenses and payments  
You will be paid any travel expenses incurred in coming to trial visits.  Your contact details 
will be given to Cardiff University finance department in order that they can process 
payment to you. 
17.  What happens to my treatment when I finish the trial? 
 
Your ophthalmologist will continue to follow you up in the NHS eye clinic, if it is considered 
necessary and decide whether you need to be treated with Bimatoprost after you have 
finished the trial.  
 
18.  If I did not take part in this research what treatment would I receive? 
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The standard treatments for patients with inactive Thyroid Eye Disease currently used at 
University Hospital of Wales involve artificial tears or surgery if required. For further 
information please ask your doctor to explain the usual care patients receive for inactive 
Thyroid Eye Disease. 
 
19. Is there anything else to be worried about if I take part? 
 
Please share this information with your partner if it is appropriate.  You should not take 
part in this study if you are pregnant, breast-feeding or you may become pregnant during 
the study period. If you could become pregnant, we will ask you to have a pregnancy test 
(urine or blood) before taking part. You must agree to use a reliable form of contraception 
during the trial, e.g. oral contraceptive and condom, intra-uterine device (IUD) and 
condom, diaphragm with spermicide and condom. This should be continued for at least 2 
months after the treatment has finished. If you do become pregnant during the course of 
the study, we would ask you to tell your study doctor immediately so we can help decide 
appropriate action.  
 
20. Will my taking part in the study be kept confidential? 
Yes. All information which is collected about you during the course of the research will be 
kept strictly confidential. Parts of your medical records and the data collected for the study 
will be looked at by authorised persons from Cardiff University, Cardiff & Vale University 
Health Board and the regulatory authorities – who are required to check that the study is 
being carried out correctly.   
You will be assigned a study identification number so that the information collected about 
you (data) held on Cardiff University IT systems will be anonymised.   
With your permission, your GP will be told that you are taking part in the study, as will any 
other doctors who are involved in your care, such as your endocrinologist. 
21. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatments that are being studied.  If this happens, your research doctor will tell 
you about it and discuss with you whether you want to continue in the study.  If you decide 
to withdraw, your research doctor will make arrangements for your normal care to 
continue.  If you decide to continue in the study you will be asked to sign an updated 
consent form. 
 
Also, on receiving new information your research doctor might consider it to be in your 
best interests to withdraw you from the study.  They will explain the reasons and arrange 
for your care to continue. 
 
22. What if something goes wrong? 
If you are harmed by taking part in this research project or if you are harmed due to 
someone’s negligence, then you may have grounds for a legal action.   
Regardless of this, if you have concerns about any aspect of the way you have been 
approached or treated during the course of this study you may wish to contact the 
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following: 
 
University Hospital of Wales, Cardiff 
Complaints Manager at Cardiff and Vale UHB is Angela Hughes, Cardiff and Vale 
University Health Board Headquarters, Whitchurch Hospital, Park Road, Whitchurch, 
Cardiff CF14 7XB, Tel: 029 20 742202. 
23. What will happen to the results of the research study? 
 
The results of the study may be presented at relevant medical and scientific meetings and 
published in an appropriate medical or scientific journal.  When all patients have completed 
the study, we can provide you with a summary of the results if you request it.  
 
24. Who is organising and funding the research? 
 
The study is being organised by Professor Colin Dayan in endocrine department and Mr 
Dan Morris and Mrs Carol Lane from Ophthalmology department. Funding for the study is 
provided from National Institute for Social Care and Health Research (NISCHR) which is 
a Welsh government body.  
 
25. Who has reviewed the study? 
 
This study has been reviewed by the South East Wales Research Ethics Committee, 
Medicines and Healthcare products Regulatory Agency (MHRA), National Institute for 
Social Care and Health Research (NISCHR), Cardiff University and Cardiff and Vale NHS 
Trust Research and Development Office. 
 
26. Contact for Further Information 
 
Mr Dan Morris and Mrs Carol Lane, Consultant Ophthalmologists, University Hospital of 
Wales, Heath Park, Cardiff CF14 4XW 
Tel:   029 20 747747 (secretary extension: 2083) 
 
Or 
 
Professor Colin Dayan, Professor Clinical Diabetes and Metabolism, School of Medicine 
Centre for Endocrine and Diabetes Science, Cardiff University, Heath Park, Cardiff CF14 
4XW 
Tel:   029 20 742182 (secretary) 
 
Or 
 
Trials Office: 
Julie Pell, Trials Coordinator: 02921 847942, pelljc@cardiff.ac.uk 
Dr Draman, Study Doctor:   02920 748481, Dramanyusofms@cardiff.ac.uk 
    Mob: 07446624212 
 
 
This information sheet is yours to keep. Thank you for taking time to read it. 
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8.4.4 Consent form 
 
  
 
Patient Identification Number for this trial: ________ 
 
 
CONSENT FORM 
Title of Project:  Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: a 
randomised controlled double blind crossover trial (BIMA study) 
 
Chief Investigator: Professor Colin Dayan, Consultant Endocrinologist  
Consultant Ophthalmologists: Mr Dan Morris / Mrs Carol Lane, Consultant 
Ophthalmologists, University Hospital of Wales, Heath Park, Cardiff CF14 4XW   
               
 
1. I confirm that I have read and understand the information sheet, 
      V2, 20 March 2014 for the above study and have had the opportunity to ask questions.
 
 
Bima Study 
 
 
Please initial 
boxes 
Eich cyf/Your ref:   
Ein cyf/Our ref:  
Ysbyty Athrofaol Cymru 
University Hospital of Wales 
 
Parc y Mynydd Bychan Heath Park 
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2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
 without giving any reason, without my medical care or legal rights being affected.  
3. I understand that sections of my medical notes may be looked at by responsible  
individuals from Cardiff University, Cardiff & Vale University Health Board 
and the regulatory authorities, where it is relevant to my taking part in research,  
and that my personal details may be shared between research staff working at the  
institutions involved in the trial.  I give permission for these individuals to have access  
to my records, and for my personal data to be used in this way.  
         
5. I agree to having photographs of my eyes taken for the purposes of research.  
                                       
6.   I agree to my GP being informed of my participation in the study.      
 7. I agree to take part in the above study      
   
OPTIONAL (you can still take part in the study, even if you do not want to initial the box 
below) 
 
1. I consent to photographs of my eyes being published in an open access journal,  
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textbook or other form of medical publication (which may include the internet), and  
therefore may be seen by the general public as well as medical professionals.  I  
understand that no other information about me would be published – only the photographs.   
 
 
 
 
________________ ________________ ____________________ 
Name of Patient Date Signature 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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8.4.5 Standard operating procedure list 
 
BIMA Study: Study specific SOPs: 
SOP Author Latest 
version 
Date 
Eye photograph Dr S Draman V1.0 06 May 2014 
Height measurement Dr S Draman V1.0 26 Nov 2013 
Weight measurement Dr S Draman V1.0 27 Nov 2013 
Emergency code break 
procedure 
J Pell/UHW 
Pharmacy 
V1.0 23 July 2014 
Pharmacy notification of 
allocation and dispensing of 
study treatments 
Dr S 
Draman/UHW 
Pharmacy 
V1.0 1 May 2014 
Ophthalmology assessments Dan Morris/S 
Draman 
V1.0 06 May 2014 
Endocrine Care Dr S Draman V1.0 26 Nov 2013 
Smoking advice Dr S Draman V1.0 26 Nov 2013 
Pregnancy Testing (to be 
used in conjunction with 
PCTO - 
Dr S Draman 
Point of Care 
Testing 
V1.0 
 
E1.3 
06 May 2014 
 
21 Dec 2012 
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All Wales Pregnancy Training 
Randomisation Testing Plan Dr S Draman  22 May 2014 
Contacting patient after invite 
letter has been sent 
Dr S Draman V1.0 20 Mar 2014 
Patient Pathway – Trial Visit Dr S Draman/Julie 
Pell 
V1.0 21 May 2014 
Patient Pathway – To appt 
and subsequent trial visit 
appts 
Dr S Draman/Julie 
Pell 
V1.0 May 2014 
 
